var images_info;if (!images_info) images_info =[]; images_info["110"]={"110002":{"type":"graphic_table","displayName":"Proposed diagnostic criteria for cutaneous polyarteritis nodosa","title":"Proposed diagnostic criteria for cutaneous polyarteritis nodosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed diagnostic criteria for cutaneous polyarteritis nodosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Characteristic cutaneous manifestations:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Subcutaneous nodules, livedo reticularis, ulcers, retiform purpura, digital ischemia </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Consistent histopathologic findings:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Fibrinoid necrotizing vasculitis of medium-sized arteries in the deep dermis/subcutis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Absence of:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Fever &#8805;38&#176;C for &#8805;2 weeks, unexplained weight loss &#8805;4 kg </li> <li>Hypertension (new-onset diastolic blood pressure &#62;90 mmHg) </li> <li>Progressive renal failure (serum blood urea nitrogen &#62;40 mg/dL or creatinine &#62;1.5 mg/dL) </li> <li>Cerebral ischemia, cerebral hemorrhage </li> <li>Myocardial infarction, ischemic heart disease, pericarditis, heart failure </li> <li>Intestinal hemorrhage, intestinal infarction </li> <li>Peripheral neuropathy remote from cutaneous lesions </li> <li>Arthralgia (arthritis) or myalgia (myositis) remote from cutaneous lesions </li> <li>Abnormal arteriography (microaneurysms, stenosis, or occlusion of visceral arteries) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nakamura T, Kanazawa N, Ikeda T, et al. Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria. Arch Dermatol Res 2009; 301:117.</li>&#xD;&#xA;    <li>Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 110002 Version 1.0</div></div></div>"},"110003":{"type":"graphic_picture","displayName":"Cutaneous polyarteritis nodosa digital infarction","title":"Cutaneous polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cutaneous polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110003_Ctns_plyrtrts_dgtl_infrctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital infarction.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110003 Version 1.0</div></div></div>"},"110007":{"type":"graphic_figure","displayName":"BP for extremely preterm infants ≤28 weeks gestation","title":"Blood pressure values for extremely preterm infants (gestational age ≤28 weeks) for the first 72 hours of life","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Blood pressure values for extremely preterm infants (gestational age ≤28 weeks)&nbsp;for the first 72 hours of life</div><div class=\"cntnt\"><img style=\"width:712px; height:516px;\" src=\"images/PEDS/110007_BP_prtrm_infnts_less_28_wks.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Population estimate of blood pressure (BP) values for extremely preterm infants (gestational age ≤28 weeks) by postnatal age in hours. Dashed line represents the blood pressure estimate while solid line represents the boundaries of the 95% confidence interval. Orange: systolic BP; blue: mean arterial BP; green: diastolic BP.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Journal of Perinatology. Vesoulis ZA, El Ters NM, Wallendorf M, Mathur AM. Empirical estimation of the normative blood pressure in infants &lt;28 weeks gestation using a massive data approach. J Perinatol 2016; 36:291. Copyright &copy; 2016. <a href=\"http://www.nature.com/jp\" target=\"_blank\">www.nature.com/jp</a>.</div><div id=\"graphicVersion\">Graphic 110007 Version 1.0</div></div></div>"},"110009":{"type":"graphic_picture","displayName":"Folliculotropic mycosis fungoides eyebrow","title":"Folliculotropic mycosis fungoides","html":"<div class=\"graphic\"><div style=\"width: 701px\" class=\"figure\"><div class=\"ttl\">Folliculotropic mycosis fungoides</div><div class=\"cntnt\"><img style=\"width:681px; height:353px;\" src=\"images/DERM/110009_Folliculotropic_mycss_fngds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Folliculotropic mycosis fungoides presenting with an indurated plaque and follicular papules&nbsp;involving the eyebrow.</div><div class=\"graphic_reference\">From: Ahn CS, ALSayyah A, Sangüeza OP. Mycosis fungoides: an updated review of clinicopathologic variants. Am J Dermatopathol 2014; 36:933. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2014&amp;issue=12000&amp;article=00001&amp;type=abstract\" target=_blank>10.1097/DAD.0000000000000207</A>. Copyright © 2014 International Society of Dermatopathology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110009 Version 1.0</div></div></div>"},"110010":{"type":"graphic_diagnosticimage","displayName":"Cuff overinflation","title":"Compressive effects of an overinflated endotracheal cuff","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Compressive effects of an overinflated endotracheal cuff</div><div class=\"cntnt\"><img style=\"width:528px; height:764px;\" src=\"images/PULM/110010_Cuffoverinflation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 9-year-old female patient admitted after motor vehicle collision and intubated due to neurologic impairment due to subdural hemorrhage. Axial CT images (A,B) of the chest with contrast demonstrate an overinflated cuff (arrows) compressing the brachiocephalic trunk (thick arrows). The patient subsequently developed intracranial ischemia due to decreased right cerebral perfusion.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Emergency Radiology. Donatelli J, Gupta A, Santhosh R, et al. To breathe or not to breathe: a review of artificial airway placement and related complications. Emerg Radiol 2015; 22:171. Copyright © 2014. <A spellcheck=true href=\"https://link.springer.com/journal/10140\" target=_blank>https://link.springer.com/journal/10140</A>.</div><div id=\"graphicVersion\">Graphic 110010 Version 3.0</div></div></div>"},"110011":{"type":"graphic_picture","displayName":"ETT holder","title":"Endotracheal tube securement devices","html":"<div class=\"graphic\"><div style=\"width: 855px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube securement devices</div><div class=\"cntnt\"><img style=\"width:835px; height:499px;\" src=\"images/PULM/110011_ETT_holder.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Panel A courtesy of Hollister Incorporated, Libertyville, Illinois.<br />Panels B and C reproduced with permission from Laerdal Medical.</div><div id=\"graphicVersion\">Graphic 110011 Version 1.0</div></div></div>"},"110013":{"type":"graphic_picture","displayName":"Vocal cord granuloma","title":"Endotracheal tube-induced vocal cord granulomas","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube-induced vocal cord granulomas</div><div class=\"cntnt\"><img style=\"width:532px; height:766px;\" src=\"images/PULM/110013_Vocalcordgranuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Operative view of a normal glottis.<br />(B) Bilateral vocal process granulomas.</div><div class=\"graphic_reference\">Reproduced with permission of the American Association for Respiratory Care, from: Pacheco-Lopez PC, Berkow LC, Hillel AT, Akst LM. Complications of airway management. Respir Care 2014; 59:1006; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2014.</div><div id=\"graphicVersion\">Graphic 110013 Version 2.0</div></div></div>"},"110015":{"type":"graphic_figure","displayName":"Normal BP for preterm infants based on GA","title":"Normative blood pressure values for preterm infants over the first 28 days of life","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Normative blood pressure values for preterm infants over the first 28 days of life</div><div class=\"cntnt\"><img style=\"width:744px; height:1129px;\" src=\"images/PEDS/110015_NormBPpreterminfantsGA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normative blood pressure trends for preterm infants over the first 28 days of life based on gestational age. Boxes delineate 10<SUP>th</SUP> and 90<SUP>th</SUP> percentiles, with vertical black marks delineating range.<br />(A) Blood pressure for neonates born at 28 to 29 weeks gestation.<br />(B) Blood pressure for neonates born at 30 to 31 weeks gestation.<br />(C) Blood pressure for neonates born at 32 to 33 weeks gestation.<br />(D) Blood pressure for neonates born at 34 to 36 weeks gestation.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Pediatric Nephrology, Normative blood pressure data in non-ventilated premature neonates from 28-36 weeks gestation, 24, 2009, 141, Kent AL, Meskell S, Falk MC, Shadbolt B, IPNA © 2008 with permission of Springer.</div><div id=\"graphicVersion\">Graphic 110015 Version 3.0</div></div></div>"},"110017":{"type":"graphic_diagnosticimage","displayName":"Tracheal stenosis","title":"Computed tomography of endotracheal tube-induced tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of endotracheal tube-induced tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:390px; height:764px;\" src=\"images/PULM/110017_Trachealstenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 54-year-old male patient with a history of a tracheostomy now with progressive difficulty breathing. Axial (A) and coronal (B) CT images of the chest demonstrate stenosis of the upper anterolateral tracheal wall (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Emergency Radiology. Donatelli J, Gupta A, Santhosh R, et al. To breathe or not to breathe: a review of artificial airway placement and related complications. Emerg Radiol 2015; 22:171. Copyright © 2014. <A spellcheck=true href=\"https://link.springer.com/journal/10140\" target=_blank>https://link.springer.com/journal/10140</A>.</div><div id=\"graphicVersion\">Graphic 110017 Version 3.0</div></div></div>"},"110018":{"type":"graphic_diagnosticimage","displayName":"Tracheoesophageal fistula","title":"Tracheoesophageal fistula on contrast imaging","html":"<div class=\"graphic\"><div style=\"width: 797px\" class=\"figure\"><div class=\"ttl\">Tracheoesophageal fistula on contrast imaging</div><div class=\"cntnt\"><img style=\"width:777px; height:732px;\" src=\"images/PULM/110018_Tracheoesophageal_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The administration of water soluble contrast demonstrates a tracheoesophageal fistula with leak into the left lower lobe (arrow) in a patients who had a prolonged intubation and tracheostomy in place for five months.</div><div class=\"graphic_reference\">From: Sanwal MK, Ganjoo P, Tandon MS. Posttracheostomy tracheoesophageal fistula. J Anaesthesiol Clin Pharmacol 2012; 28:140. DOI: <A href=\"http://www.joacp.org/article.asp?issn=0970-9185;year=2012;volume=28;issue=1;spage=140;epage=141;aulast=Sanwal\" target=_blank>10.4103/0970-9185.92478</A>. Copyright © 2012 Research Society of Anaesthesiology Clinical Pharmacology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110018 Version 1.0</div></div></div>"},"110019":{"type":"graphic_diagnosticimage","displayName":"Arytenoid joint dislocation","title":"Endotracheal tube-induced vocal cord paralysis from arytenoid joint dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube-induced vocal cord paralysis from arytenoid joint dislocation</div><div class=\"cntnt\"><img style=\"width:383px; height:764px;\" src=\"images/PULM/110019_Arytenoidjointdislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 56-year-old female patient with postextubation hoarseness due to prior endotracheal tube. Axial CT image of the neck demonstrates arteromedial position of the left arytenoid cartilage (arrow) and a dilated left laryngeal ventricle (asterisk) compatible with left vocal cord paralysis.<br />(B) Coronal CT image of the neck in the same patient demonstrates slight prominence of the ipsilateral piriform sinus (asterisk) due to the left vocal cord paralysis and mild proximal tracheal stenosis (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Emergency Radiology. Donatelli J, Gupta A, Santhosh R, et al. To breathe or not to breathe: a review of artificial airway placement and related complications. Emerg Radiol 2015; 22:171. Copyright © 2014. <A spellcheck=true href=\"https://link.springer.com/journal/10140\" target=_blank>https://link.springer.com/journal/10140</A>.</div><div id=\"graphicVersion\">Graphic 110019 Version 3.0</div></div></div>"},"110020":{"type":"graphic_picture","displayName":"Vocal cord paralysis","title":"Endotracheal tube-induced neurogenic unilateral vocal cord paralysis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube-induced neurogenic unilateral vocal cord paralysis</div><div class=\"cntnt\"><img style=\"width:540px; height:766px;\" src=\"images/PULM/110020_Vocalcordparalysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Right vocal cord paralysis, abduction. Note bowing and loss of tone on the right versus the left side. There is asymmetry in the position of the arytenoids during full abduction. The right arytenoid is anteriorly rotated, while the left moves posterolaterally during inspiration.<br />(B) Right vocal cord paralysis, adduction. Note bowing and loss of tone of the right vocal cord. There is a glottal gap on full adduction, as well as left compensatory false vocal fold compression that obstructs the view of the left true vocal cord.</div><div class=\"graphic_reference\">Reproduced with permission of the American Association for Respiratory Care, from: Pacheco-Lopez PC, Berkow LC, Hillel AT, Akst LM. Complications of airway management. Respir Care 2014; 59:1006; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2014.</div><div id=\"graphicVersion\">Graphic 110020 Version 2.0</div></div></div>"},"110026":{"type":"graphic_picture","displayName":"Blood smear - Babesia","title":"Blood smear - <em>Babesia</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blood smear - <em>Babesia</em></div><div class=\"cntnt\"><img style=\"width:200px; height:200px;\" src=\"images/ID/110026_Blood_smear_Babesia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Babesia</em> parasites in red blood cells on a stained blood smear.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Babesiosis. Available at: <A href=\"https://www.cdc.gov/dpdx/babesiosis/index.html\">https://www.cdc.gov/dpdx/babesiosis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 110026 Version 2.0</div></div></div>"},"110028":{"type":"graphic_algorithm","displayName":"Criteria for diagnosis of relapsing polychondritis","title":"Criteria for diagnosis of relapsing polychondritis","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Criteria for diagnosis of relapsing polychondritis</div><div class=\"cntnt\"><img style=\"width:766px; height:602px;\" src=\"images/RHEUM/110028_Diag_relapsing_polychondrit.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topic on treatment of relapsing polychondritis.<br />&para; Patients not responding to one agent should receive a trial of the alternative agent before concluding for the purpose of these criteria that the patient has not responded to therapy.<br />&Delta; Bilateral auricular involvement is considered as two anatomic locations.<br /><span class=\"lozenge\">&loz;</span> Refer to UpToDate topic on pathology of relapsing polychondritis.<br />&sect; Refer to UpToDate topic on diagnostic evaluation of relapsing polychondritis.</div><div id=\"graphicVersion\">Graphic 110028 Version 1.0</div></div></div>"},"110030":{"type":"graphic_picture","displayName":"Onychomatricoma dermoscopy","title":"Dermoscopic image of onychomatricoma","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of onychomatricoma</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/DERM/110030_Onychomatricoma_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychomatricoma: On dermoscopic examination, the nail plate presents a band of yellow discoloration and multiple parallel longitudinal white lines.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110030 Version 1.0</div></div></div>"},"110032":{"type":"graphic_picture","displayName":"Onychomatricoma dermoscopy 2","title":"Dermoscopic image of onychomatricoma","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of onychomatricoma</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/DERM/110032_Onychomatricoma_dermoscopy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychomatricoma: Dermoscopy of the distal nail plate edge shows woodworm-like cavities.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110032 Version 1.0</div></div></div>"},"110034":{"type":"graphic_picture","displayName":"Glomus tumor dermoscopy","title":"Dermoscopic image of glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of glomus tumor</div><div class=\"cntnt\"><img style=\"width:566px; height:756px;\" src=\"images/DERM/110034_Glomus_tumor_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glomus tumor: Nail plate dermoscopy showing branching telangiectasias.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110034 Version 1.0</div></div></div>"},"110036":{"type":"graphic_picture","displayName":"Glomus tumor dermoscopy 2","title":"Dermoscopic image of glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of glomus tumor</div><div class=\"cntnt\"><img style=\"width:561px; height:756px;\" src=\"images/DERM/110036_Glomus_tumor_dermoscopy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glomus tumor: Free edge dermoscopy shows that the lesion has a red hue.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110036 Version 1.0</div></div></div>"},"110037":{"type":"graphic_picture","displayName":"Digital myxoid cyst dermoscopy","title":"Dermoscopic image of digital myxoid cyst","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of digital myxoid cyst</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/DERM/110037_Digital_myxoid_cyst_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Myxoid cyst opening. Note the nail plate groove.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110037 Version 1.0</div></div></div>"},"110038":{"type":"graphic_picture","displayName":"Onychopapilloma dermoscopy 2","title":"Dermoscopic image of onychopapilloma","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of onychopapilloma</div><div class=\"cntnt\"><img style=\"width:593px; height:756px;\" src=\"images/DERM/110038_Onychopapilloma_dermoscopy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychopapilloma: Free edge dermoscopy shows typical keratotic mass.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110038 Version 1.0</div></div></div>"},"110039":{"type":"graphic_picture","displayName":"Wart dermoscopy","title":"Dermoscopic image of subungual wart","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of subungual wart</div><div class=\"cntnt\"><img style=\"width:564px; height:756px;\" src=\"images/DERM/110039_Wart_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subungual wart. Note typical red dots and globules.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110039 Version 1.0</div></div></div>"},"110040":{"type":"graphic_picture","displayName":"Subungual Bowen dermoscopy","title":"Dermoscopic image of subungual Bowen disease","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of subungual Bowen disease</div><div class=\"cntnt\"><img style=\"width:476px; height:634px;\" src=\"images/DERM/110040_Subungual_Bowen_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bowen disease: islands of whitish scales and targetoid structures.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110040 Version 2.0</div></div></div>"},"110041":{"type":"graphic_picture","displayName":"Nail psoriasis dermoscopy","title":"Dermoscopic image of nail psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nail psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:565px;\" src=\"images/DERM/110041_Nail_psoriasis_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail psoriasis: Dermoscopic examination of the hyponychium shows enlarged and twisted capillaries.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110041 Version 1.0</div></div></div>"},"110042":{"type":"graphic_picture","displayName":"Hemorrhagic onycholysis dermoscopy","title":"Dermoscopic image of hemorrhagic onycholysis","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of hemorrhagic onycholysis</div><div class=\"cntnt\"><img style=\"width:564px; height:756px;\" src=\"images/DERM/110042_Hemorragic_onycholysis_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic onycholysis: Dermoscopy shows multiple splinter hemorrhages and hemorrhagic spots.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110042 Version 1.0</div></div></div>"},"110043":{"type":"graphic_diagnosticimage","displayName":"Full thickness tear of the distal supraspinatus tendon","title":"Full thickness tear of the distal supraspinatus tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full thickness tear of the distal supraspinatus tendon</div><div class=\"cntnt\"><img style=\"width:287px; height:409px;\" src=\"images/RHEUM/110043_Full_tear_distl_supraspinat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2-weighted fat-suppressed MRI of the right shoulder demonstrates fluid (arrow) replacing the distal supraspinatus tendon consistent with full thickness tear.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 110043 Version 1.0</div></div></div>"},"110044":{"type":"graphic_diagnosticimage","displayName":"Supraspinatus tendon tear on MR arthrogram","title":"Supraspinatus tendon tear on MR arthrogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supraspinatus tendon tear on MR arthrogram</div><div class=\"cntnt\"><img style=\"width:288px; height:237px;\" src=\"images/RHEUM/110044_Supraspinatus_tndn_tear_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T1-weighted fat-suppressed MR arthrogram shows a torn and partially retracted supraspinatus tendon (arrow) and fluid tracking in the subacromial-subdeltoid bursa (thick arrow) through a full thickness tear.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 110044 Version 1.0</div></div></div>"},"110045":{"type":"graphic_picture","displayName":"Pseudomonas nail dermoscopy","title":"Dermoscopic image of Pseudomonas nail infection","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of Pseudomonas nail infection</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/DERM/110045_Pseudomonas_nail_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Green nail due to <em>Pseudomonas</em> colonization. Note the intense green color on dermoscopic examination.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110045 Version 1.0</div></div></div>"},"110046":{"type":"graphic_picture","displayName":"Toenail onychomycosis dermoscopy 1","title":"Dermoscopic image of toenail onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of toenail onychomycosis</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/DERM/110046_Toenail_onychomycosis_derm1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychomycosis: Free edge dermoscopy showing \"ruined\" appearance of the subungual hyperkeratosis.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110046 Version 1.0</div></div></div>"},"110047":{"type":"graphic_picture","displayName":"Toenail onychomycosis dermoscopy 2","title":"Dermoscopic image of toenail onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of toenail onychomycosis</div><div class=\"cntnt\"><img style=\"width:560px; height:756px;\" src=\"images/DERM/110047_Toenail_onychomycosis_derm2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychomycosis: The proximal margin of the onycholytic area shows yellow-white spikes projecting into the proximal nail plate.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110047 Version 1.0</div></div></div>"},"110049":{"type":"graphic_picture","displayName":"Traumatic onycholysis dermoscopy","title":"Dermoscopic image of traumatic onycholysis","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of traumatic onycholysis</div><div class=\"cntnt\"><img style=\"width:564px; height:756px;\" src=\"images/DERM/110049_Traumatic_onycholysis_dermo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traumatic onycholysis. Note the sharp proximal border.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110049 Version 1.0</div></div></div>"},"110050":{"type":"graphic_picture","displayName":"Onychotillomania dermoscopy","title":"Dermoscopic image of onychotillomania","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of onychotillomania</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/DERM/110050_Onychotillomania_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychotillomania: Dermoscopy shows hemorrhages and crusts of the nail bed and nail folds; nail pigmentation is also evident.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110050 Version 1.0</div></div></div>"},"110051":{"type":"graphic_picture","displayName":"Onychotillomania dermoscopy 2","title":"Dermoscopic image of onychotillomania","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of onychotillomania</div><div class=\"cntnt\"><img style=\"width:565px; height:756px;\" src=\"images/DERM/110051_Onychotillomania_dermoscp_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onychotillomania: melanonychia and nail bed hemorrhages.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 110051 Version 2.0</div></div></div>"},"110053":{"type":"graphic_table","displayName":"Oral glucocorticoids for prevention of Graves' orbitopathy","title":"Use of oral glucocorticoids for prevention of Graves' orbitopathy development or progression when radioactive iodine is used to treat Graves' hyperthyroidism*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of oral glucocorticoids for prevention of Graves' orbitopathy development or progression when radioactive iodine is used to treat Graves' hyperthyroidism*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">RAI without glucocorticoids</td> <td class=\"subtitle1\">RAI with oral glucocorticoids</td> </tr> <tr> <td><strong>No GO (nonsmoker)</strong></td> <td class=\"centered\">Recommend</td> <td class=\"centered\">Recommend against</td> </tr> <tr> <td><strong>No GO (smoker)</strong></td> <td class=\"centered\" colspan=\"2\">Insufficient data to recommend for or against</td> </tr> <tr> <td><strong>GO present-active and mild (risk factors absent)</strong></td> <td class=\"centered\">Acceptable<sup>&#182;</sup></td> <td class=\"centered\">Acceptable<sup>&#182;</sup></td> </tr> <tr> <td><strong>GO present-active and mild (risk factors present)</strong></td> <td class=\"centered\">Recommend against</td> <td class=\"centered\">Recommend</td> </tr> <tr> <td><strong>GO present-active and moderate-to-severe or sight-threatening</strong></td> <td class=\"centered\">Recommend against</td> <td class=\"centered\">Recommend against</td> </tr> <tr> <td><strong>GO present-inactive</strong></td> <td class=\"centered\">Recommend</td> <td class=\"centered\">Recommend against</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RAI: radioactive iodine; GO: Graves' orbitopathy; ATDs: antithyroid drugs; TRAb: thyrotropin receptor antibodies.<br />* ATDs or thyroidectomy are also recommended treatment options in each of these scenarios, and they are the preferred choice of therapy in patients with active and moderate-to-severe or sight-threatening GO.<br />¶ The decision regarding use of concurrent glucocorticoids should be made in light of the risk-benefit ratio relative to the patient's overall health. Risk factors for GO deterioration (high TRAb level, smoking) increase the benefit of glucocorticoids in preventing GO deterioration. Poorly controlled diabetes, osteoporosis, psychiatric illness, high risk for infections increase the likelihood of complications from glucocorticoids.</div><div class=\"graphic_reference\">Reproduced with permission from: Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyroidtoxicosis. Thyroid 2016; 26:1343. Copyright &copy; 2016 Mary Ann Liebert, Inc. publishers.</div><div id=\"graphicVersion\">Graphic 110053 Version 1.0</div></div></div>"},"110054":{"type":"graphic_table","displayName":"PHACE diagnostic criteria","title":"Diagnostic criteria for PHACE syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for PHACE syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ systems</td> <td class=\"subtitle1\" colspan=\"2\">Major criteria</td> <td class=\"subtitle1\">Minor criteria</td> </tr> <tr class=\"divider_bottom\"> <td>Arterial anomalies</td> <td colspan=\"2\"> <ul> <li>Anomaly of major cerebral or cervical arteries* </li> <li>Dysplasia<sup>&#182;</sup> of the large cerebral arteries </li> <li>Arterial stenosis or occlusion with or without moyamoya collaterals </li> <li>Absence or moderate-severe hypoplasia of the large cerebral and cervical arteries </li> <li>Aberrant origin or course of the large cerebral or cervical arteries except common arch variants such as bovine arch </li> <li>Persistent carotid-vertebrobasilar anastomosis (proatlantal segmental, hypoglossal, otic, and/or trigeminal arteries) </li> </ul> </td> <td> <ul> <li>Aneurysm of any of the cerebral arteries </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Structural brain</td> <td colspan=\"2\"> <ul> <li>Posterior fossa brain anomalies </li> <li>Dandy-Walker complex </li> <li>Other hypoplasia/dysplasia of the mid and/or hind brain </li> </ul> </td> <td> <ul> <li>Midline brain anomalies </li> <li>Malformation of cortical development </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cardiovascular</td> <td colspan=\"2\"> <ul> <li>Aortic arch anomalies </li> <li>Coarctation of the aorta </li> <li>Dysplasia* </li> <li>Aneurysm </li> <li>Aberrant origin of the subclavian artery with or without a vascular ring </li> </ul> </td> <td> <ul> <li>Ventricular septal defect </li> <li>Right aortic arch/double aortic arch </li> <li>Systemic venous anomalies </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ocular</td> <td colspan=\"2\"> <ul> <li>Posterior segment abnormalities </li> <li>Persistent hyperplastic primary vitreous </li> <li>Persistent fetal vasculature </li> <li>Retinal vascular anomalies </li> <li>Morning glory disc anomaly </li> <li>Optic nerve hypoplasia </li> <li>Peripapillary staphyloma </li> </ul> </td> <td> <ul> <li>Anterior segment abnormalities </li> <li>Microphthalmia </li> <li>Sclerocornea </li> <li>Coloboma </li> <li>Cataracts </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ventral/midline</td> <td colspan=\"2\"> <ul> <li>Anomaly of the midline chest and abdomen <ul> <li>Sternal defect </li> <li>Sternal pit </li> <li>Sternal cleft </li> <li>Supraumbilical raphe </li> </ul> </li> </ul> </td> <td> <ul> <li>Ectopic thyroid hypopituitarism </li> <li>Midline sternal papule/hamartoma </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" colspan=\"2\">Definite PHACE</td> <td class=\"subtitle1\" colspan=\"2\">Possible PHACE</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Hemangioma &#62;5 cm in diameter of the head, including scalp<br /> PLUS&nbsp;one major criteria or&nbsp;two minor criteria </li> <li>Hemangioma of the neck, upper trunk or trunk, and proximal upper extremity<br /> PLUS&nbsp;two major criteria </li> </ul> </td> <td colspan=\"2\"> <ul> <li>Hemangioma &#62;5 cm in diameter of the head, including scalp<br /> PLUS&nbsp;one minor criteria </li> <li>Hemangioma of the neck, upper trunk or trunk, and proximal upper extremity<br /> PLUS&nbsp;one major criteria or&nbsp;two minor criteria </li> <li>No hemangioma<br /> PLUS&nbsp;two major criteria </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PHACE: posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities.<br />* Internal carotid artery, middle cerebral artery, anterior cerebral artery, posterior cerebral artery, or vertebrobasilar.<br />¶ Includes kinking, looping, tortuosity, and/or dolichoectasia.</div><div class=\"graphic_reference\">Reproduced from: Garzon MC, Epstein LG, Heyer GL, et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr 2016; Sept 19:Epub ahead of print. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110054 Version 2.0</div></div></div>"},"110056":{"type":"graphic_diagnosticimage","displayName":"Partial thickness tear of the supraspinatus tendon","title":"Partial thickness tear of the supraspinatus tendon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partial thickness tear of the supraspinatus tendon</div><div class=\"cntnt\"><img style=\"width:279px; height:456px;\" src=\"images/RHEUM/110056_Prtl_tear_supraspinatus_tnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2-weighted fat-suppressed image of the left shoulder shows fluid (arrow) in the articular surface of the supraspinatus tendon, consistent with a partial thickness tear.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 110056 Version 1.0</div></div></div>"},"110057":{"type":"graphic_diagnosticimage","displayName":"Supraspinatus tendon tear","title":"Supraspinatus tendon tear","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Supraspinatus tendon tear</div><div class=\"cntnt\"><img style=\"width:547px; height:403px;\" src=\"images/RHEUM/110057_Supraspinatus_tendon_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of the shoulder demonstrates a full thickness tear of the supraspinatus tendon (thick arrow). There is fluid in the subacromial-subdeltoid bursa (arrows).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 110057 Version 1.0</div></div></div>"},"110058":{"type":"graphic_table","displayName":"Anticholinergic drugs and substances involved in acute poisoning","title":"Medications and other substances with anticholinergic properties that may be involved in acute poisoning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications and other substances with anticholinergic properties that may be involved in acute poisoning</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Drugs</td> </tr> <tr class=\"divider_bottom\"> <td>Antihistamines</td> <td> <ul> <li>H1 receptor antagonists (1st generation, eg, brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, dimenhydrinate, diphenhydramine, doxepin, doxylamine, hydroxyzine, meclizine, triprolidine, others) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antiparkinson</td> <td> <ul> <li>Benztropine, trihexyphenidyl </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, overactive bladder</td> <td> <ul> <li>Darifenacin, fesoterodine, flavoxate, oxybutynin, solifenacin, tolterodine, trospium </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, spasmolytic</td> <td> <ul> <li>Atropine, belladonna-containing medications, clidinium-chlordiazepoxide, dicyclomine, hyoscyamine, glycopyrrolate, homatropine, methscopolamine, propantheline, scopolamine (hyoscine) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, inhaled bronchodilator</td> <td> <ul> <li>Ipratropium, tiotropium </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Antimuscarinic, ophthalmic drops&#182; (mydriatic/cycloplegic)</td> <td> <ul> <li>Atropine, cyclopentolate, homatropine, scopolamine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Gastrointestinal</td> <td> <ul> <li>Antiemetics (eg, hydroxyzine, meclizine, promethazine, scopolamine); also refer to 1st generation antihistamines above </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Muscle relaxant</td> <td> <ul> <li>Cyclobenzaprine, orphenadrine, tizanidine </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Psychotropic</td> <td> <ul> <li>High relative anticholinergic potency: <ul> <li>Antipsychotics 1st generation: Chlorpromazine, fluphenazine, loxapine, methotrimeprazine (levomepromazine), thioridazine, trifluoperazine </li> <li>Antipsychotics 2nd generation: Clozapine </li> <li>Tricyclic antidepressants (eg, amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline) </li> </ul> </li> <li>Low relative anticholinergic potency: <ul> <li>Antipsychotics 1st generation: Haloperidol, perphenazine*, others </li> <li>Antipsychotics 2nd generation (eg, olanzapine*, quetiapine*, iloperidone, risperidone, others) </li> </ul> </li> </ul> </td> </tr> <tr> <td>Plants</td> <td> <ul> <li>Angel's trumpet (<em>Brugmansia</em> species) </li> <li>Deadly nightshade (<em>Atropa belladonna</em>) </li> <li>Henbane (<em>Hyoscyamus niger</em>) </li> <li>Jimson weed (<em>Datura stramonium</em>) </li> <li>Mandrake (<em>Mandragora officinarum</em>) </li> <li>Moonflower (<em>Datura inoxia</em>) </li> <li>Muscarinic mushroom species (particularly <em>Clitocybe</em> and <em>Inocybe</em>) </li> <li>Other muscarine-containing mushrooms include: <em>Amanita</em>, <em>Entoloma</em>, and <em>Mycena</em> species </li> <li>Nightshade species: American nightshade (<em>Solanum americanum</em>), Bittersweet woody nightshade (<em>Solanum dulcamara</em>), Black (common) nightshade (<em>Solanum nigrum</em>) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A large number of medicines are reported to have some anticholinergic activity and considerable variation exists in potency rankings assigned to specific drugs using available anticholinergic risk scales and in expert lists; this list includes only those drugs and agents more likely to be involved in anticholinergic poisoning. Increasing dose and additive effects from simultaneous use of more than one anticholinergic drug can alter the anticholinergic activity rating provided in this table.</div><div class=\"graphic_footnotes\">* Classified as moderate or high anticholinergic potency in some references or variable effects reported.<br />¶ Adverse anticholinergic effects may be observed with excessive topical use, but poisoning risk is greater with oral ingestion.</div><div class=\"graphic_reference\">Courtesy of Stephen J Traub, MD with additional data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol 2013; 69:1485.</LI>&#xD;&#xA;<LI>Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc 2015; 63:85.</LI>&#xD;&#xA;<LI>United States prescribing information available at US National Library of Medicine DailyMed website (<A href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/index.cfm</A>).</LI>&#xD;&#xA;<LI>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015; 63:2227.</LI></OL></div><div id=\"graphicVersion\">Graphic 110058 Version 1.0</div></div></div>"},"110060":{"type":"graphic_diagnosticimage","displayName":"Vocal cord granuloma II","title":"Endotracheal tube-induced vocal cord granulomas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endotracheal tube-induced vocal cord granulomas</div><div class=\"cntnt\"><img style=\"width:368px; height:766px;\" src=\"images/PULM/110060_VocalcordgranulomaII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 55-year old male patient with postextubation hoarseness due to prior tracheostomy tube. Sagittal (A) and coronal (B) CT images of the neck demonstrate a tracheal granuloma (arrows) in the left anterior wall of trachea resulting in luminal narrowing.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted by permission from: Springer: Emergency Radiology. Donatelli J, Gupta A, Santhosh R, et al. To breathe or not to breathe: a review of artificial airway placement and related complications. Emerg Radiol 2015; 22:171. Copyright © 2014. <A spellcheck=true href=\"https://link.springer.com/journal/10140\" target=_blank>https://link.springer.com/journal/10140</A>.</div><div id=\"graphicVersion\">Graphic 110060 Version 3.0</div></div></div>"},"110064":{"type":"graphic_table","displayName":"Multinational prevalence rates of substance use","title":"Multinational prevalence rates of substance use and substance use disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multinational prevalence rates of substance use and substance use disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Use/disorder</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">United States</td> <td class=\"subtitle1\">Europe</td> <td class=\"subtitle1\">Canada</td> <td class=\"subtitle1\">Australia</td> </tr> <tr> <td colspan=\"6\"><strong>Alcohol use</strong></td> </tr> <tr> <td class=\"indent1\">Ever</td> <td class=\"centered\">15 to 16</td> <td class=\"centered\">47%</td> <td class=\"centered\">90%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Binge</td> <td class=\"centered\">13</td> <td class=\"centered\">5.1%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">15 to 16</td> <td class=\"centered\">13.7%</td> <td class=\"centered\">38%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Disorder</td> <td class=\"centered\">13 to 14</td> <td class=\"centered\">1.3%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">17 to 18</td> <td class=\"centered\">15.1%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"6\"><strong>Drug use</strong></td> </tr> <tr> <td class=\"indent1\">Ever</td> <td class=\"centered\">12 to 18</td> <td class=\"centered\">40%</td> <td class=\"centered\">20%</td> <td class=\"centered\">&#62;35%</td> <td class=\"centered\">&#62;40%</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">13</td> <td class=\"centered\">25%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">17 to 18</td> <td class=\"centered\">50%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"6\"><strong>Cannabis use</strong></td> </tr> <tr> <td class=\"indent1\">Ever</td> <td class=\"centered\">12 to 17</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">7.2%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Monthly</td> <td class=\"centered\">17 to 18</td> <td class=\"centered\">14.3%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Daily</td> <td class=\"centered\">17 to 18</td> <td class=\"centered\">5.3%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"6\"><strong>Drug use disorder</strong></td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">12 to 17</td> <td class=\"centered\">11.4%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">13 to 14</td> <td class=\"centered\">3.4%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">17 to 18</td> <td class=\"centered\">16.5%</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 110064 Version 1.0</div></div></div>"},"110065":{"type":"graphic_algorithm","displayName":"Algorithm for antidepressant medication monotherapy","title":"Algorithm for antidepressant medication monotherapy during the continuation/maintenance phase for adults with unipolar major depression","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Algorithm for antidepressant medication monotherapy during the continuation/maintenance phase for adults with unipolar major depression</div><div class=\"cntnt\"><img style=\"width:490px; height:572px;\" src=\"images/PSYCH/110065_Antidepressant_med_mnthrpy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Response is defined as reduction of baseline symptoms ≥50 percent.<br />¶ For patients who do not respond to initial therapy, refer to topic for treatment resistant depression.<br />Δ Complicated episodes of unipolar major depression include episodes with suicidal ideation, psychotic features, psychomotor retardation, or severe impairment, and episodes that require more than six months of acute treatment to achieve response.<br /><FONT class=lozenge>◊</FONT> Risk of relapse is higher in patients with: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Childhood maltreatment (physical or sexual abuse, neglect, or family violence or conflict).</LI>&#xD;&#xA;<LI>Early age of onset of unipolar major depression (eg, ≤18 to 21 years of age).</LI>&#xD;&#xA;<LI>Persistent residual depressive symptoms, especially sleep disturbances and/or suicidal ideation.</LI>&#xD;&#xA;<LI>Comorbid psychiatric disorders.</LI>&#xD;&#xA;<LI>Psychosocial stressors or impairment (eg, marital conflict or inability to work)</LI>&#xD;&#xA;<LI>Negative cognitive style (eg, \"I'm no good,\" \"The future is hopeless,\" or \"There's nothing I can do\").</LI>&#xD;&#xA;<LI>Family history of unipolar depression or bipolar disorder.</LI></UL>§ Refer to topic on discontinuing antidepressants.</div><div id=\"graphicVersion\">Graphic 110065 Version 1.0</div></div></div>"},"110069":{"type":"graphic_algorithm","displayName":"Diagnosis of suspected achalasia","title":"Diagnostic evaluation in patients with suspected achalasia","html":"<div class=\"graphic\"><div style=\"width: 752px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation in patients with suspected achalasia</div><div class=\"cntnt\"><img style=\"width:732px; height:794px;\" src=\"images/GAST/110069_Diag_suspected_achalasia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LES: lower esophageal sphincter; EUS: endoscopic ultrasound; FNA: fine needle aspiration; IRP: integrated relaxation pressure.<br />* Diagnostic manometric findings of achalasia are incomplete relaxation of the LES (IRP above the upper limit of normal) and aperistalsis in the distal two-thirds of the esophagus.<br />¶ Equivocal manometric findings include incomplete LES relaxation but some preserved peristalsis; some complete LES relaxation with aperistalsis.<br />Δ Additional evaluation should be based on patient symptoms.<br /></div><div id=\"graphicVersion\">Graphic 110069 Version 1.0</div></div></div>"},"110070":{"type":"graphic_algorithm","displayName":"ACNES algorithm","title":"Approach to the diagnosis and management of anterior cutaneous nerve entrapment syndrome","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis and management of anterior cutaneous nerve entrapment syndrome</div><div class=\"cntnt\"><img style=\"width:752px; height:682px;\" src=\"images/GAST/110070_ACNES_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The presence of unexplained elevation in liver tests, amylase, lipase or tissue transglutaminase antibody, leukocytosis, or iron deficiency, should prompt evaluation for other etiologies of abdominal pain. However, the presence of these laboratory abnormalities does not exclude concomitant anterior cutaneous nerve entrapment syndrome.<br />&para; Injections at the same site must be at least one month apart. Patients should be reevaluated prior to a repeat injection for other causes of abdominal pain, paying specific attention to the type of ongoing symptoms, the degree to which symptoms have worsened, and compliance with conservative therapy.</div><div id=\"graphicVersion\">Graphic 110070 Version 1.0</div></div></div>"},"110072":{"type":"graphic_table","displayName":"MRSA parenteral antibiotics for skin soft tissue infection","title":"Parenteral antimicrobial therapy for treatment of skin and soft tissue infections due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antimicrobial therapy for treatment of skin and soft tissue infections due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antibiotics of choice*</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Daptomycin<sup>&#182;</sup></td> <td>4 mg/kg IV once daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alternative agents</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Short-acting alternative agents with parenteral or oral dosing</strong></td> </tr> <tr> <td class=\"indent2\">Linezolid</td> <td>600 mg IV (or orally) twice daily</td> </tr> <tr> <td class=\"indent2\">Tedizolid</td> <td>200 mg IV (or orally) once daily</td> </tr> <tr> <td class=\"indent2\">Delafloxacin</td> <td>300 mg IV twice daily or 450 mg orally twice daily</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Short-acting alternative agents with parenteral dosing</strong><sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Ceftaroline</td> <td>600 mg IV every 12 hours</td> </tr> <tr> <td class=\"indent2\">Telavancin</td> <td>10 mg/kg once daily</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Long-acting alternative agents with parenteral dosing</strong></td> </tr> <tr> <td class=\"indent2\">Dalbavancin</td> <td> <p>Single-dose regimen: 1500 mg once</p> Two-dose regimen: Initial dose 1000 mg, followed by 500 mg dose one week later</td> </tr> <tr> <td class=\"indent2\">Oritavancin</td> <td>1200 mg IV as a single dose</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* In areas outside the United States where teicoplanin is available, some use it as the drug of choice for initial therapy of gram-positive pathogens, while others favor its use for patients with intolerance to vancomycin.<br />&para; Dosing of daptomycin for treatment of skin and soft tissue infection is 4 mg/kg IV once daily; dosing for treatment bacteremia is at least 6 mg/kg IV once daily. (Refer to the UpToDate topic on treatment of MRSA bacteremia for further discussion.)<br />&Delta; Ceftobiprole has broad-spectrum activity against gram-positive and gram-negative organisms and is available in some countries outside the United States.</div><div class=\"graphic_reference\">Data from: Lui C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.</div><div id=\"graphicVersion\">Graphic 110072 Version 5.0</div></div></div>"},"110077":{"type":"graphic_table","displayName":"Hep A vaccine administration","title":"Hepatitis A vaccination: Dosing and schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hepatitis A vaccination: Dosing and schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vaccine</td> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Two-dose schedule (months)*</td> </tr> <tr> <td>HAVRIX<sup>&#182;</sup></td> <td class=\"centered\">1 to 18</td> <td class=\"centered\">720 (EL.U)</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0, 6 to 12</td> </tr> <tr> <td>HAVRIX<sup>&#182;</sup></td> <td class=\"centered\">&#62;18</td> <td class=\"centered\">1440 (EL.U)</td> <td class=\"centered\">1.0</td> <td class=\"centered\">0, 6 to 12</td> </tr> <tr> <td>VAQTA<sup>&#916;</sup></td> <td class=\"centered\">1 to 18</td> <td class=\"centered\">25 (U)</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0, 6 to 18</td> </tr> <tr> <td>VAQTA<sup>&#916;</sup></td> <td class=\"centered\">&#62;18</td> <td class=\"centered\">50 (U)</td> <td class=\"centered\">1.0</td> <td class=\"centered\">0, 6 to 18</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EL.U: enzyme-linked immunosorbent assay (ELISA) units; U: units.<br />* 0 months represents timing of the initial dose; subsequent numbers represent months after the initial dose.<br />¶ HAVRIX is an inactivated hepatitis A vaccine; it is also licensed for a 3-dose series in children aged 2 to 18 years, with 360 EL.U, 0.5 mL doses at 0, 1, and 6 to 12 months.<br />Δ VAQTA is an inactivated hepatitis A vaccine.</div><div class=\"graphic_reference\">Reproduced from: Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 110077 Version 2.0</div></div></div>"},"110080":{"type":"graphic_table","displayName":"Basic monitoring during anesthesia","title":"Basic monitoring during anesthesia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic monitoring during anesthesia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Primary physiologic process/parameter targeted</td> <td class=\"subtitle1\">Monitoring equipment</td> <td class=\"subtitle1\">Principle</td> <td class=\"subtitle1\">Derived information</td> <td class=\"subtitle1\">Additional function</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Oxygenation</strong></td> <td>Inspired gas O<sub>2</sub> content</td> <td>O<sub>2</sub> analyzer (with a low-limit alarm in use)</td> <td>Paramagnetic sensor, fuel (galvanic) cell, polarographic (Clark) electrode, mass spectroscopy, or Raman scattering</td> <td>Inspired/expired O<sub>2</sub> concentration when placed downstream from fresh flow control valves</td> <td>A low-level alarm is automatically activated by turning on the anesthesia machine</td> </tr> <tr class=\"divider_bottom\"> <td>Blood oxygenation</td> <td>Pulse oximeter</td> <td>The Beer-Lambert law applied to tissues and pulsatile blood flow. The relative absorbency at wavelengths of 660 and 940 nm is used to estimate saturation, which is derived from the ratio of oxyhemoglobin to the sum of oxyhemoglobin plus deoxyhemoglobin.</td> <td>Hemoglobin saturation, pulse rate, relative pulse amplitude displayed on plethysmography waveform</td> <td>Continuous evaluation of circulation, variable pitch pulse tone, and audible low-threshold alarm</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Ventilation</strong></td> <td>&nbsp;Exhaled CO<sub>2</sub></td> <td>Capnograph</td> <td>CO<sub>2</sub> molecules absorb infrared radiation at 4.26 micrometers, proportionate to the CO<sub>2</sub> concentration present in the breath sample</td> <td>ETCO<sub>2</sub>, inspired CO<sub>2</sub>, diagnostic waveforms, respiratory rate, apnea detection</td> <td>Instantaneous information about: <ul> <li>Perfusion (how effectively CO<sub>2</sub> is being transported through the vascular system) </li> <li>Metabolism (how effectively CO<sub>2</sub> is being produced by cellular metabolism) </li> <li>Confirmation of tracheal tube placement after intubation </li> </ul> </td> </tr> <tr> <td>Integrity of ventilation system during mechanical ventilation</td> <td>Disconnection alarm</td> <td>Detects the cyclical changes in airway pressure in the normal range</td> <td>Alarms if a significant&nbsp;decrease in rate or pressure occurs</td> <td>Alarms if high pressures are sensed</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary mechanics (volume, flow, pressure)</td> <td>Pulmonary flow and pressure sensors</td> <td>Volume of gas proportional to a drum movement, changes in differential pressure (near the Y-connector) or in electrical resistance (hot wire housed in a monitor or ventilator)</td> <td>Inspired and expired volume, flow, and airway pressure</td> <td>Pressure volume and flow volume loops</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Circulation</strong></td> <td>Cardiac activity</td> <td>ECG</td> <td>The ECG monitor detects, amplifies, displays, and records the ECG signal.</td> <td>Heart rate and rhythm</td> <td>ST segment depression/elevation and trend over time, with an audible alarm warning of significant arrhythmias or asystole</td> </tr> <tr class=\"divider_bottom\"> <td>Arterial BP</td> <td>Noninvasive BP monitor</td> <td>Oscillometric devices automatically inflate and deflate the cuff, and have electronic pressure sensors that record the pressure oscillations of the arteries. The pressure at which maximal oscillations occur as the cuff is deflated corresponds with MAP. Proprietary algorithms are used to calculate systolic and diastolic BP.</td> <td>Arterial BP</td> <td>Indicator of organ perfusion</td> </tr> <tr> <td><strong>Temperature</strong></td> <td>&nbsp;</td> <td>Temperature monitor</td> <td>Devices with a semiconductor, electrical resistance decreases as temperature decreases</td> <td>Core or peripheral temperature</td> <td>A greater than 2&#176;C core-to-periphery temperature gradient is indicative of low cardiac output.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">O<SUB>2</SUB>: oxygen; CO<SUB>2</SUB>: carbon dioxide; ETCO<SUB>2</SUB>: end-tidal carbon dioxide; ETT: endotracheal tube; ECG: electrocardiogram; BP: blood pressure; MAP: mean arterial pressure</div><div id=\"graphicVersion\">Graphic 110080 Version 2.0</div></div></div>"},"110083":{"type":"graphic_table","displayName":"Interpretation of CMV serology in early pregnancy","title":"Interpretation of CMV serology in early pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of CMV serology in early pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">CMV antibodies</td> <td class=\"subtitle1\">IgG avidity</td> <td class=\"subtitle1\">Interpretation</td> <td class=\"subtitle1\">Implications</td> </tr> <tr class=\"divider_bottom\"> <td>IgM&ndash; and IgG&ndash;</td> <td>Not applicable</td> <td>Uninfected or very early infection</td> <td>Counsel about behavioral measures to reduce risk of acquiring infection</td> </tr> <tr class=\"divider_bottom\"> <td>IgM+ and IgG&ndash;</td> <td>Not applicable</td> <td>May be false positive (90%) due to another virus, autoimmune disease, laboratory methods</td> <td>Repeat in two weeks</td> </tr> <tr class=\"divider_bottom\"> <td>IgM+ and IgG+</td> <td>Low</td> <td> <p>Recent infection</p> Seroconversion is diagnostic of primary infection</td> <td>Counsel about likelihood of fetal infection, possible sequelae, and options for prenatal diagnosis and management</td> </tr> <tr class=\"divider_bottom\"> <td>IgM+ and IgG+</td> <td>High</td> <td> <p>Past infection versus recurrent infection</p> A significant rise (at least double) in serial IgG titers suggests reactivation or reinfection</td> <td>Counsel about low risk of fetal infection,&nbsp;but&nbsp;possible sequelae if fetus is infected</td> </tr> <tr class=\"divider_bottom\"> <td>IgM&ndash; and IgG+</td> <td>High</td> <td> <p>Past infection</p> Absence of a significant rise in serial IgG titers suggests absence of reactivation or reinfection</td> <td> <p>Counsel about low risk of fetal infection and possible sequelae</p> No need for further testing</td> </tr> <tr> <td>IgM&ndash; and IgG+</td> <td>Low</td> <td>Unclear because all validation studies of avidity have been in the setting of true positive IgM</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; IgM: immunoglobulin M; IgG: immunoglobulin G.</div><div id=\"graphicVersion\">Graphic 110083 Version 1.0</div></div></div>"},"110084":{"type":"graphic_algorithm","displayName":"Potential outcomes of maternal CMV infection during pregnancy","title":"Potential outcomes of maternal CMV infection during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Potential outcomes of maternal CMV infection during pregnancy</div><div class=\"cntnt\"><img style=\"width:462px; height:406px;\" src=\"images/OBGYN/110084_Otcms_mtrnl_CMV_infctn_preg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus.<br />* Primary maternal CMV infection is defined as initial acquisition of virus during pregnancy. Seroconversion from negative to positive is diagnostic, if available. Primary infection is strongly suspected if immunoglobulin M (IgM) and immunoglobulin G (IgG)&nbsp;are positive and IgG has low avidity.<br />¶ Nonprimary maternal CMV infection refers to women&nbsp;whose initial acquisition of CMV virus occurred before pregnancy.&nbsp;It is characterized by presence of maternal anti-CMV antibodies before conception. Like other herpes viruses, CMV establishes latency after the host is initially infected. Women with nonprimary infection may have reactivation of latent virus or reinfection with a new strain during pregnancy.<br />Δ Symptomatic disease at birth and severe sequelae occur almost exclusively among offspring of women who seroconvert in the first half of pregnancy, particularly the first trimester. In one review, there were no symptomatic newborns among 92 pregnancies with third-trimester maternal infection. In another study, there were no symptomatic newborns among women who seroconverted in the periconception period.</div><div id=\"graphicVersion\">Graphic 110084 Version 1.0</div></div></div>"},"110090":{"type":"graphic_algorithm","displayName":"Treatment algorithm for low anterior resection syndrome (LARS)","title":"Treatment algorithm for low anterior resection syndrome (LARS)","html":"<div class=\"graphic\"><div style=\"width: 824px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for low anterior resection syndrome (LARS)</div><div class=\"cntnt\"><img style=\"width:804px; height:586px;\" src=\"images/SURG/110090_Treatment_algorithm_LARS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Symptoms suggestive of LARS include fecal incontinence or urgency, frequent or fragmented bowel movements, emptying difficulties, and increased intestinal gas.<br />¶ Treatments may be combined if patients have more than one symptom.<br />Δ Patients who have minor LARS on reassessment can be treated medically. Refer to the \"Minor LARS\" section for details.</div><div id=\"graphicVersion\">Graphic 110090 Version 1.0</div></div></div>"},"110094":{"type":"graphic_figure","displayName":"Pathogenesis HPS","title":"Pathogenesis and pathophysiology of hepatopulmonary syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathogenesis and pathophysiology of hepatopulmonary syndrome</div><div class=\"cntnt\"><img style=\"width:430px; height:786px;\" src=\"images/PULM/110094_Pathogenesis_HPS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathogenesis and pathophysiology of hepatopulmonary syndrome. Experimental HPS is induced by the technique of CBDL cirrhosis, which leads to pulmonary vasodilation, intravascular accumulation of activated macrophages and monocytes and angiogenesis. Pulmonary vasodilation is caused by NO production, following eNOS and iNOS activation<SUP>[1-5]</SUP> and CO production<SUP>[6,7]</SUP>. In CBDL lungs, ET-1 binding to its ET-1B receptor induces eNOS activation<SUP>[2,3]</SUP> while iNOS and HO activation occurs in intravascular monocytes/macrophages<SUP>[4-7]</SUP>. Activated monocytes and macrophages are recruited to the lungs because of bacterial translocation and endotoxaemia after CBDL<SUP>[4]</SUP>, in which CX3CL1/CX3CR1 signalling is responsible for correct monocyte/macrophage adherence to the pulmonary endothelium<SUP>[8]</SUP>. In addition, increased production of VEGF-A leads to endothelial cell survival and proliferation through angiogenic Akt/ERK signalling, when it binds to its VEGFR2 on pulmonary endothelial cells<SUP>[9,10]</SUP>. This combination of pulmonary vasodilation, angiogenesis, pulmonary capillary proliferation and formation of intrapulmonary arteriovenous shunts results in ventilation-diffusion mismatch, right-to-left shunting and diffusion restriction<SUP>[11]</SUP>, finally contributing to gas exchange disturbances with arterial hypoxaemia, which characterizes HPS.</div><div class=\"graphic_footnotes\">CBDL: common bile duct ligation; ET-1: endothelin-1; VEGF-A: vascular endothelial growth factor A; ET-1B receptor: endothelin-1 B receptor; VEGFR2: VEGF receptor 2; CX3CL1: chemokine fractalkine; TNFa: tumor necrosis factor a; eNOS: endothelial nitric oxide synthase; Akt: protein kinase B; ERK: extracellular signal-regulated kinase; iNOS: inducible nitric oxide synthase; HO: haem oxygenase; CX3CR1: chemokine fractalkine receptor; NO: nitric monoxide; CO: carbon monoxide; HPS: hepatopulmonary syndrome.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ling Y, Zhang J, Luo B, et al. The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology 2004; 39:1593.</LI>&#xD;&#xA;<LI>Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol 1999; 277:G944.</LI>&#xD;&#xA;<LI>Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003; 38:556.</LI>&#xD;&#xA;<LI>Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001; 164:879.</LI>&#xD;&#xA;<LI>Zhang XJ, Katsuta Y, Akimoto T, et al. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol 2003; 39:724.</LI>&#xD;&#xA;<LI>Arguedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 2005; 128:328.</LI>&#xD;&#xA;<LI>Zhang J, Ling Y, Luo B, et al. Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology 2003; 125:1441.</LI>&#xD;&#xA;<LI>Zhang J, Yang W, Luo B, et al. The role of CX(3)CL1/CX(3)CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome. J Hepatol 2012; 57:752.</LI>&#xD;&#xA;<LI>Coulon S, Heindryckx F, Geerts A, et al. Angiogenesis in chronic liver disease and its complications. Liver Int 2011; 31:146.</LI>&#xD;&#xA;<LI>Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res 2000; 86:4.</LI>&#xD;&#xA;<LI>Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24:861.</LI></OL>From: Raevens S, Geerts A, Van Steenkiste C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int 2015; 35:1646. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12791/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12791/abstract</A>. Copyright © 2015 John Wiley &amp; Sons A/S. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110094 Version 1.0</div></div></div>"},"110109":{"type":"graphic_table","displayName":"Common pregnancy-related impairments and possible accommodations","title":"Common pregnancy-related impairments and possible workplace accommodations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common pregnancy-related impairments and possible workplace accommodations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Limitation</td> <td class=\"subtitle1\">Reasonable accommodations*</td> </tr> <tr> <td>Back pain</td> <td>Prolonged or repetitive lifting, bending, or sitting</td> <td>Use of a heating pad, sitting instead of standing, lifting assistance or limitations, assistive equipment to lift, or modification of the duties of the job, such as temporary light duty</td> </tr> <tr> <td>Venous thrombosis</td> <td>Prolonged sedentary activity</td> <td>Modification of work station, breaks for exercise, private area in which to administer injections</td> </tr> <tr> <td>Carpal tunnel syndrome</td> <td>Repetitive tasks using hands</td> <td>Occasional breaks from manual tasks or typing, specialized programs that allow for dictation instead of typing, modification of work station to provide wrist support while typing</td> </tr> <tr> <td>Chronic migraines</td> <td>Exposure to bright lights or loud environments</td> <td>Change lighting in the work area, limit exposure to noise and fragrances, change schedule such as flexible schedule or telework</td> </tr> <tr> <td>Dependent edema</td> <td>Prolonged standing</td> <td>Stool or chair to sit on while working, more frequent rest breaks, modification of footwear requirements</td> </tr> <tr> <td>Dyspnea</td> <td>Ability to perform strenuous activities</td> <td>Stool or chair to sit on while working, more frequent rest breaks</td> </tr> <tr> <td>Fatigue</td> <td>Ability to perform strenuous activities or to work long hours</td> <td>Light duty to avoid strenuous activity, flexible or reduced hours, exemption from mandatory overtime, intermittent leave</td> </tr> <tr> <td>Gestational diabetes</td> <td>Ability to work prolonged periods without breaks and snacks</td> <td>Permission to take more frequent bathroom breaks, permission to eat small snacks, a private area for testing blood glucose, time off for medical appointments</td> </tr> <tr> <td>Hyperemesis gravidarum, nausea/vomiting</td> <td>Ability to work prolonged periods without bathroom breaks and snacks</td> <td>Permission to take more frequent bathroom breaks, permission to eat small snacks during work hours, modified schedules including working from home</td> </tr> <tr> <td>Hypertension</td> <td>Strenuous or prolonged physical activity</td> <td>Stool or chair for employee to sit on while working, limit lifting and bending requirements, work from home while on bed rest</td> </tr> <tr> <td>Urinary tract infections</td> <td>Ability to work prolonged periods without drinking or using the restroom</td> <td>Water bottle at work station, more frequent bathroom breaks</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The appropriate accommodation in each case will vary depending upon the woman's condition and her job. Refer to: Job Accommodation Network, <a href=\"http://www.askjan.org/\" target=\"_blank\">www.askjan.org</a>.</div><div class=\"graphic_reference\">From: Jackson RA, Gardner S, Torres LN, et al. My obstetrician got me fired: How work notes can harm pregnant patients and what to do about it. Obstet Gynecol 2015; 126:250. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&amp;issue=08000&amp;article=00004&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0000000000000971</a>. Copyright &copy; 2015 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110109 Version 1.0</div></div></div>"},"110110":{"type":"graphic_table","displayName":"Common patient requests for workplace restrictions","title":"Common patient requests for workplace restrictions and potential employment implications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common patient requests for workplace restrictions and potential employment implications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient request for work restriction</td> <td class=\"subtitle1\">Language used in note</td> <td class=\"subtitle1\">Implications of this type of note on employment</td> <td class=\"subtitle1\">How to improve note</td> </tr> <tr class=\"divider_bottom\"> <td>\"Can I have a note that states I don't have to lift and bend at work?\"</td> <td>\"Ms. C should not lift more than 10 lbs or perform activities that require bending.\"</td> <td>If lifting more than 10 lbs or bending are essential functions of her job, there may be no reasonable accommodation that her employer can provide. She may be required to take leave starting immediately. Once her family leave is exhausted, she must return to work or show that she has a disability requiring accommodation such as finite medical leave. If not, she can be terminated.</td> <td>Lifting is not generally contraindicated in pregnancy. However, if Ms. C has back pain or pregnancy is exacerbating a back injury, accommodations may be appropriate: \"Ms. C can continue to perform most functions of her job while pregnant. She has a pregnancy-related back condition that requires her to limit lifting to no more than 20 pounds twice per hour.\"</td> </tr> <tr class=\"divider_bottom\"> <td>\"I need to go on leave because I can't check my sugars at work.\"</td> <td>\"Ms. A needs to be able to check her blood glucose at work.\"</td> <td>This note lacks reference to the patient's medical condition (GDM) and needs to be more specific.</td> <td>Explain the implications of going on leave early in pregnancy to the patient, and suggest that accommodations will likely allow her to continue working: \"Ms. A has a pregnancy-related condition called gestational diabetes that requires her to monitor her blood glucose level with a simple test and to eat small snacks every two to three hours. She will need a private space in which to check her glucose.\"</td> </tr> <tr class=\"divider_bottom\"> <td>\"My work is too stressful, and I'm worried it is harming my pregnancy.\"</td> <td>\"Ms. B needs to be kept in a stress-free environment during this pregnancy.\"</td> <td>Working in a stress-filled environment may be an essential function of her job (eg, she may be an attorney, a customer service representative, or clinician). Further, removing stress is not a \"reasonable\" accommodation. Finally, no pregnancy-related impairment has been identified.</td> <td>Given that there is no pregnancy-related impairment, it is not recommended to request accommodations. If, however, a mental health diagnosis exists, accommodations can be requested.</td> </tr> <tr> <td>\"I'm too tired to work full-time.\"</td> <td>\"Ms. D must have reduced work hours during this pregnancy.\"</td> <td>While some employers may be able to offer part-time work, others will count this toward her leave thereby reducing the total leave available for delivery and post-partum. Intermittent leave may be a reasonable accommodation under the ADA.</td> <td>Confirm fatigue is severe enough to significantly limit a major life activity. Modest modifications may be sufficient: \"Ms. D has clinically significant fatigue related to her pregnancy. She can continue to work with &#62;50% of her time at work spent seated and 15-minute breaks every 4 hours.\"</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADA: Americans with Disabilities Act.</div><div class=\"graphic_reference\">From: Jackson RA, Gardner S, Torres LN, et al. My obstetrician got me fired: How work notes can harm pregnant patients and what to do about it. Obstet Gynecol 2015; 126:250. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&amp;issue=08000&amp;article=00004&amp;type=abstract\" target=\"_blank\">10.1097/AOG.0000000000000971</a>. Copyright &copy; 2015 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110110 Version 1.0</div></div></div>"},"110111":{"type":"graphic_picture","displayName":"Bilateral vocal fold cysts","title":"Bilateral vocal fold cysts","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Bilateral vocal fold cysts</div><div class=\"cntnt\"><img style=\"width:756px; height:612px;\" src=\"images/PEDS/110111_Bilateral_vocal_fold_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laryngoscopic image of a 15-year-old male singer with long-standing raspiness and acute loss of voice. There is fibrous thickening of the submucosa and fusiform fullness of the mid-vocal folds (thick arrow) with poor anterior closure (arrow) consistent with submucosal cyst/fibrosis.</div><div id=\"graphicVersion\">Graphic 110111 Version 1.0</div></div></div>"},"110112":{"type":"graphic_form","displayName":"Sample work modification letter for pregnant employees","title":"Sample work modification letter for pregnant employees","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Sample work modification letter for pregnant employees</div><div class=\"cntnt\"><img style=\"width:614px; height:794px;\" src=\"images/OBGYN/110112_Smpl_wrk_mod_lettr_pregnant.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Jackson RA, Gardner S, Torres LN, et al. My obstetrician got me fired: How work notes can harm pregnant patients and what to do about it. Obstet Gynecol 2015; 126:250. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2015&amp;issue=08000&amp;article=00004&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000000971</A>. Copyright © 2015 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110112 Version 1.0</div></div></div>"},"110113":{"type":"graphic_picture","displayName":"Vocal fold nodules in a child","title":"Vocal fold nodules","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Vocal fold nodules</div><div class=\"cntnt\"><img style=\"width:706px; height:486px;\" src=\"images/PEDS/110113_Vocal-fold-nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laryngoscopic image of a patient with chronic hoarseness. Bilateral superficial nodular changes are seen on the inferior lip of the mid-vocal folds (arrows). A normal mucosal wave was seen on stroboscopy. The patient responded to voice therapy.</div><div id=\"graphicVersion\">Graphic 110113 Version 1.0</div></div></div>"},"110114":{"type":"graphic_picture","displayName":"Vocal fold polyp","title":"Vocal fold polyp","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Vocal fold polyp</div><div class=\"cntnt\"><img style=\"width:754px; height:606px;\" src=\"images/PEDS/110114_Vocal_fold_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laryngoscopic image of a 14-year-old girl with chronic dysphonia that worsened after yelling. There is an organized submucosal polyp on the right mid-vocal fold (arrow) with very little change on the contralateral (left) vocal fold.</div><div id=\"graphicVersion\">Graphic 110114 Version 1.0</div></div></div>"},"110115":{"type":"graphic_table","displayName":"Selected note-writing instructions for work accommodations","title":"Selected note-writing instructions for work accommodations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected note-writing instructions for work accommodations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Guideline</td> <td class=\"subtitle1\">Model note language</td> <td class=\"subtitle1\">To avoid</td> </tr> <tr class=\"divider_bottom\"> <td>State patient is pregnant and needs an accommodation.</td> <td>\"Patient is affected by pregnancy, childbirth, or lactation (whichever relevant) and requires an accommodation.\"</td> <td>It is the patient's decision if she does not want to reveal her pregnancy, but she may be less likely to receive an accommodation.</td> </tr> <tr class=\"divider_bottom\"> <td>Identify patient's pregnancy-related medical conditions (eg, severe back pain, gestational diabetes, etc), if any.</td> <td>Depends on the state. In some states, disclosure of specific medical condition is not required. In some states, identifying specific condition and other medical details may be necessary to receive an accommodation. Visit www.pregnantatwork.org/healthcare-professionals/ for state-by-state guidelines.</td> <td>If guidelines at www.pregnantatwork.org/healthcare-professionals/ say that the disclosure of medical condition is not necessary in your state, maintain your patient's privacy.</td> </tr> <tr class=\"divider_bottom\"> <td>Specifically and precisely identify work limitations that are recommended medically.</td> <td>Patient \"is unable to stand for more than one hour without 15 minutes of sitting,\" \"may not climb ladders,\" or \"must take 15-minute breaks every three hours to eat a snack.\"</td> <td>Avoid vague statements, such as \"needs light duty\" or \"no physical activity.\" Also avoid imposing restrictions that are not medically indicated, because the patient could be sent out on unpaid leave or terminated if accommodation is not possible.</td> </tr> <tr class=\"divider_bottom\"> <td>Affirmatively state that the patient can continue working.</td> <td>\"Patient is able to continue working with a reasonable accommodation.\"</td> <td>This does not apply in situations in which the patient requires leave, for example to recover after cesarean delivery.</td> </tr> <tr class=\"divider_bottom\"> <td>Recommend reasonable accommodations based on your knowledge of the workplace.</td> <td>\"I recommend that my patient be given a stool to sit on while checking out customers at the cash register.\"</td> <td>Avoid recommending specific accommodations without talking to your patient about what is possible in her workplace.</td> </tr> <tr> <td>State expected duration of the accommodation.</td> <td>\"Patient's medical limitation and need for accommodation began on [DATE]. I anticipate the patient will need an accommodation until [DATE].\"</td> <td>Do not fail to include end date just because end date is uncertain. It can be changed in the future if necessary.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Karkowsky CE, Morris L. Pregnant at work: Time for prenatal care providers to act. Am J Obstet Gynecol 2016; 215:306.e1. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110115 Version 1.0</div></div></div>"},"110129":{"type":"graphic_algorithm","displayName":"Approach to initial management of adult with abdominal gunshot","title":"Approach to initial management of the adult with abdominal gunshot","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Approach to initial management of the adult with abdominal gunshot</div><div class=\"cntnt\"><img style=\"width:652px; height:482px;\" src=\"images/EM/110129_Init_mgmt_adult_ab_gunshot.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography.<br />* FAST exam can identify intraperitoneal blood. Plain radiographs can help to determine trajectory. However, neither study can determine definitively whether peritoneal penetration occurred.</div><div id=\"graphicVersion\">Graphic 110129 Version 1.0</div></div></div>"},"110159":{"type":"graphic_table","displayName":"Estimated caloric needs of nonpregnant women PI","title":"Estimated caloric needs of women who are not pregnant or breastfeeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated caloric needs of women who are not pregnant or breastfeeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age<br /> (years)</td> <td class=\"subtitle1\">Sedentary*<br /> (calories/day)</td> <td class=\"subtitle1\">Moderately active<sup>&#182;</sup><br /> (calories/day)</td> <td class=\"subtitle1\">Active<sup>&#916;</sup><br /> (calories/day)</td> </tr> <tr class=\"centered\"> <td>15 to 18</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"centered\"> <td>19 to 25</td> <td>2000</td> <td>2200</td> <td>2400</td> </tr> <tr class=\"centered\"> <td>26 to 30</td> <td>1800</td> <td>2000</td> <td>2400</td> </tr> <tr class=\"centered\"> <td>31 to 50</td> <td>1800</td> <td>2000</td> <td>2200</td> </tr> <tr class=\"centered\"> <td>51 to 55</td> <td>1600</td> <td>1800</td> <td>2200</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These estimates are based on the Estimated Energy Requirements (EER) equations, using reference heights (average) and reference weights (healthy) for each age group. These estimates apply to women who are not pregnant or breastfeeding.</div><div class=\"graphic_footnotes\">* Sedentary means a lifestyle that includes only the physical activity of independent living.<br />&para; Moderately active means a lifestyle that includes physical activity equivalent to walking about 1.5 to 3 miles per day at three to four miles per hour, in addition to the activities of independent living.<br />&Delta; Active means a lifestyle that includes physical activity equivalent to walking more than three miles per day at three to four miles per hour, in addition to the activities of independent living.</div><div class=\"graphic_reference\">Data from: US Department of Health and Human Services and US Department of Agriculture. 2015&ndash;2020 Dietary Guidelines for Americans, 8th Edition, December 2015. Available at: <a href=\"http://health.gov/dietaryguidelines/2015/guidelines/\" target=\"_blank\">http://health.gov/dietaryguidelines/2015/guidelines/</a> (Accessed on June 28, 2016).</div><div id=\"graphicVersion\">Graphic 110159 Version 1.0</div></div></div>"},"110161":{"type":"graphic_picture","displayName":"Lg cell neuroendocrine CA prostate","title":"Large cell neuroendocrine carcinoma of the prostate","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Large cell neuroendocrine carcinoma of the prostate</div><div class=\"cntnt\"><img style=\"width:508px; height:764px;\" src=\"images/ONC/110161_Lg_neuroendocrine_CA_prstt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Large cell (neuroendocrine) carcinoma is characterized by the large tumor cells with salt-pepper chromatin, forming a large nest with peripheral palisading. (B) Another case of large cell (neuroendocrine) carcinoma of the prostate metastatic to an axillary lymph node, showing similar neuroendocrine features, numerous mitotic figures, and apoptotic bodies. Both cases are positive for neuroendocrine markers by immunohistochemistry (not shown).</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 110161 Version 1.0</div></div></div>"},"110162":{"type":"graphic_figure","displayName":"pH of cleaning products","title":"Approximate pH of selected cleaning products and other substances","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Approximate pH of selected cleaning products and other substances</div><div class=\"cntnt\"><img style=\"width:484px; height:956px;\" src=\"images/PEDS/110162_pH_cleaning_products.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>All pH values are approximates</LI>&#xD;&#xA;<LI>Solvents do not have a pH because they do not ionize in aqueous solution</LI>&#xD;&#xA;<LI>pH does not measure the corrosiveness of an acid (ie, hydrochloric acid with a pH of 1 is stronger than phosphoric acid with a pH of 1)</LI></UL></div><div class=\"graphic_footnotes\">* Hair relaxers may be made with lye (pH typically 12 to 14), or without lye (pH typically 9 to 11).</div><div class=\"graphic_reference\">Adapted with permission from: Unisource Canada, Inc. pH Scale. Copyright © 2016 Veritiv Canada, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110162 Version 2.0</div></div></div>"},"110163":{"type":"graphic_figure","displayName":"Articulating high-definition videoscope","title":"Articulating high-definition videoscope","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Articulating high-definition videoscope</div><div class=\"cntnt\"><img style=\"width:754px; height:602px;\" src=\"images/SURG/110163_Flex_cam.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image courtesy of Olympus America Inc. Copyright © 2016. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110163 Version 2.0</div></div></div>"},"110164":{"type":"graphic_picture","displayName":"Setup for robotic lung surgery","title":"Setup for robotic lung surgery","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Setup for robotic lung surgery</div><div class=\"cntnt\"><img style=\"width:756px; height:724px;\" src=\"images/SURG/110164_Setup_robotic_lung_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Intuitive Surgical Robot is shown in the picture with the surgeon determining the movements of the slave robotic arms within the patient by moving his hands in the master controls of the console.</div><div class=\"graphic_reference\">© 2017 Intuitive Surgical, Inc. Used with permission.</div><div id=\"graphicVersion\">Graphic 110164 Version 1.0</div></div></div>"},"110165":{"type":"graphic_table","displayName":"Comparison of VATS with RATS","title":"Comparison of VATS with RATS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of VATS with RATS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">VATS</td> <td class=\"subtitle1\">RATS</td> </tr> <tr> <td>Accessibility of equipment, competitive vendors, flexibility of systems</td> <td class=\"centered\">+++</td> <td class=\"centered\">+</td> </tr> <tr> <td>Expense</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Ergonomics</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">++</td> </tr> <tr> <td>Use of carbon dioxide</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">++</td> </tr> <tr> <td>Ability to reduce the number of port sites (ie, multiple instruments at a single site)</td> <td class=\"centered\">+++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Movement scaling and tremor reduction</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Ease of conversion to open surgery</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td>Availability of 3D optics</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Capability in confined space</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> </tr> <tr> <td>Replication of open instrument function</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">++</td> </tr> <tr> <td>Skilled assistant needed</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">&ndash;: Not available.<br />+/&ndash;: Variable.<br />+: Limited.<br />++: Moderate.<br />+++: High.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery; RATS: robotic-assisted thoracoscopic surgery; 3D: three-dimensional.</div><div id=\"graphicVersion\">Graphic 110165 Version 1.0</div></div></div>"},"110166":{"type":"graphic_figure","displayName":"Operating rooms setup VATS","title":"Operating rooms setup VATS","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Operating rooms setup VATS</div><div class=\"cntnt\"><img style=\"width:521px; height:715px;\" src=\"images/SURG/110166_Operating_room_setup_VATS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates a common operating room setup for video-assisted thoracoscopy. The anesthesiologist is at the patient's head. The surgeon stands&nbsp;on the right or left side of the patient&nbsp;depending upon the procedure being performed. The first assistant stands opposite the surgeon. Video monitors are available on each side to provide a direct view&nbsp;for&nbsp;the surgeon, assistant(s), anesthesiologist, and surgical technician without the need for twisting. </div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery. </div><div class=\"graphic_reference\">Modified from: Demmy TL. Overview and general considerations for video-assisted thoracic surgery. In: Video-Assisted Thoracic Surgery (VATS), Demmy TL (Ed), Georgetown, TX: Landes Bioscience, 2001.</div><div id=\"graphicVersion\">Graphic 110166 Version 1.0</div></div></div>"},"110167":{"type":"graphic_figure","displayName":"3D laparoscope","title":"3D laparoscope","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">3D laparoscope</div><div class=\"cntnt\"><img style=\"width:784px; height:422px;\" src=\"images/SURG/110167_3D_laparoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Tip configuration of thoracoscope with three-dimensional video optics. <br />(B) Diagram demonstrating optical sizes needed to reproduce human three-dimensional perception for endoscopic procedures. </div><div class=\"graphic_reference\">(A) Surgical Endoscopy, The effect of a second-generation 3D endoscope on the laparoscopic precision of novices and experienced surgeons, Vol. 13, 1999, p. 1087, Taffinder N, Smith SG, Huber J, © Springer-Verlag New York Inc. 1999, with permission of Springer.<br />(B) Image Courtesy of Olympus America Inc.</div><div id=\"graphicVersion\">Graphic 110167 Version 1.0</div></div></div>"},"110168":{"type":"graphic_picture","displayName":"Thoracoscopic view of pleural metastases","title":"Thoracoscopic view of pleural metastases","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic view of pleural metastases</div><div class=\"cntnt\"><img style=\"width:756px; height:595px;\" src=\"images/SURG/110168_Thoracscpc_plrl_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left thoracoscopic view of multiple berry-like intrapleural metastases (arrows) from renal cell carcinoma.</div><div id=\"graphicVersion\">Graphic 110168 Version 1.0</div></div></div>"},"110170":{"type":"graphic_picture","displayName":"Thoracoscopic view of esophageal diverticulum","title":"Thoracoscopic view of esophageal diverticulum","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic view of esophageal diverticulum</div><div class=\"cntnt\"><img style=\"width:619px; height:497px;\" src=\"images/SURG/110170_Thrcscpcstplngesphgldvrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left thoracoscopic view of the distal esophagus with an epiphrenic diverticulum. Once the diverticulum was resected, a long myotomy was performed to prevent recurrence.</div><div id=\"graphicVersion\">Graphic 110170 Version 2.0</div></div></div>"},"110171":{"type":"graphic_picture","displayName":"Thoracoscopic myotomy for achalasia","title":"Thoracoscopic myotomy for achalasia","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic myotomy for achalasia</div><div class=\"cntnt\"><img style=\"width:551px; height:443px;\" src=\"images/SURG/110171_Thoracscpc_myotmy_achalasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this left thoracoscopic view, the arrow shows the direction of the patient's head. The appearance of the distal esophagus is shown following myotomy for dysmotility.</div><div class=\"graphic_footnotes\">P: pericardium; M: mucosa that has been stripped (the divided esophageal muscle is seen to either side); S: spine; D: diaphragm.</div><div id=\"graphicVersion\">Graphic 110171 Version 1.0</div></div></div>"},"110172":{"type":"graphic_figure","displayName":"Thoracoscopic resection esophageal tumor","title":"Thoracoscopic resection esophageal tumor","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic resection esophageal tumor</div><div class=\"cntnt\"><img style=\"width:764px; height:555px;\" src=\"images/SURG/110172_Thorocscpc_rsctn_esphgl_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Barium swallow showing a large obstructing esophageal tumor (arrow).<br />(B) Retroflexed endoscopic view of a bulky esophageal cancer invading the gastric cardia, which required induction therapy prior to esophageal resection.<br />(C) Thoracic dissection portion of minimally invasive esophagectomy. The esophagus, which contains a large residual tumor following chemoradiotherapy, is encircled by the white drain.</div><div id=\"graphicVersion\">Graphic 110172 Version 1.0</div></div></div>"},"110173":{"type":"graphic_movie","displayName":"Minimally invasive esophagectomy","title":"Minimally invasive esophagectomy","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Minimally invasive esophagectomy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/110173_Mininvsesophagectomyvid.mp4\" style=\"width:480px;height:384px\"></div><img style=\"width:504px; height:378px;\" src=\"images/SURG/110173_Mininvsesophagectomyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The video illustrates the major steps of minimally invasive esophagectomy with anastomosis in the chest. The procedure is started with a laparoscopic approach to divide the esophagus distally and create the gastric tube for subsequent reconstruction, followed by a thoracosopic approach to remove the tumor and perform the esophagogastric anastomosis.</div><div id=\"graphicVersion\">Graphic 110173 Version 1.0</div></div></div>"},"110174":{"type":"graphic_movie","displayName":"Thoracoscopic esophageal leiomyomectomy","title":"Thoracoscopic esophageal leiomyomectomy","html":"<div class=\"graphic normal\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic esophageal leiomyomectomy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/110174_Thoracscpcesophleiomyvid.mp4\" style=\"width:576px;height:400px\"></div><img style=\"width:444px; height:453px;\" src=\"images/SURG/110174_Thoracscpcesophleiomyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presented here is a 36-year-old woman who presented with three months of upper abdominal discomfort. A chest radiograph showed a retrocardiac mass. The video shows the initial endoscopic and radiologic evaluation of the submucosal tumor, followed by thoracoscopic enucleation, assessment, and confirmation of the integrity of the esophageal mucosa after tumor removal, and closure of the overlying esophageal muscle layers. In the video, the illustration to the left shows the positioning of the camera and instruments through the chest wall.</div><div class=\"graphic_reference\">Reproduced with permission from Roswell Park Cancer Institute. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110174 Version 1.0</div></div></div>"},"110175":{"type":"graphic_figure","displayName":"Thoracoscopic Nuss procedure","title":"Thoracoscopic Nuss procedure","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic Nuss procedure</div><div class=\"cntnt\"><img style=\"width:534px; height:391px;\" src=\"images/SURG/110175_Thoracoscopic_Nuss_procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figures show the initial insertion (A) and inversion (B) of a Nuss bar for the treatment of pectus excavatum using a minimally invasive approach (C). The radiograph (D) shows the appearance of the bar.</div><div class=\"graphic_reference\">Panels C and D: Courtesy of Igor Brichkov, MD.</div><div id=\"graphicVersion\">Graphic 110175 Version 1.0</div></div></div>"},"110176":{"type":"graphic_figure","displayName":"Thoracoscopes","title":"Thoracoscopes","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Thoracoscopes</div><div class=\"cntnt\"><img style=\"width:754px; height:525px;\" src=\"images/SURG/110176_Thoracoscopes.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Precision Optics Corporation. Available from: <A href=\"http://www.poci.com/endoscopes-couplers/laparoscopes.php\" target=_blank>http://www.poci.com/endoscopes-couplers/laparoscopes.php</A> (Accessed on October 31, 2016).</div><div id=\"graphicVersion\">Graphic 110176 Version 1.0</div></div></div>"},"110177":{"type":"graphic_movie","displayName":"Two-instrument control","title":"Two-instrument control","html":"<div class=\"graphic normal\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Two-instrument control</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/110177_Twoinstrumentcontrolvid.mp4\" style=\"width:688px;height:368px\"></div><img style=\"width:665px; height:347px;\" src=\"images/SURG/110177_Twoinstrumentcontrolimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The video shows the thoracoscopic view of two narrow-profile thoracoscopic instruments being used through a single 15-mm incision. In the video, the figure to the left shows the position of the instruments from the outside of the chest.</div><div class=\"graphic_reference\">Reproduced with permission from Roswell Park Cancer Institute. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110177 Version 1.0</div></div></div>"},"110178":{"type":"graphic_picture","displayName":"Thoracoscopic instruments","title":"Thoracoscopic instruments","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic instruments</div><div class=\"cntnt\"><img style=\"width:756px; height:502px;\" src=\"images/SURG/110178_Thoracoscopic_instruments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure shows narrow-profile instrumentation specifically designed for minimally invasive cardiothoracic surgery.</div><div id=\"graphicVersion\">Graphic 110178 Version 1.0</div></div></div>"},"110179":{"type":"graphic_figure","displayName":"Thoracoscopic trocars","title":"Thoracoscopic trocars","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic trocars</div><div class=\"cntnt\"><img style=\"width:766px; height:645px;\" src=\"images/SURG/110179_Thoracoscopic_trocars.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures above show assorted trocars used in video-assisted thoracoscopic surgery.</div><div class=\"graphic_reference\">​Panel A: Copyright © 2016 Sontec Instruments. Reproduced with permission.<br />Panel B: Copyright © 2016 CONMED. Reproduced with permission.<br />Panel C: © Ethicon, Inc. (2016). Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 110179 Version 1.0</div></div></div>"},"110180":{"type":"graphic_figure","displayName":"Thoracoscopic staplers","title":"Thoracoscopic staplers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic staplers</div><div class=\"cntnt\"><img style=\"width:445px; height:730px;\" src=\"images/SURG/110180_Thoracoscopicstaplers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figures show thoracoscopic stapling devices in various sizes and configurations (curved, straight). <br />(A) Grey reload: Extra-thin/vascular tissue.<br />(B) Tan reload: Vascular/medium tissue.<br />(C) Purple reload: Medium/thick tissue.<br />(D) Black reload: Extra-thick tissue.</div><div class=\"graphic_reference\">All rights reserved. Used with the permission of Medtronic.</div><div id=\"graphicVersion\">Graphic 110180 Version 1.0</div></div></div>"},"110181":{"type":"graphic_figure","displayName":"Approach to thoracoscopic port placement","title":"Approach to thoracoscopic port placement","html":"<div class=\"graphic\"><div style=\"width: 813px\" class=\"figure\"><div class=\"ttl\">Approach to thoracoscopic port placement</div><div class=\"cntnt\"><img style=\"width:793px; height:462px;\" src=\"images/SURG/110181_Apprchthrcscpcprtplcmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple approaches&nbsp;(two-port, three-port)&nbsp;are described for the placement of thoracoscopic port incisions.<SUP>[1-4]</SUP> An example of one three-port technique is illustrated. The \"dissection\" or \"access\" port is placed in the 4<SUP>th</SUP> or 5<SUP>th</SUP> intercostal space anteriorly since the intercostal spaces are wider in this area. The \"camera\" port is placed in the midaxillary line 8<SUP>th</SUP> intercostal space, and the \"retraction\" port is placed in-line with the major fissure lateral to the insertion of the diaphragm to the chest wall. The thoracoscope can be placed in any of the port sites for additional viewing angles.</div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>​Balsara KR, Balderson SS, D'Amico TA. Surgical techniques to avoid parenchymal injury during lung resection (fissureless lobectomy). Thorac Surg Clin 2010; 20:365. </LI>&#xD;&#xA;<LI>Demmy TL. Video-atlas of thoracoscopic formal lung resections emulating traditional open techniques. Ann Cardiothorac Surg 2012; 1:88. </LI>&#xD;&#xA;<LI>Fieira Costa E, Delgado Roel M, Paradela de la Morena M, et al. Technique of uniportal VATS major pulmonary resections. J Thorac Dis 2014; 6:S660. </LI>&#xD;&#xA;<LI>Sihoe AD. Uniportal video-assisted thoracic (VATS) lobectomy. Ann Cardiothorac Surg 2016; 5:133. </LI></OL></div><div id=\"graphicVersion\">Graphic 110181 Version 2.0</div></div></div>"},"110182":{"type":"graphic_figure","displayName":"Thoracoscope with working port","title":"Thoracoscope with working port","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Thoracoscope with working port</div><div class=\"cntnt\"><img style=\"width:585px; height:263px;\" src=\"images/SURG/110182_Thoracoscope_with_biopsy-aspiration_port.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture (A) shows a flexible thoracoscope with a working channel, which can be used for less complex minimally invasive thoracoscopic procedures, such as for&nbsp;pleural biopsy as shown in figure (B) or others (eg, talc pleurodesis).</div><div class=\"graphic_reference\">Panel A: Image courtesy of Olympus America Inc. Copyright © 2016. All rights reserved.<br />Panel B: Redrawn with permission from Olympus America Inc. Copyright © 2016. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110182 Version 1.0</div></div></div>"},"110183":{"type":"graphic_picture","displayName":"VATS view of thymoma","title":"VATS view of thymoma","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">VATS view of thymoma</div><div class=\"cntnt\"><img style=\"width:756px; height:566px;\" src=\"images/SURG/110183_VATS_view_thymoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right thoracoscopic view of asymptomatic anterior mediastinal masses (arrow)&nbsp;found to be early-stage thymomas.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery. </div><div id=\"graphicVersion\">Graphic 110183 Version 1.0</div></div></div>"},"110184":{"type":"graphic_figure","displayName":"VATS lung wedge resection","title":"VATS lung wedge resection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">VATS lung wedge resection</div><div class=\"cntnt\"><img style=\"width:540px; height:267px;\" src=\"images/SURG/110184_VATS_lung_wedge_resection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thoracoscopic view (A) shows wedge resection of the lung using a stapling device.&nbsp;The illustration (B) shows the positioning of the instruments,&nbsp;but&nbsp;note that the&nbsp;thoracoscope is out of the plane of view and is not seen.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery. </div><div class=\"graphic_reference\">Modified from: Demmy TL. Overview and general considerations for video-assisted thoracic surgery. In: Video-Assisted Thoracic Surgery (VATS), Demmy TL (Ed), Landes Bioscience, 2001.</div><div id=\"graphicVersion\">Graphic 110184 Version 1.0</div></div></div>"},"110185":{"type":"graphic_movie","displayName":"VATS lung nodule resection","title":"VATS lung nodule resection","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">VATS lung nodule resection</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/110185_VATSlungnoduleresectvid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:671px; height:384px;\" src=\"images/SURG/110185_VATSlungnoduleresectimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The video illustrates a thoracoscopic wedge resection of palpable lung nodule. The figure to the right of the video shows the instrument and camera orientation from the outside of the chest.</div><div class=\"graphic_reference\">Reproduced with permission from Roswell Park Cancer Institute. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110185 Version 1.0</div></div></div>"},"110186":{"type":"graphic_picture","displayName":"Thoracoscopic division vascular structures","title":"Thoracoscopic division vascular structures","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic division vascular structures</div><div class=\"cntnt\"><img style=\"width:766px; height:286px;\" src=\"images/SURG/110186_Thrcscpc_dvsn_vsclr_strctrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The major hilar structures of the right lung are shown.<br />(B) A linear endomechanical stapler is being used to divide one of the pulmonary veins.</div><div class=\"graphic_footnotes\">RUL: right upper lobe; RML: right middle lobe; PA: pulmonary artery.</div><div id=\"graphicVersion\">Graphic 110186 Version 1.0</div></div></div>"},"110187":{"type":"graphic_movie","displayName":"VATS lung resection 1","title":"VATS lung resection 1","html":"<div class=\"graphic normal\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">VATS lung resection 1</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/110187_VATSlungresection1vid.mp4\" style=\"width:510px;height:344px\"></div><img style=\"width:432px; height:333px;\" src=\"images/SURG/110187_VATSlungresection1img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The video shows the basic steps of a \"fissureless dissection\" for a left upper lobectomy. It demonstrates dissection and division of the left upper lobe pulmonary vein followed by the pulmonary artery branches. One of the smaller pulmonary artery branches is ligated with a noncutting Endo TA stapler proximally and a bipolar energy device distally. After bronchial division and dissection of lymph nodes, the fissure between the upper and lower lobes is the last tissue to be divided. The left upper lobe is placed into an endosac and removed.</div><div id=\"graphicVersion\">Graphic 110187 Version 1.0</div></div></div>"},"110188":{"type":"graphic_movie","displayName":"Minimally invasive pneumonectomy","title":"Minimally invasive pneumonectomy","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Minimally invasive pneumonectomy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/110188_Mininvspneumonectomyvid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:644px; height:331px;\" src=\"images/SURG/110188_Mininvspneumonectomyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The video illustrates the major steps of right thoracoscopic pneumonectomy, including division of the pulmonary veins, pulmonary artery, and right mainstem bronchus. In the video, the figure to the left shows the instrument and camera orientation from outside the chest.</div><div class=\"graphic_reference\">Reproduced with permission from Roswell Park Cancer Institute. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110188 Version 1.0</div></div></div>"},"110189":{"type":"graphic_picture","displayName":"VATS resection giant bullae","title":"VATS resection giant bullae","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">VATS resection giant bullae</div><div class=\"cntnt\"><img style=\"width:764px; height:569px;\" src=\"images/SURG/110189_VATS_resection_giant_bullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A to C) Initial views of distended bulla and adhesions to ribs.<br />(Panels D to F) Division of adhesions and isolation of bulla.<br />(Panels G to I) Opening of the bulla and inspection of internal parenchyma before oversewing and obliterating space with mechanical stapled sutures.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery.</div><div id=\"graphicVersion\">Graphic 110189 Version 1.0</div></div></div>"},"110190":{"type":"graphic_figure","displayName":"Minimally invasive thoracoscopic pericardial window","title":"Minimally invasive thoracoscopic pericardial window","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Minimally invasive thoracoscopic pericardial window</div><div class=\"cntnt\"><img style=\"width:533px; height:423px;\" src=\"images/SURG/110190_VATSpericardialwindow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates the port placement and approach for the&nbsp;left thoracoscopic pericardial window. </div><div class=\"graphic_reference\">de Hoyos A, Patel A, Santos RC, Landreneau RJ. Video-assisted thoracic surgery for mediastinal tumors and cysts and other diseases within the mediastinum. In: General Thoracic Surgery, 6th ed, Shields TW, LoCicero J, Ponn RB, Rusch VW (Eds),&nbsp;Lippincott Williams &amp; Wilkins, Philadelphia 2005. </div><div id=\"graphicVersion\">Graphic 110190 Version 2.0</div></div></div>"},"110191":{"type":"graphic_picture","displayName":"VATS diagnosis thoracic duct injury","title":"VATS diagnosis thoracic duct injury","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">VATS diagnosis thoracic duct injury</div><div class=\"cntnt\"><img style=\"width:756px; height:564px;\" src=\"images/SURG/110191_VATS_diag_thorcc_duct_injry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chylothorax diagnosed on thoracoscopy as milky fluid collecting in the dependent portion of the thoracic cavity.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery. </div><div id=\"graphicVersion\">Graphic 110191 Version 1.0</div></div></div>"},"110192":{"type":"graphic_picture","displayName":"Thoracoscopic sympathectomy","title":"Thoracoscopic sympathectomy","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic&nbsp;sympathectomy</div><div class=\"cntnt\"><img style=\"width:620px; height:927px;\" src=\"images/SURG/110192_VATS_sympathectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraoperative photographs before (A) and during (B) left sympathectomy. The arrows in panel A show the course of the intact left sympathetic chain. In panel B, the left sympathectomy is being performed using&nbsp;a thoracoscopic electrocautery hook.</div><div class=\"graphic_reference\">Courtesy of Igor Brichkov, MD.</div><div id=\"graphicVersion\">Graphic 110192 Version 1.0</div></div></div>"},"110197":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image TAPS","title":"Prenatal ultrasound image of the placenta in twin anemia-polycythemia sequence (TAPS)","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of the placenta in twin anemia-polycythemia sequence (TAPS)</div><div class=\"cntnt\"><img style=\"width:720px; height:652px;\" src=\"images/OBGYN/110197_Ultrasound_image_TAPS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of the placenta in twin anemia polycythemia sequence (TAPS). The donor placenta (TWIN A-D) appears thickened and hyperechogenic (dashed arrow), and the recipient placenta (TWIN B-R) appears thinner and hypoechoic (thin arrow). The demarcation between the two placental territories is easily seen (thick arrow).</div><div id=\"graphicVersion\">Graphic 110197 Version 1.0</div></div></div>"},"110199":{"type":"graphic_table","displayName":"Withholding meds prior to assessing bronchodilator reversibility","title":"Withholding medications prior to assessing bronchodilator reversibility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Withholding medications prior to assessing bronchodilator reversibility</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Minimum time to omit medication before spirometry*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inhaled beta-adrenergic agents</td> </tr> <tr> <td class=\"indent1\">Albuterol</td> <td>4 to 8 hours (or overnight)</td> </tr> <tr> <td class=\"indent1\">Metaproterenol</td> <td>4 to 8 hours</td> </tr> <tr> <td class=\"indent1\">Terbutaline</td> <td>8 hours</td> </tr> <tr> <td class=\"indent1\">Salmeterol</td> <td>12 hours</td> </tr> <tr> <td class=\"indent1\">Formoterol</td> <td>12 hours</td> </tr> <tr> <td class=\"indent1\">Indacaterol</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vilanterol</td> <td>24 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inhaled anticholinergic agents</td> </tr> <tr> <td class=\"indent1\">Ipratropium</td> <td>4 to 8 hours</td> </tr> <tr> <td class=\"indent1\">Aclidinium</td> <td>12 hours</td> </tr> <tr> <td class=\"indent1\">Glycopyrrolate</td> <td>24 hours</td> </tr> <tr> <td class=\"indent1\">Tiotropium</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Umeclidinium</td> <td>24 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Oral bronchodilators</td> </tr> <tr> <td class=\"indent1\">Albuterol tablet</td> <td>12&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Long-acting albuterol tablet</td> <td>24&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Roflumilast</td> <td>24&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Terbutaline tablet</td> <td>12&nbsp;hours</td> </tr> <tr> <td class=\"indent1\">Long-acting theophylline</td> <td>48&nbsp;hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These times are based on the recommendations of the ATS/ERS Task Force and on the usual duration of action of the individual agents.</div><div class=\"graphic_reference\">Reference: Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.</div><div id=\"graphicVersion\">Graphic 110199 Version 2.0</div></div></div>"},"110204":{"type":"graphic_figure","displayName":"Pulmonary bleb versus bulla","title":"Pulmonary bleb versus bulla","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Pulmonary bleb versus bulla</div><div class=\"cntnt\"><img style=\"width:485px; height:676px;\" src=\"images/SURG/110204_Pulmonary_bulla_versus_bleb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates the essential features of a pulmonary bleb compared with a&nbsp;pulmonary bulla.</div><div id=\"graphicVersion\">Graphic 110204 Version 1.0</div></div></div>"},"110205":{"type":"graphic_table","displayName":"Similarities and differences among TTTS, TAPS, and sIUGR","title":"Similarities and differences among TTTS, TAPS, and sIUGR","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Similarities and differences among TTTS, TAPS, and sIUGR</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ultrasound Finding</td> <td class=\"subtitle1\">TTTS</td> <td class=\"subtitle1\">TAPS</td> <td class=\"subtitle1\">sIUGR</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fluid discordance</strong></td> <td class=\"centered\">+++++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Growth discordance</strong><br /> (&#62;25%)</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+++++</td> </tr> <tr class=\"divider_bottom\"> <td><strong>MCA Doppler discordance</strong><br /> (&#62;1.5 MoM in donor/anemic AND &#60;0.8 MoM in recipient/plethoric)</td> <td class=\"centered\">++</td> <td class=\"centered\">+++++</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Small fetal bladder</strong></td> <td class=\"centered\">++++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ductus venosus abnormalities</strong></td> <td class=\"centered\">+++++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td><strong>Fetal hydrops</strong></td> <td class=\"centered\">+++++</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">\"+\" signifies the&nbsp;prominence of&nbsp;the&nbsp;ultrasound finding. \"-\" signifies that the ultrasound finding is not associated with the diagnosis.</div><div class=\"graphic_footnotes\">TTTS: twin-twin transfusion syndrome; TAPS: twin anemia polycythemia sequence; sIUGR: selective intrauterine growth restriction; MCA: middle cerebral artery; MoM: multiples of the median.</div><div id=\"graphicVersion\">Graphic 110205 Version 1.0</div></div></div>"},"110210":{"type":"graphic_picture","displayName":"Linear nevoid hypopigmentation","title":"Linear nevoid hypopigmentation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear nevoid hypopigmentation</div><div class=\"cntnt\"><img style=\"width:421px; height:766px;\" src=\"images/DERM/110210_Linear_nevoid_hypopigmenttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear nevoid hypopigmentation. Hypopigmentation along Blaschko's lines in narrow and broader bands (A) on the upper arm and chest of an infant (B) and thigh of a 10-year-old girl.</div><div class=\"graphic_reference\">From: Molho-Pessach V, Schaffer JV. Blaschko lines and other patterns of cutaneous mosaicism. Clin Dermatol 2011; 29:205. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110210 Version 1.0</div></div></div>"},"110211":{"type":"graphic_picture","displayName":"Linear nevoid hyperpigmentation","title":"Linear nevoid hyperpigmentation","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Linear nevoid hyperpigmentation</div><div class=\"cntnt\"><img style=\"width:506px; height:756px;\" src=\"images/DERM/110211_Linear_nevoid_hyperpigmnttn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear nevoid hyperpigmentation. Streaks and swirls of hyperpigmentation on the lateral trunk.</div><div class=\"graphic_reference\">Courtesy of Karen Chernoff, MD, and Julie Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 110211 Version 1.0</div></div></div>"},"110212":{"type":"graphic_picture","displayName":"Pigmentary mosaicism","title":"Pigmentary mosaicism​","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Pigmentary mosaicism​</div><div class=\"cntnt\"><img style=\"width:561px; height:756px;\" src=\"images/DERM/110212_Pigmentary_mosaicism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive pigmentary mosaicism along Blaschko lines. In patients with generalized streaks and swirls, it can be difficult to determine whether the \"abnormal\" skin is hypo- or hyperpigmented.</div><div class=\"graphic_reference\">From: Molho-Pessach V, Schaffer JV. Blaschko lines and other patterns of cutaneous mosaicism. Clin Dermatol 2011; 29:205. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110212 Version 1.0</div></div></div>"},"110214":{"type":"graphic_picture","displayName":"Segmental pigmentation disorder","title":"Segmental pigmentation disorder","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Segmental pigmentation disorder</div><div class=\"cntnt\"><img style=\"width:503px; height:756px;\" src=\"images/DERM/110214_Segmental_pigmentatn_dsordr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental pigmentation disorder with block-like hypopigmentation on the abdomen, with midline demarcation superiorly and slight extension past the midline inferiorly.</div><div class=\"graphic_reference\">From: Molho-Pessach V, Schaffer JV. Blaschko lines and other patterns of cutaneous mosaicism. Clin Dermatol 2011; 29:205. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110214 Version 1.0</div></div></div>"},"110216":{"type":"graphic_picture","displayName":"Phylloid hypomelanosis","title":"Phylloid hypomelanosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Phylloid hypomelanosis</div><div class=\"cntnt\"><img style=\"width:756px; height:388px;\" src=\"images/DERM/110216_Phylloid_hypomelanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phylloid hypomelanosis due to 13q mosaicism. Note the leaf-like as well as oval, thumbprint-like, hypopigmented macules on the front of chest and abdomen and on the back.</div><div class=\"graphic_reference\">From: Dhar SU, Robbins-Furman P, Levy ML, et al. Tetrasomy 13q mosaicism associated with phylloid hypomelanosis and precocious puberty. Am J Med Genet A 2009; 149:993. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajmg.a.32758/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajmg.a.32758/abstract</A>. Copyright © 2009 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110216 Version 1.0</div></div></div>"},"110220":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of normal versus absent fetal stomach","title":"Ultrasound of normal versus absent fetal stomach","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Ultrasound of normal versus absent fetal stomach</div><div class=\"cntnt\"><img style=\"width:703px; height:391px;\" src=\"images/OBGYN/110220_US_nrmVabsent_fetal_stomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal fetal stomach.<br />(B) Absent fetal stomach and polyhydramnios (amniotic fluid index 37). After delivery, esophageal atresia was confirmed.</div><div id=\"graphicVersion\">Graphic 110220 Version 1.0</div></div></div>"},"110221":{"type":"graphic_figure","displayName":"Ureteroneocystostomy","title":"Ureteroneocystostomy in gynecologic surgery","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Ureteroneocystostomy in gynecologic surgery</div><div class=\"cntnt\"><img style=\"width:781px; height:537px;\" src=\"images/OBGYN/110221_Ureteroneocystostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extravesical technique for ureteroneocystostomy.<br />(A) The distal ureter is freshened and spatulated for 1 cm. The detrusor muscle is incised for 1 to 2 cm on the posterolateral aspect of the bladder to expose the epithelium.<br />(B) The lateral aspect of the anastomosis is completed before incising the urothelium.<br />(C) The epithelium is incised and a stent introduced across the anastomosis.<br />(D) The ureteral anastomosis is completed and the serosa is closed over the ureter.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright EJ, Handa VL. Operative injuries to the ureter. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Wolters Kluwer, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 110221 Version 1.0</div></div></div>"},"110222":{"type":"graphic_figure","displayName":"Ureteral anastomosis","title":"Ureteral anastomosis in gynecologic surgery","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Ureteral anastomosis in gynecologic surgery</div><div class=\"cntnt\"><img style=\"width:766px; height:682px;\" src=\"images/OBGYN/110222_Ureteral_anastomosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ureteral anastomosis.<br />(A) The ends of the ureters are trimmed obliquely and spatulated.<br />(B) Fine delayed absorbable sutures are used to approximate the ends of the ureter.<br />(C) The anastomosis is done over a double-J or pigtail stent. A suction catheter is placed retroperitoneally at the site of anastomosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright EJ, Handa VL. Operative injuries to the ureter. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Wolters Kluwer, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 110222 Version 1.0</div></div></div>"},"110223":{"type":"graphic_table","displayName":"WHO diagnostic criteria chronic neutrophilic leukemia","title":"WHO diagnostic criteria for chronic neutrophilic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria for chronic neutrophilic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol> <li>Peripheral blood&nbsp;WBC &#8805;25 &times; 10<sup>9</sup>/L </li> </ol> </td> </tr> <tr> <td class=\"indent2\">Segmented neutrophils plus band forms &#8805;80% of WBCs</td> </tr> <tr> <td class=\"indent2\">Neutrophil precursors (promyelocytes, myelocytes, and metamyelocytes) &#60;10% of WBC</td> </tr> <tr> <td class=\"indent2\">Myeloblasts rarely observed</td> </tr> <tr> <td class=\"indent2\">Monocyte count &#60;1 &times; 10<sup>9</sup>/L</td> </tr> <tr> <td class=\"indent2\">No dysgranulopoiesis</td> </tr> <tr> <td> <ol start=\"2\"> <li>Hypercellular bone marrow</li> </ol> </td> </tr> <tr> <td class=\"indent2\">Neutrophil granulocytes increased in percentage and number</td> </tr> <tr> <td class=\"indent2\">Neutrophil maturation appears normal</td> </tr> <tr> <td class=\"indent2\">Myeloblasts &#60;5% of nucleated cells</td> </tr> <tr> <td> <ol start=\"3\"> <li>Not meeting WHO criteria for <em>BCR-ABL1<sup>+</sup></em> CML, PV, ET, or PMF </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>No rearrangement of <em>PDGFRA</em>, <em>PDGFRB</em>, or <em>FGFR1</em>, or <em>PCM1-JAK2</em> </li> </ol> </td> </tr> <tr> <td> <ol start=\"5\"> <li>Presence of <em>CSF3R</em> T618I or other activating <em>CSF3R</em> mutation </li> </ol> </td> </tr> <tr> <td>or</td> </tr> <tr> <td class=\"indent1\">In the absence of a <em>CSFR3R</em> mutation, persistent neutrophilia (at least 3 months), splenomegaly and no identifiable cause of reactive neutrophilia including absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The diagnosis of chronic neutrophilic leukemia requires all five criteria.</div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; ET: essential thrombocythemia; PV: polycythemia vera; PMF: primary myelofibrosis; WBC: white blood cell count; WHO: World Health Organization</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110223 Version 2.0</div></div></div>"},"110224":{"type":"graphic_table","displayName":"WHO diagnostic criteria polycythemia vera","title":"WHO diagnostic criteria polycythemia vera","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria polycythemia vera</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Major criteria</td> </tr> <tr> <td> <ol> <li>Hemoglobin &#62;16.5 g/dL in men </li> </ol> </td> </tr> <tr> <td> <ol style=\"list-style-type: none;\"> <li>Hemoglobin &#62;16.0 g/dL in women </li> </ol> </td> </tr> <tr> <td> <ol style=\"list-style-type: none;\"> <li>or, </li> </ol> </td> </tr> <tr> <td> <ol style=\"list-style-type: none;\"> <li>Hematocrit &#62;49% in men </li> </ol> </td> </tr> <tr> <td> <ol style=\"list-style-type: none;\"> <li>Hematocrit &#62;48% in women </li> </ol> </td> </tr> <tr> <td> <ol style=\"list-style-type: none;\"> <li>or, </li> </ol> </td> </tr> <tr> <td> <ol style=\"list-style-type: none;\"> <li>Increased red cell mass* </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Bone marrow&nbsp;biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size) </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>Presence of <em>JAK2</em> V617F or <em>JAK2</em> exon 12 mutation </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Minor criterion</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Subnormal serum erythropoietin level </li> </ol> </td> </tr> <tr class=\"highlight_gray_text\"> <td>Diagnosis of PV requires meeting either all 3 major criteria, or the first 2 major criteria and the minor criterion<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MF: myelofibrosis; PV: polycythemia vera; WHO: World Health Organization<br />* More than 25% above mean normal predicted value.<br />¶ Criterion number 2 (bone marrow&nbsp;biopsy) may not be required in cases with sustained absolute erythrocytosis: hemoglobin levels &gt;18.5 g/dL in men (hematocrit, 55.5%) or &gt;16.5 g/dL in women (hematocrit, 49.5%) if major criterion 3 and the minor criterion are present. However, initial myelofibrosis (present in up to 20% of patients) can only be detected by performing a&nbsp;bone marrow&nbsp;biopsy; this finding may predict a more rapid progression to overt myelofibrosis (post-PV MF).<br /></div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110224 Version 2.0</div></div></div>"},"110225":{"type":"graphic_table","displayName":"WHO diagnostic criteria essential thrombocythemia","title":"WHO diagnostic criteria essential thrombocythemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria essential thrombocythemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Major criteria</td> </tr> <tr> <td> <ol> <li>Platelet count &#8805;450 &times; 10<sup>9</sup>/L </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Bone marrow&nbsp;biopsy showing proliferation mainly of the megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade 1) increase in reticulin fibers. </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>Not meeting WHO criteria for <em>BCR-ABL1<sup>+</sup></em> CML, PV, PMF, myelodysplastic syndromes, or other myeloid neoplasms </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"4\"> <li>Presence of <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Minor criterion</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Presence of a clonal marker or absence of evidence for reactive thrombocytosis </li> </ol> </td> </tr> <tr class=\"highlight_gray_text\"> <td>Diagnosis of ET requires meeting all 4 major criteria or the first 3 major criteria and the minor criterion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; ET: essential thrombocythemia; PMF: primary myelofibrosis; PV: polycythemia vera; WHO: World Health Organization</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright © 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110225 Version 2.0</div></div></div>"},"110226":{"type":"graphic_table","displayName":"WHO diagnostic criteria pre-primary myelofibrosis","title":"WHO diagnostic criteria pre-primary myelofibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria pre-primary myelofibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Major criteria</td> </tr> <tr> <td> <ol> <li>Megakaryocytic proliferation and atypia, without reticulin fibrosis &#62;grade 1, accompanied by increased age-adjusted&nbsp;bone marrow&nbsp;cellularity, granulocytic proliferation, and often decreased erythropoiesis </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Not meeting the WHO criteria for <em>BCR-ABL1<sup>+</sup></em> CML, PV, ET, myelodysplastic syndromes, or other myeloid neoplasms </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>Presence of <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation or in the absence of these mutations, presence of another clonal marker,* or absence of minor reactive&nbsp;bone marrow&nbsp;reticulin fibrosis<sup>&#182;</sup> </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">Presence of at least 1 of the following, confirmed in 2 consecutive determinations:</td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\"> <li>Anemia not attributed to a comorbid condition </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Leukocytosis &#8805;11 &times; 10<sup>9</sup>/L </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"3\"> <li>Palpable splenomegaly </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"4\"> <li>LDH increased to above upper normal limit of institutional reference range </li> </ol> </td> </tr> <tr class=\"highlight_gray_text\"> <td>Diagnosis of prePMF requires meeting all 3 major criteria, and at least 1 minor criterion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; ET: essential thrombocythemia; PMF: primary myelofibrosis; PV: polycythemia vera; WHO: World Health Organization<br />*&nbsp;In the absence of any of the 3 major clonal mutations, the search for the most frequent accompanying mutations (eg, <EM>ASXL1</EM>, <EM>EZH2</EM>, <EM>TET2</EM>, <EM>IDH1/IDH2</EM>, <EM>SRSF2</EM>, <EM>SF3B1</EM>) are of help in determining the clonal nature of the disease.<br />¶&nbsp;Minor (grade 1) reticulin fibrosis secondary to infection, autoimmune disorder or other chronic inflammatory conditions, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110226 Version 2.0</div></div></div>"},"110227":{"type":"graphic_table","displayName":"WHO diagnostic criteria overt primary myelofibrosis","title":"WHO diagnostic criteria overt primary myelofibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria overt primary myelofibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Major criteria</td> </tr> <tr> <td> <ol> <li>Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3 </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>Not meeting WHO criteria for ET, PV, <em>BCR-ABL1<sup>+</sup></em> CML, myelodysplastic syndromes, or other myeloid neoplasms </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td> <ol start=\"3\"> <li>Presence of <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation or, in the absence of these mutations, presence of another clonal marker,* or absence of reactive myelofibrosis<sup>&#182; </sup></li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\" style=\"background-color: #ffffff;\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">Presence of at least 1 of the following, confirmed in 2 consecutive determinations:</td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\"> <li>Anemia not attributed to a comorbid condition </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"2\"> <li>Leukocytosis &#8805;11 &times; 10<sup>9</sup>/L </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"3\"> <li>Palpable splenomegaly </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"4\"> <li>LDH increased to above upper normal limit of institutional reference range </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol style=\"list-style-type: lower-alpha;\" start=\"5\"> <li>Leukoerythroblastosis </li> </ol> </td> </tr> <tr class=\"highlight_gray_text\"> <td>Diagnosis of overt PMF requires meeting all 3 major criteria, and at least 1 minor criterion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; ET: essential thrombocythemia; LDH: lactate dehydrogenase; PMF: primary myelofibrosis; PV: polycythemia vera<br />*&nbsp;In the absence of any of the 3 major clonal mutations, the search for the most frequent accompanying mutations (eg, <EM>ASXL1</EM>, <EM>EZH2</EM>, <EM>TET2</EM>, <EM>IDH1/IDH2</EM>, <EM>SRSF2</EM>, <EM>SF3B1</EM>) are of help in determining the clonal nature of the disease.<br />¶&nbsp;Bone marrow&nbsp;fibrosis secondary to infection, autoimmune disorder, or other chronic inflammatory conditions, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110227 Version 2.0</div></div></div>"},"110228":{"type":"graphic_table","displayName":"WHO grading myelofibrosis","title":"WHO grading myelofibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO grading myelofibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody> <colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Definition</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">MF-0</td> <td>Scattered linear reticulin with no intersections (crossovers) corresponding to normal bone marrow</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">MF-1</td> <td>Loose network of reticulin with many intersections, especially in perivascular areas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">MF-2</td> <td>Diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of thick fibers mostly consistent with collagen, and/or focal osteosclerosis*</td> </tr> <tr> <td class=\"centered\">MF-3</td> <td>Diffuse and dense increase in reticulin with extensive intersections and coarse bundles of thick fibers consistent with collagen, usually associated with osteosclerosis*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Semiquantitative grading of&nbsp;bone marrow&nbsp;fibrosis with minor modifications concerning collagen and osteosclerosis. Fiber density should be assessed only in hematopoietic areas.</div><div class=\"graphic_footnotes\">MF: myelofibrosis. <br />* In grades MF-2 or MF-3 an additional trichrome stain is recommended.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110228 Version 2.0</div></div></div>"},"110229":{"type":"graphic_table","displayName":"WHO diagnostic criteria chronic myelomonocytic leukemia","title":"WHO diagnostic criteria chronic myelomonocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria chronic myelomonocytic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Persistent peripheral blood monocytosis &#8805;1 &times; 10<sup>9</sup>/L, with monocytes accounting for &#8805;10% of the WBC count </li> </ul> </td> </tr> <tr> <td> <ul> <li>Not meeting WHO criteria for <em>BCR-ABL1<sup>+</sup></em> CML, PMF, PV, or ET* </li> </ul> </td> </tr> <tr> <td> <ul> <li>No evidence of <em>PDGFRA</em>, <em>PDGFRB</em>, or <em>FGFR1</em> rearrangement or <em>PCM1-JAK2</em> (should be specifically excluded in cases with eosinophilia) </li> </ul> </td> </tr> <tr> <td> <ul> <li>&#60;20% blasts in the blood and bone marrow<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Dysplasia in 1 or more myeloid lineages. If myelodysplasia is absent or minimal, the diagnosis of CMML may still be made if the other requirements are met and one of the following is present: </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>An acquired clonal cytogenetic or molecular genetic abnormality is present in hemopoietic cells<sup>&#916;</sup> <strong>or</strong></li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>The monocytosis (as previously defined) has persisted for at least 3 months <strong>and</strong> all other causes of monocytosis have been excluded. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diagnosis of chronic myelomonocytic leukemia requires all of criteria described above.</div><div class=\"graphic_footnotes\">CML: chronic myeloid leukemia; CMML: chronic myelomonocytic leukemia; ET: essential thrombocythemia; MPN: myeloproliferative neoplasm; PMF: primary myelofibrosis; PV: polycythemia vera; WHO: World Health Organization.<br />* Cases of MPN can be associated with monocytosis or they can develop it during the course of the disease. These cases may simulate CMML. In these rare instances, a previous documented history of MPN excludes CMML, whereas the presence of MPN features in the bone marrow and/or of MPN-associated mutations (<em>JAK2</em>, <em>CALR</em>, or <em>MPL</em>) tend to support MPN with monocytosis rather than CMML.<br />&para; Blasts and blast equivalents include myeloblasts, monoblasts, and promonocytes. Promonocytes are monocytic precursors with abundant light gray or slightly basophilic cytoplasm with a few scattered, fine lilac-colored granules, finely distributed, stippled nuclear chromatin, variably prominent nucleoli, and delicate nuclear folding or creasing. Abnormal monocytes, which can be present both in the&nbsp;peripheral blood&nbsp;and bone marrow, are excluded from the blast count.<br />&Delta; The presence of mutations in genes often associated with CMML (eg, <em>TET2</em>, <em>SRSF2</em>, <em>ASXL1</em>, <em>SETBP1</em>) in the proper clinical contest can be used to support a diagnosis. It should be noted however, that many of these mutations can be age-related or be present in subclones. Therefore, caution would have to be used in the interpretation of these genetic results.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110229 Version 2.0</div></div></div>"},"110230":{"type":"graphic_table","displayName":"WHO diagnostic criteria atypical CML, BCR-ABL1 negative","title":"WHO diagnostic criteria atypical chronic myeloid leukemia, BCR-ABL1 negative","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria atypical chronic myeloid leukemia, BCR-ABL1 negative</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Peripheral blood&nbsp;leukocytosis due to increased numbers of neutrophils and their precursors (promyelocytes, myelocytes, metamyelocytes) comprising &#8805;10% of leukocytes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Dysgranulopoiesis, which may include abnormal chromatin clumping </li> </ul> </td> </tr> <tr> <td> <ul> <li>No or minimal absolute basophilia; basophils usually &#60;2% of leukocytes </li> </ul> </td> </tr> <tr> <td> <ul> <li>No or minimal absolute monocytosis; monocytes &#60;10% of leukocytes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Hypercellular&nbsp;bone marrow&nbsp;with granulocytic proliferation and granulocytic dysplasia, with or without dysplasia in the erythroid and megakaryocytic lineages </li> </ul> </td> </tr> <tr> <td> <ul> <li>&#60;20% blasts in the blood and&nbsp;bone marrow&nbsp;</li> </ul> </td> </tr> <tr> <td> <ul> <li>No evidence of <em>PDGFRA</em>, <em>PDGFRB</em>, or <em>FGFR1</em> rearrangement, or <em>PCM1-JAK2</em> </li> </ul> </td> </tr> <tr> <td> <ul> <li>Not meeting WHO criteria for <em>BCR-ABL1<sup>+</sup></em> CML, PMF, PV, or ET* </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diagnosis of atypical CML, BCR-ABL1- requires meeting all of the criteria above.</div><div class=\"graphic_footnotes\">aCML: atypical chronic myeloid leukemia; CML: chronic myeloid leukemia; CNL: chronic neutrophilic leukemia; ET: essential thrombocythemia; MPN: myeloproliferative neoplasm; PMF: primary myelofibrosis; PV: polycythemia vera; WHO: World Health Organization<br />* Cases of MPN, particularly those in accelerated phase and/or in post-polycythemic or post-essential thrombocythemic myelofibrosis, if neutrophilic, may simulate aCML. A previous history of MPN, the presence of MPN features in the&nbsp;bone marrow&nbsp;and/or MPN-associated mutations (in <EM>JAK2</EM>, <EM>CALR</EM>, or <EM>MPL</EM>) tend to exclude a diagnosis of aCML. Conversely, a diagnosis of aCML is supported by the presence of <EM>SETBP1</EM> and/or <EM>ETNK1</EM> mutations. The presence of a <EM>CSF3R</EM> mutation is uncommon in aCML and if detected should prompt a careful morphologic review to exclude an alternative diagnosis of CNL or other myeloid neoplasm.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110230 Version 2.0</div></div></div>"},"110231":{"type":"graphic_table","displayName":"WHO dx criteria MDS/MPN with ring sideroblasts, thrombocytosis","title":"WHO diagnostic criteria MDS/MPN with ring sideroblasts and thrombocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria MDS/MPN with ring sideroblasts and thrombocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Anemia associated with erythroid lineage dysplasia with or without multilineage dysplasia, &#8805;15% ring sideroblasts,* &#60;1% blasts in&nbsp;peripheral blood&nbsp;and &#60;5% blasts in the&nbsp;bone marrow&nbsp;</li> </ul> </td> </tr> <tr> <td> <ul> <li>Persistent thrombocytosis with platelet count &#8805;450 &times; 10<sup>9</sup>/L </li> </ul> </td> </tr> <tr> <td> <ul> <li>Presence of a <em>SF3B1</em> mutation or, in the absence of <em>SF3B1</em> mutation, no history of recent cytotoxic or growth factor therapy that could explain the myelodysplastic/myeloproliferative features<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>No <em>BCR-ABL1</em> fusion gene, no rearrangement of <em>PDGFRA</em>, <em>PDGFRB</em>, or <em>FGFR1</em>; or <em>PCM1-JAK2</em>; no (3;3)(q21;q26), inv(3)(q21q26) or del(5q)<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td> <ul> <li>No preceding history of MPN, MDS (except MDS-RS), or other type of MDS/MPN </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Diagnosis of MDS/MPN with ring sideroblasts and thrombocytosis requires all of the criteria listed above.</div><div class=\"graphic_footnotes\">MDS/MPN: myelodysplastic syndrome/myeloproliferative neoplasm; MDS/MPN-RS-T: myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis; MDS: myelodysplastic syndrome; MDS-RS: myelodysplastic syndrome with ring sideroblasts; MPN: myeloproliferative neoplasm<br />* At least 15% ring sideroblasts required even if <EM>SF3B1</EM> mutation is detected.<br />¶ A diagnosis of MDS/MPN-RS-T is strongly supported by the presence of <EM>SF3B1</EM> mutation together with a mutation in <EM>JAK2</EM> V617F, <EM>CALR</EM>, or <EM>MPL</EM> genes.<br />Δ In a case which otherwise fulfills the diagnostic criteria for MDS with isolated del(5q)-no or minimal absolute basophilia; basophils usually &lt;2% of leukocytes.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110231 Version 2.0</div></div></div>"},"110232":{"type":"graphic_table","displayName":"WHO diagnostic criteria for JMML","title":"WHO diagnostic criteria for juvenile myelomonocytic leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO diagnostic criteria for juvenile myelomonocytic leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Clinical and hematologic features (all 4 features mandatory)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Peripheral blood&nbsp;monocyte count &#8805;1 &times; 10<sup>9</sup>/L </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Blast percentage in&nbsp;peripheral blood&nbsp;and&nbsp;bone marrow&nbsp;&#60;20% </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Splenomegaly </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Absence of Philadelphia chromosome (<em>BCR/ABL1</em> rearrangement) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">II. Genetic studies (1 finding sufficient)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Somatic mutation in <em>PTPN11</em>* or <em>KRAS</em>* or <em>NRAS</em>* </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Clinical diagnosis of NF1 or <em>NF1</em> mutation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Germ line <em>CBL</em> mutation and loss of heterozygosity of CBL<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">III. For patients without genetic features, besides the clinical and hematologic features listed under I, the following criteria must be fulfilled:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Monosomy 7 or any other chromosomal abnormality or at least 2 of the following criteria: </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Hemoglobin F increased for age </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Myeloid or erythroid precursors on&nbsp;peripheral blood&nbsp;smear </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>GM-CSF hypersensitivity in colony assay </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>Hyperphosphorylation of STAT5 </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; NF1: neurofibromatosis type 1; GM-CSF: granulocyte-macrophage colony-stimulating factor; JMML: juvenile myelomonocytic leukemia. <br />* Germ line mutations (indicating Noonan syndrome) need to be excluded.<br />¶ Occasional cases with heterozygous splice site mutations.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood 2015; 125:1083. Copyright © 2015; permission conveyed through Copyright Clearance Center, Inc.<br />Modified in:<br /><OL>&#xD;&#xA;<LI>Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</LI></OL></div><div id=\"graphicVersion\">Graphic 110232 Version 4.0</div></div></div>"},"110233":{"type":"graphic_table","displayName":"2016 WHO myelodysplastic syndrome subtypes","title":"2016 WHO myelodysplastic syndrome subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2016 WHO myelodysplastic syndrome subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name</td> <td class=\"subtitle1\">Dysplastic lineages</td> <td class=\"subtitle1\">Cytopenias*</td> <td class=\"subtitle1\">Ring sideroblasts as % of marrow erythroid elements</td> <td class=\"subtitle1\">BM and PB blasts</td> <td class=\"subtitle1\">Cytogenetics by conventional karyotype analysis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>MDS with single lineage dysplasia (MDS-SLD)</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">1 or 2</td> <td>&#60;15%/&#60;5%<sup>&#182;</sup></td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>MDS with multilineage dysplasia (MDS-MLD)</strong></td> <td class=\"centered\">2 or 3</td> <td class=\"centered\">1 to 3</td> <td>&#60;15%/&#60;5%<sup>&#182;</sup></td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr> <td colspan=\"6\"><strong>MDS with ring sideroblasts (MDS-RS)</strong></td> </tr> <tr> <td class=\"indent1\">MDS-RS with single lineage dysplasia (MDS-RS-SLD)</td> <td class=\"centered\">1</td> <td class=\"centered\">1 or 2</td> <td>&#8805;15%/&#8805;5%<sup>&#182;</sup></td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MDS-RS with multilineage dysplasia (MDS-RS-MLD)</td> <td class=\"centered\">2 or 3</td> <td class=\"centered\">1 to 3</td> <td>&#8805;15%/&#8805;5%<sup>&#182;</sup></td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>Any, unless fulfills all criteria for MDS with isolated del(5q)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>MDS with isolated del(5q)</strong></td> <td class=\"centered\">1 to 3</td> <td class=\"centered\">1 to 2</td> <td>None or any</td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>del(5q) alone or with 1 additional abnormality except &ndash;7 or del(7q)</td> </tr> <tr> <td colspan=\"6\"><strong>MDS with excess blasts (MDS-EB)</strong></td> </tr> <tr> <td class=\"indent1\">MDS-EB-1</td> <td class=\"centered\">0 to 3</td> <td class=\"centered\">1 to 3</td> <td>None or any</td> <td>BM 5 to 9% or PB 2 to 4%,<br /> no Auer rods</td> <td>Any</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MDS-EB-2</td> <td class=\"centered\">0 to 3</td> <td class=\"centered\">1 to 3</td> <td>None or any</td> <td>BM 10 to 19% or PB 5 to 19% or Auer rods</td> <td>Any</td> </tr> <tr> <td colspan=\"6\"><strong>MDS, unclassifiable (MDS-U)</strong></td> </tr> <tr> <td class=\"indent1\">With 1% blood blasts</td> <td class=\"centered\">1 to 3</td> <td class=\"centered\">1 to 3</td> <td>None or any</td> <td>BM &#60;5%,<br /> PB = 1%,<sup>&#916;</sup><br /> no Auer rods</td> <td>Any</td> </tr> <tr> <td class=\"indent1\">With single lineage dysplasia and pancytopenia</td> <td class=\"centered\">1</td> <td class=\"centered\">3</td> <td>None or any</td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>Any</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Based on defining cytogenetic abnormality</td> <td class=\"centered\">0</td> <td class=\"centered\">1 to 3</td> <td>&#60;15%<sup>&#9674;</sup></td> <td>BM &#60;5%,<br /> PB &#60;1%,<br /> no Auer rods</td> <td>MDS-defining abnormality</td> </tr> <tr> <td><strong>Refractory cytopenia of childhood</strong></td> <td class=\"centered\">1 to 3</td> <td class=\"centered\">1 to 3</td> <td>None</td> <td>BM &#60;5%,<br /> PB &#60;2%</td> <td>Any</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BM: bone marrow; PB: peripheral blood; MDS: myelodysplastic syndrome<br />* Cytopenias defined as: hemoglobin, &lt;10 g/dL; platelet count, &lt;100 × 10<SUP>9</SUP>/L; and absolute neutrophil count, &lt;1.8 × 10<SUP>9</SUP>/L. Rarely, MDS may present with mild anemia or thrombocytopenia above these levels.&nbsp;Peripheral blood&nbsp;monocytes must be &lt;1 × 10<SUP>9</SUP>/L.<br />¶ If <EM>SF3B1</EM> mutation is present.<br />Δ One percent&nbsp;peripheral blood&nbsp;blasts must be recorded on at least 2 separate occasions.<br /><FONT class=lozenge>◊</FONT> Cases with ≥15% ring sideroblasts by definition have significant erythroid dysplasia, and are classified as MDS-RS-SLD.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110233 Version 3.0</div></div></div>"},"110234":{"type":"graphic_table","displayName":"AML with MDS-related changes cytogenetic findings","title":"Cytogenetic abnormalities diagnostic of acute myeloid leukemia with myelodysplasia-related changes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytogenetic abnormalities diagnostic of&nbsp;acute myeloid leukemia with myelodysplasia-related changes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Complex karyotype (3 or more abnormalities)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Unbalanced abnormalities</td> </tr> <tr> <td class=\"indent1\">&ndash;7/del(7q)</td> </tr> <tr> <td class=\"indent1\">del(5q)/t(5q)</td> </tr> <tr> <td class=\"indent1\">i(17q)/t(17p)</td> </tr> <tr> <td class=\"indent1\">&ndash;13/del(13q)</td> </tr> <tr> <td class=\"indent1\">del(11q)</td> </tr> <tr> <td class=\"indent1\">del(12p)/t(12p)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">idic(X)(q13)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Balanced abnormalities</td> </tr> <tr> <td class=\"indent1\">t(11;16)(q23.3;p13.3)</td> </tr> <tr> <td class=\"indent1\">t(3;21)(q26.2;q22.1)</td> </tr> <tr> <td class=\"indent1\">t(1;3)(p36.3;q21.2)</td> </tr> <tr> <td class=\"indent1\">t(2;11)(p21;q23.3)</td> </tr> <tr> <td class=\"indent1\">t(5;12)(q32;p13.2)</td> </tr> <tr> <td class=\"indent1\">t(5;7)(q32;q11.2)</td> </tr> <tr> <td class=\"indent1\">t(5;17)(q32;p13.2)</td> </tr> <tr> <td class=\"indent1\">t(5;10)(q32;q21.2)</td> </tr> <tr> <td class=\"indent1\">t(3;5)(q25.3;q35.1)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The cytogenetic abnormalities listed are sufficient to diagnose acute myeloid leukemia with myelodysplasia-related changes when ≥20%&nbsp;peripheral blood or bone marrow blasts are present and prior therapy has been excluded.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110234 Version 3.0</div></div></div>"},"110235":{"type":"graphic_picture","displayName":"Epidermal nevus hypopigmented","title":"Epidermal nevus","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Epidermal nevus</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/110235_Epidermal_nevus_hypopigmntd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epidermal nevus presenting as a hypopigmented, slightly elevated linear lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110235 Version 1.0</div></div></div>"},"110236":{"type":"graphic_figure","displayName":"Normative blood pressure values for extremely preterm infants","title":"Normative blood pressure values for extremely preterm infants (gestational age ≤28 weeks) over the first 24 hours","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Normative blood pressure values for extremely preterm infants (gestational age ≤28 weeks)&nbsp;over the first 24 hours</div><div class=\"cntnt\"><img style=\"width:598px; height:726px;\" src=\"images/PEDS/110236_Nrm_BP_extrmly_prtrm_infnts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Systolic (A), diastolic (B), and mean (C) arterial blood pressure curves over the first 24 hours for extremely preterm infants (n = 367).</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Journal of Perinatology. Batton B, Li L, Das D, et al. Evolving blood pressure dynamics for extremely preterm infants. J Perinatol 2014; 34:301. Copyright &copy; 2014. <a href=\"http://www.nature.com/jp\" target=\"_blank\">www.nature.com/jp</a>.</div><div id=\"graphicVersion\">Graphic 110236 Version 1.0</div></div></div>"},"110237":{"type":"graphic_figure","displayName":"Changes in BP for EPT: First 24 hours of life","title":"Changes in blood pressure for extremely preterm infant based on gestational age over the first 24 hours of life","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Changes in blood pressure for extremely preterm infant based on gestational age over the first 24 hours of life</div><div class=\"cntnt\"><img style=\"width:634px; height:732px;\" src=\"images/PEDS/110237_Changes_BP_EPT_first_24hrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gestational-age specific changes in the systolic (A), diastolic (B), and mean (C) arterial blood pressure 50<sup>th</sup> percentile curves over the first 24 hours.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Journal of Perinatology. Batton B, Li L, Das D, et al. Evolving blood pressure dynamics for extremely preterm infants. J Perinatol 2014; 34:301. Copyright &copy; 2014. <a href=\"http://www.nature.com/jp\" target=\"_blank\">www.nature.com/jp</a>.</div><div id=\"graphicVersion\">Graphic 110237 Version 1.0</div></div></div>"},"110238":{"type":"graphic_picture","displayName":"Goltz syndrome","title":"Focal dermal hypoplasia (Goltz syndrome)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Focal dermal hypoplasia (Goltz syndrome)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110238_Goltz_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear hypopigmented bands along the lines of Blaschko, with areas of dermal atrophy and fat herniation.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110238 Version 1.0</div></div></div>"},"110239":{"type":"graphic_table","displayName":"WHO classification of myeloid neoplasms and acute leukemia","title":"WHO classification of myeloid neoplasms and acute leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO classification of myeloid neoplasms and acute leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Myeloproliferative neoplasms (MPN)</td> </tr> <tr> <td class=\"indent1\">Chronic myeloid leukemia (CML), <em>BCR-ABL1<sup>+</sup></em></td> </tr> <tr> <td class=\"indent1\">Chronic neutrophilic leukemia (CNL)</td> </tr> <tr> <td class=\"indent1\">Polycythemia vera (PV)</td> </tr> <tr> <td class=\"indent1\">Primary myelofibrosis (PMF)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>PMF, prefibrotic/early stage </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>PMF, overt fibrotic stage </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Essential thrombocythemia (ET)</td> </tr> <tr> <td class=\"indent1\">Chronic eosinophilic leukemia, not otherwise specified (NOS)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MPN, unclassifiable</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_single\">Mastocytosis</td> </tr> <tr> <td class=\"subtitle1_single\">Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of <em>PDGFRA</em>, <em>PDGFRB</em>, or <em>FGFR1</em>, or with <em>PCM1-JAK2</em></td> </tr> <tr> <td class=\"indent1\">Myeloid/lymphoid neoplasms with <em>PDGFRA</em> rearrangement</td> </tr> <tr> <td class=\"indent1\">Myeloid/lymphoid neoplasms with <em>PDGFRB</em> rearrangement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Myeloid/lymphoid neoplasms with <em>FGFR1</em> rearrangement</td> </tr> <tr> <td class=\"subtitle1_single\">Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)</td> </tr> <tr> <td class=\"indent1\">Chronic myelomonocytic leukemia (CMML)</td> </tr> <tr> <td class=\"indent1\">Atypical chronic myeloid leukemia (aCML), BCR-ABL1<sup>&ndash;</sup></td> </tr> <tr> <td class=\"indent1\">Juvenile myelomonocytic leukemia (JMML)</td> </tr> <tr> <td class=\"indent1\">MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MDS/MPN, unclassifiable</td> </tr> <tr> <td class=\"subtitle1_single\">Myelodysplastic syndromes (MDS)</td> </tr> <tr> <td class=\"indent1\">MDS with single lineage dysplasia</td> </tr> <tr> <td class=\"indent1\">MDS with ring sideroblasts (MDS-RS)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>MDS-RS and single lineage dysplasia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>MDS-RS and multilineage dysplasia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">MDS with multilineage dysplasia</td> </tr> <tr> <td class=\"indent1\">MDS with excess blasts</td> </tr> <tr> <td class=\"indent1\">MDS with isolated del(5q)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MDS, unclassifiable</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_single\">Myeloid neoplasms with germ line predisposition</td> </tr> <tr> <td class=\"subtitle1_single\">Acute myeloid leukemia (AML) and related neoplasms</td> </tr> <tr> <td class=\"indent1\">AML with recurrent genetic abnormalities</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with t(8;21)(q22;q22.1);<em>RUNX1-RUNX1T1</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);<em>CBFB-MYH11</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>APL with <em>PML-RARA</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with t(9;11)(p21.3;q23.3);<em>MLLT3-KMT2A</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with t(6;9)(p23;q34.1);<em>DEK-NUP214</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); <em>GATA2</em>, <em>MECOM</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);<em>RBM15-MKL1</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with mutated <em>NPM1</em> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with biallelic mutations of <em>CEBPA</em> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">AML with myelodysplasia-related changes</td> </tr> <tr> <td class=\"indent1\">Therapy-related myeloid neoplasms</td> </tr> <tr> <td class=\"indent1\">AML, NOS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with minimal differentiation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML without maturation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>AML with maturation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute myelomonocytic leukemia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute monoblastic/monocytic leukemia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pure erythroid leukemia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute megakaryoblastic leukemia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute basophilic leukemia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute panmyelosis with myelofibrosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Myeloid sarcoma</td> </tr> <tr> <td class=\"indent1\">Myeloid proliferations related to Down syndrome</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Transient abnormal myelopoiesis (TAM) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Myeloid leukemia associated with Down syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Blastic plasmacytoid dendritic cell neoplasm</td> </tr> <tr> <td class=\"subtitle1_single\">Acute leukemias of ambiguous lineage</td> </tr> <tr> <td class=\"indent1\">Acute undifferentiated leukemia</td> </tr> <tr> <td class=\"indent1\">Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); <em>BCR-ABL1</em></td> </tr> <tr> <td class=\"indent1\">MPAL with t(v;11q23.3); <em>KMT2A</em> rearranged</td> </tr> <tr> <td class=\"indent1\">MPAL, B/myeloid, NOS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">MPAL, T/myeloid, NOS</td> </tr> <tr> <td class=\"subtitle1_single\">B-lymphoblastic leukemia/lymphoma</td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma, NOS</td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities</td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);<em>BCR-ABL1</em></td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);<em>KMT2A</em> rearranged</td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); <em>ETV6-RUNX1</em></td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with hyperdiploidy</td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with hypodiploidy</td> </tr> <tr> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) <em>IL3-IGH</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);<em>TCF3-PBX1</em></td> </tr> <tr> <td class=\"subtitle1_single\" style=\"border-bottom: medium none;\">T-lymphoblastic leukemia/lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Provisional entities are not included.</div><div class=\"graphic_reference\">Modified with permission of the American Society of Hematology, from Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110239 Version 2.0</div></div></div>"},"110240":{"type":"graphic_table","displayName":"WHO classification of lymphoid, histiocytic, dendritic neoplasms","title":"2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mature B cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Chronic lymphocytic leukemia/small lymphocytic lymphoma</td> </tr> <tr> <td class=\"indent1\">Monoclonal B cell lymphocytosis*</td> </tr> <tr> <td class=\"indent1\">B cell prolymphocytic leukemia</td> </tr> <tr> <td class=\"indent1\">Splenic marginal zone lymphoma</td> </tr> <tr> <td class=\"indent1\">Hairy cell leukemia</td> </tr> <tr> <td class=\"indent1\">Lymphoplasmacytic lymphoma</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Waldenstr&#246;m macroglobulinemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Monoclonal gammopathy of undetermined significance (MGUS), IgM*</td> </tr> <tr> <td class=\"indent1\">&#181; heavy chain disease</td> </tr> <tr> <td class=\"indent1\">&#947; heavy chain disease</td> </tr> <tr> <td class=\"indent1\">&#945; heavy chain disease</td> </tr> <tr> <td class=\"indent1\">Monoclonal gammopathy of undetermined significance (MGUS), IgG/A*</td> </tr> <tr> <td class=\"indent1\">Plasma cell myeloma</td> </tr> <tr> <td class=\"indent1\">Solitary plasmacytoma of bone</td> </tr> <tr> <td class=\"indent1\">Extraosseous plasmacytoma</td> </tr> <tr> <td class=\"indent1\">Monoclonal immunoglobulin deposition diseases*</td> </tr> <tr> <td class=\"indent1\">Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</td> </tr> <tr> <td class=\"indent1\">Nodal marginal zone lymphoma</td> </tr> <tr> <td class=\"indent1\">Follicular lymphoma</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>In situ follicular neoplasia* </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Duodenal-type follicular lymphoma* </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pediatric-type follicular lymphoma*</td> </tr> <tr> <td class=\"indent1\">Primary cutaneous follicle center lymphoma</td> </tr> <tr> <td class=\"indent1\">Mantle cell lymphoma</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>In situ mantle cell neoplasia* </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diffuse large B cell lymphoma (DLBCL), NOS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Germinal center B cell type* </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Activated B cell type* </li> </ul> </td> </tr> <tr> <td class=\"indent1\">T cell/histiocyte-rich large B cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Primary DLBCL of the central nervous system (CNS)</td> </tr> <tr> <td class=\"indent1\">Primary cutaneous DLBCL, leg type</td> </tr> <tr> <td class=\"indent1\">EBV<sup>+</sup> DLBCL, NOS*</td> </tr> <tr> <td class=\"indent1\">DLBCL associated with chronic inflammation</td> </tr> <tr> <td class=\"indent1\">Lymphomatoid granulomatosis</td> </tr> <tr> <td class=\"indent1\">Primary mediastinal (thymic) large B cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Intravascular large B cell lymphoma</td> </tr> <tr> <td class=\"indent1\">ALK<sup>+</sup> large B cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Plasmablastic lymphoma</td> </tr> <tr> <td class=\"indent1\">Primary effusion lymphoma</td> </tr> <tr> <td class=\"indent1\">Burkitt lymphoma</td> </tr> <tr> <td class=\"indent1\">High-grade B cell lymphoma, with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements*</td> </tr> <tr> <td class=\"indent1\">High-grade B cell lymphoma, NOS*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Mature T and NK neoplasms</td> </tr> <tr> <td class=\"indent1\">T cell prolymphocytic leukemia</td> </tr> <tr> <td class=\"indent1\">T cell large granular lymphocytic leukemia</td> </tr> <tr> <td class=\"indent1\">Aggressive NK cell leukemia</td> </tr> <tr> <td class=\"indent1\">Systemic EBV<sup>+</sup> T cell lymphoma of childhood*</td> </tr> <tr> <td class=\"indent1\">Hydroa vacciniforme-like lymphoproliferative disorder*</td> </tr> <tr> <td class=\"indent1\">Adult T cell leukemia/lymphoma</td> </tr> <tr> <td class=\"indent1\">Extranodal NK/T cell lymphoma, nasal type</td> </tr> <tr> <td class=\"indent1\">Enteropathy-associated T cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Monomorphic epitheliotropic intestinal T cell lymphoma*</td> </tr> <tr> <td class=\"indent1\">Hepatosplenic T cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Subcutaneous panniculitis-like T cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Mycosis fungoides</td> </tr> <tr> <td class=\"indent1\">S&#233;zary syndrome</td> </tr> <tr> <td class=\"indent1\">Primary cutaneous CD30<sup>+</sup> T cell lymphoproliferative disorders</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lymphomatoid papulosis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Primary cutaneous anaplastic large cell lymphoma </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Primary cutaneous &#947;&#948; T cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Peripheral T cell lymphoma, NOS</td> </tr> <tr> <td class=\"indent1\">Angioimmunoblastic T cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Anaplastic large cell lymphoma, ALK<sup>+</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anaplastic large cell lymphoma, ALK<sup>&ndash;</sup>*</td> </tr> <tr> <td class=\"subtitle1_single\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Nodular lymphocyte predominant Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Classical Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Nodular sclerosis classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lymphocyte-rich classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Mixed cellularity classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Lymphocyte-depleted classical Hodgkin lymphoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Post-transplant lymphoproliferative disorders (PTLD)</td> </tr> <tr> <td class=\"indent1\">Plasmacytic hyperplasia PTLD</td> </tr> <tr> <td class=\"indent1\">Infectious mononucleosis PTLD</td> </tr> <tr> <td class=\"indent1\">Florid follicular hyperplasia PTLD*</td> </tr> <tr> <td class=\"indent1\">Polymorphic PTLD</td> </tr> <tr> <td class=\"indent1\">Monomorphic PTLD (B and T/NK cell types)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Classical Hodgkin lymphoma PTLD</td> </tr> <tr> <td class=\"subtitle1_single\">Histiocytic and dendritic cell neoplasms</td> </tr> <tr> <td class=\"indent1\">Histiocytic sarcoma</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Langerhans cell sarcoma</td> </tr> <tr> <td class=\"indent1\">Indeterminate dendritic cell tumor</td> </tr> <tr> <td class=\"indent1\">Interdigitating dendritic cell sarcoma</td> </tr> <tr> <td class=\"indent1\">Follicular dendritic cell sarcoma</td> </tr> <tr> <td class=\"indent1\">Fibroblastic reticular cell tumor</td> </tr> <tr> <td class=\"indent1\">Disseminated juvenile xanthogranuloma</td> </tr> <tr> <td class=\"indent1\">Erdheim-Chester disease*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Provisional entities are not listed.</div><div class=\"graphic_footnotes\">* Changes from the 2008 classification.</div><div class=\"graphic_reference\">Modified with permission of the American Society of Hematology, from Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375. Copyright &copy; 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110240 Version 2.0</div></div></div>"},"110242":{"type":"graphic_picture","displayName":"Conradi-Hunermann-Happle syndrome","title":"Conradi-Hünermann-Happle syndrome​","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Conradi-Hünermann-Happle syndrome​</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/110242_Conradi-Hunermann-Happle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conradi-Hünermann-Happle syndrome in a newborn presenting with erythroderma and linear scaly areas that characteristically follow the lines of Blaschko.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110242 Version 1.0</div></div></div>"},"110243":{"type":"graphic_picture","displayName":"Erythema nodosum pathology 2","title":"Erythema nodosum","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Erythema nodosum</div><div class=\"cntnt\"><img style=\"width:766px; height:577px;\" src=\"images/DERM/110243_Erythemanodosumpathology2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Septal panniculitis with mixed inflammatory infiltrate containing histiocytes, lymphocytes, neutrophils, and eosinophils.<br />(B) Meischer's radial granulomas (small, nodular aggregates of histiocytes surrounding \"banana-shaped\" extracellular clefts). Neutrophils surround the granulomas.<br />(C) Multinucleated giant cells (a feature of late-stage erythema nodosum).<br />(D) Septal inflammation with eosinophils, sparing the adipocytes.</div><div class=\"graphic_reference\">Courtesy of Alireza Sepehr, MD.</div><div id=\"graphicVersion\">Graphic 110243 Version 1.0</div></div></div>"},"110252":{"type":"graphic_table","displayName":"General measures for treatment of elevated ICP in children","title":"General measures for treatment of elevated ICP in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General measures for treatment of elevated ICP in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Early consultation with a neurosurgeon&nbsp;to guide medical management and address surgical causes of elevated ICP*</li> </ul> </td> </tr> <tr> <td> <ul> <li>Secure the airway using RSI (use cervical spine immobilization in trauma patients) for the following: </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Signs of herniation </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Refractory hypoxia </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Hypoventilation </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>GCS &#8804;8 or &#60;12 and rapidly declining </li> </ul> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <ul> <li>Loss of airway protective reflexes </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li>Rapid treatment of hypoxia, hypercarbia, and hypotension </li> </ul> </td> </tr> <tr> <td> <ul> <li>Elevation of the head 15 to 30 degrees while maintaining the head in a midline position </li> </ul> </td> </tr> <tr> <td> <ul> <li>Aggressively treating fever with antipyretics and cooling blankets </li> </ul> </td> </tr> <tr> <td> <ul> <li>Control of shivering in intubated patients with muscle relaxants (eg, vecuronium, rocuronium) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Administering prophylactic anticonvulsants (eg, levetiracetam, phenytoin, or phenobarbital) to patients who are at high risk of developing seizures </li> </ul> </td> </tr> <tr> <td> <ul> <li>Maintaining adequate analgesia to blunt the response to noxious stimuli </li> </ul> </td> </tr> <tr> <td> <ul> <li>In intubated patients: </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\" style=\"list-style-type: disc;\"> <li>Maintaining the head in a midline position and taping, rather than tying endotracheal tubes to the face </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\" style=\"list-style-type: disc;\"> <li>Avoiding high positive pressures and end expiratory pressures </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\" style=\"list-style-type: disc;\"> <li>Maintaining adequate sedation and, in some patients, muscle relaxation to permit controlled ventilation </li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\" style=\"list-style-type: disc;\"> <li>Administration of lidocaine (1 mg/kg intravenously) before endotracheal tube suctioning to blunt the gag and cough responses </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICP: intracranial pressure; RSI: rapid sequence intubation; GCS: Glasgow coma scale.<br />*Refer to UpToDate topics on the management of elevated ICP in children. </div><div id=\"graphicVersion\">Graphic 110252 Version 2.0</div></div></div>"},"110254":{"type":"graphic_table","displayName":"Causes of TME in children","title":"Causes of acute toxic-metabolic encephalopathy in children and their clinical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute toxic-metabolic encephalopathy in children and their clinical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">Mental status changes</td> <td class=\"subtitle1\">Seizures</td> <td class=\"subtitle1\">Focal neurologic signs</td> <td class=\"subtitle1\">Elevated ICP</td> <td class=\"subtitle1\">Characteristic neuroimaging findings</td> <td class=\"subtitle1\">Other features</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hypoxic-ischemic encephalopathy</strong></td> <td>Ranges from lethargy to coma*</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">Edema, infarction, restricted DWI signal changes</td> <td> <ul> <li>Typically a straightforward diagnosis after an obvious precipitating event, such as drowning, airway obstruction, or cardiopulmonary arrest </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Sepsis</strong></td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">T2 FLAIR and restricted DWI signal changes</td> <td> <ul> <li>Signs of systemic infection (eg, fever, elevated WBC) </li> <li>Diagnosis is confirmed with appropriate microbiology studies </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Metabolic disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypoglycemia</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Signs of increased epinephrine release (eg, tremor, diaphoresis) may be present, but are not universal </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diabetic ketoacidosis</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">Cerebral edema</td> <td> <ul> <li>Nausea, vomiting, abdominal pain, hyperventilation (Kussmaul breathing) </li> <li>May occur in new-onset DM or as a complication of known DM </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inborn errors of metabolism</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td colspan=\"4\">Depends on specific disorder<sup>&#182;</sup></td> <td> <ul> <li>Patients may have recurrent episodes of encephalopathic changes associated with vomiting and hypotonia that may be associated with an intercurrent illness or prolonged fasting </li> <li>Laboratory abnormalities may include hypoglycemia, hyperammonemia, or lactic acidosis, depending on the type of inborn error of metabolism<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Electrolyte derangements</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypernatremia</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Pontine or extrapontine myelinolyses</td> <td> <ul> <li>Nonspecific initial manifestations include irritability, restlessness, weakness, vomiting, muscular twitching, fever, and, in infants, high-pitched cry and tachypnea </li> <li>Encephalopathy is not typically seen until serum sodium level exceeds 160 mEq/L </li> <li>Most common cause of hypernatremia in children is excessive fluid losses; patients may have manifestations of hypovolemia, including tachycardia, dry mucous membranes, and poor peripheral perfusion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hyponatremia</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">Edema; pontine or extrapontine myelinolyses</td> <td> <ul> <li>Neurologic symptoms are typically observed with plasma sodium levels &#60;125 mEq/L </li> <li>Severe symptoms (lethargy, obtundation, and seizures) may occur as the level falls below 120 mEq/L </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypercalcemia</td> <td>Irritability, behavioral changes; ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Anorexia, nausea, vomiting, hypertension, bradycardia, nephrocalcinosis, pruritus, headache, weakness </li> <li>Life-threatening symptoms may occur with serum concentrations &#62;15 mg/dL (3.75 mmol/L) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypocalcemia</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Tetany, positive Trousseau and Chvostek signs, laryngospasm </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypermagnesemia</td> <td>Ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Fixed dilated pupils</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Weakness, respiratory depression, hypotension, ECG changes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypomagnesemia</td> <td>Delirium, irritability, hallucinations; ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Tremors, muscle twitching, myoclonic jerks, choreiform movements, and nystagmus; coma and generalized seizures may occur in severe cases </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Endocrine disorders</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypothyroidism</td> <td>Apathy, slow cognition, psychosis; ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Hyponatremia, hypothermia, bradycardia, central hypoventilation </li> <li>History of fatigue, weight gain, constipation, and cold intolerance </li> <li>A precipitating trigger (eg, infection, burn) may be present </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hyperthyroidism</td> <td>Agitation, irritability, psychosis, and, rarely, coma</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Tremor, tachycardia, cardiac dysrhythmias, hypertension fever, fatigue, weight loss </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adrenal crisis</td> <td>Delirium; mood and behavioral changes; cognitive impairments; psychosis; hallucinations; ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Hypotension, nausea and vomiting, abdominal pain, fever, hypernatremia, hypokalemia </li> <li>Potential triggers include dehydration, trauma, surgery, infection, or other physical stress or stopping glucocorticoid treatment </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hypertension</strong></td> <td>Irritability, anxiety, agitation</td> <td class=\"centered\">PRES: ++ <br /> HTE: +</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Cortical and white matter signal changes in parieto-occipital region T2 and FLAIR</td> <td> <ul> <li>Severe hypertension </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Organ failure</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatic failure</td> <td>Delirium, apathy; ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">+</td> <td class=\"centered\">Decerebrate/decorticate posture</td> <td class=\"centered\">+</td> <td class=\"centered\">Edema</td> <td> <ul> <li>Jaundice, ascites, and other clinically evident signs of liver failure are usually present </li> <li>Asterixis, grimacing, jerking movements </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Renal failure/uremia</td> <td>Disorientation, hallucinations, rambling speech; ranges from mild (eg, confusion, disorientation, lethargy) to severe (eg, coma)*</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td> <ul> <li>Laboratory evidence of severe renal impairment </li> <li>Anorexia, tremor, weakness, peripheral neuropathy, myoclonus, and asterixis (\"uremic flap\") </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Reye syndrome</strong></td> <td>Confusion, rapidly evolves to coma</td> <td class=\"centered\">++</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">++</td> <td class=\"centered\">Edema, restricted DWI signal changes</td> <td> <ul> <li>Hepatomegaly, markedly elevated transaminases, hyperammonemia, hypoglycemia, metabolic acidosis </li> <li>Typically begins several days after apparent recovery from a viral illness, especially varicella or influenza A or B </li> </ul> </td> </tr> <tr> <td><strong>Drugs and toxins</strong></td> <td colspan=\"6\">Depends on specific agent<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICP: intracranial pressure; DWI: diffusion-weighted imaging; FLAIR: fluid attenuation inversion recovery; WBC: white blood cell; DM: diabetes mellitus; ECG: electrocardiogram; PRES: posterior reversible encephalopathy syndrome; HTE: hypertensive encephalopathy.<br />* The severity of encephalopathy generally reflects the degree of metabolic derangement or hypoxic insult, with the exception of uremic encephalopathy, in which the severity of encephalopathy does not always correlate with the degree of azotemia.<br />¶ Refer to separate UpToDate content on inborn errors of metabolism for additional details.<br />Δ Numerous drugs and toxins can cause encephalopathy in children. Broad categories include sedatives (eg, benzodiazepines, barbiturates, alcohol, opiates), anticholinergic agents (eg, tricyclic antidepressants, antipsychotic medication, antihistamines), anticonvulsants (eg, phenytoin, carbamazepine, valproate), salicylates, immunosuppressive agents, antibiotics, and environmental toxins (eg, lead, organophosphates). Refer to separate UpToDate content on these agents for further details.</div><div id=\"graphicVersion\">Graphic 110254 Version 2.0</div></div></div>"},"110257":{"type":"graphic_table","displayName":"MRSA parenteral bacteremia osteomyelitis","title":"Parenteral antibiotics for treatment of bacteremia and osteomyelitis due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral antibiotics for treatment of bacteremia and osteomyelitis due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antibiotics of choice</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose</td> </tr> <tr> <td class=\"indent1\">Daptomycin</td> <td>6 to 10 mg/kg IV once daily*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Teicoplanin</td> <td>6 to 12 mg/kg IV once daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alternative agents</td> </tr> <tr> <td class=\"indent1\">Ceftaroline</td> <td>600 mg IV every 12 hours</td> </tr> <tr> <td class=\"indent1\">Telavancin</td> <td>10 mg/kg IV once daily</td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td>600 mg IV (or orally) twice daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Standard daptomycin dosing (as approved by the US Food and Drug Administration) for treatment of bacteremia or osteomyelitis is 6 mg/kg IV once daily. Because daptomycin exhibits concentration-dependent killing, some experts recommend doses of up to 8 to 10 mg/kg IV once daily, which appear safe; further study is needed.<sup>[1,2]</sup></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.</li>&#xD;&#xA;    <li>Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Ther Chemother 2006; 50:3245.</li>&#xD;&#xA;    <li>Lui C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 110257 Version 2.0</div></div></div>"},"110259":{"type":"graphic_table","displayName":"Protein-energy wasting assessment","title":"Protein-energy wasting assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protein-energy wasting assessment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assessment</td> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Dietary</strong></td> <td>History <ul class=\"decimal_heading\"> <li>Loss of appetite </li> <li>Loss of weight </li> <li>Gastrointestinal symptoms </li> <li>Depression </li> </ul> </td> <td>Monthly</td> </tr> <tr> <td>Comorbidities <ul class=\"decimal_heading\"> <li>Alcoholism </li> <li>Diabetes </li> <li>Gastrointestinal disease </li> </ul> </td> <td>Monthly</td> </tr> <tr> <td>Psychosocial <ul class=\"decimal_heading\"> <li>Access and affordability to food </li> <li>Ability to prepare meals </li> <li>Support of family members </li> </ul> </td> <td>Monthly</td> </tr> <tr class=\"divider_bottom\"> <td>Protein nitrogen appearance (PNA)</td> <td>Monthly</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Physical examination</strong></td> <td>Postdialysis weight</td> <td>Serial monitoring</td> </tr> <tr class=\"divider_bottom\"> <td>Bioimpedance analysis (BIA)</td> <td>(For research purposes)</td> </tr> <tr> <td><strong>Laboratory</strong></td> <td>Serum albumin</td> <td>Monthly</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 110259 Version 1.0</div></div></div>"},"110260":{"type":"graphic_table","displayName":"Interval compressed chemotherapy for Ewing sarcoma","title":"Interval compressed chemotherapy for Ewing sarcoma<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interval compressed chemotherapy for Ewing sarcoma<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\" colspan=\"6\">Induction chemotherapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Regimen</td> <td class=\"subtitle2_left\">Drug</td> <td class=\"subtitle2_left\">Dose</td> <td class=\"subtitle2_left\" colspan=\"3\">&nbsp;Timing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"4\">A</td> <td>Vincristine</td> <td>2 mg/m<sup>2</sup> (maximum 2 mg) IV over 1 minute, day 1</td> <td rowspan=\"4\" colspan=\"3\">Weeks 1, 5, and 9</td> </tr> <tr class=\"divider_bottom\"> <td>Doxorubicin</td> <td>37.5 mg/m<sup>2</sup> IV over 1 to 15 minutes, days 1 and 2</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> IV over 30 to 60 minutes, day 1, with mesna</td> </tr> <tr class=\"divider_bottom\"> <td>Filgrastim</td> <td>5 mcg/kg per day (maximum 300 mcg) starting day 3*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"3\">B</td> <td>Ifosfamide</td> <td>1800 mg/m<sup>2</sup> IV over 1 hour, days 1 to 5, with mesna</td> <td rowspan=\"3\" colspan=\"3\">Weeks 3, 7, and 11</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV over 1 to 2 hours, days 1 to 5</td> </tr> <tr class=\"divider_bottom\"> <td>Filgrastim</td> <td>5 mcg/kg per day (maximum 300 mcg) starting day 6*</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"6\">Consolidation chemotherapy<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Regimen</td> <td class=\"subtitle2_left\">Drug</td> <td class=\"subtitle2_left\">Dose</td> <td class=\"subtitle2_left\">Surgery alone</td> <td class=\"subtitle2_left\">RT alone</td> <td class=\"subtitle2_left\">Surgery and RT</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"4\">A</td> <td>Vincristine</td> <td>2 mg/m<sup>2</sup> (maximum 2 mg) IV over 1 minute, day 1</td> <td rowspan=\"4\">Weeks 15 and 19</td> <td rowspan=\"4\">Weeks 13 (with the start of RT) and 25</td> <td rowspan=\"4\">Weeks 15 (with the start of RT) and 27</td> </tr> <tr class=\"divider_bottom\"> <td>Doxorubicin</td> <td>37.5 mg/m<sup>2</sup> IV over 1 to 15 minutes, days 1 and 2</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> IV over 30 to 60 minutes, day 1, with mesna</td> </tr> <tr class=\"divider_bottom\"> <td>Filgrastim</td> <td>5 mcg/kg per day (maximum 300 mcg) starting day 3*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"3\">B</td> <td>Ifosfamide</td> <td>1800 mg/m<sup>2</sup> IV over 1 hour, days 1 to 5, with mesna</td> <td rowspan=\"3\">Weeks 17, 21, 25, and 29</td> <td rowspan=\"3\">Weeks 15, 19, 23, and 27</td> <td rowspan=\"3\">Weeks 17, 21, 25, and 29</td> </tr> <tr class=\"divider_bottom\"> <td>Etoposide</td> <td>100 mg/m<sup>2</sup> IV over 1 to 2 hours, days 1 to 5</td> </tr> <tr class=\"divider_bottom\"> <td>Filgrastim</td> <td>5 mcg/kg per day (maximum 300 mcg) starting day 6*</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">C</td> <td class=\"divider_bottom\">Vincristine</td> <td class=\"divider_bottom\">2 mg/m<sup>2</sup> (maximum 2 mg) IV over 1 minute, day 1</td> <td rowspan=\"3\">Weeks 23 and 27</td> <td rowspan=\"3\">Weeks 17 and 21</td> <td rowspan=\"3\">Weeks 19 and 23</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> IV over 30 to 60 minutes, day 1, with mesna</td> </tr> <tr> <td>Filgrastim</td> <td>5 mcg/kg per day (maximum 300 mcg) starting day 3*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; RT: radiation therapy.<br />* Daily filgrastim until absolute neutrophil count &gt;750 x 10<SUP>6</SUP>/L and platelet count &gt;75 x 10<SUP>9</SUP>/L. Proceed with next cycle of chemotherapy 24 hours after last filgrastim dose.<br />¶ Local therapy between weeks 13 and 15. Surgery at week 13, if it is planned. Start of RT delayed to week 15 if surgery also undertaken.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Protocol supplement from: Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:4148. Available at: <A href=\"http://ascopubs.org/doi/suppl/10.1200/jco.2011.41.5703/suppl_file/Protocol_JCO.2011.41.5703.pdf\">http://ascopubs.org/doi/suppl/10.1200/jco.2011.41.5703/suppl_file/Protocol_JCO.2011.41.5703.pdf</A> (Accessed on November 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 110260 Version 1.0</div></div></div>"},"110261":{"type":"graphic_table","displayName":"Rx of acute severe hypertension in pregnancy","title":"Treatment of acute severe hypertension in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of acute severe hypertension in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Initial dose</td> <td class=\"subtitle1\">Follow-up</td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"2\">Labetalol</td> <td>20 mg IV gradually over 2 minutes.</td> <td>Repeat BP measurement at 10-minute intervals: <ul class=\"decimal_heading\"> <li>If BP remains above target level at 10 minutes, give 40 mg IV over 2 minutes. </li> <li>If BP remains above target level at 20 minutes, give 80 mg IV over 2 minutes. </li> <li>If BP remains above target level at 30 minutes, give 80 mg IV over 2 minutes. </li> <li>If BP remains above target level at 40 minutes, give 80 mg IV over 2 minutes. </li> </ul> Cumulative maximum dose is 300 mg. If target BP is not achieved, switch to another agent.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>A continuous IV infusion of 1 to 2 mg/minute can be used instead of intermittent therapy or started after 20 mg IV dose.</p> Requires use of programmable infusion pump and continuous noninvasive monitoring of blood pressure and heart rate.</td> <td> <p>Adjust dose within this range to achieve target blood pressure.</p> Cumulative maximum dose is 300 mg. If target BP is not achieved, switch to another agent.</td> </tr> <tr class=\"divider_bottom\"> <td>Hydralazine</td> <td> <p>5 mg IV gradually over 1 to 2 minutes.*</p> Adequate&nbsp;reduction of blood pressure is less predictable than with IV labetalol.</td> <td>Repeat BP measurement at 20-minute intervals: <ul> <li>If BP remains above target level at 20 minutes, give 5 or 10 mg IV over 2 minutes, depending on the initial response. </li> <li>If BP remains above target level at 40 minutes, give 10 mg IV over 2 minutes, depending on the previous response. </li> </ul> Cumulative maximum dose is 20 mg. If target BP is not achieved, switch to another agent.</td> </tr> <tr class=\"divider_bottom\"> <td>Nifedipine immediate release<sup>&#182;</sup></td> <td> <p>10 mg orally.</p> May be associated with a precipitous drops in BP in some women, with associated FHR decelerations for which emergency&nbsp;cesarean delivery&nbsp;may be indicated. As such, this regimen is not typically used as a first-line option and is usually reserved only for women without IV access<span style=\"font-size: 10px;\"></span><span>​</span><span>​</span><span>​</span><span>​</span><span style=\"font-size: 10px;\"></span><span style=\"font-size: 10px;\"></span>.&nbsp;If used, FHR should be monitored while administering short-acting nifedipine.</td> <td>Repeat BP measurement at 20-minute intervals: <ul> <li>If BP remains above target at 20 minutes, give 10 or 20 mg orally<sup>&#182;</sup>, depending on the initial response. </li> <li>If BP remains above target at 40 minutes, give 10 or 20 mg orally<sup>&#182;</sup>, depending on the previous response. </li> </ul> If target BP is not achieved, switch to another class of agent.</td> </tr> <tr class=\"divider_bottom\"> <td>Nifedipine extended release</td> <td>30 mg orally.</td> <td> <p>If target BP is not achieved in 1 to 2 hours, another dose can be administered.</p> If target BP is not achieved, switch to another class of agent.</td> </tr> <tr> <td>Nicardipine (parenteral)</td> <td> <p>A continuous IV infusion of 3 to 9 mg/hour.</p> <p>Onset of action is delayed by 5 to 15 minutes; in general, rapid titration is avoided to minimize risk of overshooting dose.</p> Requires use of a programmable infusion pump and continuous noninvasive monitoring of blood pressure and heart rate.</td> <td>Adjust dose within this range to achieve target BP.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; BP: blood pressure; FHR: fetal heart rate.<br />* If IV access is not immediately available, hydralazine may be given intramuscularly (IM) at a dose of 10 mg.<br />¶ Capsules should be swallowed whole and not punctured or otherwise given sublingually.</div><div class=\"graphic_reference\">Data from: American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol 2015; 125:521.</div><div id=\"graphicVersion\">Graphic 110261 Version 2.0</div></div></div>"},"110268":{"type":"graphic_table","displayName":"Adrenal organ injury scale","title":"Adrenal organ injury scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adrenal organ injury scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Description of injury</td> </tr> <tr> <td class=\"centered\">I</td> <td>Contusion</td> </tr> <tr> <td class=\"centered\">II</td> <td>Laceration involving only cortex (&#60;2 cm)</td> </tr> <tr> <td class=\"centered\">III</td> <td>Laceration extending into medulla (&#8805;2 cm)</td> </tr> <tr> <td class=\"centered\">IV</td> <td>&#62;50% parenchymal destruction</td> </tr> <tr> <td class=\"centered\">V</td> <td> <p>Total parenchymal destruction (including massive intraparenchymal hemorrhage)</p> Avulsion from blood supply</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for bilateral lesions up to grade V.</div><div class=\"graphic_reference\">From: Moore EE, Malangoni MA, Cogbill TH, et al. Organ injury scaling VII: cervical vascular, peripheral vascular, adrenal, penis, testis, and scrotum. J Trauma 1996; 41:523. Copyright &copy; 1992 American Association for the Surgery of Trauma. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110268 Version 1.0</div></div></div>"},"110269":{"type":"graphic_table","displayName":"Ureter injury scale","title":"Ureter injury scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ureter injury scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury type</td> <td class=\"subtitle1\">Description of injury</td> </tr> <tr> <td class=\"centered\">I</td> <td>Hematoma</td> <td>Contusion or hematoma without devascularization</td> </tr> <tr> <td class=\"centered\">II</td> <td>Laceration</td> <td>&#60;50% transection</td> </tr> <tr> <td class=\"centered\">III</td> <td>Laceration</td> <td>&#8805;50% transection</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Laceration</td> <td>Complete transection with &#60;2 cm devascularization</td> </tr> <tr> <td class=\"centered\">V</td> <td>Laceration</td> <td>Avulsion with &#62;2 cm of devascularization</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for bilateral up to grade III.</div><div class=\"graphic_reference\">From: Moore EE, Cogbill TH, Jurkovich GJ, et al. Organ injury scaling. III: Chest wall, abdominal vascular, ureter, bladder, and urethra. J Trauma 1992; 33:337. Copyright © 1992 American Association for the Surgery of Trauma. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110269 Version 1.0</div></div></div>"},"110270":{"type":"graphic_table","displayName":"Bladder injury scale","title":"Bladder injury scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bladder injury scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury type</td> <td class=\"subtitle1\">Description of injury</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">I</td> <td>Hematoma</td> <td>Contusion, intramural hematoma</td> </tr> <tr> <td>Laceration</td> <td>Partial thickness</td> </tr> <tr> <td class=\"centered\">II</td> <td>Laceration</td> <td>Extraperitoneal bladder wall laceration &#60;2 cm</td> </tr> <tr> <td class=\"centered\">III</td> <td>Laceration</td> <td>Extraperitoneal (&#8805;2 cm) or intraperitoneal (&#60;2 cm) bladder wall laceration</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Laceration</td> <td>Intraperitoneal bladder wall laceration &#8805;2 cm</td> </tr> <tr> <td class=\"centered\">V</td> <td>Laceration</td> <td>Intraperitoneal or extraperitoneal bladder wall laceration extending into the bladder neck or ureteral orifice (trigone)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for multiple lesions up to grade III.</div><div class=\"graphic_reference\">From: Moore EE, Cogbill TH, Jurkovich GJ, et al. Organ injury scaling. III: Chest wall, abdominal vascular, ureter, bladder, and urethra. J Trauma 1992; 33:337. Copyright © 1992 American Association for the Surgery of Trauma. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110270 Version 2.0</div></div></div>"},"110271":{"type":"graphic_table","displayName":"Urethra injury scale","title":"Urethra injury scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urethra injury scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury type</td> <td class=\"subtitle1\">Description of injury</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">I</td> <td>Contusion</td> <td>Blood at urethral meatus; urethrography normal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">II</td> <td>Stretch injury</td> <td>Elongation of urethra without extravasation on urethrography</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">III</td> <td>Partial disruption</td> <td>Extravasation of urethrography contrast at injury site with visualization in the bladder</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered divider_bottom\">IV</td> <td class=\"divider_bottom\">Complete disruption</td> <td>Extravasation of urethrography contrast at injury site without visualization in the bladder; &#60;2 cm of urethral separation</td> </tr> <tr> <td class=\"centered\">V<sup>[1]</sup></td> <td>Complete disruption</td> <td>Complete transection with &#8805;2 cm urethral separation, or extension into the prostate or vagina</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for bilateral injuries up to grade III.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Moore EE, Cogbill TH, Malangoni M, et al. Scaling system for organ specific injuries: Urethra Injury, AAST update. Available at: <a href=\"http://www.aast.org/Library/TraumaTools/InjuryScoringScales.aspx\" target=\"_blank\">http://www.aast.org/Library/TraumaTools/InjuryScoringScales.aspx</a> (Accessed on September 13, 2017).</li>&#xD;&#xA;</ol>&#xD;&#xA;From:Moore EE, Cogbill TH, Jurkovich GJ, et al. Organ injury scaling. III: Chest wall, abdominal vascular, ureter, bladder, and urethra. J Trauma 1992; 33:337. Copyright &copy; 1992 American Association for the Surgery of Trauma. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110271 Version 2.0</div></div></div>"},"110272":{"type":"graphic_table","displayName":"DM1 phenotype and CTG repeat length","title":"A summary of the clinical phenotype and CTG repeat length in myotonic dystrophy type 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A summary of the clinical phenotype and CTG repeat length in myotonic dystrophy type 1</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Phenotype</td> <td class=\"subtitle1\">Clinical signs</td> <td class=\"subtitle1\">CTG repeat size</td> <td class=\"subtitle1\">Age of onset (years)</td> <td class=\"subtitle1\">Age of death (years)</td> </tr> <tr> <td>Premutation</td> <td>None</td> <td class=\"centered\">38 to 49</td> <td class=\"centered\">N/A</td> <td class=\"centered\">N/A</td> </tr> <tr> <td>Mild</td> <td>Cataracts, mild myotonia</td> <td class=\"centered\">50 to 150 </td> <td class=\"centered\">20 to 70</td> <td class=\"centered\">Normal life span</td> </tr> <tr> <td>Classical</td> <td>Muscle weakness with respiratory failure, myotonia, cataracts, cardiac arrhythmias, EDS</td> <td class=\"centered\">50 to 1000</td> <td class=\"centered\">10 to 30</td> <td class=\"centered\">48 to 60</td> </tr> <tr> <td>Childhood onset</td> <td>Psychosocial problems, low IQ, incontinence</td> <td class=\"centered\">&#62;800</td> <td class=\"centered\">1 to 10</td> <td class=\"centered\">N/A</td> </tr> <tr> <td>Congenital</td> <td>Infantile hypotonia, respiratory failure, learning disability, feeding difficulty</td> <td class=\"centered\">&#62;1000</td> <td class=\"centered\">Birth</td> <td class=\"centered\">45 (neonatal deaths not included)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table demonstrates the correlation between type of myotonic dystrophy type 1, clinical features, CTG repeat size, age of onset, and death. The correlation of age of onset with CTG repeat size is modest when the expansion size is measured in leucocyte DNA.</div><div class=\"graphic_footnotes\">EDS: excessive daytime sleepiness; IQ: intelligence quotient; N/A: not available; DNA: deoxyribonucleic acid.</div><div class=\"graphic_reference\">From: Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 2014; 27:599. DOI: <A href=\"http://journals.lww.com/co-neurology/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00014&amp;type=abstract\" target=_blank>10.1097/WCO.0000000000000128</A>. Copyright © 2014. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110272 Version 1.0</div></div></div>"},"110273":{"type":"graphic_algorithm","displayName":"Estimation LAP and severity of diastolic dysfunction ","title":"Estimation of left atrial pressure and severity of diastolic dysfunction in patients with left ventricular ejection fraction <50 percent OR a left ventricular ejection fraction ≥50 percent and diastolic dysfunction*","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Estimation of left atrial pressure and severity of diastolic dysfunction in patients with left ventricular ejection fraction &lt;50 percent OR a left ventricular ejection fraction &ge;50 percent and diastolic dysfunction*</div><div class=\"cntnt\"><img style=\"width:840px; height:314px;\" src=\"images/CARD/110273_LAprssr_svrty_dstlc_dysfnct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is a guide to estimation of left atrial pressure and severity of diastolic dysfunction in patients with left ventricular systolic dysfunction and/or diastolic dysfunction. For guidance on the evaluation of patients who have symptoms that may be caused by diastolic dysfunction, refer to UpToDate content on the diagnosis and evaluation of diastolic heart failure.</div><div class=\"graphic_footnotes\">E: peak velocity of early left ventricular filling; A: peak velocity of late left ventricular filling; e':&nbsp;peak early diastolic velocity of left ventricular myocardium adjacent to the mitral annulus by tissue Doppler;&nbsp;TR: tricuspid&nbsp;regurgitation;&nbsp;LA: left atrial<br />* The above algorithm should not be applied to patients with no LV systolic or diastolic dysfunction (ie, those with LVEF ≥50 percent and no diastolic dysfunction or with indeterminate diastolic function).<br />¶ For patients with LVEF ≤50 percent, if one of the three numbered parameters cannot be measured, a pulmonary vein S/D ratio &lt;1 can be substituted as a criterion suggestive of elevated LAP.<br />Δ This criterion should not be used in patients with significant pulmonary disease.<br /><FONT class=lozenge>◊</FONT> The LA volume index criterion should not be used in athletes or in patients with atrial fibrillation or more than mild mitral stenosis or regurgitation.<br />§ This includes patients in whom only two criteria are evaluable and one is positive and one is negative. This also includes patients in whom only one criterion is evaluable.</div><div class=\"graphic_reference\">Adapted from: Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29:277.</div><div id=\"graphicVersion\">Graphic 110273 Version 1.0</div></div></div>"},"110274":{"type":"graphic_table","displayName":"Modified Observer's Assessment of Alertness/Sedation Scale","title":"Modified Observer's Assessment of Alertness/Sedation Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Observer's Assessment of Alertness/Sedation Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Responsiveness</td> </tr> <tr> <td class=\"centered\">5</td> <td>Responds readily to name spoken in normal tone</td> </tr> <tr> <td class=\"centered\">4</td> <td>Lethargic response to name spoken in normal tone</td> </tr> <tr> <td class=\"centered\">3</td> <td>Responds after name called loudly or repeatedly or both</td> </tr> <tr> <td class=\"centered\">2</td> <td>Responds only after mild prodding or mild shaking</td> </tr> <tr> <td class=\"centered\">1</td> <td>Responds only to painful stimulation</td> </tr> <tr> <td class=\"centered\">0</td> <td>No response to painful stimulation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol 1990; 10:244.</div><div id=\"graphicVersion\">Graphic 110274 Version 3.0</div></div></div>"},"110276":{"type":"graphic_table","displayName":"Plasma concentrations of propofol for different sedation levels","title":"Mean and CI of plasma concentrations of propofol required to obtain each of the different levels of sedation according to the Observer's Assessment of Alertness/Sedation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mean and CI of plasma concentrations of propofol required to obtain each of the different levels of sedation according to the Observer's Assessment of Alertness/Sedation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">OAA/S score</td> <td class=\"subtitle1\">Responsiveness category</td> <td class=\"subtitle1\">Cp<sub>t</sub> of propofol<br /> (mcg/mL)</td> <td class=\"subtitle1\">95% CI<br /> (mcg/mL)</td> </tr> <tr> <td class=\"centered\">4</td> <td>Lethargic response to name spoken in normal tone</td> <td class=\"centered\">1.3 &#177; 0.33</td> <td class=\"centered\">1.2-1.4</td> </tr> <tr> <td class=\"centered\">3</td> <td>Responds only after name is called loudly and or repeatedly</td> <td class=\"centered\">1.7 &#177; 0.39</td> <td class=\"centered\">1.6-1.8</td> </tr> <tr> <td class=\"centered\">2</td> <td>Responds only after mild prodding or shaking</td> <td class=\"centered\">2.0 &#177; 0.4</td> <td class=\"centered\">1.9-2.1</td> </tr> <tr> <td class=\"centered\">1</td> <td>Responds only after squeezing the trapezius</td> <td class=\"centered\">2.4 &#177; 0.5</td> <td class=\"centered\">2.2-2.5</td> </tr> <tr> <td class=\"centered\">0</td> <td>Does not respond after squeezing the trapezius</td> <td class=\"centered\">2.8 &#177; 0.6</td> <td class=\"centered\">2.6-3.0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Results are presented as mean (±SD).</div><div class=\"graphic_footnotes\">CI: confidence inter<SPAN style=\"COLOR: black\">vals; Cp<SUB>t</SUB>: plasma concentrations; OAA</SPAN>/S: Observer's Assessment of Alertness/Sedation; SD: standard deviation.</div><div class=\"graphic_reference\">Canadian Journal of Anaesthesia, Clinical assessment of target-controlled infusion of propofol during monitored anesthesia care, Vol. 46, 1999, p. 235, Casati A, Fanelli G, Casaletti E, et al, copyright © Canadian Anesthesiologists' Society 1999, with permission of Springer.</div><div id=\"graphicVersion\">Graphic 110276 Version 2.0</div></div></div>"},"110278":{"type":"graphic_waveform","displayName":"ECG adolescent with HCM","title":"ECG adolescent with HCM","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">ECG adolescent with HCM</div><div class=\"cntnt\"><img style=\"width:768px; height:456px;\" src=\"images/CARD/110278_ECG_adolescent_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fifteen-year-old patient with HCM and a documented disease-causing mutation in the gene <EM>MYBP3</EM>. The ECG was performed with limb leads at standard voltage calibration (10 mm = 1 mV) and precordial leads at half standard voltage calibration (5 mm = 1 mV). Note the markedly increased voltage consistent with left ventricular hypertrophy, T-wave inversion in inferior and lateral leads, and prolonged QTc interval (measured at 480 msec).</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110278 Version 2.0</div></div></div>"},"110279":{"type":"graphic_waveform","displayName":"ECG neonate with HCM and Pompe disease","title":"ECG neonate with HCM and Pompe disease","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">ECG neonate with HCM and Pompe disease</div><div class=\"cntnt\"><img style=\"width:768px; height:578px;\" src=\"images/CARD/110279_ECG_neonate_HCM_Pompe_disea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A neonatal patient with Pompe disease. The ECG is performed with all leads at standard voltage calibration (10 mm = 1 mV). Note the biatrial enlargement and extreme biventricular hypertrophy with strain.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110279 Version 1.0</div></div></div>"},"110280":{"type":"graphic_diagnosticimage","displayName":"2D TTE parasternal long axis HCM in adolescent","title":"2D TTE parasternal long axis HCM in adolescent","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">2D TTE parasternal long axis HCM in adolescent</div><div class=\"cntnt\"><img style=\"width:756px; height:524px;\" src=\"images/CARD/110280_2D_TEE_prstrnl_lng_axs_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM with marked asymmetric septal hypertrophy seen on transthoracic echocardiography from the parasternal long axis view. This patient has a documented disease-causing mutation in the gene MYBP3.</div><div class=\"graphic_footnotes\">TTE: transthoracic echocardiography; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110280 Version 1.0</div></div></div>"},"110284":{"type":"graphic_picture","displayName":"Restrictive dermopathy","title":"Restrictive dermopathy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Restrictive dermopathy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110284_Restrictive_dermopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hard, adherent, and shiny skin in a premature neonate with restrictive dermopathy. Note the erosions at flexures sites.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110284 Version 1.0</div></div></div>"},"110287":{"type":"graphic_figure","displayName":"Bronchopulmonary segments","title":"Bronchopulmonary segments","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Bronchopulmonary segments</div><div class=\"cntnt\"><img style=\"width:617px; height:787px;\" src=\"images/SURG/110287_Bronchopulmonary_segments.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 110287 Version 1.0</div></div></div>"},"110288":{"type":"graphic_picture","displayName":"Thoracoscopic view of subpleural blebs and bulla","title":"Thoracoscopic view of subpleural blebs and bulla","html":"<div class=\"graphic\"><div style=\"width: 737px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic view of subpleural blebs and bulla</div><div class=\"cntnt\"><img style=\"width:717px; height:693px;\" src=\"images/SURG/110288_Thrcscpc_pnmthrx_assc_blebs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show a thoracoscopic view of bullae and blebs associated with spontaneous pneumothorax. Those shown in Panels A and C are largely intact. In Panel B, the bulla was likely ruptured by the operator to improve the field of view. To excise these lesions, the base of a bulla can be stapled, with or without buttressing material, thereby decreasing the chance of air leak from the surface of the lung.</div><div id=\"graphicVersion\">Graphic 110288 Version 1.0</div></div></div>"},"110289":{"type":"graphic_picture","displayName":"Thoracoscopic view of pleural empyema","title":"Thoracoscopic view of pleural empyema","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic view of pleural empyema</div><div class=\"cntnt\"><img style=\"width:756px; height:486px;\" src=\"images/SURG/110289_Thoracoscpc_pleural_empyema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thoracoscopic view of fibrinopurulent effusion in patient with tuberculous empyema.</div><div id=\"graphicVersion\">Graphic 110289 Version 1.0</div></div></div>"},"110290":{"type":"graphic_picture","displayName":"Sisaipho pattern of alopecia areata","title":"Sisaipho pattern of alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Sisaipho pattern of alopecia areata</div><div class=\"cntnt\"><img style=\"width:524px; height:528px;\" src=\"images/DERM/110290_Sisaipho_pttrn_alopecia_are.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alopecia areata involving the central scalp and sparing the periphery.</div><div class=\"graphic_reference\">From: Fonda-Pascual P, Vano-Galvan S, Garcia-Hernandez MJ, Camacho F. Alopecia Areata Sisaipho: Clinical and Therapeutic Approach in 13 Patients in Spain. Int J Trichology 2016; 8:99. DOI: <A href=\"http://www.ijtrichology.com/article.asp?issn=0974-7753;year=2016;volume=8;issue=2;spage=99;epage=100;aulast=Fonda-Pascual\" target=_blank>10.4103/0974-7753.188039</A>. Copyright © 2016 Hair Research Society of India. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110290 Version 1.0</div></div></div>"},"110292":{"type":"graphic_figure","displayName":"Falciform and round ligament","title":"Falciform and round ligament reinforcement of distal pancreatectomy stump","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Falciform and round ligament reinforcement of distal pancreatectomy stump</div><div class=\"cntnt\"><img style=\"width:565px; height:579px;\" src=\"images/SURG/110292_Falciform_and_round_ligaments_of_the_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) The falciform and/or round ligament of the liver are detached from the anterior abdominal wall while keeping vascular supply from the liver. <br />(Panel B) The vascularized falciform/round ligament pedicle is passed into the lesser sac through a defect created in the lesser omentum (ie, gastrohepatic ligament). <br />(Panel C) The vascularized pedicle is sutured to the distal pancreatectomy stump as a reinforcement to prevent postoperative pancreatic leak/fistula formation.<br />Vascularized pedicles, such as the falciform ligament and the round ligament of the liver (ie, ligamentum teres, which contains the remnant of fetal umbilical vein), have been used as reinforcements to cover the cut surface of the distal pancreatectomy stump.&nbsp;Success varied between studies; refer to topic for details.&nbsp;</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>​Hassenpflug M, Bruckner T, Knebel P, et al. DISCOVER trial - Distal resection of the pancreas with or without coverage of the pancreatic remnant: study protocol of a randomised controlled trial. Trials 2013; 14:430.</LI>&#xD;&#xA;<LI>Iannitti DA, Coburn NG, Somberg J, et al. Use of the round ligament of the liver to decrease pancreatic fistulas: a novel technique. J Am Coll Surg 2006; 203:857.</LI></OL></div><div id=\"graphicVersion\">Graphic 110292 Version 1.0</div></div></div>"},"110293":{"type":"graphic_table","displayName":"Postpartum hemorrhage cart","title":"Example of instruments, equipment, and medications to assemble for a postpartum hemorrhage emergency cart","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of instruments, equipment, and medications to assemble for a postpartum hemorrhage emergency cart</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Equipment/supplies for starting an intravenous line (14-, 16-, 18-, and 20-gauge peripheral venous catheter, 1 L Lactated Ringer's solution for injection, intravenous tubing, four-way stopcock, tape) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Urinary catheter kit, urimeter </li> </ul> </td> </tr> <tr> <td> <ul> <li>Lubricating gel </li> </ul> </td> </tr> <tr> <td> <ul> <li>Assorted sizes of sterile gloves, including elbow-length gloves </li> </ul> </td> </tr> <tr> <td> <ul> <li>Vaginal retractors, including a long right-angle retractor </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sterile speculum, long weighted speculum </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sponge forceps </li> </ul> </td> </tr> <tr> <td> <ul> <li>Vaginal packs, 2 by 2 and 4 by 4 sponge gauze packs,&nbsp;gauze bandage rolls </li> </ul> </td> </tr> <tr> <td> <ul> <li>Balloon catheter kit for intrauterine tamponade </li> </ul> </td> </tr> <tr> <td> <ul> <li>Sterile utility bowl, 20 and 60&nbsp;mL syringes, irrigation water </li> </ul> </td> </tr> <tr> <td> <ul> <li>Banjo curettes </li> </ul> </td> </tr> <tr> <td> <ul> <li>Long needle holder </li> </ul> </td> </tr> <tr> <td> <ul> <li>Appropriate sutures for cervical and vaginal laceration repair and for uterine compression sutures </li> </ul> </td> </tr> <tr> <td> <ul> <li>Uterine forceps </li> </ul> </td> </tr> <tr> <td> <ul> <li>Freestanding mobile task light, battery-powered headlamp </li> </ul> </td> </tr> <tr> <td> <ul> <li>Illustrations showing how to perform relevant procedures (eg, uterine compression, uterine artery ligation, intrauterine balloon placement, replacement of inverted uterus) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment/supplies for drawing blood (eg, syringes; needles; red, green, blue, and tiger top tubes; alcohol prep pads; tourniquet) for laboratory studies (eg, type and cross, coagulation studies, CBC, platelets, electrolytes, ionized calcium, potassium) with prewritten lab and blood bank requisition orders; instructions on how to order tests and blood and how to activate the massive transfusion protocol </li> </ul> </td> </tr> <tr> <td> <ul> <li>Biohazard bag </li> </ul> </td> </tr> <tr> <td> <ul> <li>Adult oxygen nonrebreather mask </li> </ul> </td> </tr> <tr> <td> <ul> <li>Tubing and filter for blood transfusion </li> </ul> </td> </tr> <tr> <td> <ul> <li>Equipment for warming irrigation and intravenous fluids </li> </ul> </td> </tr> <tr> <td> <ul> <li>Pressure infusor bag </li> </ul> </td> </tr> <tr> <td> <ul> <li>Tape, bandages </li> </ul> </td> </tr> <tr> <td> <ul> <li>Medications: <ul> <li>Kit for transabdominal intramyometrial injection of carboprost under ultrasound guidance: 20 mL&nbsp;syringe, 20&nbsp;mL sterile saline for injection, 6 inch 20-gauge and 6 inch 22-gauge amniocentesis needles </li> <li>Misoprostol, five 200 mcg tablets </li> <li>Oxytocin, 10 to 40 units per 500 to 1000 mL NS 1 bag </li> <li>Methylergonovine, 0.2 mg/mL 1 ampule (requires refrigeration) </li> <li>Carboprost, 250 mcg/mL 1 ampule (requires refrigeration) </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; NS: normal saline.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>California Maternal Quality Care Collaborative Improving Response to Obstetric Hemorrhage Toolkit V2.0. <a href=\"http://www.cmqcc.org/resources-tool-kits\" target=\"_blank\">www.cmqcc.org/resources-tool-kits</a> (Accessed on October 31, 2016).</li>&#xD;&#xA;    <li>Texas Children's Hospital-Pavilion for Women postpartum hemorrhage cart inventory list.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 110293 Version 1.0</div></div></div>"},"110294":{"type":"graphic_table","displayName":"Prostate cancer screening decision aid","title":"Should I be screened for prostate cancer?","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Should I be screened for prostate cancer?</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>The answer to this question is not the same for everyone. Your doctor can help you decide based on your values and preferences.</p> <p>The main test used to screen for prostate cancer is a blood test called a \"PSA test.\" Doctors offer screening in the hopes of catching prostate cancer early &ndash; before it has a chance to grow, spread, or cause symptoms. But it is not clear if getting screened for prostate cancer can extend a man's life or help him avoid any symptoms or problems.</p> <p>It might help to ask yourself the following questions when deciding whether or not to be screened:</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Am I at high risk for prostate cancer?</strong> <ul class=\"decimal_heading\"> <li>On average, 1 in 6 men will get prostate cancer. But some men are at higher risk, including black men and men with a close relative who had the disease. If you're not sure, your doctor can help you figure out if you are at high risk. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Do I want to know if I have prostate cancer?</strong> <ul class=\"decimal_heading\"> <li>Some cancers found by screening tests are slow growing, and would not cause harm for many years or might never cause harm. That means you could go through treatment for a cancer that would not have caused you harm.</li> <li>Some people feel better having as much information as possible. Other people prefer to take a \"wait and see\" approach. Think about which bothers you more &ndash;&nbsp;the possibility of not catching cancer as early as possible, or the risks that come with tests and treatments you might not otherwise have needed. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>How do I feel about the possibility of getting a \"false positive\" result?</strong> <ul class=\"decimal_heading\"> <li>2 out of every 3 positive PSA tests end up being \"false positives.\" This means the test suggests&nbsp;cancer when there is actually no cancer. This can lead to unneeded worry and extra tests, including a biopsy (see next question). </li> <li>Other things besides cancer can cause a PSA test to be positive. These include an enlarged prostate, riding a bicycle, or ejaculating (having an orgasm) within a few days before the test. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Am I willing to have a prostate biopsy to check for cancer?</strong> <ul class=\"decimal_heading\"> <li>If your PSA test comes back positive, you will then need another test called a \"biopsy\" to look for cancer. This test can be painful and comes with some risk of infection. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Would I want to be treated if I learned I had prostate cancer?</strong> <ul class=\"decimal_heading\"> <li>For some men, \"active surveillance\" might be an option. Men who choose this option do not have treatment right away. But they do have routine tests to check whether the cancer starts to grow more quickly. If so, they can start active treatment then. </li> <li>Some men wish to get treatment right away, or their doctors suggest treatment (rather than active surveillance) based on their cancer. Possible options include radiation and surgery. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>How do I feel about the risks of being treated for prostate cancer?</strong> <ul class=\"decimal_heading\"> <li>The risks of treatments like radiation and surgery include leaking urine, problems with sex, bowel problems, and even death (although that risk is very small). </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>How would I feel about getting a serious (or even deadly) form of prostate cancer if I had decided not to get screened?</strong> <ul class=\"decimal_heading\"> <li>Although this is rare, it might help to think about whether you would regret not having done everything possible to find cancer early. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PSA: prostate-specific antigen.</div><div id=\"graphicVersion\">Graphic 110294 Version 2.0</div></div></div>"},"110302":{"type":"graphic_diagnosticimage","displayName":"2D TTE parasternal short axis HCM in adolescent","title":"2D TTE parasternal short axis HCM in adolescent","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">2D TTE parasternal short axis HCM in adolescent</div><div class=\"cntnt\"><img style=\"width:756px; height:524px;\" src=\"images/CARD/110302_2D_TEE_prstrnl_shrt_axs_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM with marked asymmetric septal hypertrophy seen on transthoracic echocardiography from the parasternal short axis&nbsp;view. This patient has a documented disease-causing mutation in the gene MYBP3.</div><div class=\"graphic_footnotes\">TTE: transthoracic echocardiography; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110302 Version 1.0</div></div></div>"},"110311":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical four-chamber HCM in adolescent","title":"2D TTE apical four-chamber HCM in adolescent","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">2D TTE apical four-chamber HCM in adolescent</div><div class=\"cntnt\"><img style=\"width:756px; height:520px;\" src=\"images/CARD/110311_2D_TEE_apical_4chamber_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM with marked asymmetric septal hypertrophy seen on transthoracic echocardiography from the apical four-chamber view. This patient has a documented disease-causing mutation in the gene MYBP3.</div><div class=\"graphic_footnotes\">TTE: transthoracic&nbsp;echocardiography; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110311 Version 2.0</div></div></div>"},"110312":{"type":"graphic_diagnosticimage","displayName":"2D TTE parasternal long axis HCM and Pompe","title":"2D TTE parasternal long axis HCM and Pompe","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">2D TTE parasternal long axis HCM and Pompe</div><div class=\"cntnt\"><img style=\"width:756px; height:514px;\" src=\"images/CARD/110312_2D_TEE_prstrnl_lng_HCM_Pomp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM with symmetric hypertrophy seen on transthoracic echocardiography&nbsp;from the parasternal long axis view. This patient has a documented disease-causing mutation in the gene MYBP3.</div><div class=\"graphic_footnotes\">TTE: transthoracic echocardiography; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110312 Version 1.0</div></div></div>"},"110318":{"type":"graphic_diagnosticimage","displayName":"2D TTE parasternal short axis HCM and Pompe","title":"2D TTE parasternal short axis HCM and Pompe","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">2D TTE parasternal short axis HCM and Pompe</div><div class=\"cntnt\"><img style=\"width:756px; height:516px;\" src=\"images/CARD/110318_2D_TEE_prstrnl_shrt_HCM_Pom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM with symmetric hypertrophy seen on transthoracic echocardiography from the parasternal short axis view. This patient has a documented disease-causing mutation in the gene MYBP3.</div><div class=\"graphic_footnotes\">TTE: transthoracic&nbsp;echocardiography; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110318 Version 1.0</div></div></div>"},"110319":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical four-chamber HCM and Pompe","title":"2D TTE apical four-chamber HCM and Pompe","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">2D TTE apical four-chamber HCM and Pompe</div><div class=\"cntnt\"><img style=\"width:756px; height:511px;\" src=\"images/CARD/110319_2D_TEE_apical_4cham_HCM_Pom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCM with symmetric hypertrophy seen on transthoracic echocardiography from the apical four chamber view. This patient has a documented disease-causing mutation in the gene MYBP3.</div><div class=\"graphic_footnotes\">TTE: transthoracic&nbsp;echocardiography; HCM: hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 110319 Version 1.0</div></div></div>"},"110320":{"type":"graphic_figure","displayName":"Protein C and S function","title":"Protein C and S function in the termination of coagulation","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Protein C and S function in the termination of coagulation</div><div class=\"cntnt\"><img style=\"width:476px; height:226px;\" src=\"images/HEME/110320_ProteinSfunction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Protein C is activated on the endothelial cell membrane, where it is anchored by the endothelial protein C receptor. Activated protein C and protein S assemble on the platelet membrane. Protein S acts as a cofactor for protein C in proteolytically cleaving activated factors V and VIII (factors Va and VIIIa). </div><div class=\"graphic_footnotes\">TM: thrombomodulin; T: thrombin; EPCR: endothelial protein C receptor; PC: protein C; PS: protein S; APC: activated protein C; Va:&nbsp;activated factor V; VIIIa: activated factor VIII. </div><div class=\"graphic_reference\">Reproduced with permission from: Bunn HF, Bauer KA. Thrombotic Disorders. In: Pathophysiology of Blood Disorders, Bunn HF, Aster JC (Eds), McGraw-Hill Education, New York 2011. Copyright © 2011 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 110320 Version 3.0</div></div></div>"},"110321":{"type":"graphic_diagnosticimage","displayName":"CMR four-chamber HCM with LGE showing fibrosis","title":"CMR four-chamber HCM with LGE showing fibrosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">CMR four-chamber HCM with LGE showing fibrosis</div><div class=\"cntnt\"><img style=\"width:756px; height:756px;\" src=\"images/CARD/110321_CMR_4cham_HCM_LGE_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrosis as demonstrated by late gadolinium enhancement on CMR imaging shows up as white on the background of black myocardium. This is seen in the four-chamber view.</div><div class=\"graphic_footnotes\">CMR: cardiac magnetic resonance; HCM: hypertrophic cardiomyopathy; LGE: late gadolinium enhancement.</div><div id=\"graphicVersion\">Graphic 110321 Version 1.0</div></div></div>"},"110322":{"type":"graphic_diagnosticimage","displayName":"CMR short axis HCM with LGE showing fibrosis","title":"CMR short axis HCM with LGE showing fibrosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">CMR short axis HCM with LGE showing fibrosis</div><div class=\"cntnt\"><img style=\"width:756px; height:756px;\" src=\"images/CARD/110322_CMR_shrt_HCM_LGE_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrosis as demonstrated by late gadolinium enhancement on CMR imaging shows up as white on the background of black myocardium. This is seen in the short axis view.</div><div class=\"graphic_footnotes\">CMR: cardiac magnetic resonance; HCM: hypertrophic cardiomyopathy; LGE: late gadolinium enhancement.</div><div id=\"graphicVersion\">Graphic 110322 Version 1.0</div></div></div>"},"110343":{"type":"graphic_figure","displayName":"Sagittal view of female pelvis and rectovaginal septum","title":"Sagittal view of female pelvis and rectovaginal septum","html":"<div class=\"graphic\"><div style=\"width: 832px\" class=\"figure\"><div class=\"ttl\">Sagittal view of female pelvis and rectovaginal septum</div><div class=\"cntnt\"><img style=\"width:812px; height:816px;\" src=\"images/OBGYN/110343_Sagittal_view_female_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of female pelvis with posterior cul-de-sac and rectovaginal septum in bold text.</div><div class=\"graphic_reference\">Reproduced with permission from: Delancey JOL. Surgical anatomy of the female pelvis. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Wolters Kluwer, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 110343 Version 1.0</div></div></div>"},"110373":{"type":"graphic_table","displayName":"Etiology neonatal shock","title":"Etiology of neonatal shock based on pathogenesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of neonatal shock based on pathogenesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Disorder</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Hypovolemic</td> </tr> <tr> <td class=\"indent1\">Hemorrhage</td> <td> <ul> <li>Fetomaternal hemorrhage </li> <li>Severe bleeding (eg, subgaleal hemorrhage, umbilical cord rupture, internal bleeding) </li> <li>Twin-twin transfusion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Non-hemorrhage</td> <td> <ul> <li>Third spacing from acute intestinal injury (eg, volvulus, necrotizing enterocolitis) </li> <li>Gastrointestinal fluid loss from congenital chloridorrhea </li> <li>Polyuria due to congenital diabetes insipidus </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Distributive</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Non-sepsis</td> <td> <ul> <li>Adrenal insufficiency </li> <li>Hydrops fetalis </li> <li>Neonatal toxic shock syndrome </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cardiogenic</td> </tr> <tr> <td class=\"indent1\">Cardiomyopathic</td> <td> <ul> <li>Myocardial ischemia/hypoxemia </li> <li>Myocarditis </li> <li>Congenital cardiomyopathy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Arrhythmogenic</td> <td> <ul> <li>Congenital complete heart block </li> <li>Tachyarrhythmia (eg, SVT, VT) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Structural</td> <td>Congenital heart disease: <ul class=\"decimal_heading\"> <li>Hypoplastic left heart syndrome </li> <li>Critical aortic stenosis </li> <li>Critical coarctation of the aorta </li> <li>Interrupted aortic arch </li> <li>Obstructed total anomalous pulmonary venous connection </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Obstructive</td> </tr> <tr> <td class=\"indent1\">Pulmonary vascular</td> <td> <ul> <li>Severe pulmonary hypertension </li> <li>Pulmonary embolus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mechanical</td> <td> <ul> <li>Tension pneumothorax </li> <li>Pericardial tamponade </li> <li>Constrictive pericarditis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; VT: ventricular tachycardia.</div><div id=\"graphicVersion\">Graphic 110373 Version 1.0</div></div></div>"},"110390":{"type":"graphic_algorithm","displayName":"Evaluation of late pregnancy bleeding","title":"Evaluation of late pregnancy bleeding","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Evaluation of late pregnancy bleeding</div><div class=\"cntnt\"><img style=\"width:722px; height:354px;\" src=\"images/OBGYN/110390_Eval_late_preg_bleeding.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Hemodynamic instability and fetal heart rate abnormalities may represent obstetric emergencies that both influence the likely diagnosis and require modification of the evaluation.<br />¶ In women with uterine bleeding and a previous cesarean delivery or transmyometrial surgery, the possibility of uterine rupture should always be considered. Uterine rupture is most likely to occur during labor or as a result of abdominal trauma but may occur spontaneously. Abdominal pain, fetal heart rate abnormalities, and maternal hemodynamic instability due to intra-abdominal bleeding are likely but not always present.<br />Δ Women with bleeding and contractions in the second trimester but less than 20 weeks of gestation are diagnosed with threatened miscarriage rather than labor. Ectopic pregnancy is rare at this gestational age; the location is generally non-tubal (eg, corneal or abdominal) and may be detected by careful ultrasound examination.<br /><FONT class=lozenge>◊</FONT> Bloody show is the term used to describe the small amount of blood with mucus discharge that may precede the onset of labor by as much as 72 hours.<br />§ If there is no visible blood on speculum examination, consider rectal bleeding (such as hemorrhoids) as the possible source of bleeding.</div><div id=\"graphicVersion\">Graphic 110390 Version 2.0</div></div></div>"},"110391":{"type":"graphic_diagnosticimage","displayName":"Normal lung and pneumothorax with ultrasound m mode","title":"Normal lung and pneumothorax using ultrasound m mode","html":"<div class=\"graphic\"><div style=\"width: 1470px\" class=\"figure\"><div class=\"ttl\">Normal lung and pneumothorax&nbsp;using ultrasound m mode</div><div class=\"cntnt\"><img style=\"width:1450px; height:574px;\" src=\"images/EM/110391_Pneumothorax_US_m_mode.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both sets of&nbsp;ultrasound&nbsp;pictures above&nbsp;show the&nbsp;m mode images below&nbsp;and&nbsp;standard images above.&nbsp;Panel A shows the appearance of a normal lung segment.&nbsp;In the m mode images, the parietal and visceral pleura are divided by the pleural line. Compare&nbsp;the parietal pleura in panel A, which appears as a series of&nbsp;parallel, non-fluctuating lines (\"waves\") to the visceral pleura, which&nbsp;appears more granular, like sand (\"beach\").&nbsp;The presence of these&nbsp;normal findings, sometimes described as the \"seashore sign,\"&nbsp;rules out pneumothorax in this location.&nbsp;Panel B shows&nbsp;an abnormal lung&nbsp;appearance consistent with pneumothorax. Both above and below the parietal line, only parallel, non-fluctuating lines are seen.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 110391 Version 1.0</div></div></div>"},"110393":{"type":"graphic_figure","displayName":"Zones of the retroperitoneum","title":"Zones of the retroperitoneum","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Zones of the retroperitoneum</div><div class=\"cntnt\"><img style=\"width:543px; height:678px;\" src=\"images/SURG/110393_Zones_of_the_retroperitoneum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates the zones of the retroperitoneum and their contents.</div><div id=\"graphicVersion\">Graphic 110393 Version 1.0</div></div></div>"},"110394":{"type":"graphic_table","displayName":"Drugs commonly used for monitored anesthesia care","title":"Drugs commonly used for monitored anesthesia care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs commonly used for monitored anesthesia care</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Dose range</td> <td class=\"subtitle1\">Onset</td> <td class=\"subtitle1\">Duration</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Midazolam</td> <td>0.5&nbsp;to 2 mg IV prior to propofol over 2 to 3 minutes; may repeat after 2 to 5 minutes</td> <td>1 to 2.5 minutes</td> <td>10 to 40 minutes</td> <td> <ul> <li>Potentiates the effects of other agents<sup>[1]</sup> </li> <li>Sedative and anxiolytic </li> <li>Prolonged effect or delayed recovery in older adults, obese, or impaired hepatic function </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Propofol</td> <td>250 to 500 mcg/kg IV bolus</td> <td>30 seconds</td> <td>5 to 10 minutes</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Sedative and amnestic, no analgesia </li> <li>Rapid recovery without residual </li> <li>Pain on injection common </li> <li>Respiratory depression and hypotension can occur </li> <li>Reduce dose by 20% in older adults </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>25 to 75 mcg/kg/minute IV infusion</td> <td>3 to 4 minutes, without bolus</td> <td>4 minutes after discontinuation of infusion</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Dexmedetomidine</td> <td>Loading: 0.5 to 1 mcg/kg over 10 to 20 minutes<sup>[2]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">5 to 10 minutes</td> <td class=\"divider_bottom\" rowspan=\"2\">30 to 40 minutes<sup>[1]</sup></td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Sedative, analgesic, without amnesia </li> <li>Bradycardia and hypotension or hypertension may occur </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Maintenance: 0.2 to 1 mcg/kg/hour</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine</td> <td>0.25 to 0.5 mg/kg IV</td> <td>1 to 2 minutes</td> <td>20 to 60 minutes</td> <td> <ul> <li>Dissociative sedative, amnestic, analgesic </li> <li>Minimal cardiac or respiratory depression in small doses </li> <li>Emergence reactions, nausea and vomiting possible </li> <li>Prolonged effect in older adults </li> </ul> </td> </tr> <tr> <td>Opioids</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <ul> <li>Analgesic, minimal sedation </li> <li>Respiratory depression, nausea and vomiting may occur </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fentanyl</td> <td>0.5 to 2 mcg/kg IV, administered in intermittent boluses of 25 to 50 mcg IV</td> <td>2 to 3 minutes</td> <td>30 to 60 minutes</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Remifentanil</td> <td>0.1 mcg/kg/minute IV, started 5 minutes prior to stimulus; wean to 0.05 mcg/kg/minute IV as possible<sup>&#182;</sup></td> <td>1 to 1.5 minutes</td> <td>3 to 5 minutes after discontinuation of infusion</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous<br />* Doses should be modified based on patient factors (eg, doses reduced for older adult patients) and when combinations of drugs are administered.<br />¶ Remifentanil dose should be reduced when administered with midazolam or propofol.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dailymed: Midazolam (midazolam hydrochloride injection). <a href=\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=737361a0-8db1-4d3c-ba5e-44df3f49fa22\" target=\"_blank\">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=737361a0-8db1-4d3c-ba5e-44df3f49fa22</a> (Accessed on October 20, 2016).</li>&#xD;&#xA;    <li>Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002; 95:461.</li>&#xD;&#xA;</ol>&#xD;&#xA;Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45:855.</li>&#xD;&#xA;    <li>Falk J, Zed P. Etomidate for procedural sedation in the emergency department. Ann Pharmacother 2004; 38:1272.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 110394 Version 3.0</div></div></div>"},"110395":{"type":"graphic_figure","displayName":"Arterial evaluation before creating an arteriovenous fistula","title":"Arterial evaluation before creating an arteriovenous fistula","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Arterial evaluation before creating an arteriovenous fistula</div><div class=\"cntnt\"><img style=\"width:714px; height:376px;\" src=\"images/SURG/110395_Arterial_evaluation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates the steps in performing an arterial evaluation prior to the creation of an arteriovenous (AV) fistula for hemodialysis. </div><div id=\"graphicVersion\">Graphic 110395 Version 1.0</div></div></div>"},"110396":{"type":"graphic_picture","displayName":"Evidence of previous central catheters","title":"Evidence of previous central catheters","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Evidence of previous central catheters</div><div class=\"cntnt\"><img style=\"width:756px; height:756px;\" src=\"images/SURG/110396_Evidence_previous_catheters.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physical examination shows evidence of multiple prior central catheter access points (arrows).</div><div id=\"graphicVersion\">Graphic 110396 Version 1.0</div></div></div>"},"110397":{"type":"graphic_figure","displayName":"Allen test performed with pulse oximeter","title":"Allen test performed with pulse oximeter","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Allen test performed with pulse oximeter</div><div class=\"cntnt\"><img style=\"width:744px; height:464px;\" src=\"images/SURG/110397_Allen_test_wth_pulse_oximtr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A modified Allen test can be performed using a pulse oximetry probe, which&nbsp;should be placed on the patient's index finger. The ulnar and radial arteries are compressed. The loss of the pulse oximeter waveform is an objective measure that compression is adequate. A return of a pulse wave following the release of the ulnar artery indicates a negative test (ie, a patent ulnar artery). The test can then be repeated by compressing the ulnar artery again and then releasing the radial artery to demonstrate its patency. </div><div id=\"graphicVersion\">Graphic 110397 Version 1.0</div></div></div>"},"110398":{"type":"graphic_waveform","displayName":"Spectral Doppler ultrasound showing reactive hyperemia","title":"Spectral Doppler ultrasound showing reactive hyperemia","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Spectral Doppler ultrasound showing reactive hyperemia</div><div class=\"cntnt\"><img style=\"width:801px; height:404px;\" src=\"images/SURG/110398_US_reactive_hyperemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Triphasic pulse wave pre-ischemia.<br />(B) Biphasic pulse wave post-ischemia illustrating reactive hyperemia.</div><div id=\"graphicVersion\">Graphic 110398 Version 1.0</div></div></div>"},"110399":{"type":"graphic_diagnosticimage","displayName":"Radial artery ultrasound","title":"Radial artery ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Radial artery ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:745px;\" src=\"images/SURG/110399_Radial_artery_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image shows the diameter measurement of the radial artery at 0.23 cm.</div><div id=\"graphicVersion\">Graphic 110399 Version 1.0</div></div></div>"},"110400":{"type":"graphic_diagnosticimage","displayName":"Measurement of vein distensibility","title":"Measurement of vein distensibility","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Measurement of vein distensibility</div><div class=\"cntnt\"><img style=\"width:765px; height:461px;\" src=\"images/SURG/110400_Vein_distensibility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Appearance of the vein without outflow occlusion.<br />(B) Following placement of a blood pressure cuff more proximally, the vein diameter has increased approximately 60 percent.</div><div id=\"graphicVersion\">Graphic 110400 Version 1.0</div></div></div>"},"110401":{"type":"graphic_picture","displayName":"Arm optimal for physical examination","title":"Arm optimal for physical examination","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Arm optimal for physical examination</div><div class=\"cntnt\"><img style=\"width:756px; height:311px;\" src=\"images/SURG/110401_Arm_optimal_physical_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows an upper extremity with venous anatomy that is ideal for supporting an arteriovenous fistula.</div><div id=\"graphicVersion\">Graphic 110401 Version 1.0</div></div></div>"},"110402":{"type":"graphic_diagnosticimage","displayName":"Vein mapping for arteriovenous fistula creation","title":"Vein mapping for arteriovenous fistula creation","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">Vein mapping for arteriovenous fistula creation</div><div class=\"cntnt\"><img style=\"width:785px; height:593px;\" src=\"images/SURG/110402_Msrmnt_intrnl_upr_arm_cphlc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image demonstrates the use of ultrasound for vein mapping. The diameter and depth of the right cephalic vein are easily measured and confirmed to be appropriate for arteriovenous (AV) fistula creation.</div><div id=\"graphicVersion\">Graphic 110402 Version 1.0</div></div></div>"},"110403":{"type":"graphic_diagnosticimage","displayName":"Vein mapping using venography","title":"Vein mapping using venography","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Vein mapping using venography</div><div class=\"cntnt\"><img style=\"width:766px; height:766px;\" src=\"images/SURG/110403_Vein_mapping_venography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard venography can be used to map the veins prior to creation of an arteriovenous fistula.<br />(A) The left cephalic vein (1) can be seen&nbsp;at the&nbsp;wrist and is without stenosis along its course.<br />(B) The cephalic vein (1) continues without stenosis to the antecubital fossa extending&nbsp;to the upper arm (2) and contributing to the basilic vein in the upper arm.<br />(C) The cephalic (2) and basilic (3) veins continue without stenosis. A prominent vein valve is seen in the basilic vein (3).<br />(D) In the upper arm, the cephalic vein (2) drains into the axillary vein (4) to form the subclavian vein (5). The demonstrated course of each of these veins is without obstruction or stenosis.</div><div id=\"graphicVersion\">Graphic 110403 Version 1.0</div></div></div>"},"110421":{"type":"graphic_figure","displayName":"AD inheritance","title":"Autosomal dominant inheritance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autosomal dominant inheritance</div><div class=\"cntnt\"><img style=\"width:368px; height:338px;\" src=\"images/PC/110421_AD_inheritance.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on Mendelian inheritance patterns and specific conditions for additional information.</div><div class=\"graphic_reference\">Courtesy of Benjamin A Raby, MD, MPH.</div><div id=\"graphicVersion\">Graphic 110421 Version 4.0</div></div></div>"},"110428":{"type":"graphic_figure","displayName":"Growth of medical literature","title":"Exponential growth of the medical literature from 1946 to 2015","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Exponential growth of the medical literature from 1946 to 2015</div><div class=\"cntnt\"><img style=\"width:583px; height:979px;\" src=\"images/PEDS/110428_Growth_med_literature.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Total number of new publications listed in MEDLINE by year.<br />(Panel B) Number of publications of randomized trials listed in MEDLINE by year. Data were derived from searching Ovid MEDLINE® 1946 to February Week 4 2015 (searched on March 2, 2015) using the \"Find Citation\" tab for each year 1946 to 2013. The total number of citations was recorded. This was then limited to randomized controlled trials.</div><div id=\"graphicVersion\">Graphic 110428 Version 1.0</div></div></div>"},"110429":{"type":"graphic_figure","displayName":"EBM schematic","title":"Schematic diagram of components of evidence-based medicine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic diagram of components of evidence-based medicine</div><div class=\"cntnt\"><img style=\"width:400px; height:155px;\" src=\"images/PEDS/110429_EBM_schematic.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Evidence-based medicine is the care of patients using the best available research evidence to guide clinical decision making. The focus is upon applying the results of research involving patients and important clinical outcomes (eg, death, symptoms). Evidence-based medicine is meant to complement, not replace, clinical judgment tailored to individual patients. Similarly, evidence-based medicine and the delivery of culturally, socially, and individually sensitive and effective care are complementary, not contradictory.</div><div class=\"graphic_footnotes\">EBM: evidence-based medicine.</div><div id=\"graphicVersion\">Graphic 110429 Version 1.0</div></div></div>"},"110430":{"type":"graphic_table","displayName":"PICO table","title":"Components of the \"PICO\" question","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of the \"PICO\" question</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Topic of the clinical question</td> </tr> <tr> <td class=\"subtitle2\">Intervention</td> <td class=\"subtitle2\">Diagnosis</td> <td class=\"subtitle2\">Prognosis</td> </tr> <tr> <td class=\"centered\"><strong>P</strong></td> <td class=\"centered\">Relevant Patient population</td> <td class=\"centered\">Relevant Patient population</td> <td class=\"centered\">Relevant Patient population</td> </tr> <tr> <td class=\"centered\"><strong>I</strong></td> <td class=\"centered\">Intervention being considered</td> <td class=\"centered\">Test being applied</td> <td class=\"centered\">Risk factor being evaluated</td> </tr> <tr> <td class=\"centered\"><strong>C</strong></td> <td class=\"centered\">Comparison intervention</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Comparison patient population</td> </tr> <tr> <td class=\"centered\"><strong>O</strong></td> <td class=\"centered\">Outcomes</td> <td class=\"centered\">Outcome/diagnosis</td> <td class=\"centered\">Outcomes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PICO: Patient population, Intervention, Comparison, Outcome.</div><div id=\"graphicVersion\">Graphic 110430 Version 1.0</div></div></div>"},"110434":{"type":"graphic_table","displayName":"SCD complications acute presentations","title":"Acute presentations of sickle cell disease complications, often presenting with pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute presentations of sickle cell disease complications, often presenting with pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Potential<br /> diagnoses</td> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Clinical</td> <td class=\"subtitle1\">Laboratory/imaging/<br /> other testing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Acute systemic illness</td> </tr> <tr> <td class=\"indent1\">Multiorgan failure</td> <td> <ul> <li>Chronic pain, lung disease, or renal insufficiency </li> </ul> </td> <td> <ul> <li>Fever, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> RR, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> HR, BP changes </li> <li>Nonfocal neurologic changes </li> <li>Pain is often severe with rapid organ failure </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> hemoglobin and platelets </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> bilirubin, LDH, creatinine </li> <li>Signs of rhabdomyolysis </li> <li>Infiltrate on CXR </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hemolytic transfusion reaction (HTR)</td> <td> <ul> <li>Recent transfusion (within 24 hours for acute HTR; up to one month for delayed HTR) </li> <li>History of alloimmunization </li> </ul> </td> <td> <ul> <li>Jaundice, dark urine </li> <li>Fever, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> HR </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> hemoglobin and platelets </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> bilirubin, LDH </li> <li>Positive Coombs (direct antiglobulin) test </li> <li>Hemoglobinuria </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Headache</td> </tr> <tr> <td class=\"indent1\">Stroke</td> <td> <ul> <li>Prior stroke or silent cerebral infarct </li> <li>History of <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> transcranial Doppler velocities </li> </ul> </td> <td> <ul> <li>Headache </li> <li>Focal or non-focal neurologic findings </li> </ul> </td> <td> <ul> <li>Brain imaging helpful if positive but may initially be negative </li> <li>Presumptive treatment with simple transfusion is done while obtaining brain imaging if suspicion is high </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Brain aneurysm</td> <td> <ul> <li>Usually asymptomatic but may have headache, loss of visual acuity, or facial pain </li> </ul> </td> <td> <ul> <li>Usually negative if unruptured but may have cranial neuropathies </li> </ul> </td> <td> <ul> <li>Positive MRI or CT angiography </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Meningitis*</td> <td> <ul> <li>Fever, meningeal symptoms </li> </ul> </td> <td> <ul> <li>Meningismus </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> WBC count </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Migraine</td> <td> <ul> <li>Aura </li> <li>Typical migraine symptoms for that patient </li> </ul> </td> <td> <ul> <li>May show focal or nonfocal findings </li> </ul> </td> <td> <ul> <li>No diagnostic laboratory test </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Chest pain</td> </tr> <tr> <td class=\"indent1\">Acute chest syndrome (ACS) or pneumonia* (indistinguishable)</td> <td> <ul> <li>History of pulmonary disease, prior ACS, asthma, recent infection </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> RR, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> oxygen saturation </li> <li>Children: Fever, cough </li> <li>Adults: Afebrile, severe pain that may initially overshadow the pulmonary symptoms </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> hemoglobin </li> <li>Infiltrate on CXR helpful if present, but may initially be negative, and absence does not eliminate possibility of ACS </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> <td> <ul> <li>History of DVT helpful if present but often absent </li> <li>Pregnancy, recent surgery, indwelling catheter, or other hypercoagulable state </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> RR, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> HR </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> oxygen saturation </li> <li>Extremity pain/swelling </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> D-dimer </li> <li>Imaging decisions depend on pretest probability and D-dimer </li> <li>Chest imaging and/or extremity imaging may be appropriate </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pulmonary fat embolism</td> <td> <ul> <li>History of pulmonary disease or recent surgery </li> <li>Severe extremity pain </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> oxygen saturation </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> RR </li> <li>Nonfocal neurologic symptoms </li> <li>Patients may deteriorate rapidly and develop multi-organ failure </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> hemoglobin, platelets </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> nucleated RBCs </li> <li>Infiltrate on CXR </li> <li>Diagnosed by bronchoscopy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Acute coronary syndrome</td> <td> <ul> <li>History of cardiac disease, pulmonary hypertension, or <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> QT interval </li> <li>Patients with SCD and severe vaso-occlusive pain are increasingly recognized to have acute myocardial ischemia without major vessel disease </li> </ul> </td> <td> <ul> <li>Atypical chest pain </li> <li>Radiation to arm(s) </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> cardiac biomarkers </li> <li>Abnormal EKG </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rib infarct</td> <td> <ul> <li>Recurrent sternal pain </li> </ul> </td> <td> <ul> <li>Focal rib tenderness </li> <li>Pain on inspiration </li> <li>Splinting may cause hypoventilation </li> </ul> </td> <td> <ul> <li>Negative CXR </li> <li>Positive bone imaging </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Abdominal pain</td> </tr> <tr> <td class=\"indent1\">Splenic sequestration</td> <td> <ul> <li>History of splenic or hepatic sequestration </li> <li>Infants with hemoglobin SS; adults with SCD variants </li> </ul> </td> <td> <ul> <li>Variable abdominal pain, requires a high index of suspicion </li> <li>Hemodynamic instability, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> HR, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> BP </li> <li>Splenic enlargement (rapidly enlarging spleen needs to be closely monitored) </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> hemoglobin, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> platelet count </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> reticulocyte count </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hepatic sequestration</td> <td> <ul> <li>History of splenic or hepatic sequestration </li> <li>History of underlying hepatic disease </li> <li>May be exacerbated by hepatic iron overload, HCV infection, or other causes of liver dysfunction </li> </ul> </td> <td> <ul> <li>Right upper quadrant pain and/or tenderness </li> <li>Hemodynamic instability, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> HR, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> BP </li> <li>Acute hepatomegaly, can progress to acute hepatic failure </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8595;</span> hemoglobin </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> PT, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> aPTT </li> <li>hyperbilirubinemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gallstones or cholecystitis*</td> <td> <ul> <li>History of gallstones </li> </ul> </td> <td> <ul> <li>Acute RUQ pain or tenderness </li> <li>Jaundice </li> <li>Nausea </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> bilirubin, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> transaminases </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> WBC </li> <li>Positive RUQ ultrasound or other imaging </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Renal infarct</td> <td>&nbsp;</td> <td> <ul> <li>Hematuria </li> <li>Back pain and/or flank or CVA tenderness </li> </ul> </td> <td> <ul> <li>RBCs on urinalysis </li> <li>Variable <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> in creatinine </li> <li>Acute papillary necrosis on renal imaging </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ectopic pregnancy</td> <td> <ul> <li>Sexually active reproductive age female </li> </ul> </td> <td> <ul> <li>Lower abdominal pain, especially after menses </li> <li>Abnormal uterine bleeding or discharge </li> <li>Nonspecific symptoms (urinary frequency, vaginal discharge) </li> <li>Abdominal and pelvic examinations are often unremarkable if the pregnancy has not ruptured </li> <li>Cervical motion tenderness, adnexal tenderness, or uterine tenderness are common with rupture </li> <li>An adnexal mass may be palpable </li> <li>Excessive pressure on the adnexa should be avoided because it may cause rupture </li> </ul> </td> <td> <ul> <li>Positive pregnancy test </li> <li>Diagnosed by serial quantitative HCG testing and transvaginal ultrasound </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pelvic inflammatory disease</td> <td> <ul> <li>Sexually active female </li> </ul> </td> <td> <ul> <li>Lower abdominal pain, especially after menses </li> <li>Abnormal uterine bleeding or discharge </li> <li>Nonspecific symptoms (urinary frequency, vaginal discharge) </li> <li>Fever in severe cases </li> <li>Cervical motion tenderness, adnexal tenderness, or uterine tenderness are defining characteristics </li> <li>Purulent vaginal or endocervical discharge </li> </ul> </td> <td> <ul> <li>Clinical diagnosis </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> WBC may be present but is not highly sensitive or specific </li> <li>Additional testing includes pregnancy test, urinalysis, microscopy of vaginal discharge, testing for chlamydia, gonorrhea, HIV, and syphilis </li> <li>Imaging for selected cases to evaluate for complications such as tubo-ovarian abscess or to exclude ectopic pregnancy </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Urinary tract infection or pyelonephritis*</td> <td> <ul> <li>Urinary tract infection can precipitate an acute pain episode </li> </ul> </td> <td> <ul> <li>Fever </li> <li>Suprapubic tenderness </li> <li>Children: May not report any symptoms </li> <li>Adults: May have urgency, frequency, dysuria, flank pain </li> </ul> </td> <td> <ul> <li>Positive urinalysis and culture </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Opioid-induced constipation</td> <td> <ul> <li>Recent opioid use, typically within the previous 72 hours </li> <li>Lack of a consistent bowel regimen </li> </ul> </td> <td> <ul> <li>Reduced bowel movements </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Extremity or bone pain</td> </tr> <tr> <td class=\"indent1\">Acute synovitis or avascular necrosis (AVN) of a joint</td> <td> <ul> <li>History of avascular necrosis </li> </ul> </td> <td> <ul> <li>Hip pain </li> <li>Limp </li> <li>Limited range of motion </li> <li>Pain accompanied by joint swelling </li> </ul> </td> <td> <ul> <li>Radiography is negative in early stages of AVN </li> <li>MRI may be needed to document findings </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dactylitis</td> <td> <ul> <li>Infant or young child (rarely seen above the age of four years) </li> </ul> </td> <td> <ul> <li>Pain with swelling and warmth of the fingers or toes </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gout</td> <td> <ul> <li>Older adults </li> <li>History of renal disease, hypertension, or gout </li> </ul> </td> <td> <ul> <li>Joint pain in atypical areas such as phalanges, angles, elbows, wrists </li> <li>Pain accompanied by joint swelling </li> <li>Monoarticular joint pain may be accompanied by more diffuse pain from vaso-occlusion </li> </ul> </td> <td> <ul> <li>Variably <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> creatinine, urate </li> <li>Urate crystals in joint fluid </li> </ul> </td> </tr> <tr> <td class=\"indent1\">DVT</td> <td> <ul> <li>Pregnancy, recent surgery, indwelling catheter, or other hypercoagulable state </li> </ul> </td> <td> <ul> <li>Pain with leg swelling </li> </ul> </td> <td> <ul> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> D-dimer </li> <li>Compression ultrasonography or other noninvasive testing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Osteomyelitis</td> <td> <ul> <li>History of bone infarction, avascular necrosis, or gastroenteritis </li> </ul> </td> <td> <ul> <li>Can present with generalized bone pain </li> <li>Pain accompanied by swelling, tenderness, warmth </li> <li>Variable joint involvement (can be multifocal) </li> </ul> </td> <td> <ul> <li>Diagnosis often delayed; often confused with bone infarct (much less common) </li> <li><span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> WBC </li> <li>Blood, bone, and joint aspirate cultures positive for salmonella, staphylococcus </li> <li>Imaging may show periosteal elevation and/or fluid collection </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Generalized/diffuse pain</td> </tr> <tr> <td class=\"indent1\">Neuropathic pain</td> <td> <ul> <li>History of chronic pain and ineffective opioids </li> </ul> </td> <td> <ul> <li>Pain described as burning, shooting, or tingling </li> <li>Hyperalgesia to touch or temperature </li> </ul> </td> <td> <ul> <li>No diagnostic laboratory tests </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Opioid or steroid withdrawal</td> <td> <ul> <li>Recent hospitalization for pain episode </li> <li>Sudden withdrawal of opioid or steroid without tapering </li> </ul> </td> <td> <ul> <li>Pain may be severe </li> <li>Agitation, <span style=\"font-size: 1.4em; font-family: Consolas, 'Andale Mono', 'Lucida Console', 'Lucida Sans Typewriter', Monaco, 'Courier New', monospace; vertical-align: middle;\">&#8593;</span> tremors </li> <li>Gastrointestinal symptoms </li> <li>Sweating </li> </ul> </td> <td> <ul> <li>No diagnostic laboratory tests </li> <li>A common cause of readmission </li> <li>When withdrawal is expected, we prefer to use the Clinical Opiate Withdrawal Scale (COWS), an 11-item scale designed to be administered by a clinician </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These conditions often present with acute pain in individuals with SCD. Both the pain and the complication should be addressed as rapidly as possible. Refer to UpToDate topics on specific complications and management of acute pain for further information.</div><div class=\"graphic_footnotes\">SCD: sickle cell disease; RR: respiratory rate; HR: heart rate; BP: blood pressure; LDH: lactate dehydrogenase; HTR: hemolytic transfusion reaction; ACS: acute chest syndrome; RUQ: right upper quadrant; WBC: white blood cell count; CVA: costovertebral angle; DVT: deep vein thrombosis; HCV: hepatitis C virus; HCG: human chorionic gonadotropin; PT: prothrombin time; aPTT: activated partial thromboplastin time; RBC: red blood cell; CXR: chest radiography; MRI: magnetic resonance imaging; CT: computed tomography.<br />* Individuals with SCD are functionally asplenic and at risk for severe infections, especially with encapsulated organisms.</div><div id=\"graphicVersion\">Graphic 110434 Version 3.0</div></div></div>"},"110435":{"type":"graphic_figure","displayName":"Hierarchy of evidence","title":"From evidence to evidence-based resources","html":"<div class=\"graphic\"><div style=\"width: 950px\" class=\"figure\"><div class=\"ttl\">From evidence to evidence-based resources</div><div class=\"cntnt\"><img style=\"width:930px; height:320px;\" src=\"images/PEDS/110435_Hierarchyofevidence.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hierarchy of evidence and level of processing that contribute to evidence-based resources.</div><div class=\"graphic_footnotes\">EBM: evidence-based medicine.</div><div class=\"graphic_reference\">Reproduced with permission from: Agoritsas T, Vandvik PO, Neumann I, et al. Finding Current Best Evidence. In: Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd Ed, Guyatt G, Rennie D, Meade MO, Cook DJ. (Eds), McGraw-Hill Education, New York 2015. Copyright © 2015 McGraw-Hill Education. McGraw-Hill Education makes no representations or warranties as to the accuracy of any information contained in the McGraw-Hill Education Material, including any warranties of merchantability or fitness for a particular purpose. In no event shall McGraw-Hill Education have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with the McGraw-Hill Education Material, even if McGraw-Hill Education has been advised of the possibility of such damages.</div><div id=\"graphicVersion\">Graphic 110435 Version 3.0</div></div></div>"},"110436":{"type":"graphic_table","displayName":"Rx interactions of immunosuppressants in solid-organ transplants","title":"Examples of common drug interactions of immunosuppressants used in solid-organ transplant: Cyclosporine, tacrolimus, sirolimus, and everolimus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of common drug interactions of immunosuppressants used in solid-organ transplant: Cyclosporine, tacrolimus, sirolimus, and everolimus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Common types of drug interactions</td> <td class=\"subtitle1\">Examples of interacting drugs</td> <td class=\"subtitle1\">Approach to management in the absence of appropriate noninteracting alternatives</td> </tr> <tr class=\"divider_bottom\"> <td>Coadministration of drugs that inhibit CYP3A metabolism and/or P-gp efflux can <strong>increase immunosuppressant serum concentrations</strong>, leading to significant toxicities.</td> <td> <ul> <li>Amiodarone </li> <li>ART-boosting agents (eg, ritonavir, cobicistat) </li> <li>Azole antifungals (eg, fluconazole, posaconazole, voriconazole) </li> <li>HIV protease inhibitors (eg, atazanavir, nelfinavir, saquinavir) </li> <li>Macrolide antibiotics (except azithromycin) </li> <li>Non-dihydropyridine calcium channel blockers </li> <li><span style=\"font-family: Verdana; color: #000000;\">Ombitasvir-paritaprevir-ritonavir with or without dasabuvir (an HCV, direct-acting antiviral regimen)</span> </li> <li>Grapefruit juice </li> </ul> </td> <td> <ul> <li>Closely monitor immunosuppressant concentrations and signs of toxicity (eg, tremors and headaches).</li> <li>Substantial, including preemptive, dose reduction of immunosuppressant drug may be needed (eg, on average, only 25% of the standard dose of cyclosporine is required if administered concomitantly with HIV protease inhibitors).</li> <li>Some combinations are considered contraindicated according to product labeling; refer to appropriate topic reviews for detail.</li> <li>Lists of CYP3A and P-gp <strong>inhibitors</strong> are provided as separate tables within UpToDate.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Coadministration of drugs that induce CYP3A metabolism and/or P-gp efflux pumping can <strong>decrease immunosuppressant serum concentrations</strong>, increasing the risk of organ rejection.</td> <td> <ul> <li>Antiseizure drugs, enzyme inducing&nbsp;(eg, carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone) </li> <li>Enzalutamide </li> <li>Nafcillin </li> <li>Rifamycins (eg, rifabutin, rifampin, rifapentine) </li> <li>St. John's wort </li> </ul> </td> <td> <ul> <li>Closely monitor immunosuppressant serum concentrations and signs of organ rejection.</li> <li>Significant immunosuppressant dose increases may be needed.</li> <li>Avoid concomitant treatment with everolimus if possible.</li> <li>Enzyme induction can require up to two weeks to achieve maximum effect and persists for up to two weeks after discontinuation of the interacting medication. Clinically significant effects can occur within hours to days of starting a CYP inducer.</li> <li>Lists of CYP3A and P-gp <strong>inducers</strong> are provided as separate tables within UpToDate.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Coadministration of nephrotoxic drugs with cyclosporine or tacrolimus can cause <strong>additive or synergistic kidney injury</strong>.</td> <td> <ul> <li>Aminoglycosides </li> <li>Amphotericin B </li> <li>Colchicine </li> <li>Nonsteroidal antiinflammatory drugs (NSAIDs) </li> </ul> </td> <td> <ul> <li>Concomitant administration of cyclosporine and tacrolimus with other potentially nephrotoxic drugs should be avoided.</li> <li>Suggested dose adjustments for use with colchicine are available in the Lexicomp monograph included within UpToDate.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Coadministration of drugs that increase serum potassium with cyclosporine or tacrolimus may cause <strong>severe hyperkalemia</strong>.</td> <td> <ul> <li>ACE inhibitors/ARBs </li> <li>Amiloride </li> <li>Spironolactone </li> <li>Triamterene </li> <li>Trimethoprim, trimethoprim-sulfamethoxazole (cotrimoxazole) </li> </ul> </td> <td> <ul> <li>Closely monitor serum potassium levels.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Coadministration of cyclosporine with&nbsp;sirolimus can <strong>increase sirolimus concentrations</strong>.</td> <td> <ul> <li>Cyclosporine </li> </ul> </td> <td> <ul> <li>Separate administration of sirolimus from cyclosporine by four hours; give sirolimus at a consistent time with respect to cyclosporine.</li> <li>Closely monitor immunosuppressant serum concentrations.</li> </ul> </td> </tr> <tr> <td>Coadministration of statin drugs with cyclosporine can <strong>increase statin levels and risk of myotoxicity</strong>.</td> <td> <ul> <li>Atorvastatin </li> <li>Lovastatin </li> <li>Pitavastatin </li> <li>Rosuvastatin </li> <li>Simvastatin </li> </ul> </td> <td> <ul> <li>Pravastatin and fluvastatin are preferred due to decreased interactions.</li> <li>Tacrolimus may be preferred over cyclosporine in patients&nbsp;receiving statin therapy.</li> <li>Cyclosporine and simvastatin should not be used together.</li> <li>Some combinations are considered contraindicated or statin daily dose limits are&nbsp;recommended&nbsp;in the product labeling; refer to the Lexicomp monographs included within UpToDate for detailed information.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI><STRONG>Important note:</STRONG> The interactions listed in this table illustrate some of the common types of interactions with immunosuppressive drugs; this is <STRONG>not</STRONG> a complete list, and many other significant drug interactions can occur.</LI>&#xD;&#xA;<LI>Cyclosporine, tacrolimus, sirolimus, and everolimus are highly dependent upon CYP3A metabolism for clearance and are also substrates of P-gp drug efflux pump. Some interactions can lead to subtherapeutic or dangerously toxic levels of immunosuppressant concentrations.</LI>&#xD;&#xA;<LI>When appropriate noninteracting alternatives are readily available, consider modifying treatment to avoid combined use with potent metabolic inhibitors/inducers or agents known to have additive toxicities with immunosuppressants.</LI>&#xD;&#xA;<LI>Drug therapy should be managed by transplant specialists with expertise in therapeutic drug monitoring, and doses should be adjusted based upon measurement of immunosuppressant concentrations, particularly whenever drug therapy is altered. If there are any concerns about the safety of a given medication or supplement, they should be discussed with the patient's transplant center prior to initiation.</LI></UL></div><div class=\"graphic_footnotes\">CYP: cytochrome P450 metabolism; P-gp: P-glycoprotein drug efflux pump; ART: HIV antiretroviral therapy; HIV: human immunodeficiency virus; HCV: hepatitis C virus; ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker.</div><div class=\"graphic_reference\">Prepared with data from Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 110436 Version 7.0</div></div></div>"},"110437":{"type":"graphic_algorithm","displayName":"PHACE surveillance algorithm","title":"Initial screening, follow-up, and referral of patients with PHACE syndrome","html":"<div class=\"graphic\"><div style=\"width: 1018px\" class=\"figure\"><div class=\"ttl\">Initial screening, follow-up, and referral of patients with PHACE syndrome</div><div class=\"cntnt\"><img style=\"width:998px; height:658px;\" src=\"images/DERM/110437_PHACE_surveillance_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial screening tests should be performed in every patient suspected to have PHACE syndrome. The decision regarding additional evaluation or referral should be made for the individual patient, based upon the results of the screening tests.</div><div class=\"graphic_footnotes\">PHACE: posterior fossa anomalies, hemangiomas, arterial anomalies, cardiac anomalies, and eye anomalies; MRI: magnetic resonance imaging; MRA: magnetic resonance angiography.<br />* Ocular abnormalities that have been associated with PHACE syndrome: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Retinal vascular abnormalities</LI>&#xD;&#xA;<LI>Persistent fetal vasculature</LI>&#xD;&#xA;<LI>Iris vessel hypertrophy</LI>&#xD;&#xA;<LI>\"Morning-glory\" disc</LI>&#xD;&#xA;<LI>Peripapillary staphyloma</LI>&#xD;&#xA;<LI>Optic nerve hypoplasia</LI>&#xD;&#xA;<LI>Microphthalmia</LI>&#xD;&#xA;<LI>Coloboma</LI>&#xD;&#xA;<LI>Congenital cataracts</LI>&#xD;&#xA;<LI>Sclerocornea</LI>&#xD;&#xA;<LI>Iris hypoplasia</LI>&#xD;&#xA;<LI>Exophthalmos</LI>&#xD;&#xA;<LI>Congenital third nerve palsy</LI>&#xD;&#xA;<LI>Horner syndrome</LI></UL>​¶ Risk stratification in patients with PHACE syndrome based on severity of cerebral arterial anomalies: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Low risk: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anomalous origin of arteries</LI>&#xD;&#xA;<LI>Variants in the circle of Willis</LI>&#xD;&#xA;<LI>Persistent fetal vessels</LI></UL></LI>&#xD;&#xA;<LI>Intermediate risk: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Narrowing proximal to the circle of Willis but intact circle of Willis</LI>&#xD;&#xA;<LI>Stenosis of the proximal&nbsp;internal carotid artery&nbsp;if there is normal collateral flow in&nbsp;anterior cerebral artery&nbsp;and posterior cerebral artery</LI></UL></LI>&#xD;&#xA;<LI>High risk: &#xD;&#xA;<UL>&#xD;&#xA;<LI>&gt;25% narrowing of principal cerebral vessels in association with an incomplete circle of Willis</LI>&#xD;&#xA;<LI>Tandem stenosis that causes a risk of diminished cerebral perfusion</LI>&#xD;&#xA;<LI>Signs of chronic or silent ischemia, existing infarction, border zone ischemic changes, presence of lenticulostriate collateral dilation, pial collaterals</LI></UL></LI></UL></div><div class=\"graphic_reference\">Original figure modified for this publication. Garzon MC, Epstein LG, Heyer GL, et at. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr 2016; 178:24. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110437 Version 2.0</div></div></div>"},"110439":{"type":"graphic_figure","displayName":"Structure of the IgG subclasses","title":"Structure of the IgG subclasses","html":"<div class=\"graphic\"><div style=\"width: 1290px\" class=\"figure\"><div class=\"ttl\">Structure of the IgG subclasses</div><div class=\"cntnt\"><img style=\"width:1270px; height:594px;\" src=\"images/ALLRG/110439_Structure_IgG_subclasses.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgG: immunoglobulin <SPAN style=\"COLOR: black\">G; FR: framework region; VL:</SPAN> variable region of light chain; VH: variable region of heavy chain; CL constant region of light chain; CH1: constant region of heavy chain 1; S-S: disulfide bond; H: hinge region; CH2: constant region of heavy chain 2; CH3: constant region of heavy chain 3; CDR: complementarity-<FONT color=black>determining region; V: variable region; D: diversity segment; J: joining segment; CHS: coding region at the C-terminal end of a secreted immunoglobulin heavy chain; H1: hinge region 1; H2: hinge region 2; H3: hinge region 3; H4: hinge region 4.</FONT><br /></div><div class=\"graphic_reference\">With kind permission of Marie-Paule Lefranc, IMGT®, the International ImMunoGeneTics Information System®. Available at: <A href=\"http://www.imgt.org/\" target=_blank>http://www.imgt.org</A> (Accessed on October 21,2016).</div><div id=\"graphicVersion\">Graphic 110439 Version 1.0</div></div></div>"},"110440":{"type":"graphic_table","displayName":"Dermatoses of pregnancy clinical features","title":"Clinical features of specific dermatoses of pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of specific dermatoses of pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Atopic eruption of pregnancy</td> <td class=\"subtitle1\">Polymorphic eruption of pregnancy</td> <td class=\"subtitle1\">Pemphigoid gestationis</td> <td class=\"subtitle1\">Intrahepatic cholestasis of pregnancy</td> </tr> <tr> <td><strong>Time of onset</strong></td> <td>75% of cases before third trimester.</td> <td>Last weeks of pregnancy or immediately postpartum.</td> <td>Last trimester or postpartum.</td> <td>Late pregnancy.</td> </tr> <tr> <td><strong>Pregnancy</strong></td> <td>Not relevant.</td> <td>First.</td> <td>Not relevant.</td> <td>Not relevant.</td> </tr> <tr> <td><strong>Personal or family history of atopy, atopic diatheses, and/or elevated IgE levels</strong></td> <td>Yes, compulsory.</td> <td>Not relevant.</td> <td>Not relevant.</td> <td>Not relevant.</td> </tr> <tr> <td rowspan=\"2\"><strong>Clinical features</strong></td> <td>20% of patients suffer from an&nbsp;exacerbation of pre-existing atopic dermatitis&nbsp;with a typical clinical picture.</td> <td>Urticarial papules and plaques arise from striae distensae usually on the abdomen, characteristically sparing the umbilical region. After&nbsp;one or&nbsp;two days, the lesions spread also to the thighs and the buttocks and may become frankly polymorphous showing vesicles (but never blisters), a nonurticated erythema, targetoid lesion, and E-type.</td> <td>Urticarial papules and plaques with usually tense blisters with typical periumbilical involvement and spreading to the trunk and the extremities.</td> <td>Pruritus and exclusively secondary skin lesions (excoriations, prurigo). Total serum bile acid levels &#62;11 mmol/L.</td> </tr> <tr> <td>80% will experience atopic skin changes for the first time ever or after a long remission (ie, after childhood eczema), with&nbsp;two main features: (1) E-type: Widespread eczematous changes affecting typical atopic sites, such as face, neck, upper chest, and the flexural surfaces of the extremities; and (2) P-type: Small erythematous P-type disseminated on trunk and limbs and typical prurigo nodules, mostly located on the shins and arms.</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Maternal prognosis</strong></td> <td>Unimpaired; common development of nipple and hand eczema after delivery.</td> <td>Unimpaired.</td> <td>Exacerbations and remissions during pregnancy, flare-up in 75% delivery, resolves then within weeks to months but may recur with menstruation and hormonal contraception.</td> <td>Risk for gall stones and intra/postpartum hemorrhage.</td> </tr> <tr> <td><strong>Recurrence in subsequent pregnancies</strong></td> <td>Yes.</td> <td>No.</td> <td>Yes, often with earlier onset and severer course.</td> <td>Yes.</td> </tr> <tr> <td><strong>Fetal prognosis</strong></td> <td>Unaffected, but there is a higher risk of developing atopic skin changes later on.</td> <td>Excellent. No cutaneous involvement of the newborn.</td> <td>Increase for small-for-date and premature babies. 10% of newborns develop mild skin lesions that resolve spontaneously within days to weeks.</td> <td>Increased risk of prematurity (19 to 60%), intrapartal fetal distress (22 to 33%), and stillbirths (1 to 2%).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div class=\"graphic_reference\">From: Massone C, Cerroni L, Heidrun N, et al. Histopathological Diagnosis of Atopic Eruption of Pregnancy and Polymorphic Eruption of Pregnancy: A Study on 41 Cases. Am J Dermatopathol 2014; 36:812. DOI: <a href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2014&amp;issue=10000&amp;article=00006&amp;type=abstract\" target=\"_blank\">10.1097/DAD.0000000000000067</a>. DOI: 10.1213/ANE.0000000000001275. Copyright &copy; 2014 International Society of Dermatopathology. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110440 Version 1.0</div></div></div>"},"110479":{"type":"graphic_diagnosticimage","displayName":"Ultrasound diagnosis of celiac artery compression syndrome","title":"Ultrasound diagnosis of celiac artery compression syndrome","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Ultrasound diagnosis of celiac artery compression syndrome</div><div class=\"cntnt\"><img style=\"width:618px; height:354px;\" src=\"images/SURG/110479_US_DX_CACS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doppler spectral images of the proximal celiac trunk. <br />(A) During expiration, PS&nbsp;and ED velocities are elevated (308 and 81 cm/second). <br />(B)&nbsp;With&nbsp;inspiration, PS and ED velocities decrease to normal values (135 and 46 cm/second). </div><div class=\"graphic_footnotes\">PS: peak systolic; ED: end diastolic; RI: resistive index; S/D: systolic-to-diastolic ratio. </div><div class=\"graphic_reference\">Reproduced with permission from: Ozel A, Toksoy G, Ozdogan O, et al. Ultrasonographic diagnosis of median arcuate ligament syndrome: A report of two cases. Med Ultrason 2012; 14:154. Copyright © 2012 \"Iuliu Hatieganu\" Medical Publishing House.</div><div id=\"graphicVersion\">Graphic 110479 Version 1.0</div></div></div>"},"110486":{"type":"graphic_table","displayName":"Gustilo-Anderson open fracture grading","title":"Gustilo-Anderson open fracture grading","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gustilo-Anderson open fracture grading</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16.66%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Wound size</td> <td class=\"subtitle1\">Contamination</td> <td class=\"subtitle1\">Fracture</td> <td class=\"subtitle1\">Vascular injury requiring repair</td> <td class=\"subtitle1\">Soft tissue coverage</td> </tr> <tr> <td class=\"centered\">I</td> <td>Wound &#60;1 cm</td> <td>Minimal</td> <td>Minimal comminution;<br /> No periosteal stripping</td> <td>No</td> <td>Adequate</td> </tr> <tr> <td class=\"centered\">II</td> <td>Wound &#62;1 cm</td> <td>Moderate</td> <td>Moderate comminution;<br /> Minimal periosteal stripping</td> <td>No</td> <td>Adequate </td> </tr> <tr> <td class=\"centered\">IIIA</td> <td>Any size</td> <td>Severe</td> <td>Severe comminution or segmental fractures;<br /> Periosteal stripping</td> <td>No</td> <td>Adequate; may become inadequate with debridements</td> </tr> <tr> <td class=\"centered\">IIIB</td> <td>Any size</td> <td>Severe</td> <td>Severe comminution or segmental fractures;<br /> Periosteal stripping</td> <td>No</td> <td>Inadequate (rotation flap or free flap)</td> </tr> <tr> <td class=\"centered\">IIIC</td> <td>Any size</td> <td>Severe</td> <td>Severe comminution or segmental fractures; Periosteal stripping</td> <td>Yes</td> <td>Inadequate (rotation flap or free flap)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am 1976; 58:453.</LI>&#xD;&#xA;<LI>Gustilo RB, Gruninger RP, Davis T. Classification of type III (severe) open fractures relative to treatment and results. Orthopedics 1987; 10:1781.</LI></OL></div><div id=\"graphicVersion\">Graphic 110486 Version 1.0</div></div></div>"},"110488":{"type":"graphic_diagnosticimage","displayName":"Calcification of forearm arteries in diabetic patient","title":"Calcification of forearm arteries in diabetic patient","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Calcification of forearm arteries in diabetic patient</div><div class=\"cntnt\"><img style=\"width:756px; height:723px;\" src=\"images/SURG/110488_Calcifictn_arters_diabetic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic (digital subtraction) image of right forearm and wrist showing severe calcification of the radial artery.</div><div id=\"graphicVersion\">Graphic 110488 Version 1.0</div></div></div>"},"110489":{"type":"graphic_figure","displayName":"Middle temporal vein","title":"Location and course of the middle temporal vein","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Location and course of the middle temporal vein</div><div class=\"cntnt\"><img style=\"width:644px; height:800px;\" src=\"images/DERM/110489_Middle_temporal_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean distance between the middle temporal vein and the zygomatic arch. Data obtained from a cadaver study from a Korean population.</div><div class=\"graphic_footnotes\">* Mean value.<br />¶ Range.</div><div class=\"graphic_reference\">From: Jung W, Youn KH, Won SY, et al. Clinical implications of the middle temporal vein with regard to temporal fossa augmentation. Dermatol Surg 2014; 40:618. DOI: <A href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2014&amp;issue=06000&amp;article=00003&amp;type=abstract\" target=_blank>10.1111/dsu.0000000000000004</A>. Copyright © 2014 American Society for Dermatologic Surgery. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110489 Version 1.0</div></div></div>"},"110492":{"type":"graphic_algorithm","displayName":"Approach to selecting treatments for social anxiety disorder","title":"Approach to selecting treatments for social anxiety disorder (SAD)","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Approach to selecting treatments for social anxiety disorder (SAD)</div><div class=\"cntnt\"><img style=\"width:522px; height:764px;\" src=\"images/PSYCH/110492_Apprch_treatments_SAD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBT: cognitive-behavioral therapy; SSRI: selective serotonergic reuptake inhibitor; SNRI: serotonergic noradrenergic reuptake inhibitor; MAOI: monoamine oxidase inhibitor; SUD: substance use disorder.<br />* In addition to the medication suggestions that follow, CBT is a reasonable treatment alternative at each step where the patient has responded inadequately.<br />¶ Provided patient can adhere to medication and dietary restrictions. MAOI cannot be used concurrently with SSRI/SNRI. Discontinuation of SSRI/SNRI should be followed by a washout period prior to initiating MAOI (refer to topic for more information).</div><div id=\"graphicVersion\">Graphic 110492 Version 2.0</div></div></div>"},"110493":{"type":"graphic_picture","displayName":"Abdominal aorta and its visceral branches","title":"Abdominal aorta and its visceral branches","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Abdominal aorta and its visceral branches</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/SURG/110493_Abdmnl_aorta_viscrl_brnchs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows the aorta dissected from its bed. The red loops encircle the supraceliac aorta proximally and the left iliac artery distally. From right to left (cranial to caudal)&nbsp;are the celiac axis, SMA, left renal artery, left renal vein,&nbsp;and IMA.</div><div class=\"graphic_footnotes\">IMA: inferior mesenteric artery; SMA: superior mesenteric artery.</div><div id=\"graphicVersion\">Graphic 110493 Version 1.0</div></div></div>"},"110494":{"type":"graphic_picture","displayName":"Ischemic bowel from acute embolic occlusion","title":"Ischemic bowel from acute embolic occlusion","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Ischemic bowel from acute embolic occlusion</div><div class=\"cntnt\"><img style=\"width:756px; height:552px;\" src=\"images/SURG/110494_Ischmc_bwl_act_emblc_occlsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows the appearance of the small intestine. The operator's hand is holding the proximal jejunum, which is relatively spared, suggesting acute embolic occlusion of the superior mesenteric artery rather than acute-on-chronic occlusion. The more distal jejunum and the ileum are dusky and ischemic but appear viable.</div><div id=\"graphicVersion\">Graphic 110494 Version 1.0</div></div></div>"},"110495":{"type":"graphic_diagnosticimage","displayName":"Acute embolic arterial occlusion on CT","title":"Acute embolic arterial occlusion on CT","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Acute embolic arterial occlusion on CT</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/SURG/110495_Acute_emblc_artrl_occlsn_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image&nbsp;is a sagittal view of the aorta showing occlusion of the superior mesenteric artery just distal to its takeoff from the aorta (thin arrow) without any associated mural calcifications like those seen in the distal aorta. The origin of the celiac axis (thick arrow) is also without calcification.</div><div id=\"graphicVersion\">Graphic 110495 Version 1.0</div></div></div>"},"110496":{"type":"graphic_diagnosticimage","displayName":"Acute embolic superior mesenteric occlusion on arteriography","title":"Acute embolic superior mesenteric occlusion on arteriography","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Acute embolic superior mesenteric occlusion on arteriography</div><div class=\"cntnt\"><img style=\"width:584px; height:756px;\" src=\"images/SURG/110496_Act_emblc_sprr_msntrc_oclsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows a catheter in the superior mesenteric artery. There is an abrupt cutoff distal to the jejunal branches, typical of a superior mesenteric artery embolism.</div><div class=\"graphic_footnotes\">RT: right (side of patient); RAO: right anterior oblique; FD: focal distance.</div><div id=\"graphicVersion\">Graphic 110496 Version 1.0</div></div></div>"},"110497":{"type":"graphic_table","displayName":"Change in birth rate from 1990 to 2014","title":"Change in birth rate per 1000 women from 1990 to 2014 by age cohort","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Change in birth rate per 1000 women from 1990 to 2014 by age cohort</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"7\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">15 to 19</td> <td class=\"subtitle1\">20 to 24</td> <td class=\"subtitle1\">25 to 29</td> <td class=\"subtitle1\">30 to 34</td> <td class=\"subtitle1\">35 to 39</td> <td class=\"subtitle1\">40 to 44</td> <td class=\"subtitle1\">45 to 49</td> </tr> <tr> <td><strong>1990</strong></td> <td class=\"centered\">59.9</td> <td class=\"centered\">116.5</td> <td class=\"centered\">120.2</td> <td class=\"centered\">80.8</td> <td class=\"centered\">31.9</td> <td class=\"centered\">5.5</td> <td class=\"centered\">0.2</td> </tr> <tr> <td><strong>2014</strong></td> <td class=\"centered\">24.2</td> <td class=\"centered\">79.0</td> <td class=\"centered\">105.8</td> <td class=\"centered\">100.8</td> <td class=\"centered\">51.0</td> <td class=\"centered\">10.6</td> <td class=\"centered\">0.8</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Hamilton BE, Martin JA, Osterman MJ, Curtin SC, Matthews TJ. Births: Final data for 2014. Natl Vital Stat Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 110497 Version 1.0</div></div></div>"},"110498":{"type":"graphic_diagnosticimage","displayName":"Acute thrombotic mesenteric arterial occlusion","title":"Acute thrombotic mesenteric arterial occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute thrombotic mesenteric arterial occlusion</div><div class=\"cntnt\"><img style=\"width:419px; height:756px;\" src=\"images/SURG/110498_Act_thrmbtc_msntrc_artrl_oc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sagittal image shows calcification at the origins of the celiac (thick arrow) artery as well as calcification distally in the aorta. Diffuse calcifications are also seen along the course of the superior mesenteric artery, and the vessel is thrombosed (thin arrow).</div><div id=\"graphicVersion\">Graphic 110498 Version 1.0</div></div></div>"},"110499":{"type":"graphic_picture","displayName":"Acute mesenteric arterial occlusion with nonviable bowel","title":"Acute mesenteric arterial occlusion with nonviable bowel","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Acute mesenteric arterial occlusion with nonviable bowel</div><div class=\"cntnt\"><img style=\"width:600px; height:720px;\" src=\"images/SURG/110499_Msntrc_artrl_occlsn_nnvbl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows the appearance of advanced mesenteric ischemia with nonviable bowel.</div><div id=\"graphicVersion\">Graphic 110499 Version 1.0</div></div></div>"},"110500":{"type":"graphic_diagnosticimage","displayName":"Catheter-directed mechanical thrombectomy of mesenteric embolism","title":"Catheter-directed mechanical thrombectomy of mesenteric embolism","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Catheter-directed mechanical thrombectomy of mesenteric embolism</div><div class=\"cntnt\"><img style=\"width:765px; height:495px;\" src=\"images/SURG/110500_Cthtr-drctd_thrmbctmy_msntr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images show the appearance of the superior mesenteric artery (arrows) before (A)&nbsp;and after (B) catheter-directed thrombolysis using a catheter placed into the origin of the superior mesenteric artery.</div><div class=\"graphic_footnotes\">RT: right (side of patient); RAO: right anterior oblique; FD: focal distance.</div><div id=\"graphicVersion\">Graphic 110500 Version 1.0</div></div></div>"},"110502":{"type":"graphic_picture","displayName":"Nonviable segment of bowel","title":"Nonviable segment of bowel","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Nonviable segment of bowel</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/SURG/110502_Nonviable_segment_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows the appearance of the intestine in a patient with acute mesenteric arterial occlusion. The deeply colored ischemic bowel is nonviable (arrow) and will require resection.</div><div id=\"graphicVersion\">Graphic 110502 Version 1.0</div></div></div>"},"110503":{"type":"graphic_picture","displayName":"Mesenteric artery exposure","title":"Mesenteric artery exposure","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Mesenteric artery exposure</div><div class=\"cntnt\"><img style=\"width:756px; height:425px;\" src=\"images/SURG/110503_Mesenteric_artry_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows exposure of the superior mesenteric artery (SMA) within the root of the small bowel mesentery. The blue and yellow loops encircle the SMA proximally and distally. The red loop encircles a crossing anterior jejunal vein branch that is often present and can be inadvertently injured during exposure. </div><div id=\"graphicVersion\">Graphic 110503 Version 1.0</div></div></div>"},"110504":{"type":"graphic_picture","displayName":"Mesenteric embolectomy","title":"Mesenteric embolectomy","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Mesenteric embolectomy</div><div class=\"cntnt\"><img style=\"width:754px; height:424px;\" src=\"images/SURG/110504_Mesenteric_embolectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse arteriotomy (arrow)&nbsp;has been made in the superior mesenteric artery proximal to the first jejunal branch. Thrombus is seen protruding from the arteriotomy consistent with embolism.</div><div id=\"graphicVersion\">Graphic 110504 Version 1.0</div></div></div>"},"110506":{"type":"graphic_picture","displayName":"Fluorescein testing for bowel viability","title":"Fluorescein testing for bowel viability","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Fluorescein testing for bowel viability</div><div class=\"cntnt\"><img style=\"width:756px; height:564px;\" src=\"images/SURG/110506_Fluorescein_bowel_viability.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intraoperative image shows the appearance of the bowel after the injection of fluorescein. With ultraviolet light from a Wood's lamp, the viable, well-perfused portions of bowel fluoresce bright green. The dusky portion that is not perfused will require resection.</div><div id=\"graphicVersion\">Graphic 110506 Version 1.0</div></div></div>"},"110507":{"type":"graphic_figure","displayName":"Maternal age and adverse pregnancy outcome","title":"Maternal age and adverse pregnancy outcome","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Maternal age and adverse pregnancy outcome</div><div class=\"cntnt\"><img style=\"width:478px; height:460px;\" src=\"images/OBGYN/110507_Mtrnl_age_advrs_prgnncy_out.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Predictive probability of miscarriage &gt;11 weeks (Mis), preeclampsia (PE), small for gestational age (SGA) fetus, gestational diabetes mellitus (GDM), and large for gestational age (LGA) fetus plotted against maternal age.</div><div class=\"graphic_reference\">From: Khalil A, Syngelaki A, Maiz N, et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2013; 42:634. <A href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/uog.12494/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/uog.12494/abstract</A>. Copyright © 2013 International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110507 Version 1.0</div></div></div>"},"110510":{"type":"graphic_table","displayName":"Cell-free fetal DNA screening by maternal age","title":"Positive predictive value of cell-free fetal DNA screening for fetal trisomies by maternal age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Positive predictive value of cell-free fetal DNA screening for fetal trisomies by maternal age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Maternal age (years)</td> <td class=\"subtitle1\">Trisomy 21</td> <td class=\"subtitle1\">Trisomy 18</td> <td class=\"subtitle1\">Trisomy 13</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\">48</td> <td class=\"centered\">14</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"centered\">25</td> <td class=\"centered\">51</td> <td class=\"centered\">15</td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"centered\">30</td> <td class=\"centered\">61</td> <td class=\"centered\">21</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"centered\">35</td> <td class=\"centered\">79</td> <td class=\"centered\">39</td> <td class=\"centered\">21</td> </tr> <tr> <td class=\"centered\">40</td> <td class=\"centered\">93</td> <td class=\"centered\">69</td> <td class=\"centered\">50</td> </tr> <tr> <td class=\"centered\">45</td> <td class=\"centered\">98</td> <td class=\"centered\">90</td> <td class=\"centered\">NA</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data are percentages unless otherwise specified. Positive predictive values were obtained using the NIPT/Cell Free DNA Screening Predictive Value Calculator from the Perinatal Quality Foundation.<SUP>[1]</SUP> The calculations are based on prevalence at 16 weeks of gestation using sensitivities and specificities obtained from Gil and colleagues.<SUP>[2]</SUP></div><div class=\"graphic_footnotes\">NA: not available.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>NIPT/Cell Free DNA Screening Predictive Value Calculator from the Perinatal Quality Foundation. Available at:&nbsp;<A href=\"https://www.perinatalquality.org/vendors/nsgc/nipt/\">https://www.perinatalquality.org/vendors/nsgc/nipt/</A> (Retrieved July 21, 2017).</LI>&#xD;&#xA;<LI>Gil MM, Quezada MS, Revello R, et al. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015; 45:249.</LI></OL>From: Dashe JS. Aneuploidy screening in pregnancy. Obstet Gynecol 2016; 128(1):181-94. DOI: <A href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2016&amp;issue=07000&amp;article=00026&amp;type=abstract\" target=_blank>10.1097/AOG.0000000000001385</A>. Copyright © 2016 American College of Obstetricians and Gynecologists. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110510 Version 4.0</div></div></div>"},"110511":{"type":"graphic_figure","displayName":"Birth rates by maternal age cohort from 2007 to 2015","title":"Birth rates by maternal age cohort from 2007 to 2015 in the United States​","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">Birth rates by maternal age cohort from 2007 to 2015 in the United States​</div><div class=\"cntnt\"><img style=\"width:820px; height:448px;\" src=\"images/OBGYN/110511_Birth_matrnl_age_2007_2015.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: For each age group, differences are significant from 2007 to 2014, 2007 to 2015, and 2014 to 2015 (p &lt;0.05).</div><div class=\"graphic_reference\">Reproduced from: Martin JA, Hamilton BE, Osterman MJ. Births in the United States, 2015. NCHS Data Brief 2016; 258:1.</div><div id=\"graphicVersion\">Graphic 110511 Version 1.0</div></div></div>"},"110512":{"type":"graphic_figure","displayName":"Risks of very advanced maternal age pregnancies","title":"Risks of very advanced maternal age pregnancies","html":"<div class=\"graphic\"><div style=\"width: 1046px\" class=\"figure\"><div class=\"ttl\">Risks of very advanced maternal age pregnancies</div><div class=\"cntnt\"><img style=\"width:1026px; height:556px;\" src=\"images/OBGYN/110512_Risks_advnd_matrnl_age_preg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incidence of adverse maternal and infant outcome in very advanced maternal age patients and 30-year-old patients within the overall group and within subgroups (singleton and multiple-fetus pregnancies).</div><div class=\"graphic_footnotes\">GDM: gestational diabetes mellitus; GHT: gestational hypertension; PTB: preterm birth; wk: weeks of gestation; VAMA: very advanced maternal age.<br />* p &lt;0.05 (chi-square test).<br />¶ p &lt;0.01.</div><div class=\"graphic_reference\">Reproduced with permission from: Haslinger C, Stoiber B, Capanna F, et al. Postponed pregnancies and risks of very advanced maternal age. Swiss Med Wkly 2016; 146:w14330. Copyright © 2016 EMH Swiss Medical Publishers Ltd. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110512 Version 1.0</div></div></div>"},"110515":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound image of a true umbilical cord knot","title":"Prenatal ultrasound image of a true umbilical cord knot","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound image of a true umbilical cord knot</div><div class=\"cntnt\"><img style=\"width:756px; height:602px;\" src=\"images/OBGYN/110515_Prntl_US_true_umbl_crd_knot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound image of a true umbilical cord knot shows the characteristic \"hanging noose\" sign: A cross-section view of the cord closely surrounded by a loop of cord.</div><div class=\"graphic_reference\">From: Hasbun J, Alcalde JL, Sepulveda W. Three-dimensional power Doppler sonography in the prenatal diagnosis of a true knot of the umbilical cord: value and limitations. J Ultrasound Med 2007; 26:1215. <A href=\"http://onlinelibrary.wiley.com/doi/10.7863/jum.2007.26.9.1215/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.7863/jum.2007.26.9.1215/abstract</A>. Copyright © 2007 American Institute of Ultrasound in Medicine. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110515 Version 1.0</div></div></div>"},"110516":{"type":"graphic_diagnosticimage","displayName":"Three-dimensional power Doppler ultrasound of a true knot","title":"Three-dimensional power Doppler ultrasound image of a true knot of the umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Three-dimensional power Doppler ultrasound image of a true knot of the umbilical cord</div><div class=\"cntnt\"><img style=\"width:749px; height:756px;\" src=\"images/OBGYN/110516_3D_Doppler_US_true_knot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reformatted view of a true knot as depicted by three-dimensional power Doppler ultrasound.</div><div class=\"graphic_reference\">From: Hasbun J, Alcalde JL, Sepulveda W. Three-dimensional power Doppler sonography in the prenatal diagnosis of a true knot of the umbilical cord: value and limitations. J Ultrasound Med 2007; 26:1215. <A href=\"http://onlinelibrary.wiley.com/doi/10.7863/jum.2007.26.9.1215/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.7863/jum.2007.26.9.1215/abstract</A>. Copyright © 2007 American Institute of Ultrasound in Medicine. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\" target=_blank>permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110516 Version 1.0</div></div></div>"},"110517":{"type":"graphic_picture","displayName":"True knot of umbilical cord at delivery","title":"True knot of umbilical cord at delivery","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">True knot of umbilical cord at delivery</div><div class=\"cntnt\"><img style=\"width:756px; height:560px;\" src=\"images/OBGYN/110517_True_knot_umb_cord_delivery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 110517 Version 1.0</div></div></div>"},"110518":{"type":"graphic_diagnosticimage","displayName":"Gray-scale and color Doppler U/S of velamentous cord insertion","title":"Gray-scale and color Doppler ultrasound of a velamentous cord insertion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gray-scale and color Doppler ultrasound of a velamentous cord insertion</div><div class=\"cntnt\"><img style=\"width:425px; height:766px;\" src=\"images/OBGYN/110518_Dopp_US_velamnts_crd_insrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Velamentous umbilical cord insertion.<br />(A) Gray-scale image of umbilical cord (arrow) inserting into the fetal membranes, away from the placenta (P).<br />(B) Color Doppler shows flow in the umbilical vessels separate from the cord and extending to the placenta.</div><div id=\"graphicVersion\">Graphic 110518 Version 1.0</div></div></div>"},"110519":{"type":"graphic_diagnosticimage","displayName":"Gray-scale and color Doppler ultrasound of fetal gastroschisis","title":"Gray-scale and color Doppler ultrasound of fetal gastroschisis","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Gray-scale and color Doppler ultrasound of fetal gastroschisis</div><div class=\"cntnt\"><img style=\"width:470px; height:764px;\" src=\"images/OBGYN/110519_Dopp_US_fetl_gastroschisis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The abdominal wall defect can be seen adjacent to the cord insertion site. There is loss of continuity of the abdominal skin line where the bowel protrudes through the abdominal wall defect.<br />(B) Color Doppler shows umbilical vessels/cord adjacent to the abdominal wall defect and herniated abdominal organs.</div><div id=\"graphicVersion\">Graphic 110519 Version 1.0</div></div></div>"},"110527":{"type":"graphic_figure","displayName":"Pathophysiologic pathways for postoperative nausea and vomiting","title":"Pathophysiologic pathways for postoperative nausea and vomiting","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Pathophysiologic pathways for postoperative nausea and vomiting</div><div class=\"cntnt\"><img style=\"width:533px; height:798px;\" src=\"images/ANEST/110527_Pathophysiologic_pathways_for_PONV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postoperative nausea and vomiting may occur via multiple peripheral and central mechanisms, mediated by a variety of neurotransmitters and receptors. For further information, refer to UpToDate content on postoperative nausea and vomiting.</div><div class=\"graphic_footnotes\">NTS: nucleus tractus solitarius; AP: area postrema; CPG: central pattern generator; NK1: neurokinin 1; 5 HT3:5-hydroxytryptamine&nbsp;(serotonin); GI: gastrointestinal; CNS: central nervous system</div><div id=\"graphicVersion\">Graphic 110527 Version 1.0</div></div></div>"},"110532":{"type":"graphic_table","displayName":"DDAVP use for hemostasis","title":"Administration of DDAVP for hemostasis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Administration of DDAVP for hemostasis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody> <colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Caveats</td> </tr> <tr> <td><strong>Uses</strong></td> <td> <ul> <li>Response to a test dose should be established before dDAVP is used to treat bleeding or for surgical prophylaxis. </li> <li>Do not use in children &#60;2 years of age. </li> <li>Avoid or use with extreme care in individuals with coronary heart disease. </li> <li>Avoid or use with extreme care in pregnant women. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">VWD</td> <td> <ul> <li>Do not use for type 2B unless it is shown in baseline trial that any platelet drop is temporary. Do not use in type 3 VWD because therapy may be ineffective. </li> <li>For severe VWD, the first dose of DDAVP may be accompanied by factor VIII administration. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hemophilia A</td> <td> <ul> <li>Do not use if baseline factor VIII activity level is &#60;1% because it will not be effective. </li> <li>Do not use for hemophilia B (factor IX deficiency). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Uremic bleeding</td> <td> <ul> <li>Off label use in the United States. </li> </ul> </td> </tr> <tr> <td><strong>Dosing</strong></td> <td> <ul> <li>May be repeated once daily for three to five days. Beyond five days, tachyphylaxis renders it ineffective. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Intravenous or subcutaneous</td> <td> <ul> <li>Intravenous: 0.3 mcg/kg (maximum 20 mcg) diluted in 50 mL of normal saline and infused over 20 to 30 minutes. </li> <li>Subcutaneous: 0.3 mcg/kg (maximum 20 mcg) subcutaneously; subcutaneous form is not available in the United States. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nasal spray</td> <td> <ul> <li>Use spray intended for hemostasis (concentration of 1.5 mg/mL; dose 150 mcg/spray), <strong>not</strong> the spray for enuresis (concentration of 0.01%). </li> <li>Weight &#60;50 kg: One spray in one nostril (total dose 150 mcg). </li> <li>Weight &#8805;50 kg: One spray in each nostril (total dose 300 mcg). </li> </ul> </td> </tr> <tr> <td colspan=\"2\"><strong>Adverse events</strong></td> </tr> <tr> <td class=\"indent1\">Hyponatremia</td> <td> <ul> <li>Avoid excess free water intake (oral or intravenous). </li> <li>Monitor serum sodium. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Thrombotic events</td> <td> <ul> <li>Especially of concern in individuals with pre-existing increased risk factors such as coronary heart disease. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Headache, flushing, hypotension, hypertension</td> <td> <ul> <li>May be alleviated by slowing the infusion. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Administration of DDAVP causes release of stored von Willebrand factor and factor VIII from platelets and endothelial cells. Refer to UpToDate for details of the management of VWD, hemophilia, and uremic bleeding. Refer to Lexicomp drug information on Desmopressin (DDAVP) for additional prescribing information.</div><div class=\"graphic_footnotes\">VWD: von Willebrand disease.</div><div id=\"graphicVersion\">Graphic 110532 Version 1.0</div></div></div>"},"110537":{"type":"graphic_figure","displayName":"Survival T1 to T2 non-small cell lung cancer tumors","title":"Survival of pathologically staged T1 to T2 N0R0 tumors and clinically staged T1 to T2 N0 tumors","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Survival of pathologically staged T1 to T2 N0R0 tumors and clinically staged T1 to T2 N0 tumors</div><div class=\"cntnt\"><img style=\"width:574px; height:776px;\" src=\"images/ONC/110537_Survivl_T1_T2_non_small_lng.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Survival of pathologically staged T1 to T2 N0R0 tumors according to size only, at 1-cm intervals.<br />(B) Survival of clinically staged T1 to T2 N0 tumors according to size only, at 1-cm intervals.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer.</div><div class=\"graphic_reference\">Reproduced from: Rami-Porta R, Bolejack V, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10:990. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110537 Version 1.0</div></div></div>"},"110543":{"type":"graphic_table","displayName":"Properties of IgG subclasses","title":"Properties of IgG subclasses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of IgG subclasses</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Subclass</td> <td class=\"subtitle1\">IgG1</td> <td class=\"subtitle1\">IgG2</td> <td class=\"subtitle1\">IgG3</td> <td class=\"subtitle1\">IgG4</td> </tr> <tr> <td>% of total IgG</td> <td class=\"centered\">60 to 70</td> <td class=\"centered\">20 to 30</td> <td class=\"centered\">5 to 8</td> <td class=\"centered\">1 to 4</td> </tr> <tr> <td>Heavy chain</td> <td class=\"centered\">gamma1</td> <td class=\"centered\">gamma2</td> <td class=\"centered\">gamma3</td> <td class=\"centered\">gamma4</td> </tr> <tr> <td>Number of heavy chains (CH)</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> </tr> <tr> <td>MW</td> <td class=\"centered\">150 kD</td> <td class=\"centered\">150 kD</td> <td class=\"centered\">150 kD</td> <td class=\"centered\">150 kD</td> </tr> <tr> <td>Half-life (days)</td> <td class=\"centered\">21 to 24</td> <td class=\"centered\">21 to 24</td> <td class=\"centered\">7 to 8</td> <td class=\"centered\">21 to 24</td> </tr> <tr> <td>Ability to activate classical complement pathway</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td colspan=\"5\">Important in antibody response to:</td> </tr> <tr> <td class=\"indent1\">Proteins</td> <td class=\"centered\">++</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Polysaccharides</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+++</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> </tr> <tr> <td class=\"indent1\">Allergens</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> </tr> <tr> <td>Fc-gamma-receptor binding</td> <td class=\"centered\">I, II, III</td> <td class=\"centered\">II</td> <td class=\"centered\">I, II, III</td> <td class=\"centered\">I, II</td> </tr> <tr> <td>Placental transport</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; CH: constant heavy chain; MW: molecular weight.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:S41.</LI>&#xD;&#xA;<LI>Carsetti R, Plebani A, Ugazio AG, et al. B lymphocytes and immunoglobulins. In: Immunology IV: Clinical Application in Health and Disease, Bellanti JA (Ed), Care Press, Bethesda, MD 2012. p.163.</LI>&#xD;&#xA;<LI>van der Berg M, Weemaes CMR, Cunningham-Rundles C. Isotype defects. In: Immune Deficiencies, Sullivan KE, Stiehm ER (Eds), Academic Press Elsevier, Amsterdam 2014. p.389.</LI></OL></div><div id=\"graphicVersion\">Graphic 110543 Version 1.0</div></div></div>"},"110544":{"type":"graphic_diagnosticimage","displayName":"Accessory navicular plain radiograph","title":"Accessory navicular plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 932px\" class=\"figure\"><div class=\"ttl\">Accessory navicular plain radiograph</div><div class=\"cntnt\"><img style=\"width:912px; height:440px;\" src=\"images/EM/110544_Accssry_naviculr_radgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above are oblique (panel A)&nbsp;and lateral (panel B)&nbsp;foot radiographs showing an accessory tarsal navicular bone. Notice the smooth, rounded borders of the accessory, and the regular cortical surface between the accessory and the navicular body. These features are typical of accessory bones, and distinguish accessory bones from avulsion fractures.</div><div class=\"graphic_reference\">Courtesy of David Keblish, MD.</div><div id=\"graphicVersion\">Graphic 110544 Version 1.0</div></div></div>"},"110545":{"type":"graphic_picture","displayName":"Palpation of navicular for acute fracture assessment","title":"Palpation of the tarsal navicular bone for assessment of acute, non-stress fracture","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Palpation of the tarsal navicular bone for assessment of acute, non-stress fracture</div><div class=\"cntnt\"><img style=\"width:764px; height:576px;\" src=\"images/EM/110545_Palptn_naviculr_acute_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The antero-posterior, oblique, and lateral images above can serve to help guide palpation of the tarsal navicular bone. The navicular bone is outlined in blue, and the surrounding tendons of the extensor hallicus longus, tibialis anterior, and posterior tibialis are labeled. Dorsal avulsion fractures typically cause tenderness at the dorsal navicular (indicated by blue and black Xs). Tuberosity fractures typically cause tenderness at the medial navicular (red X). Fractures of the navicular body can cause tenderness at any or all regions of the navicular.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 110545 Version 1.0</div></div></div>"},"110546":{"type":"graphic_diagnosticimage","displayName":"Avulsion fracture of dorsal navicular","title":"Small avulsion fracture of dorsal navicular","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">Small avulsion fracture of dorsal navicular</div><div class=\"cntnt\"><img style=\"width:673px; height:756px;\" src=\"images/EM/110546_Avulsn_frac_dorsl_naviculr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph of the&nbsp;left ankle reveals a&nbsp;small avulsion fracture at the dorsal aspect of the tarsal navicular (arrow).</div><div class=\"graphic_reference\">Courtesy of Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 110546 Version 1.0</div></div></div>"},"110547":{"type":"graphic_diagnosticimage","displayName":"Displaced dorsal avulsion fracture of the navicular","title":"Displaced dorsal avulsion fracture of the navicular","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Displaced dorsal avulsion fracture of the navicular</div><div class=\"cntnt\"><img style=\"width:756px; height:455px;\" src=\"images/EM/110547_Dorsl_avulsn_frac_naviculr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain&nbsp;radiograph of the&nbsp;left foot reveals a&nbsp;mildly displaced dorsal avulsion fracture of the navicular (arrow) with overlying soft tissue edema. Note also the incidental finding of a bipartite os peroneum&nbsp;accessory bone (thick arrow).</div><div class=\"graphic_reference\">Courtesy of Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 110547 Version 1.0</div></div></div>"},"110548":{"type":"graphic_diagnosticimage","displayName":"Nondisplaced superior navicular fracture","title":"Nondisplaced superior navicular fracture","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Nondisplaced superior navicular fracture</div><div class=\"cntnt\"><img style=\"width:756px; height:445px;\" src=\"images/EM/110548_Nndsplcd_supr_naviculr_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral plain radiograph of the&nbsp;right foot shows a&nbsp;nondisplaced, dorsal navicular avulsion fracture (arrow) involving greater than 20 percent of the joint surface with associated soft tissue swelling.</div><div class=\"graphic_reference\">Courtesy of Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 110548 Version 1.0</div></div></div>"},"110553":{"type":"graphic_diagnosticimage","displayName":"MRI tarsal navicular fracture","title":"MRI tarsal navicular fracture","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">MRI tarsal navicular fracture</div><div class=\"cntnt\"><img style=\"width:517px; height:1025px;\" src=\"images/EM/110553_MRI_tarsal_naviculr_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) MRI, right foot, sagittal T2 Fat Suppression (FS) view: This image shows a&nbsp;comminuted fracture of the navicular (type 3) with intra-articular extension involving the more inferior medial talonavicular articulation (arrow). Secondary edema within the talus (thick arrow), as well as anterior process of the calcaneus (dashed arrow), can be seen.<br />(Panel B) MRI, right foot, sagittal T1 view: This image shows a&nbsp;comminuted fracture of the navicular (type 3) with intra-articular extension involving the more inferior medial talonavicular articulation (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 110553 Version 1.0</div></div></div>"},"110558":{"type":"graphic_diagnosticimage","displayName":"Navicular body fracture","title":"Navicular body fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Navicular body fracture</div><div class=\"cntnt\"><img style=\"width:445px; height:756px;\" src=\"images/EM/110558_Navicular_body_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This antero-posterior (AP) radiograph of the&nbsp;left foot&nbsp;reveals a&nbsp;mildly displaced fracture (type 2) at the&nbsp;dorsal superior aspect of the navicular (arrow) with overlying soft tissue edema.</div><div class=\"graphic_reference\">Courtesy of Shane Larson, MD.</div><div id=\"graphicVersion\">Graphic 110558 Version 1.0</div></div></div>"},"110564":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph navicular body fracture close-up","title":"Plain radiograph navicular body fracture close-up","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Plain radiograph navicular body fracture close-up</div><div class=\"cntnt\"><img style=\"width:612px; height:577px;\" src=\"images/EM/110564_Xray_navicular_body_fractre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The close-up image above taken from a plain radiograph shows a fracture of the navicular body (arrow).&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: Rowe LJ, Yochum TR, Maola CJ. Trauma. In: Yochum and Rowe's Essentials of Skeletal Radiology, 3rd ed, Yochum TR, Rowe LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 110564 Version 1.0</div></div></div>"},"110567":{"type":"graphic_figure","displayName":"Survival for pN1 and pN2 lung cancer by number of nodal stations","title":"Survival for pN1 and pN2 lung cancer according to single versus multiple nodal stations for R0 and any R settings","html":"<div class=\"graphic\"><div style=\"width: 864px\" class=\"figure\"><div class=\"ttl\">Survival for pN1 and pN2 lung cancer according to single versus multiple nodal stations for R0 and any R settings</div><div class=\"cntnt\"><img style=\"width:844px; height:770px;\" src=\"images/ONC/110567_Explor_pN1_pN2_lung_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exploratory analyses of survival in pN1 and pN2 according to the number of metastatic nodal stations (single versus multiple) for R0 and any R settings (T-any M0). The pN1 category is divided into pN1 single (N1a) and pN1 multiple (N1b). The pN2 category is further divided into pN2 single (N2a) and pN2 multiple (N2b). Despite their different categories, the survival curves for pN1b and pN2a overlap, with five-year survival rates of 50 and 49% for R0 resection, respectively.</div><div class=\"graphic_reference\">Reproduced from: Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10:1675. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110567 Version 1.0</div></div></div>"},"110568":{"type":"graphic_figure","displayName":"The 7th edition and 8th edition M categories lung","title":"The 7th edition and 8th edition M categories","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">The 7th edition and 8th edition M categories</div><div class=\"cntnt\"><img style=\"width:810px; height:296px;\" src=\"images/ONC/110568_7th_8th_ed_M_categories_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EDC: electronic data capture; N: number of patients.</div><div class=\"graphic_reference\">Reproduced from: Eberhardt WE, Mitchell A, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2015; 10:1515. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110568 Version 1.0</div></div></div>"},"110569":{"type":"graphic_table","displayName":"Proposed diagnostic criteria for tumid lupus erythematosus","title":"Proposed diagnostic criteria for tumid lupus erythematosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed diagnostic criteria for tumid lupus erythematosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criteria</td> <td class=\"subtitle1\">Findings in study patients</td> </tr> <tr> <td>Clinical</td> <td>Erythematous, succulent, urticarial-like, nonscarring plaques with a smooth surface in sun-exposed areas.</td> </tr> <tr> <td>Histologic</td> <td>Perivascular and periadnexal lymphocytic infiltration, interstitial mucin deposition, and, in some cases, scattered neutrophils; no epidermal involvement or alteration of the dermoepidermal junction.</td> </tr> <tr> <td>Phototesting</td> <td>Reproduction of skin lesions after UVA and/or UVB irradiation.</td> </tr> <tr> <td>Treatment</td> <td>Rapid and effective systemic treatment with antimalarials.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UVA: ultraviolet A; UVB: ultraviolet B.</div><div class=\"graphic_reference\">Reproduced with permission from: Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136(8):1033-41. Copyright &copy; 2000 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110569 Version 2.0</div></div></div>"},"110571":{"type":"graphic_figure","displayName":"Overall survival 7th and 8th edition TNM lung","title":"Overall survival by clinical stage according to the seventh edition (A) and the eighth edition (B) groupings using the entire database available for the eighth edition","html":"<div class=\"graphic\"><div style=\"width: 764px\" class=\"figure\"><div class=\"ttl\">Overall survival by clinical stage according to the seventh edition (A) and the eighth edition (B) groupings using the entire database available for the eighth edition</div><div class=\"cntnt\"><img style=\"width:744px; height:492px;\" src=\"images/ONC/110571_Overall_srv_7th_8th_TNM_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival by clinical stage according to the seventh edition (A) and the eighth edition (B) groupings using the entire database available for the eighth edition. Survival is weighted by type of database submission: registry versus other.</div><div class=\"graphic_footnotes\">N: number of patients; MST: median survival time; NR: not reached.</div><div class=\"graphic_reference\">Reproduced from: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110571 Version 1.0</div></div></div>"},"110572":{"type":"graphic_picture","displayName":"Tumid lupus erythematosus on cheek","title":"Tumid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tumid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:756px; height:514px;\" src=\"images/DERM/110572_Tumid_lupus_erythmtss_cheek.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, edematous plaque without surface change on the right cheek.</div><div id=\"graphicVersion\">Graphic 110572 Version 1.0</div></div></div>"},"110573":{"type":"graphic_figure","displayName":"Overall survival pathologic 7th and 8th ed TNM lung","title":"Overall survival by pathologic stage according to the seventh edition (A) and the eighth edition (B) groupings using the entire database available for the eighth edition","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Overall survival by pathologic stage according to the seventh edition (A) and the eighth edition (B) groupings using the entire database available for the eighth edition</div><div class=\"cntnt\"><img style=\"width:746px; height:460px;\" src=\"images/ONC/110573_Ovrll_surv_path_7th_8th_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival by pathologic stage according to the seventh edition (A) and the eighth edition (B) groupings using the entire database available for the eighth edition. Survival is weighted by type of database submission: registry versus other.</div><div class=\"graphic_footnotes\">N: number of patients; MST: median survival time; NR: not reached.</div><div class=\"graphic_reference\">Reproduced from: Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:39. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110573 Version 1.0</div></div></div>"},"110574":{"type":"graphic_picture","displayName":"Tumid lupus erythematosus on back","title":"Tumid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Tumid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:661px; height:756px;\" src=\"images/DERM/110574_Tumid_lupus_erythmtss_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous, edematous papules and plaques on the upper back.</div><div id=\"graphicVersion\">Graphic 110574 Version 1.0</div></div></div>"},"110575":{"type":"graphic_picture","displayName":"Tumid lupus erythematosus on forehead","title":"Tumid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tumid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:756px; height:364px;\" src=\"images/DERM/110575_Tumid_lupus_erythmtss_frhd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous and edematous papules lacking surface change on the forehead.</div><div id=\"graphicVersion\">Graphic 110575 Version 1.0</div></div></div>"},"110582":{"type":"graphic_figure","displayName":"AR inheritance","title":"Autosomal recessive inheritance","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Autosomal recessive inheritance</div><div class=\"cntnt\"><img style=\"width:512px; height:292px;\" src=\"images/PC/110582_AR_inheritance.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on Mendelian inheritance patterns and specific conditions for additional information.</div><div class=\"graphic_reference\">Courtesy of Benjamin A Raby, MD, MPH.</div><div id=\"graphicVersion\">Graphic 110582 Version 1.0</div></div></div>"},"110584":{"type":"graphic_table","displayName":"Levels of immunoglobulins in sera of normal subjects by age","title":"Levels of immunoglobulins in sera of normal subjects by age*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Levels of immunoglobulins in sera of normal subjects by age*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">IgG (mg/dL)</td> <td class=\"subtitle1\">IgM (mg/dL)</td> <td class=\"subtitle1\">IgA (mg/dL)</td> <td class=\"subtitle1\">Total immunoglobulin (mg/dL)</td> </tr> <tr> <td>Newborn</td> <td class=\"centered\">1031&#177;200<sup>&#182;</sup></td> <td class=\"centered\">11&#177;5</td> <td class=\"centered\">2&#177;3</td> <td class=\"centered\">1044&#177;201</td> </tr> <tr> <td>1 to 3 months</td> <td class=\"centered\">430&#177;119</td> <td class=\"centered\">30&#177;11</td> <td class=\"centered\">21&#177;13</td> <td class=\"centered\">481&#177;127</td> </tr> <tr> <td>4 to 6 months</td> <td class=\"centered\">427&#177;186</td> <td class=\"centered\">43&#177;17</td> <td class=\"centered\">28&#177;18</td> <td class=\"centered\">498&#177;204</td> </tr> <tr> <td>7 to 12 months</td> <td class=\"centered\">661&#177;219</td> <td class=\"centered\">54&#177;23</td> <td class=\"centered\">37&#177;18</td> <td class=\"centered\">752&#177;242</td> </tr> <tr> <td>13 to 24 months</td> <td class=\"centered\">762&#177;209</td> <td class=\"centered\">58&#177;23</td> <td class=\"centered\">50&#177;24</td> <td class=\"centered\">870&#177;258</td> </tr> <tr> <td>25 to 36 months</td> <td class=\"centered\">892&#177;183</td> <td class=\"centered\">61&#177;19</td> <td class=\"centered\">71&#177;37</td> <td class=\"centered\">1024&#177;205</td> </tr> <tr> <td>3 to 5 years</td> <td class=\"centered\">929&#177;228</td> <td class=\"centered\">56&#177;18</td> <td class=\"centered\">93&#177;27</td> <td class=\"centered\">1078&#177;245</td> </tr> <tr> <td>6 to 8 years</td> <td class=\"centered\">923&#177;256</td> <td class=\"centered\">65&#177;25</td> <td class=\"centered\">124&#177;45</td> <td class=\"centered\">1112&#177;293</td> </tr> <tr> <td>9 to 11 years</td> <td class=\"centered\">1124&#177;235</td> <td class=\"centered\">79&#177;33</td> <td class=\"centered\">131&#177;60</td> <td class=\"centered\">1334&#177;254</td> </tr> <tr> <td>12 to 16 years</td> <td class=\"centered\">946&#177;124</td> <td class=\"centered\">59&#177;20</td> <td class=\"centered\">148&#177;63</td> <td class=\"centered\">1153&#177;169</td> </tr> <tr> <td>Adults</td> <td class=\"centered\">1158&#177;305</td> <td class=\"centered\">99&#177;27</td> <td class=\"centered\">200&#177;61</td> <td class=\"centered\">1457&#177;353</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M; IgA: immunoglobulin.<br />* The values were divided from measurements made in 296 healthy children and adults. Levels were determined by the radial diffusion technique using specific rabbit antisera to human immunoglobulins.<br />¶ One standard deviation.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 37, 715-27, Copyright &copy; 1966 by the AAP.</div><div id=\"graphicVersion\">Graphic 110584 Version 2.0</div></div></div>"},"110585":{"type":"graphic_table","displayName":"Normal human blood lymphocyte subpopulations at various ages","title":"Normal human blood lymphocyte subpopulations at various ages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal human blood lymphocyte subpopulations at various ages</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Subpopulations</td> <td class=\"subtitle1\" colspan=\"7\">Age groups</td> </tr> <tr> <td class=\"subtitle2\">Core blood</td> <td class=\"subtitle2\">2 to 3 months</td> <td class=\"subtitle2\">4 to 8 months</td> <td class=\"subtitle2\">12 to 23 months</td> <td class=\"subtitle2\">2 to 5 years</td> <td class=\"subtitle2\">7 to 17 years</td> <td class=\"subtitle2\">Adult</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Total lymphocytes</td> </tr> <tr> <td class=\"indent1\">Median cells/uL (% total leukocytes)</td> <td class=\"centered\">5400 (41%)</td> <td class=\"centered\">5680 (66%)</td> <td class=\"centered\">5990 (64%)</td> <td class=\"centered\">5160 (59%)</td> <td class=\"centered\">4060 (50%)</td> <td class=\"centered\">2400 (40%)</td> <td class=\"centered\">2100 (32%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Confidence intervals</td> <td class=\"centered\">4200 (35%) to 6900 (47%)*</td> <td class=\"centered\">2920 (55%) to 8840 (78%)</td> <td class=\"centered\">3610 (45%) to 8840 (79%)</td> <td class=\"centered\">2180 (44%) to 8270 (72%)</td> <td class=\"centered\">2400 (38%) to 5810 (64%)</td> <td class=\"centered\">2000 (36%) to 2700 (43%)*</td> <td class=\"centered\">1600 (28%) to 2400 (39%)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">CD3 T cells</td> </tr> <tr> <td class=\"indent1\">Median cells/uL (% total lymphocytes)</td> <td class=\"centered\">3100 (55%)</td> <td class=\"centered\">4030 (72%)</td> <td class=\"centered\">4270 (71%)</td> <td class=\"centered\">3300 (66%)</td> <td class=\"centered\">3040 (72%)</td> <td class=\"centered\">1800 (70%)</td> <td class=\"centered\">1600 (73%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Confidence intervals</td> <td class=\"centered\">2400 (49%) to 3700 (62%)*</td> <td class=\"centered\">2070 (55%) to 6540 (78%)</td> <td class=\"centered\">2280 (45%) to 6450 (79%)</td> <td class=\"centered\">1460 (53%) to 5440 (81%)</td> <td class=\"centered\">1610 (62%) to 4230 (80%)</td> <td class=\"centered\">1400 (66%) to 2000 (76%)*</td> <td class=\"centered\">960 (61%) to 2600 (84%)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">CD4 T cells</td> </tr> <tr> <td class=\"indent1\">Median cells/uL (% total lymphocytes)</td> <td class=\"centered\">1900 (35%)</td> <td class=\"centered\">2830 (52%)</td> <td class=\"centered\">2950 (49%)</td> <td class=\"centered\">2070 (43%)</td> <td class=\"centered\">1800 (42%)</td> <td class=\"centered\">800 (37%)</td> <td class=\"centered\">940 (46%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Confidence intervals</td> <td class=\"centered\">1500 (28%) to 2400 (42%)*</td> <td class=\"centered\">1460 (41%) to 5116 (64%)</td> <td class=\"centered\">1690 (36%) to 4600 (61%)</td> <td class=\"centered\">1020 (31%) to 3600 (54%)</td> <td class=\"centered\">900 (35%) to 2860 (51%)</td> <td class=\"centered\">700 (33%) to 1100 (41%)*</td> <td class=\"centered\">540 (32%) to 1660 (60%)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">CD8 T cells</td> </tr> <tr> <td class=\"indent1\">Median cells/uL (% total lymphocytes)</td> <td class=\"centered\">1500 (29%)</td> <td class=\"centered\">1410 (25%)</td> <td class=\"centered\">1450 (24%)</td> <td class=\"centered\">1320 (25%)</td> <td class=\"centered\">1180 (30%)</td> <td class=\"centered\">800 (30%)</td> <td class=\"centered\">520 (27%)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Confidence intervals</td> <td class=\"centered\">1200 (26%) to 2000 (33%)*</td> <td class=\"centered\">650 (16%) to 2450 (35%)</td> <td class=\"centered\">720 (16%) to 2490 (34%)</td> <td class=\"centered\">570 (16%) to 2230 (38%)</td> <td class=\"centered\">630 (22%) to 1910 (38%)</td> <td class=\"centered\">600 (27%) to 900 (35%)*</td> <td class=\"centered\">270 (13%) to 930 (40%)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">B cells<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Median cells/uL (% total lymphocytes)</td> <td class=\"centered\">1000 (20%)<sup>&#182;</sup></td> <td class=\"centered\">900 (23%)</td> <td class=\"centered\">900 (23%)</td> <td class=\"centered\">900 (23%)</td> <td class=\"centered\">900 (24%)</td> <td class=\"centered\">400 (16%)<sup>&#182;</sup></td> <td class=\"centered\">246 (13%)<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Confidence intervals</td> <td class=\"centered\">200 (14%) to 1500 (23%)*</td> <td class=\"centered\">500 (19%) to 1500 (31%)</td> <td class=\"centered\">500 (19%) to 1500 (31%)</td> <td class=\"centered\">500 (19%) to 1500 (31%)</td> <td class=\"centered\">700 (21%) to 1300 (28%)</td> <td class=\"centered\">300 (12%) to 500 (22%)*</td> <td class=\"centered\">122 (10%) to 632 (31%)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">CD4:CD8 ratio</td> </tr> <tr> <td class=\"indent1\">Median</td> <td class=\"centered\">1.2</td> <td class=\"centered\">2.2</td> <td class=\"centered\">2.1</td> <td class=\"centered\">1.6</td> <td class=\"centered\">1.4</td> <td class=\"centered\">1.3</td> <td class=\"centered\">1.7</td> </tr> <tr> <td class=\"indent1\">Confidence intervals</td> <td class=\"centered\">0.8 to 1.8</td> <td class=\"centered\">1.3 to 3.5</td> <td class=\"centered\">1.2 to 3.5</td> <td class=\"centered\">1.0 to 3.0</td> <td class=\"centered\">1.0 to 2.1</td> <td class=\"centered\">1.1 to 1.4</td> <td class=\"centered\">0.9 to 4.5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Confidence intervals given are the 5<SUP>th</SUP> to 95<SUP>th</SUP> percentiles except where indicated (*). B cells use the CD20 antigen except where indicated (<SUP>¶</SUP>).<FONT color=#ff0000><br /></FONT>Each subgroup contains at least 22 health subjects.</div><div class=\"graphic_footnotes\"><FONT color=#ff0000><FONT color=black>* These are the 25<SUP>th</SUP> to 75<SUP>th</SUP> percentiles.</FONT><br /><FONT color=black>¶&nbsp;These use the CD19 antigen.</FONT></FONT></div><div class=\"graphic_reference\">This book chapter was published in Immunologic Disorders in Infants and Children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA, Immunodeficiency disorders: General considerations, 311, Copyright Elsevier (2004).</div><div id=\"graphicVersion\">Graphic 110585 Version 1.0</div></div></div>"},"110591":{"type":"graphic_figure","displayName":"A mechanism of injury for capitate fracture","title":"One possible mechanism of injury for capitate fracture","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">One possible mechanism of injury for capitate fracture</div><div class=\"cntnt\"><img style=\"width:529px; height:440px;\" src=\"images/EM/110591_Mchnsm_injry_capitate_fracs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanism of carpal fractures from falls on outstretched hand with wrist going into marked dorsiflexion.<br />(A) Wrist in marked dorsiflexion. Capitate is at 90-degree angle to radius.<br />(B) Scaphoid fractures as result of increased dorsiflexion at midcarpal joint.<br />(C) Dorsal lip of radius strikes capitate, causing it to fracture.<br />(D) Proximal fragment of capitate is rotated 90 degrees.<br />(E) Return of wrist to neutral position. Proximal fragment of capitate is now rotated 180 degrees.</div><div class=\"graphic_reference\">Reproduced from: Cannon DL. Wrist disorders. In: Campbell's Operative Orthopaedics, Canale ST, Beatty JH (Eds),12 ed, Mosby, Philadelphia 2012. p.3383. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110591 Version 1.0</div></div></div>"},"110592":{"type":"graphic_table","displayName":"Screening for nutrition and comorbidities celiac disease","title":"Suggested screening for nutritional deficiencies and other comorbidities in children with celiac disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested screening for nutritional deficiencies and other comorbidities in children with celiac disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Screening test</td> <td class=\"subtitle1\">At diagnosis of celiac disease</td> <td class=\"subtitle1\">Follow-up*</td> </tr> <tr> <td>Height, weight, and BMI</td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\"><strong>Yes</strong></td> </tr> <tr> <td>tTG-IgA antibodies</td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\"><strong>Yes</strong></td> </tr> <tr> <td>CBC</td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Ferritin, iron, TIBC</td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\">PRN</td> </tr> <tr> <td>Vitamin D</td> <td class=\"centered\">Yes</td> <td class=\"centered\">PRN</td> </tr> <tr> <td>Calcium, phosphorus, alkaline phosphatase, PTH</td> <td class=\"centered\">PRN</td> <td class=\"centered\">PRN</td> </tr> <tr> <td>DEXA</td> <td class=\"centered\">PRN</td> <td class=\"centered\">PRN<sup>&#182;</sup></td> </tr> <tr> <td>Folate</td> <td class=\"centered\">PRN</td> <td class=\"centered\">PRN</td> </tr> <tr> <td>Other vitamins, zinc, and trace elements</td> <td class=\"centered\">PRN</td> <td class=\"centered\">PRN</td> </tr> <tr> <td>ALT, AST</td> <td class=\"centered\">Yes</td> <td class=\"centered\">PRN</td> </tr> <tr> <td>Diabetes screening (A1C, OGTT, or islet autoantibodies)</td> <td class=\"centered\">PRN</td> <td class=\"centered\">PRN&nbsp;</td> </tr> <tr> <td>TSH<sup>&#916;</sup></td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\">Yes</td> </tr> <tr> <td>HBsAb</td> <td class=\"centered\">Yes</td> <td class=\"centered\">PRN</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Recommended approaches to laboratory screening for pediatric patients with celiac disease, based on review of the evidence and voting by a consensus panel. \"Yes\" indicates a recommendation for routine screening in all patients (<STRONG>bold</STRONG> denotes a strong recommendation); PRN indicates a recommendation for testing only in selected patients, based on individual risk factors, clinical signs or symptoms, or prior test results.</div><div class=\"graphic_footnotes\">BMI: body mass index; tTG-IgA: immunoglobulin A antibodies to tissue transglutaminase; CBC: complete blood count; TIBC: total iron binding capacity; PTH: parathyroid hormone; DEXA: dual electron x-ray absorptiometry; ALT: alanine aminotransferase; AST: aspartate aminotransferase; A1C: hemoglobin A1C; OGTT: oral glucose tolerance test; TSH: thyroid stimulating hormone; HBsAb: hepatitis B s antibody.<br />* Follow-up testing is typically done about six months after beginning a gluten-free diet. For patients whose serologies become negative, we repeat testing annually.<br />¶ DEXA screening is suggested for patients who do not adhere to a gluten-free diet.<br />Δ Testing for antithyroid antibodies was not recommended, except as follow-up testing for patients with abnormal TSH.</div><div class=\"graphic_reference\">Based on recommendations by an expert panel, in: Snyder J, Butzner JD, DeFelice AR, et al. Evidence-Informed Expert Recommendations for the Management of Celiac Disease in Children. Pediatrics 2016; 138.</div><div id=\"graphicVersion\">Graphic 110592 Version 2.0</div></div></div>"},"110595":{"type":"graphic_table","displayName":"Primary anetoderma associated conditions","title":"Possible conditions* associated with primary anetoderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible conditions* associated with primary anetoderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Antiphospholipid antibodies </li> <li>Systemic lupus erythematosus </li> <li>Autoimmune thyroid disease (Graves' disease) </li> <li>Autoimmune thrombocytopenia </li> <li>Autoimmune hemolysis </li> <li>Sj&#246;gren's syndrome </li> <li>Addison's disease </li> <li>Systemic sclerosis </li> <li>Vitiligo </li> <li>Alopecia areata </li> <li>Multiple sclerosis </li> <li>Alpha-1 antitrypsin deficiency </li> <li>Protein C and S deficiency </li> <li>Antithrombin III deficiency </li> <li>Cocaine </li> <li>Tuberculosis </li> <li>Human immunodeficiency virus (HIV) </li> <li>Lyme disease </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;In some cases, based on a single case report.</div><div class=\"graphic_reference\">Adapted from: Kineston DP, Xia Y, Turiansky GM. Anetoderma: a case report and review of the literature. Cutis 2008; 81:501.</div><div id=\"graphicVersion\">Graphic 110595 Version 1.0</div></div></div>"},"110600":{"type":"graphic_table","displayName":"Secondary anetoderma associated conditions","title":"Possible conditions* associated with secondary anetoderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Possible conditions* associated with secondary anetoderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Autoimmune</td> </tr> <tr> <td class=\"indent1 divider_bottom\"> <ul> <li>Lupus panniculitis </li> <li>Discoid lupus </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"indent1 divider_bottom\"> <ul> <li>Varicella </li> <li>Syphilis </li> <li>Leprosy </li> <li>Molluscum contagiosum </li> <li>Human immunodeficiency virus (HIV) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1 divider_bottom\"> <ul> <li>Acne </li> <li>Insect bites </li> <li>Prurigo nodularis </li> <li>Juvenile xanthogranuloma </li> <li>Congenital self-healing reticulohistiocytosis </li> <li>Urticaria pigmentosa </li> <li>Post-hepatitis B vaccination </li> <li>Granuloma annulare </li> <li>Takayasu's arteritis </li> <li>Application of leeches </li> <li>Nodular amyloidosis </li> <li>Angular cheilitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Tumor/deposition</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pilomatrixoma </li> <li>Schwannoma </li> <li>B cell lymphomas </li> <li>Mycosis fungoides </li> <li>Hamartomatous congenital melanocytic nevi </li> <li>Myxofibrosarcoma </li> <li>Dermatofibroma </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In some cases, based on a single case report.</div><div class=\"graphic_reference\">Adapted from: Kineston DP, Xia Y, Turiansky GM. Anetoderma: a case report and review of the literature. Cutis 2008; 81:501.</div><div id=\"graphicVersion\">Graphic 110600 Version 1.0</div></div></div>"},"110605":{"type":"graphic_figure","displayName":"Skin anatomy: Cellulitis, erysipelas, and skin abscess","title":"Skin anatomy: Cellulitis, erysipelas, and skin abscess","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Skin anatomy: Cellulitis, erysipelas, and skin abscess</div><div class=\"cntnt\"><img style=\"width:585px; height:211px;\" src=\"images/ID/110605_Cellulitis_erysipelas_absc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cellulitis and erysipelas manifest as areas of skin erythema, edema, and warmth; they develop as a result of bacterial entry via breaches in the skin barrier. Cellulitis involves the deeper dermis and subcutaneous fat; in contrast, erysipelas involves the upper dermis, and there is clear demarcation between involved and uninvolved tissue. A skin abscess is a collection of pus within the dermis or subcutaneous space.</div><div id=\"graphicVersion\">Graphic 110605 Version 2.0</div></div></div>"},"110607":{"type":"graphic_picture","displayName":"Split ear lobe","title":"Split ear lobe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Split ear lobe</div><div class=\"cntnt\"><img style=\"width:430px; height:288px;\" src=\"images/PEDS/110607_Split_ear_lobe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tearing of the ear lobe related to wearing an earring that was too heavy.</div><div id=\"graphicVersion\">Graphic 110607 Version 1.0</div></div></div>"},"110611":{"type":"graphic_algorithm","displayName":"Approach to treatment for stimulant use disorder","title":"Approach to treatment for stimulant use disorder","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Approach to treatment for stimulant use disorder</div><div class=\"cntnt\"><img style=\"width:490px; height:440px;\" src=\"images/PSYCH/110611_Trtmnt_stimulant_use_dsrdr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBT: cognitive-behavioral therapy.</div><div id=\"graphicVersion\">Graphic 110611 Version 1.0</div></div></div>"},"110617":{"type":"graphic_table","displayName":"Major salivary gland tumors TNM 2017 pathologic staging","title":"Major salivary gland tumors TNM pathologic staging AJCC UICC 2017 ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major salivary gland tumors TNM&nbsp;pathologic staging AJCC UICC 2017 </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension*</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension*</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm and/or tumor having extraparenchymal extension*</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced disease</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Moderately advanced disease.<br /> Tumor invades skin, mandible, ear canal, and/or facial nerve.</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Very advanced disease.<br /> Tumor invades skull base and/or pterygoid plates and/or encases carotid artery.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger&nbsp;than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T0, T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T0, T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110617 Version 2.0</div></div></div>"},"110618":{"type":"graphic_algorithm","displayName":"Fertility preservation and counseling for Turner syndrome","title":"Algorithmic approach to decision-making for fertility preservation in girls and women with Turner syndrome","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to decision-making&nbsp;for fertility preservation&nbsp;in girls and women with Turner syndrome</div><div class=\"cntnt\"><img style=\"width:724px; height:332px;\" src=\"images/ENDO/110618_Fertilty_prsrvtn_Turner_syn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A proposed algorithmic approach to decision-making for fertility preservation in females diagnosed with Turner syndrome. For prepubertal girls with sufficient ovarian reserve, expert experience dictates utility of serial serum anti-Müllerian hormone (AMH) assessments to delay intervention to a postpubertal age so that oocyte cryopreservation can be considered. Serum AMH level of less than 2 ng/mL corresponds to levels in the lower quartile for girls 5 to 13 years of age.<SUP>[1]</SUP> In postpubertal girls, because the risk of follicle loss is extremely high and can proceed at a fast pace, we recommend fertility preservation regardless of the initial AMH.</div><div class=\"graphic_footnotes\">AFC: antral follicle count; FSH: follicle-stimulating hormone; LH: luteinizing hormone.<br />* Girls whose serum AMH remains &gt;2 ng/mL should be followed with serial measures through puberty before selecting a fertility preservation technique.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Purushothaman R, Lazareva O, Oktay K, et al: Markers of ovarian reserve in young girls with Turner's syndrome. Fertil Steril 2010; 94:1557.</LI></OL>Reproduced from: Oktay K, Bedoschi G, Berkowitz K, et al. Fertility Preservation in Women with Turner Syndrome: A Comprehensive Review and Practical Guidelines. J Pediatr Adolesc Gynecol 2016; 29:409. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110618 Version 2.0</div></div></div>"},"110619":{"type":"graphic_picture","displayName":"Salmon patch 2","title":"Nevus simplex","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Nevus simplex</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/110619_Salmon_patch_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nevus simplex, also called salmon patch or stork bite, presenting in a newborn as a splotchy red macular lesion on the nape of the neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110619 Version 1.0</div></div></div>"},"110620":{"type":"graphic_table","displayName":"STS head and neck TNM 2017","title":"Soft tissue sarcoma of the head and neck TNM staging AJCC UICC 2017*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Soft tissue sarcoma of the head and neck TNM staging AJCC UICC 2017*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Tumor &#8804;2 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>Tumor &#62;2 to &#8804;4 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Tumor &#62;4 cm</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Tumor with invasion of adjoining structures</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>Tumor with orbital invasion, skull base/dural invasion, invasion of central compartment viscera, involvement of facial skeleton, or invasion of pterygoid muscles</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td>Tumor with brain parenchymal invasion, carotid artery encasement, prevertebral muscle invasion, or central nervous system involvement via perineural spread</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\">N criteria</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional lymph node metastases or unknown lymph node status</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td>Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>Distant metastasis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.<br />* This is a new classification that needs data collection before defining a prognostic stage grouping.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110620 Version 5.0</div></div></div>"},"110626":{"type":"graphic_picture","displayName":"Malignant fibrous histiocytoma","title":"Malignant fibrous histiocytoma","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Malignant fibrous histiocytoma</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/110626_Malignant_fibrous_histicytm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malignant fibrous histiocytoma presenting as an ulcerated nodule.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110626 Version 1.0</div></div></div>"},"110627":{"type":"graphic_picture","displayName":"Malignant fibrous histiocytoma nose","title":"Malignant fibrous histiocytoma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Malignant fibrous histiocytoma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110627_Malignnt_fibrs_hstcytm_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malignant fibrous histiocytoma presenting as an ulcerated nodule on the ala nasi.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110627 Version 1.0</div></div></div>"},"110628":{"type":"graphic_table","displayName":"Oropharyngeal (p16 negative) CA TNM 2017 pathological staging","title":"Oropharyngeal (p16 negative) cancer TNM pathological staging AJCC UICC 2017 ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oropharyngeal (p16 negative) cancer TNM&nbsp;pathological staging AJCC UICC 2017 </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Oropharynx (p16&ndash;)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor 2 cm or smaller in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor larger than 2 cm but not larger than 4 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced local disease</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.*</td> </tr> <tr> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\">* <em>NOTE:</em> Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN) - Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong> larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong> a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong> multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+); <strong>or</strong> a single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong> multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+); <strong>or</strong> a single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, 1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110628 Version 2.0</div></div></div>"},"110631":{"type":"graphic_table","displayName":"Hypopharyngeal cancer TNM 2017 pathologic staging","title":"Hypopharyngeal cancer TNM pathologic staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypopharyngeal cancer TNM pathologic staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades more than one subsite of hypopharynx or an adjacent site, or measures larger than 2 cm but not larger than 4 cm in greatest dimension without fixation of hemilarynx</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced and very advanced local disease</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.*</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN) &ndash; Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> A single ipsalateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110631 Version 2.0</div></div></div>"},"110634":{"type":"graphic_table","displayName":"Eyelid neoplasms TNM 2017","title":"Eyelid neoplasms TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eyelid neoplasms TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\" subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;10 mm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor does not invade the tarsal plate or eyelid margin</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor invades the tarsal plate or eyelid margin</td> </tr> <tr> <td class=\"indent2\">T1c</td> <td colspan=\"3\">Tumor involves full thickness of the eyelid</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#62;10 mm but &#8804;20 mm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td colspan=\"3\">Tumor does not invade the tarsal plate or eyelid margin</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td colspan=\"3\">Tumor invades the tarsal plate or eyelid margin</td> </tr> <tr> <td class=\"indent2\">T2c</td> <td colspan=\"3\">Tumor involves full thickness of the eyelid</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor &#62;20 mm but &#8804;30 mm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td colspan=\"3\">Tumor does not invade the tarsal plate or eyelid margin</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td colspan=\"3\">Tumor invades the tarsal plate or eyelid margin</td> </tr> <tr> <td class=\"indent2\">T3c</td> <td colspan=\"3\">Tumor involves full thickness of the eyelid</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Any eyelid tumor that invades adjacent ocular, orbital, or facial structures</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Tumor invades ocular or intraorbital structures</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Tumor invades (or erodes through) the bony walls of the orbit or extends to the paranasal sinuses or invades the lacrimal sac/nasolacrimal duct or brain</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No evidence of lymph node involvement</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral regional lymph node, &#8804;3 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node based on clinical evaluation or imaging findings</td> </tr> <tr> <td class=\"indent2\">N1b</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node based on lymph node biopsy</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, &#62;3 cm in greatest dimension, or in bilateral or contralateral lymph nodes</td> </tr> <tr> <td class=\"indent2\">N2a</td> <td colspan=\"3\">Metastasis documented based on clinical evaluation or imaging findings</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N2b</td> <td colspan=\"3\">Metastasis documented based on microscopic findings on lymph node biopsy</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2b-c, T3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110634 Version 2.0</div></div></div>"},"110635":{"type":"graphic_table","displayName":"Differentiated and anaplastic thyroid carcinoma TNM 2017","title":"Differentiated and anaplastic thyroid carcinoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiated and anaplastic thyroid carcinoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Papillary, follicular, poorly differentiated, Hurthle cell and anaplastic thyroid carcinoma</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"4\">Tumor &#8804;2 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td colspan=\"4\">Tumor &#8804;1 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td colspan=\"4\">Tumor &#62;1 cm but &#8804;2 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"4\">Tumor &#62;2 cm but &#8804;4 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"4\">Tumor &#62;4 cm limited to the thyroid, or gross extrathyroidal extension invading only strap muscles</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td colspan=\"4\">Tumor &#62;4 cm limited to the thyroid</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td colspan=\"4\">Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"4\">Includes gross extrathyroidal extension</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"4\">Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size</td> </tr> <tr> <td class=\"indent3\">T4b</td> <td colspan=\"4\">Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"5\"><em>NOTE:</em> All categories may be subdivided: (s) solitary tumor and (m) multifocal tumor (the largest tumor determines the classification).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"4\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"4\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"4\">No evidence of locoregional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N0a</td> <td colspan=\"4\">One or more cytologically or histologically confirmed benign lymph nodes</td> </tr> <tr> <td class=\"indent2\">N0b</td> <td colspan=\"4\">No radiologic or clinical evidence of locoregional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"4\">Metastasis to regional nodes</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td colspan=\"4\">Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1b</td> <td colspan=\"4\">Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"4\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"4\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"4\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Differentiated</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When age at diagnosis is...</strong></td> <td><strong>And T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">&#60;55 years</td> <td>Any T</td> <td>Any N</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">&#60;55 years</td> <td>Any T</td> <td>Any N</td> <td>M1</td> <td>II</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T1</td> <td>N0/NX</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T1</td> <td>N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T2</td> <td>N0/NX</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T2</td> <td>N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T3a/T3b</td> <td>Any N</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T4a</td> <td>Any N</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">&#8805;55 years</td> <td>T4b</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">&#8805;55 years</td> <td>Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Anaplastic</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1-T3a</td> <td>N0/NX</td> <td>M0</td> <td colspan=\"2\">IVA</td> </tr> <tr> <td class=\"indent2\">T1-T3a</td> <td>N1</td> <td>M0</td> <td colspan=\"2\">IVB</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>Any N</td> <td>M0</td> <td colspan=\"2\">IVB</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>Any N</td> <td>M0</td> <td colspan=\"2\">IVB</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td colspan=\"2\">IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110635 Version 2.0</div></div></div>"},"110636":{"type":"graphic_table","displayName":"Medullary thyroid carcinoma TNM 2017","title":"Medullary thyroid carcinoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medullary thyroid carcinoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\" subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;2 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor &#8804;1 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor &#62;1 cm but &#8804;2 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#62;2 cm but &#60;4 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor &#8805;4 cm or with extrathyroidal extension</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td colspan=\"3\">Tumor &#8805;4 cm in greatest dimension limited to the thyroid</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td colspan=\"3\">Tumor of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid or omohyoid muscles)</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Advanced disease</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Moderately advanced disease.<br /> Tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Very advanced disease.<br /> Tumor of any size with extension toward the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels.</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No evidence of locoregional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N0a</td> <td colspan=\"3\">One or more cytologically or histologically confirmed benign lymph nodes</td> </tr> <tr> <td class=\"indent2\">N0b</td> <td colspan=\"3\">No radiologic or clinical evidence of locoregional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis to regional nodes</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td colspan=\"3\">Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1b</td> <td colspan=\"3\">Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T1-3</td> <td>N1a</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1-3</td> <td>N1b</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110636 Version 2.0</div></div></div>"},"110637":{"type":"graphic_table","displayName":"Parathyroid carcinoma TNM 2017","title":"Parathyroid carcinoma proposed TNM definitions AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parathyroid carcinoma proposed TNM definitions AJCC UICC&nbsp;2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>Atypical parathyroid neoplasm (neoplasm of uncertain malignant potential)*</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Localized to the parathyroid gland with extension limited to soft tissue</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>Direct invasion into the thyroid gland</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Direct invasion into recurrent laryngeal nerve, esophagus, trachea, skeletal muscle, adjacent lymph nodes, or thymus</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Direct invasion into major blood vessel or spine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">* Defined as tumors that are histologically or clinically worrisome but do not fulfill the more robust criteria (ie, invasion, metastasis) for carcinoma. They generally include tumors that have two or more concerning features, such as fibrous bands, mitotic figures, necrosis, trabecular growth, or adherence to surrounding tissues intraoperatively. Atypical parathyroid neoplasms usually have a smaller dimension, weight, and volume than carcinomas and are less likely to have coagulative tumor necrosis.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>Regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td>Metastasis to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes) or superior mediastinal lymph nodes (level VII)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1b</td> <td>Metastasis to unilateral, bilateral, or contralateral cervical (levels I, II, III, IV, or V) or retropharyngeal nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td>Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Prognostic stage groups</td> </tr> <tr> <td colspan=\"2\">There are not enough data to propose anatomic stage and prognostic groups for parathyroid carcinoma.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Because the available data on tumor characteristics and prognosis are so limited, the AJCC acknowledge that proposing a staging system at this time would be premature. Instead, the AJCC propose and define specific variables to be ascertained and recorded prospectively to facilitate development of a formal staging system in the future.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110637 Version 3.0</div></div></div>"},"110639":{"type":"graphic_table","displayName":"Adrenal cortical carcinoma TNM 2017","title":"Adrenal cortical carcinoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adrenal cortical carcinoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;5 cm in greatest dimension, no extra-adrenal invasion</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#62;5 cm, no extra-adrenal invasion</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor of any size with local invasion but not invading adjacent organs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor of any size that invades adjacent organs (kidney, diaphragm, pancreas, spleen, or liver) or large blood vessels (renal vein or vena cava)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in regional lymph node(s)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Any N</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110639 Version 2.0</div></div></div>"},"110640":{"type":"graphic_table","displayName":"HPV related oropharyngeal carcinoma TNM 2017 clinical staging","title":"HPV related oropharyngeal carcinoma TNM clinical staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HPV related oropharyngeal carcinoma TNM clinical staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No primary identified</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor 2 cm or smaller in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor larger than 2 cm but not larger than 4 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond.*</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N) - Clinical N (cN)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"3\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">One or more ipsilateral lymph nodes, none larger than 6 cm</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Contralateral or bilateral lymph nodes, none larger than 6 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N3</td> <td colspan=\"3\">Lymph node(s) larger than 6 cm</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"3\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups - Clinical</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">When T is...</td> <td class=\"subtitle2_left\">And N is...</td> <td class=\"subtitle2_left\">And M is...</td> <td class=\"subtitle2_left\">Then the stage group is...</td> </tr> <tr> <td class=\"indent1\">T0, T1, or T2</td> <td>N0 or N1</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T0, T1, or T2</td> <td>N2</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0, N1, or N2</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T0, T1, T2, T3, or T4</td> <td>N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0, N1, N2, or N3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.<br />* Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110640 Version 3.0</div></div></div>"},"110641":{"type":"graphic_table","displayName":"HPV related oropharyngeal carcinoma TNM 2017 pathologic staging","title":"HPV related oropharyngeal carcinoma TNM pathologic staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">HPV related oropharyngeal carcinoma TNM pathologic staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No primary identified</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor 2 cm or smaller in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor larger than 2 cm but not larger than 4 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond.*</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N) - Pathological N (pN)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"3\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">pN0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">pN1</td> <td colspan=\"3\">Metastasis in four or fewer lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">pN2</td> <td colspan=\"3\">Metastasis in more than four lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"3\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups - Pathological</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">When T is...</td> <td class=\"subtitle2_left\">And N is...</td> <td class=\"subtitle2_left\">And M is...</td> <td class=\"subtitle2_left\">Then the stage group is...</td> </tr> <tr> <td class=\"indent1\">T0, T1, or T2</td> <td>N0, N1</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T0, T1, or T2</td> <td>N2</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3 or T4</td> <td>N0, N1</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3 or T4</td> <td>N2</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPV: human papillomavirus; TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.<br />* Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110641 Version 2.0</div></div></div>"},"110643":{"type":"graphic_table","displayName":"Lung cancer screening decision aid","title":"Should I be screened for lung cancer?","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Should I be screened for lung cancer?</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td> <p>The answer to this question is not the same for everyone. Your doctor can help you decide based on your values and preferences. <strong>Quitting smoking</strong> is as important as screening to lower your chances of dying from lung cancer. Quitting smoking will improve your health in other ways, too.</p> <p>The main test used to screen for lung cancer is a test called a low-dose CT scan (or \"CAT scan\"). Doctors offer screening to some people in the hopes of catching lung cancer early &ndash; before it has a chance to grow, spread, or cause symptoms. If you have cancer, catching it early can improve your chance of being cured and living longer.</p> It might help to ask yourself the following questions when deciding whether or not to be screened:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Do I qualify for lung cancer screening?</strong> <ul class=\"decimal_heading\"> <li>Lung cancer screening is recommended for people who are at high risk. To qualify for lung cancer screening, the answers to these 4 questions ALL need to be \"Yes\": <ul> <li>Are you between 55 and 80 years old? (Note that Medicare will only pay for the screening test if you are 55 to 77 years old.) </li> <li>Do you smoke, or did you quit smoking in the last 15 years? </li> <li>Have you smoked an amount that is equal to at least 1 pack a day for 30 years? Your doctor can help you figure this out if you're not sure. Examples of this amount include: <ul> <li>1 pack a day for at least 30 years </li> <li>2 packs a day for at least 15 years </li> <li>3 packs a day for at least 10 years </li> </ul> </li> <li>Is your health good enough to get treatment if you do have cancer? (Your doctor can help you answer this question.) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Do I want to know if I have lung cancer?</strong> <ul class=\"decimal_heading\"> <li>In general, the best chance for cure is finding and treating lung cancer early, before it can spread. </li> <li>Some cancers found by screening tests are slow growing and would not cause harm for many years. That means you could go through treatment for a cancer that would not have caused you harm anytime soon. </li> <li>Some people feel better having as much information as possible. Other people prefer to take a \"wait and see\" approach. Think about how you would feel about each of these situations: <ul> <li>The possibility of not catching cancer early, when it can still be treated and maybe cured </li> <li>Going through tests and treatments you might not have needed if you didn't get screened </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>How do I feel about the possibility of getting a \"false positive\" result?</strong> <ul class=\"decimal_heading\"> <li>19 out of every 20 positive lung cancer screening tests end up being \"false positives.\" This means the test finds something that could be cancer, but it turns out not to be cancer after more testing. This can lead to unneeded worry and extra tests. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Am I willing to have more tests to check for cancer if my test is positive?</strong> <ul class=\"decimal_heading\"> <li>If your CT scan test comes back positive, your doctor might suggest other imaging tests. For example, you might need another CT scan in the future to see if anything has changed. </li> <li>Or, you might need another test such as a \"biopsy\" to look for cancer. This test comes with some risks. The biopsy might show cancer, which means you would need more treatment. Or, the biopsy might show no cancer. </li> <li>Insurance does not always cover all of the tests, so you might want to think about how much you might need to pay. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Would I want to be treated if I learned I had lung cancer?</strong> <ul class=\"decimal_heading\"> <li>Treatment for lung cancer might include surgery, radiation therapy, and/or chemotherapy. </li> <li>The goal of screening is to catch cancers at an early stage, when treatment is likely to cure the cancer. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Am I willing to have screening every year?</strong> <ul class=\"decimal_heading\"> <li>Lung cancer screening needs to be done every year, for as long as you still qualify. (See \"Do I qualify for lung cancer screening?\" above.) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>How worried am I about radiation exposure?</strong> <ul class=\"decimal_heading\"> <li>Being exposed to radiation can increase your risk of cancer. However, low-dose CT scans expose you to less radiation than regular CT scans. </li> <li>For most people, the benefit of finding lung cancer early is much greater than the risk of radiation exposure. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>If I decide not to get screened, are there other things I can do to prevent lung cancer or catch it early?</strong> <ul class=\"decimal_heading\"> <li>Yes &ndash; you can quit smoking, if you still smoke. Over time, your risk of lung cancer will go down. </li> <li>Tell your doctor if you have new or worse symptoms such as coughing, trouble breathing, coughing up blood, chest pain, or weight loss. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 110643 Version 8.0</div></div></div>"},"110644":{"type":"graphic_picture","displayName":"Anetoderma shoulder","title":"Anetoderma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Anetoderma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110644_Anetoderma_shoulder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple saccular outpouchings on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110644 Version 1.0</div></div></div>"},"110646":{"type":"graphic_picture","displayName":"Anetoderma extensive","title":"Anetoderma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Anetoderma</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/110646_Anetoderma_extensive.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small saccular outpouchings on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110646 Version 1.0</div></div></div>"},"110648":{"type":"graphic_picture","displayName":"Mid-dermal elastolysis","title":"Mid-dermal elastolysis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Mid-dermal elastolysis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110648_Mid-dermal_elastolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wrinkled patch on abdomen.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110648 Version 1.0</div></div></div>"},"110649":{"type":"graphic_picture","displayName":"Cutis laxa","title":"Cutis laxa","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cutis laxa</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110649_Cutis_laxa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wrinkled skin on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110649 Version 1.0</div></div></div>"},"110655":{"type":"graphic_table","displayName":"Common scorpions by region and potential toxicity","title":"Common scorpions by region and potential toxicity*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common scorpions by region and potential toxicity*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><span class=\"red\">For assistance in managing a patient with a suspected scorpion envenomation, contact a regional poison control center (WHO list of <a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">international poison control centers</a> or, in the United States, call <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>). A list of major scorpion antivenoms with manufacturer contact information is available <a href=\"http://wikitoxin.toxicology.wikispaces.net/Scorpions\" target=\"_blank\">here</a>.</span></td> </tr> <tr> <td class=\"subtitle1\">Region</td> <td class=\"subtitle1\">Scorpion species</td> <td class=\"subtitle1\">Clinical manifestations</td> <td class=\"subtitle1\">RCTs in humans show antivenom reduces duration and severity of symptoms?</td> </tr> <tr class=\"divider_bottom\"> <td>North Africa</td> <td> <p><em>Androctonus</em></p> <p><em>Buthus</em></p> <p><em><em>Leiurus</em></em></p> </td> <td> <ul> <li>Autonomic storm </li> <li>Myocardial depression </li> <li>Pulmonary edema </li> </ul> </td> <td>No</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td> <p>Middle East (including Turkey, Iran, and Lebanon)</p> <p>Israel</p> </td> <td> <p><em>Leiurus</em></p> <p><em>Androctonus</em></p> </td> <td> <ul> <li>Autonomic storm </li> <li>Cardiac dysfunction </li> <li>Pulmonary edema </li> <li>Acute pancreatitis </li> </ul> </td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"2\">Asia</td> <td> <p><em>Hottentotta </em>(<em>Mesobuthus</em>, India, Pakistan, and Sri Lanka)</p> <p><em>Androctonus</em></p> </td> <td> <ul> <li>Autonomic storm </li> <li>Myocardial depression </li> <li>Pulmonary edema </li> </ul> </td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><em>Hemiscorpius</em> (Iran)</td> <td> <ul> <li>Local tissue necrosis, rarely hemolysis and acute kidney injury </li> </ul> </td> <td>No</td> </tr> <tr class=\"divider_bottom\" style=\"background-color: #eafaf1;\"> <td> <p>South America</p> <p>Caribbean (Trinidad)</p> </td> <td><em>Tityus</em></td> <td> <ul> <li>Autonomic storm </li> <li>Myocardial depression </li> <li>Pulmonary edema </li> <li>Acute pancreatitis </li> </ul> </td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td rowspan=\"2\">Central America, Mexico, and southwestern United States</td> <td><em>Centruroides</em></td> <td> <ul> <li>Autonomic signs (primarily parasympathetic) </li> <li>Neuromuscular toxicity </li> </ul> </td> <td rowspan=\"2\">Yes</td> </tr> <tr class=\"divider_bottom\"> <td><em>Tityus</em> (Central America only)</td> <td> <ul> <li>As above </li> </ul> </td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>Southern Africa</td> <td><em>Parabuthus</em></td> <td> <ul> <li>Autonomic signs (primarily parasympathetic) </li> <li>Neuromuscular toxicity </li> </ul> </td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>Autonomic storm</STRONG> occurs after stings of \"Old World\" scorpions that inhabit North Africa, the Middle East, Asia, and South America. It manifests as a combination of: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI><STRONG>Parasympathetic signs:</STRONG> Salivation, lacrimation, vomiting, diarrhea, bronchorrhea, bronchospasm, diaphoresis, bradycardia, hypotension, miosis, and priapism.</LI>&#xD;&#xA;<LI><STRONG>Sympathetic signs:</STRONG> Tachycardia, hypertension, agitation, dilated pupils, and hyperthermia.</LI>&#xD;&#xA;<LI><STRONG>Cardiac conduction abnormalities</STRONG> arise from the combined autonomic effects and occur in up to half of patients. They include atrial tachycardia, preventricular contractions, T-wave and ST-T wave changes, and bundle branch block.</LI>&#xD;&#xA;<LI><STRONG>Myocardial depression</STRONG> is caused by the autonomic disturbance and can progress to cardiogenic shock with pulmonary edema.</LI></UL>&#xD;&#xA;<UL style=\"LIST-STYLE-TYPE: none\">&#xD;&#xA;<LI>Parasympathetic findings are present for the first few hours after an \"Old World\" scorpion sting; sympathetic effects and myocardial depression persist.</LI></UL><STRONG>Neuromuscular toxicity</STRONG> follows stings by \"New World\" scorpions that live in Mexico, Central America, Western and Southern Africa, and parts of the United States. Findings consist of: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI><STRONG>Cranial nerve dysfunction</STRONG> with slurred speech, dysphagia, drooling, tongue fasciculations, blurred vision, and abnormal eye movements (eg, conjugate, roving, slow and involuntary motion with multidirectional conjugate saccades [similar to opsoclonus] and unsustained primary positional nystagmus).</LI>&#xD;&#xA;<LI><STRONG>Somatic skeletal muscle dysfunction</STRONG> appearing as undulating and writhing restlessness, fasciculations, extremity shaking and jerking, opisthotonos (arching of the back), and emprosthotonos (tetanic forward body flexion) with preservation of alertness.</LI></UL></div><div class=\"graphic_footnotes\">RCT: randomized controlled trials.<br />* Envenomation with systemic effects occur in approximately one-third of stings. With the exception of stings by <EM>Hemiscorpius lepturus</EM>, all of these scorpion stings are associated with local pain and paresthesias. Refer to UpToDate topics on scorpion stings for further discussion of clinical manifestations, diagnosis, and treatment of scorpion stings.</div><div id=\"graphicVersion\">Graphic 110655 Version 4.0</div></div></div>"},"110656":{"type":"graphic_table","displayName":"Head and neck cancer of unknown primary TNM 2017","title":"Head and neck cancer of unknown primary TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Head and neck cancer of unknown primary TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">For patients who are treated with primary nonsurgical treatment without a cervical lymph node dissection.</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"4\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastasis in any node(s) with clinically overt ENE(+) (ENE<sub>c</sub>)*</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) with clinically overt ENE(+) (ENE<sub>c</sub>)*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em><strong>NOTES:</strong></em><br /> 1. Midline nodes are considered ipsilateral nodes.<br /> * ENE<sub>c</sub> is defined as invasion of skin, infiltration of musculature, dense tethering or fixation to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction.<br /> <em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">For patients who are treated surgically with a cervical lymph node dissection.</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"4\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong> larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node 3 cm or less in greatest dimension and ENE(+); <strong>or</strong> a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong> multiple ipsilateral, contralateral, or bilateral nodes any size and ENE(+) in any node; <strong>or</strong> a single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong> multiple ipsilateral, contralateral, or bilateral nodes any size and ENE(+) in any node; <strong>or</strong> a single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em><strong>NOTES:</strong></em><br /> 1. Midline nodes are considered ipsilateral nodes.<br /> 2. ENE detected on histopathologic examination is designated as ENE<sub>mi</sub> (microscopic ENE &#8804;2 mm) or ENE<sub>ma</sub> (major ENE &#62;2 mm).<br /> Both ENE<sub>mi</sub> and ENE<sub>ma</sub> qualify as ENE(+) for definition of pN.<br /> <em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Prognostic stage groups for metastatic cervical adenopathy and unknown primary tumor <strong>except</strong> for EBV-related and HPV-related tumors.</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T0</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension; EBV: Epstein-Barr virus; HPV: human papillomavirus.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110656 Version 2.0</div></div></div>"},"110657":{"type":"graphic_table","displayName":"Major salivary gland tumors TNM 2017 clinical staging","title":"Major salivary gland tumors TNM clinical staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major salivary gland tumors TNM clinical staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension*</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension*</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm and/or tumor having extraparenchymal extension*</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced disease</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Moderately advanced disease.<br /> Tumor invades skin, mandible, ear canal, and/or facial nerve.</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Very advanced disease.<br /> Tumor invades skull base and/or pterygoid plates and/or encases carotid artery.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><em>* NOTE: </em>Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in any node(s) with clinically overt ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) with clinically overt ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T0, T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T0, T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110657 Version 2.0</div></div></div>"},"110658":{"type":"graphic_table","displayName":"Nasopharyngeal cancer TNM 2017","title":"Nasopharyngeal cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nasopharyngeal cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No tumor identified, but EBV-positive cervical node(s) involvement</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebreal muscles)</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"3\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N3</td> <td colspan=\"3\">Unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"3\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>Stage 0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>Stage I</td> </tr> <tr> <td class=\"indent1\">T1, T0</td> <td>N1</td> <td>M0</td> <td>Stage II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>Stage II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>Stage II</td> </tr> <tr> <td class=\"indent1\">T1, T0</td> <td>N2</td> <td>M0</td> <td>Stage III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N2</td> <td>M0</td> <td>Stage III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>Stage III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>Stage III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N2</td> <td>M0</td> <td>Stage III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>Stage IVA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>Stage IVA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N2</td> <td>M0</td> <td>Stage IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>Stage IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>Stage IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; EBV: Epstein-Barr virus.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110658 Version 2.0</div></div></div>"},"110659":{"type":"graphic_table","displayName":"Oropharyngeal (p16 negative) CA TNM 2017 clinical staging","title":"Oropharyngeal (p16 negative) cancer TNM clinical staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oropharyngeal (p16 negative) cancer TNM clinical staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Oropharynx (p16&ndash;)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor 2 cm or smaller in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor larger than 2 cm but not larger than 4 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced local disease</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.*</td> </tr> <tr> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\">* <em>NOTE:</em> Mucosal extension to lingual surface of epiglottis from primary tumors of the base of he tongue and vallecula does not constitute invasion of the larynx.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN) - Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong> metastasis in any node(s) and clinically overt ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) and clinically overt ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, 1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110659 Version 2.0</div></div></div>"},"110661":{"type":"graphic_table","displayName":"Hypopharyngeal cancer TNM 2017 clinical staging","title":"Hypopharyngeal cancer TNM clinical staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypopharyngeal cancer TNM clinical staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades more than one subsite of hypopharynx or an adjacent site, or measures larger than 2 cm but not larger than 4 cm in greatest dimension without fixation of hemilarynx</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced and very advanced local disease</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.*</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN) &ndash; Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in any node(s) and clinically overt ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) and clinically overt ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Oropharynx (p16&ndash;) and hypopharynx</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110661 Version 2.0</div></div></div>"},"110663":{"type":"graphic_table","displayName":"Melanoma TNM 2017 definitions","title":"Eighth edition AJCC melanoma TNM definitions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eighth edition AJCC melanoma TNM definitions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\">Thickness</td> <td class=\"subtitle2_left\">Ulceration status</td> </tr> <tr> <td class=\"indent1\">TX: Primary tumor thickness cannot be assessed (eg, diagnosis by curettage)</td> <td>Not applicable</td> <td>Not applicable</td> </tr> <tr> <td class=\"indent1\">T0: No evidence of primary tumor (eg, unknown primary or completely regressed melanoma)</td> <td>Not applicable</td> <td>Not applicable</td> </tr> <tr> <td class=\"indent1\">Tis (melanoma <em>in situ</em>)</td> <td>Not applicable</td> <td>Not applicable</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>&#8804;1.0 mm</td> <td>Unknown or unspecified</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>&#60;0.8 mm</td> <td>Without ulceration</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">T1b</td> <td>&#60;0.8 mm</td> <td>With ulceration</td> </tr> <tr> <td>0.8 to 1 mm</td> <td>With or without ulceration</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>&#62;1 to 2 mm</td> <td>Unknown or unspecified</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td>&#62;1 to 2 mm</td> <td>Without ulceration</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td>&#62;1 to 2 mm</td> <td>With ulceration</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>&#62;2 to 4 mm</td> <td>Unknown or unspecified</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td>&#62;2 to 4 mm</td> <td>Without ulceration</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td>&#62;2 to 4 mm</td> <td>With ulceration</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>&#62;4 mm</td> <td>Unknown or unspecified</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>&#62;4 mm</td> <td>Without ulceration</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td>&#62;4 mm</td> <td>With ulceration</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2\" style=\"text-align: left;\" rowspan=\"2\">N category</td> <td class=\"subtitle2\" colspan=\"2\">Extent of regional lymph node and/or lymphatic metastasis</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle2_left\">Number of tumor-involved regional lymph node</td> <td class=\"subtitle2_left\">Presence of in-transit, satellite, and/or microsatellite metastases</td> </tr> <tr> <td class=\"indent1\">NX</td> <td> <p>Regional nodes not assessed (eg, SLN biopsy not performed, regional nodes previously removed for another reason).</p> <strong>Exception:</strong> Pathological N category is not required for T1 melanomas, use cN.</td> <td>No</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional metastases detected</td> <td>No</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>One tumor-involved node or in-transit, satellite, and/or microsatellite metastases with no tumor-involved nodes</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td>One clinically occult (ie, detected by SLN biopsy)</td> <td>No</td> </tr> <tr> <td class=\"indent2\">N1b</td> <td>One clinically detected</td> <td>No</td> </tr> <tr> <td class=\"indent2\">N1c</td> <td>No regional lymph node disease</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">N2</td> <td>Two or three tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with one tumor-involved node</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">N2a</td> <td>Two or three clinically occult (ie, detected by SLN biopsy)</td> <td>No</td> </tr> <tr> <td class=\"indent2\">N2b</td> <td>Two or three, at least one of which was clinically detected</td> <td>No</td> </tr> <tr> <td class=\"indent2\">N2c</td> <td>One clinically occult or clinically detected</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">N3</td> <td>Four or more tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">N3a</td> <td>Four or more clinically occult (ie, detected by SLN biopsy)</td> <td>No</td> </tr> <tr> <td class=\"indent2\">N3b</td> <td>Four or more, at least one of which was clinically detected, or presence of any number of matted nodes</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N3c</td> <td>Two or more clinically occult or clinically detected and/or presence of any number of matted nodes</td> <td>Yes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2\" style=\"text-align: left;\" rowspan=\"2\">M category</td> <td class=\"subtitle2\" colspan=\"2\">M criteria</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle2_left\">Anatomic site</td> <td class=\"subtitle2_left\">LDH level</td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No evidence of distant metastasis</td> <td>Not applicable</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>Evidence of distant metastasis</td> <td>See below</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td rowspan=\"3\">Distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node</td> <td>Not recorded or unspecified</td> </tr> <tr> <td class=\"indent3\">M1a(0)</td> <td>Not elevated</td> </tr> <tr> <td class=\"indent3\">M1a(1)</td> <td>Elevated</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td rowspan=\"3\">Distant metastasis to lung with or without M1a sites of disease</td> <td>Not recorded or unspecified</td> </tr> <tr> <td class=\"indent3\">M1b(0)</td> <td>Not elevated</td> </tr> <tr> <td class=\"indent3\">M1b(1)</td> <td>Elevated</td> </tr> <tr> <td class=\"indent2\">M1c</td> <td rowspan=\"3\">Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease</td> <td>Not recorded or unspecified</td> </tr> <tr> <td class=\"indent3\">M1c(0)</td> <td>Not elevated</td> </tr> <tr> <td class=\"indent3\">M1c(1)</td> <td>Elevated</td> </tr> <tr> <td class=\"indent2\">M1d</td> <td rowspan=\"3\">Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease</td> <td>Not recorded or unspecified</td> </tr> <tr> <td class=\"indent3\">M1d(0)</td> <td>Normal</td> </tr> <tr> <td class=\"indent3\">M1d(1)</td> <td>Elevated</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Suffixes for M category: (0) LDH not elevated, (1) LDH elevated. No suffix is used if LDH is not recorded or is unspecified.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; SLN: sentinel lymph node; LDH: lactate dehydrogenase; CNS: central nervous system.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110663 Version 3.0</div></div></div>"},"110664":{"type":"graphic_table","displayName":"Melanoma TNM 2017 prognostic stage groups","title":"Eighth edition AJCC melanoma TNM prognostic stage groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eighth edition AJCC melanoma TNM prognostic stage groups</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Clinical (cTNM)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Clinical staging includes microstaging of the primary melanoma and clinical/radiologic/biopsy evaluation for metastases. By convention, clinical staging should be used after biopsy of the primary melanoma, with clinical assessment for regional and distant metastases. Note that pathological assessment of the primary melanoma is used for both clinical and pathological classification. Diagnostic biopsies to evaluate possible regional and/or distant metastasis also are included. Note there is only one stage group for clinical Stage III melanoma.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle2_left\">When T is...</td> <td class=\"subtitle2_left\">And N is...</td> <td class=\"subtitle2_left\">And M is...</td> <td class=\"subtitle2_left\">Then the clinical stage group is...</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N0</td> <td>M0</td> <td>IIC</td> </tr> <tr> <td class=\"indent1\">Any T, Tis</td> <td>&#8805;N1</td> <td>M0</td> <td>III</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pathological (pTNM)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Pathological staging includes microstaging of the primary melanoma, including any additional staging information from the wide-\u001fexcision (surgical) specimen that constitutes primary tumor surgical treatment and pathological information about the regional lymph nodes after SLN biopsy or therapeutic lymph node dissection for clinically evident regional lymph node disease.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle2_left\">When T is...</td> <td class=\"subtitle2_left\">And N is...</td> <td class=\"subtitle2_left\">And M is...</td> <td class=\"subtitle2_left\">Then the pathological stage group is...</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N0</td> <td>M0</td> <td>IIC</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>N1b, N1c</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>N2b, N2c, N3b, or N3c</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T1a/b-T2a</td> <td>N1a or N2a</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1a/b-T2a</td> <td>N1b/c or N2b</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T2b/T3a</td> <td>N1a-N2b</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T1a-T3a</td> <td>N2c or N3a/b/c</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T3b/T4a</td> <td>Any N &#8805;N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N1a-N2c</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>N3a/b/c</td> <td>M0</td> <td>IIID</td> </tr> <tr> <td class=\"indent1\">Any T, Tis</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pathological Stage 0 (melanoma <em>in situ</em>) and T1 do not require pathological evaluation of lymph nodes to complete pathological staging; use cN information to assign their pathological stage.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; SLN: sentinel lymph node.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110664 Version 4.0</div></div></div>"},"110667":{"type":"graphic_figure","displayName":"J-shaped association of systolic BP and CV events in CAD/HTN","title":"J-shaped association of systolic blood pressure and cardiovascular events in patients with coronary artery disease and treated hypertension","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">J-shaped association of systolic blood pressure and cardiovascular events in patients with coronary artery disease and treated hypertension</div><div class=\"cntnt\"><img style=\"width:624px; height:372px;\" src=\"images/NEPH/110667_JsasscsystlBPCVCADHTN.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: An international cohort study. Lancet 2016. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110667 Version 2.0</div></div></div>"},"110668":{"type":"graphic_figure","displayName":"J-shaped association of diastolic BP and CV events in CAD/HTN","title":"J-shaped association of diastolic blood pressure and cardiovascular events in patients with coronary artery disease and treated hypertension","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">J-shaped association of diastolic blood pressure and cardiovascular events in patients with coronary artery disease and treated hypertension</div><div class=\"cntnt\"><img style=\"width:628px; height:374px;\" src=\"images/NEPH/110668_JsasscdstlBPCVCADHTN.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: An international cohort study. Lancet 2016. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110668 Version 2.0</div></div></div>"},"110669":{"type":"graphic_figure","displayName":"CSF shunts","title":"CSF shunts","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">CSF shunts</div><div class=\"cntnt\"><img style=\"width:508px; height:689px;\" src=\"images/PEDS/110669_CSF_shunts.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 110669 Version 2.0</div></div></div>"},"110670":{"type":"graphic_table","displayName":"Cardiogenic shock in acute MI","title":"2013 ACCF/AHA guideline summary: Treatment of Cardiogenic shock in patients with acute myocardial infarction*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2013 ACCF/AHA guideline summary: Treatment of Cardiogenic shock in patients with acute myocardial infarction*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Class I - There is evidence and/or general agreement that the following approaches are indicated in the treatment of cardiogenic shock in patients with an acute MI:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Emergency revascularization with either PCI or CABG is recommended in suitable patients with cardiogenic shock due to pump failure after STEMI irrespective of the time delay from MI onset. <em>(Level of Evidence: B)</em> </li> <li>In the absence of contraindications, fibrinolytic therapy should be administered to patients with STEMI and cardiogenic shock who are unsuitable candidates for either PCI or CABG. <em>(Level of Evidence: B)</em> </li> </ul> </td> </tr> <tr> <td><strong>Class IIa - The weight of evidence or opinions is in favor of the usefulness of the following approaches in the treatment of cardiogenic shock in patients with an acute MI:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>The use of intra-aortic balloon pump counterpulsation can be useful for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy. <em>(Level of Evidence: B)</em> </li> </ul> </td> </tr> <tr> <td><strong>Class IIb - The weight of evidence or opinions shows uncertain benefit or harm of the treatment of cardiogenic shock in patients with an acute MI:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Alternative left ventricular assist devices for circulatory support may be considered in patients with refractory cardiogenic shock. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACCF/AHA: American College of Cardiology Foundation/American Heart Association; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft surgery; MI: myocardial infarction; STEMI: ST elevation myocardial infarction.<br />* These guidelines were for patients with ST elevation MI or MI associated with left bundle branch block. Similar principles apply to cardiogenic shock developing in patients with non-ST elevation MI.</div><div class=\"graphic_reference\">Data from: O'Gara PT, Kushner FG, Casey DE, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management Of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 2013; 61:e78.</div><div id=\"graphicVersion\">Graphic 110670 Version 2.0</div></div></div>"},"110671":{"type":"graphic_table","displayName":"Pharmacologic treatment of intraoperative arrhythmias","title":"Pharmacologic treatment of intraoperative arrhythmias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic treatment of intraoperative arrhythmias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Recommended dosage (IV)</td> </tr> <tr> <td>Adenosine</td> <td>6 mg rapid bolus; if not effective within 1 to 2 minutes, give 12 mg; if not effective within 1 to 2 minutes, may repeat 12 mg.</td> </tr> <tr> <td>Metoprolol</td> <td>1.0&nbsp;to 5 mg bolus over two minutes; may repeat two times.</td> </tr> <tr> <td>Esmolol</td> <td>1 mg/kg initial bolus, followed by&nbsp;150 mcg/kg per minute infusion</td> </tr> <tr> <td>Verapamil</td> <td>0.075 to 0.15 mg/kg bolus over two minutes; may give additional 10 mg after 30 minutes. If no response, start 0.005 mg/kg per minute&nbsp;infusion.</td> </tr> <tr> <td>Diltiazem</td> <td>0.25 mg/kg bolus over two minutes; start 5 to 15 mg/hr infusion.</td> </tr> <tr> <td>Amiodarone</td> <td>150 mg IV bolus over 10 minutes, then start infusion at 0.1 mg/min for six hours, followed by 0.5 mg/min for 18 hours.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</div><div id=\"graphicVersion\">Graphic 110671 Version 1.0</div></div></div>"},"110672":{"type":"graphic_picture","displayName":"Erythema induratum on legs","title":"Erythema induratum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema induratum</div><div class=\"cntnt\"><img style=\"width:302px; height:600px;\" src=\"images/DERM/110672_Erythema_induratum_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema induratum (nodular vasculitis). The posterior leg is a favored site. Nodules may ulcerate.</div><div class=\"graphic_reference\">Fung MA. Panniculitis. In: Dermatopathology: A Volume in the Series: Foundations in Diagnostic Pathology, 2nd ed, Busam KJ, Goldblum JR (Eds), Elsevier, Philadelphia 2015.</div><div id=\"graphicVersion\">Graphic 110672 Version 1.0</div></div></div>"},"110673":{"type":"graphic_picture","displayName":"Erythema induratum histopathology","title":"Erythema induratum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema induratum</div><div class=\"cntnt\"><img style=\"width:368px; height:844px;\" src=\"images/DERM/110673_Erythema_induratm_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema induratum (nodular vasculitis).<br />(A) Mostly lobular panniculitis with vasculitis. The vessel type involved by vasculitis is variable and may include centrilobular venules, septal veins, or septal arteries; vasculitis may not be demonstrated in every biopsy or every tissue section.<br />(B) There is a mixed granulomatous infiltrate replacing the lobules with zones of extravascular necrosis.<br />(C) The zones of necrosis are associated with cellular debris.</div><div class=\"graphic_reference\">Fung MA. Panniculitis. In: Dermatopathology: A Volume in the Series: Foundations in Diagnostic Pathology, 2nd ed, Busam KJ, Goldblum JR (Eds), Elsevier, Philadelphia 2015.</div><div id=\"graphicVersion\">Graphic 110673 Version 1.0</div></div></div>"},"110675":{"type":"graphic_figure","displayName":"Comparison of international and US guidelines for CU treatment","title":"Comparison of international and United States guidelines for chronic urticarial treatment","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Comparison of international and United States guidelines for chronic urticarial treatment</div><div class=\"cntnt\"><img style=\"width:652px; height:677px;\" src=\"images/ALLRG/110675_Intrntnl_US_gdlns_CU_trtmnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CU: chronic urticaria; EAACI: European Academy of Allergy and Clinical Immunology; GA<SUP>2</SUP>LEN: Global Allergy and Asthma European Network; EDF: European Dermatology Forum; WAO: World Allergy Organization; NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div class=\"graphic_reference\">Reproduced with permission from: Beck LA, Bernstein JA, Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol 2016.</div><div id=\"graphicVersion\">Graphic 110675 Version 1.0</div></div></div>"},"110677":{"type":"graphic_figure","displayName":"Meta-analysis of transfusion thresholds","title":"Meta-analysis of outcomes with restrictive versus liberal transfusion thresholds: mortality at 30 days","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Meta-analysis of outcomes with restrictive versus liberal transfusion thresholds: mortality at 30 days</div><div class=\"cntnt\"><img style=\"width:730px; height:496px;\" src=\"images/HEME/110677_2016_Cochrane_rstr_vs_librl.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plot shows risk ratios&nbsp;for mortality at 30 days in randomized trials published through May 2016 that&nbsp;compared a&nbsp;restrictive transfusion threshold (transfusing for a hemoglobin level below 7 to 8 g/dL) with a&nbsp;liberal transfusion threshold (transfusing for a hemoglobin level below 9 to 10 g/dL)&nbsp;in a variety of medical and surgical populations including adults and children.&nbsp;Refer to UpToDate for recommendations regarding specific&nbsp;transfusion thresholds in&nbsp;specific populations.</div><div class=\"graphic_reference\">From: Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review). Cochrane Database Syst Rev 2016; 10:CD002042. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD002042.pub4/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD002042.pub4/abstract</a>. Copyright &copy; 2016 The Cochrane Collaboration. Modified with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 110677 Version 1.0</div></div></div>"},"110678":{"type":"graphic_table","displayName":"Features of congenital Zika syndrome","title":"Clinical features of congenital Zika syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of congenital Zika syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Details</td> </tr> <tr class=\"divider_bottom\"> <td>Microcephaly</td> <td> <ul> <li>Defined as occipitofrontal circumference &#60;3<sup>rd</sup> percentile</li> <li>Both proportionate and disproportionate microcephaly can occur</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Other cranial dysmorphisms</td> <td> <ul> <li>Craniofacial disproportion</li> <li>Overriding cranial sutures</li> <li>Craniosynostosis</li> <li>Cutis gyrata (redundant scalp)</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ocular abnormalities</td> <td> <ul> <li>Focal pigmentary mottling</li> <li>Chorioretinal atrophy</li> <li>Optic nerve abnormalities</li> <li>Microphthalmia</li> <li>Cataracts</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hearing loss</td> <td> <ul> <li>Sensorineural hearing loss</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Arthrogryposis</td> <td> <ul> <li>Congenital contractures (arthrogryposis)</li> <li>Unilateral or bilateral club foot</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Neuromotor abnormalities</td> <td> <ul> <li>Hypertonia/spasticity</li> <li>Hyperreflexia</li> <li>Irritability</li> <li>Dysphagia and feeding difficulties</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Seizures</td> <td> <ul> <li>Focal or generalized</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Small size for gestational age</td> <td> <ul> <li>Defined as birth weight &#60;10<sup>th</sup> percentile for gestational age</li> </ul> </td> </tr> <tr> <td>Neuroimaging abnormalities</td> <td> <ul> <li>Intracranial calcifications (most commonly at the junction between the cortical and subcortical white matter)</li> <li>Ventriculomegaly</li> <li>Reduced brain volume</li> <li>Delayed myelination</li> <li>Simplified gyral patterns (eg, polymicrogyria, pachygyria)</li> <li>Hypogenesis of the corpus callosum</li> <li>Hypoplasia of the brainstem and cerebellum</li> <li>Enlargement of the cisterna magna</li> <li>Increased extra-axial fluid</li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 110678 Version 1.0</div></div></div>"},"110679":{"type":"graphic_picture","displayName":"Grip for inserting LMA","title":"Grip for inserting laryngeal mask airway (LMA)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Grip for inserting laryngeal mask airway (LMA)</div><div class=\"cntnt\"><img style=\"width:756px; height:565px;\" src=\"images/EM/110679_Grip_inserting_LMA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above demonstrates the proper grip for inserting a laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110679 Version 1.0</div></div></div>"},"110680":{"type":"graphic_movie","displayName":"Insertion of laryngeal mask airway","title":"Insertion of laryngeal mask airway","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Insertion of laryngeal mask airway</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110680_Insertlaryngealmaskvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110680_Insertlaryngealmaskimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video demonstrates proper insertion technique for a laryngeal mask airway (LMA). A single-use LMA is used.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110680 Version 1.0</div></div></div>"},"110681":{"type":"graphic_table","displayName":"Anal cancer TNM 2017","title":"Anal cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anal cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor not assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">High-grade squamous intraepithelial lesion (previously termed carcinoma <em>in situ</em>, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia)</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;2 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#62;2 cm but &#8804;5 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor &#62;5 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td colspan=\"3\">Metastasis in inguinal, mesorectal, or internal iliac lymph nodes</td> </tr> <tr> <td class=\"indent2\">N1b</td> <td colspan=\"3\">Metastasis in external iliac lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1c</td> <td colspan=\"3\">Metastasis in external iliac with any N1a nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110681 Version 2.0</div></div></div>"},"110683":{"type":"graphic_table","displayName":"Comparison of breastmilk, HMF, and preterm formula","title":"Intakes of key nutrients from various enteral nutrition feedings for preterm infants in the United States, assuming milk intake of 160 mL/kg per day","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intakes of key nutrients from various enteral nutrition feedings for preterm infants in the United States, assuming milk intake of 160 mL/kg per day</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Target intake*</td> <td class=\"subtitle1\">Unfortified human milk<sup>&#182;</sup><sup>&#916;</sup> (&#8776;20 kcal/oz)</td> <td class=\"subtitle1\">Fortified human milk<sup>&#182;</sup><sup>&#9674;</sup>(&#8776;24 kcal/oz)</td> <td class=\"subtitle1\">Preterm formula (24 kcal/oz)</td> </tr> <tr> <td><strong>Energy (kcal/kg/day)</strong></td> <td class=\"centered\">128</td> <td class=\"centered\">104</td> <td class=\"centered\">128</td> <td class=\"centered\">129</td> </tr> <tr> <td><strong>Protein (g/kg/day)</strong></td> <td class=\"centered\">3.5 to 4</td> <td class=\"centered\">1.6</td> <td class=\"centered\">4.1 to 4.3</td> <td class=\"centered\">4.3 to 4.6</td> </tr> <tr> <td><strong>Fat (g/kg/day)</strong></td> <td class=\"centered\">5 to 7</td> <td class=\"centered\">5.6</td> <td class=\"centered\">6.3 to 8.3</td> <td class=\"centered\">5.6 to 7.0</td> </tr> <tr> <td><strong>Carbohydrate (g/kg/day)</strong></td> <td class=\"centered\">12 to 14</td> <td class=\"centered\">11.2</td> <td class=\"centered\">11.2 to 13.6</td> <td class=\"centered\">12.9 to 13.6</td> </tr> <tr> <td><strong>Calcium (mg/kg)</strong></td> <td class=\"centered\">150 to 220</td> <td class=\"centered\">40</td> <td class=\"centered\">192 to 197</td> <td class=\"centered\">210 to 234</td> </tr> <tr> <td><strong>Phosphorus (mg/kg)</strong></td> <td class=\"centered\">75 to 140</td> <td class=\"centered\">22</td> <td class=\"centered\">103 to 110</td> <td class=\"centered\">117 to 129</td> </tr> <tr> <td><strong>Vitamin D (international units/day)</strong></td> <td class=\"centered\">400</td> <td class=\"centered\">0.3</td> <td class=\"centered\">189 to 253</td> <td class=\"centered\">194&nbsp;to 384</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Recommendations for preterm infants weighing 1000 to 1500 g.<br />¶ Human milk data are based on mature human milk.<br />Δ For human milk, the energy content is based on mean content of 65 kcal/dL; protein content is based on mean of 1&nbsp;g/dL; fat content is based on mean of 3.5 g/dL; and carbohydrate content is based on a mean of 11.5 to 13 g/dL.<SUP>[2]</SUP><br /><FONT class=lozenge>◊</FONT> Human milk fortifier (HMF) nutrition information is based upon common&nbsp;liquid HMF available in the United States.<SUP>[2]</SUP><br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm and term breast milk. BMC Pediatr 2014; 14:216.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Pediatric Nutrition Handbook, 7th ed, Kleinman RE, Greer FR (Eds), American Academy of Pediatrics, Elk Grove Village 2014.</LI></OL></div><div id=\"graphicVersion\">Graphic 110683 Version 2.0</div></div></div>"},"110684":{"type":"graphic_figure","displayName":"Fish-hook removal cut it out technique","title":"Fish-hook removal: Cut it out technique","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Fish-hook removal: Cut it out technique</div><div class=\"cntnt\"><img style=\"width:464px; height:570px;\" src=\"images/EM/110684_Fish-hook_removal_cut_it_out_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Only use this technique as a last resort. For other techniques, refer to UpToDate topics on fish-hook removal. Anesthetize the skin at the entrance site. Make an incision with a scalpel along the body of the hook to the barb. For deeply embedded hooks, use a hemostat to bluntly dissect to the barb once the skin incision is made. Remove the hook along the path of the incision.</div><div id=\"graphicVersion\">Graphic 110684 Version 1.0</div></div></div>"},"110694":{"type":"graphic_picture","displayName":"Pustular psoriasis pregnancy","title":"Pustular psoriasis of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pustular psoriasis of pregnancy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110694_Pustular_psoriasis_pregnncy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pustular psoriasis of pregnancy, previously called impetigo herpetiformis, presenting with erythematous plaques studded at the borders with sterile pustules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110694 Version 1.0</div></div></div>"},"110696":{"type":"graphic_picture","displayName":"Erythema annulare centrifugum on buttocks","title":"Erythema annulare centrifugum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema annulare centrifugum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110696_Erythema_annlr_cntrfgm_butt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gyrate erythematous plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110696 Version 1.0</div></div></div>"},"110700":{"type":"graphic_picture","displayName":"Erythema annulare centrifugum on buttocks 2","title":"Erythema annulare centrifugum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema annulare centrifugum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110700_Erythema_annlr_cntrfgm_btt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques with trailing scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110700 Version 1.0</div></div></div>"},"110701":{"type":"graphic_movie","displayName":"LMA Fastrach deflation and lubrication","title":"LMA Fastrach deflation and lubrication","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">LMA Fastrach deflation and lubrication</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110701_LMAFastrachdeflatlubvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110701_LMAFastrachdeflatlubimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Before inserting the LMA Fastrach, the mask must be deflated completely and lubricated, as shown in this video clip.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110701 Version 1.0</div></div></div>"},"110702":{"type":"graphic_movie","displayName":"LMA Fastrach insertion","title":"LMA Fastrach insertion","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">LMA Fastrach insertion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110702_LMAFastrachinsertionvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110702_LMAFastrachinsertionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LMA Fastrach can be used as a supraglottic airway, but is designed to serve as a conduit to tracheal intubation. Insertion technique for the LMA Fastrach is demonstrated in this video clip.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110702 Version 2.0</div></div></div>"},"110703":{"type":"graphic_movie","displayName":"LMA Fastrach up-down repositioning","title":"LMA Fastrach up-down repositioning","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">LMA Fastrach up-down repositioning</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110703_LMAFastrachupdownvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110703_LMAFastrachupdownimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During placement of the LMA Fastrach, the epiglottis tip may fold, causing a cuff leak. The up-down repositioning maneuver shown here may help to remove the fold and stop the leak.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110703 Version 1.0</div></div></div>"},"110704":{"type":"graphic_movie","displayName":"LMA Fastrach repositioning maneuvers for cuff leak","title":"LMA Fastrach repositioning maneuvers for stopping a cuff leak","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">LMA Fastrach repositioning maneuvers for stopping a cuff leak</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110704_LMAFastrachcuffleakvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110704_LMAFastrachcuffleakimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After the LMA Fastrach is inserted, cuff leaks may be present. Three basic maneuvers that can be used to improve the seal of the cuff and stop such leaks are shown in this video clip. The first maneuver shown involves rotating the handle side to side (handle moves in the coronal plane). The second involves rotating the handle up and down (handle moves in the sagittal plane). The third involves lifting the handle as if raising a skillet, with the handle remaining parallel to the floor.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110704 Version 1.0</div></div></div>"},"110705":{"type":"graphic_movie","displayName":"LMA Fastrach removal after tracheal intubation","title":"LMA Fastrach removal after tracheal intubation","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">LMA Fastrach removal after tracheal intubation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110705_LMAFastrachremovalvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110705_LMAFastrachremovalimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows the proper technique for removing the LMA Fastrach after a tracheal tube has been successfully placed. Note that this procedure is complex and as a general rule should not be performed on a patient without having practiced the technique in advance. Improper technique may cause the tracheal tube to become dislodged or the pilot balloon to be torn.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110705 Version 1.0</div></div></div>"},"110706":{"type":"graphic_movie","displayName":"air-Q airway removal following intubation","title":"air-Q airway removal following intubation","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">air-Q airway removal following intubation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110706_AQremovalintubationvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110706_AQremovalintubationimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The technique for removing the air-Q supraglottic airway following successful placement of a tracheal tube is shown in this video clip.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110706 Version 2.0</div></div></div>"},"110707":{"type":"graphic_picture","displayName":"Air-Q stylet placement","title":"Air-Q stylet placement","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Air-Q stylet placement</div><div class=\"cntnt\"><img style=\"width:632px; height:756px;\" src=\"images/EM/110707_Air-Q_stylet_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows how the Air-Q stylet should appear when it is properly&nbsp;located in an appropriately sized Air-Q supraglottic airway following placement of a tracheal tube via the airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110707 Version 1.0</div></div></div>"},"110708":{"type":"graphic_table","displayName":"Classification of acute cellular rejection in pancreas allograft","title":"Classification of acute cellular rejection in pancreas allograft","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of acute cellular rejection in pancreas allograft</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Acute cellular rejection</td> <td class=\"subtitle1\">Histopathology</td> </tr> <tr> <td>Borderline</td> <td> <ul> <li>Active septal inflammation (activated lymphocytes &#177; eosinophils) </li> </ul> </td> </tr> <tr> <td>Grade I (mild)</td> <td> <ul> <li>Active septal inflammation with one of the following: <ul> <li>Venulitis (subendothelial inflammatory cells in septal veins) </li> <li>Ductitis (infiltration and damage of ductal epithelium) </li> <li>Inflammation of nerve branches (rarely seen at the microscope) </li> <li>Focal acinar inflammation (1 to 2 inflammatory foci* per lobule with absent or minimal acinar cell injury) </li> </ul> </li> </ul> </td> </tr> <tr> <td>Grade II (moderate)</td> <td> <ul> <li>Multifocal acinar inflammation (&#8805;3 inflammatory foci per lobule, but not diffuse, with single cell injury/dropout), and/or </li> <li>Minimal intimal arteritis (&#60;25% luminal compromise) </li> </ul> </td> </tr> <tr> <td>Grade III (severe)</td> <td> <ul> <li>Diffuse acinar inflammation with multicell injury, and/or </li> <li>Moderate to severe intimal arteritis (&#62;25% luminal compromise with evidence of intimal injury), and/or </li> <li>Transmural/necrotizing arteritis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Histological grading of acute cellular rejection.</div><div class=\"graphic_footnotes\">* A focus acinar inflammation is a collection of ≥10 lymphocytes/eosinophils within an acinar area.</div><div class=\"graphic_reference\">Adapted from: Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11:1792. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2011.03670.x/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2011.03670.x/abstract</A>. Copyright © 2011 The American Society of Transplantation and the American Society of Transplant Surgeons. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\">permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110708 Version 1.0</div></div></div>"},"110709":{"type":"graphic_table","displayName":"Soft tissue sarcoma definition of grade 2017","title":"Definition of histologic grade for soft tissue sarcomas at various sites AJCC UICC 2017 ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of histologic grade for soft tissue sarcomas at various sites AJCC UICC 2017 </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Tumor differentiation</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Tumor differentiation is histology specific and is generally scored as follows:</strong></td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>Differentiation score</strong></td> <td><strong>Definition</strong></td> </tr> <tr> <td class=\"indent2\">1</td> <td>Sarcomas closely resembling normal adult mesenchymal tissue (eg, low-grade leiomyosarcoma)</td> </tr> <tr> <td class=\"indent2\">2</td> <td>Sarcomas for which histologic typing is certain (eg, myxoid/round cell liposarcoma)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">3</td> <td>Embryonal and undifferentiated sarcomas, sarcomas of doubtful type, synovial sarcomas, soft tissue osteosarcoma, Ewing sarcoma/primitive neuroectodermal tumor (PNET) of soft tissue</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Histology-specific tumor differentiation score</strong></td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>Histologic type</strong></td> <td><strong>Score</strong></td> </tr> <tr> <td class=\"indent2\">Atypical lipomatous tumor/well-differentiated liposarcoma</td> <td>1</td> </tr> <tr> <td class=\"indent2\">Myxoid liposarcoma</td> <td>2</td> </tr> <tr> <td class=\"indent2\">Round cell liposarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Pleomorphic liposarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Dedifferentiated liposarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Fibrosarcoma</td> <td>2</td> </tr> <tr> <td class=\"indent2\">Myxofibrosarcoma</td> <td>2</td> </tr> <tr> <td class=\"indent2\">Undifferentiated pleomorphic sarcoma (formerly termed malignant fibrous histiocytoma, pleomorphic type)</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Well-differentiated leiomyosarcoma</td> <td>1</td> </tr> <tr> <td class=\"indent2\">Conventional leiomyosarcoma</td> <td>2</td> </tr> <tr> <td class=\"indent2\">Poorly differentiated/pleomorphic/epithelioid leiomyosarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Biphasic/monophasic synovial sarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Poorly differentiated synovial sarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Pleomorphic rhabdomyosarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Mesenchymal chondrosarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Extraskeletal osteosarcoma</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Ewing sarcoma/PNET</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Malignant rhabdoid tumor</td> <td>3</td> </tr> <tr> <td class=\"indent2\">Undifferentiated sarcoma, not otherwise specified</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"><em>NOTE:</em> Grading of gastrointestinal stromal tumor, malignant peripheral nerve sheath tumor, embryonal and alveolar rhabdomyosarcoma and angiosarcoma (rapid growth, dissemination common), as well as extraskeletal myxoid chondrosarcoma, alveolar soft part sarcoma, clear cell sarcoma, and epithelioid sarcoma (slower growth, dissemination common) is not recommended under this system. The case for grading malignant peripheral nerve sheath tumor is debated. Although all these histologies have a high rate of dissemination, survival with metastatic disease varies widely.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">Mitotic count</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">In the most mitotically active area of the sarcoma, 10 successive high-power fields (HPF; one HPF at 400x magnification = 0.1734 mm<sup>2</sup>) are assessed using a 40x objective.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle2_left\">Mitotic count score</td> <td class=\"subtitle2_left\">Definition</td> </tr> <tr> <td class=\"indent1\">1</td> <td>0 to 9 mitoses per 10 HPF</td> </tr> <tr> <td class=\"indent1\">2</td> <td>10 to 19 mitoses per 10 HPF</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3</td> <td>&#8805;20 mitoses per 10 HPF</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">Tumor necrosis</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Evaluated on gross examination and validated with histologic sections.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle2_left\">Necrosis score</td> <td class=\"subtitle2_left\">Definition</td> </tr> <tr> <td class=\"indent1\">0</td> <td>No necrosis</td> </tr> <tr> <td class=\"indent1\">1</td> <td>&#60;50% tumor necrosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2</td> <td>&#8805;50% tumor necrosis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_single\" colspan=\"2\">FNCLCC histologic grade</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">G</td> <td class=\"subtitle2_left\">G definition</td> </tr> <tr> <td class=\"indent1\">GX</td> <td>Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td>Total differentiation, mitotic count and necrosis score of 2 or 3</td> </tr> <tr> <td class=\"indent1\">G2</td> <td>Total differentiation, mitotic count and necrosis score of 4 or 5</td> </tr> <tr> <td class=\"indent1\">G3</td> <td>Total differentiation, mitotic count and necrosis score of 6, 7, or 8</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Histology-specific tumor differentiation score modified from: Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350. Reprinted with permission. Copyright © 1997 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110709 Version 3.0</div></div></div>"},"110710":{"type":"graphic_table","displayName":"Grading of antibody-mediated rejection in pancreas allograft","title":"Classification of antibody-mediated rejection in the pancreas allograft","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification&nbsp;of antibody-mediated rejection in the pancreas allograft</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibody-mediated rejection</td> <td class=\"subtitle1\">Morphological tissue injury</td> </tr> <tr> <td>Grade I (mild)</td> <td>Well-preserved architecture with mild interacinar inflammation and rare acinar cell damage</td> </tr> <tr> <td>Grade II (moderate)</td> <td>Overall preserved architecture with interacinar infiltrates with multi-acinar cell damage/dropout, extravasation of red blood cells, and interacinar capillaritis</td> </tr> <tr> <td>Grade III (severe)</td> <td>Architectural disarray, interstitial hemorrhage, multifocal parenchymal necrosis, arterial and venous wall necrosis and thrombosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11:1792. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2011.03670.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-6143.2011.03670.x/abstract</a>. Copyright &copy; 2011 The American Society of Transplantation and the American Society of Transplant Surgeons. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 110710 Version 1.0</div></div></div>"},"110711":{"type":"graphic_table","displayName":"STS extrem and trunk TNM 2017","title":"Soft tissue sarcoma of the extremities and trunk TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Soft tissue sarcoma of the extremities and trunk TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"4\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"4\">Tumor 5 cm or less in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"4\">Tumor more than 5 cm and less than or equal to 10 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"4\">Tumor more than 10 cm and less than or equal to 15 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"4\">Tumor more than 15 cm in greatest dimension</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"4\">N criteria</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"4\">No regional lymph node metastasis or unknown lymph node status</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"4\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"4\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"4\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"4\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Definition of grade (G)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">G</td> <td class=\"subtitle2_left\" colspan=\"5\">G definition</td> </tr> <tr> <td class=\"indent1\">GX</td> <td colspan=\"4\">Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"4\">Total differentiation, mitotic count and necrosis score of 2 or 3</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"4\">Total differentiation, mitotic count and necrosis score of 4 or 5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td colspan=\"4\">Total differentiation, mitotic count and necrosis score of 6, 7, or 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">When T is...</td> <td class=\"subtitle2_left\">And N is...</td> <td class=\"subtitle2_left\">And M is...</td> <td class=\"subtitle2_left\">And grade is...</td> <td class=\"subtitle2_left\">Then the stage group is...</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T2, T3, T4</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3, T4</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>Any G</td> <td>IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>Any G</td> <td>IV</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Tumor differentiation</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Tumor differentiation is histology specific and is generally scored as follows:</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Differentiation score</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">1</td> <td colspan=\"4\">Sarcomas closely resembling normal adult mesenchymal tissue (eg, low-grade leiomyosarcoma)</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"4\">Sarcomas for which histologic typing is certain (eg, myxoid/round cell liposarcoma)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3</td> <td colspan=\"4\">Embryonal and undifferentiated sarcomas, sarcomas of doubtful type, synovial sarcomas, soft tissue osteosarcoma, Ewing sarcoma/primitive neuroectodermal tumor (PNET) of soft tissue</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Mitotic count</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">In the most mitotically active area of the sarcoma, 10 successive high-power fields (HPF; one HPF at 400x magnification = 0.1734 mm<sup>2</sup>) are assessed using a 40x objective.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Mitotic count score</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">1</td> <td colspan=\"4\">0 to 9 mitoses per 10 HPF</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"4\">10 to 19 mitoses per 10 HPF</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3</td> <td colspan=\"4\">&#8805;20 mitoses per 10 HPF</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Tumor necrosis</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Evaluated on gross examination and validated with histologic sections.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Necrosis score</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">0</td> <td colspan=\"4\">No necrosis</td> </tr> <tr> <td class=\"indent1\">1</td> <td colspan=\"4\">&#60;50% tumor necrosis</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"4\">&#8805;50% tumor necrosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110711 Version 5.0</div></div></div>"},"110712":{"type":"graphic_picture","displayName":"Tracheal tube reverse curvature for use in LMA Fastrach","title":"Tracheal tube reverse curvature for placement in an LMA Fastrach for intubation","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Tracheal tube reverse curvature for placement in an LMA Fastrach for intubation</div><div class=\"cntnt\"><img style=\"width:756px; height:565px;\" src=\"images/EM/110712_Trchl_tube_rvrs_LMA_Fastrch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When using a standard tracheal tube for intubation via an LMA Fastrach, the position of the tracheal tube is reversed, as shown in the photograph above, to improve the ease of placement.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110712 Version 1.0</div></div></div>"},"110713":{"type":"graphic_table","displayName":"STS retroperitoneum TNM 2017","title":"Retroperitoneal soft tissue sarcoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Retroperitoneal soft tissue sarcoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"4\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"4\">Tumor 5 cm or less in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"4\">Tumor more than 5 cm and less than or equal to 10 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"4\">Tumor more than 10 cm and less than or equal to 15 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"4\">Tumor more than 15 cm in greatest dimension</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"4\">N criteria</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"4\">No regional lymph node metastasis or unknown lymph node status</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"4\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"4\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"4\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"4\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Definition of grade (G)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">G</td> <td class=\"subtitle2_left\" colspan=\"5\">G definition</td> </tr> <tr> <td class=\"indent1\">GX</td> <td colspan=\"4\">Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"4\">Total differentiation, mitotic count and necrosis score of 2 or 3</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"4\">Total differentiation, mitotic count and necrosis score of 4 or 5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td colspan=\"4\">Total differentiation, mitotic count and necrosis score of 6, 7, or 8</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">When T is...</td> <td class=\"subtitle2_left\">And N is...</td> <td class=\"subtitle2_left\">And M is...</td> <td class=\"subtitle2_left\">And grade is...</td> <td class=\"subtitle2_left\">Then the stage group is...</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T2, T3, T4</td> <td>N0</td> <td>M0</td> <td>G1, GX</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3, T4</td> <td>N0</td> <td>M0</td> <td>G2, G3</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>Any G</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>Any G</td> <td>IV</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Tumor differentiation</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Tumor differentiation is histology specific and is generally scored as follows:</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Differentiation score</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">1</td> <td colspan=\"4\">Sarcomas closely resembling normal adult mesenchymal tissue (eg, low-grade leiomyosarcoma)</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"4\">Sarcomas for which histologic typing is certain (eg, myxoid/round cell liposarcoma)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3</td> <td colspan=\"4\">Embryonal and undifferentiated sarcomas, sarcomas of doubtful type, synovial sarcomas, soft tissue osteosarcoma, Ewing sarcoma/primitive neuroectodermal tumor (PNET) of soft tissue</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Mitotic count</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">In the most mitotically active area of the sarcoma, 10 successive high-power fields (HPF; one HPF at 400x magnification = 0.1734 mm<sup>2</sup>) are assessed using a 40x objective.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Mitotic count score</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">1</td> <td colspan=\"4\">0 to 9 mitoses per 10 HPF</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"4\">10 to 19 mitoses per 10 HPF</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3</td> <td colspan=\"4\">&#8805;20 mitoses per 10 HPF</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Tumor necrosis</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\">Evaluated on gross examination and validated with histologic sections.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td><strong>Necrosis score</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">0</td> <td colspan=\"4\">No necrosis</td> </tr> <tr> <td class=\"indent1\">1</td> <td colspan=\"4\">&#60;50% tumor necrosis</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"4\">&#8805;50% tumor necrosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110713 Version 4.0</div></div></div>"},"110714":{"type":"graphic_picture","displayName":"LMA protector","title":"LMA protector","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LMA protector</div><div class=\"cntnt\"><img style=\"width:375px; height:250px;\" src=\"images/EM/110714_LMA_protector_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LMA protector pictured above is a single-use device that can be used for intubation.</div><div class=\"graphic_reference\">Property of Teleflex Incorporated. Copyright © 2013 Teleflex Incorporated. All rights reserved. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 110714 Version 1.0</div></div></div>"},"110715":{"type":"graphic_figure","displayName":"Tetralogy of Fallot PI","title":"Tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:539px; height:367px;\" src=\"images/PI/110715_Tetralogy_of_Fallot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tetralogy of Fallot (also called \"TOF\") is a heart condition made up of 4 related heart problems:&#xD;&#xA;<ol>&#xD;&#xA;    <li>There is a hole between the 2 lower chambers (the \"ventricles\").</li>&#xD;&#xA;    <li>The main blood vessel that brings blood to the body (the \"aorta\") lies over the hole between the ventricles.</li>&#xD;&#xA;    <li>The main blood vessel that goes to the lungs (the \"pulmonary artery\") is narrowed.</li>&#xD;&#xA;    <li>The muscle of the lower right ventricle is thickened.</li>&#xD;&#xA;</ol>&#xD;&#xA;These problems cause babies with this condition to have less oxygen in their blood than is normal. This can make the skin, lips, fingernails, and toenails look blue.</div><div id=\"graphicVersion\">Graphic 110715 Version 3.0</div></div></div>"},"110717":{"type":"graphic_movie","displayName":"Air-Q supraglottic airway insertion","title":"Air-Q supraglottic airway insertion","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Air-Q supraglottic airway insertion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110717_AirQsupraglairinsertvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110717_AirQsupraglairinsertimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows insertion of the Air-Q supraglottic airway.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110717 Version 2.0</div></div></div>"},"110718":{"type":"graphic_movie","displayName":"Intubation via the Air-Q supraglottic airway","title":"Intubation via the Air-Q supraglottic airway","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Intubation via the Air-Q supraglottic airway</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110718_IntubatnAirQsupraglotvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110718_IntubatnAirQsupraglotimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The procedure for performing tracheal intubation via the Air-Q supraglottic airway is demonstrated in this video clip. The procedure is complex and should be well practiced before it is used on a patient.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110718 Version 1.0</div></div></div>"},"110719":{"type":"graphic_movie","displayName":"Swivel adapter for endoscopic intubation via supraglottic airway","title":"Attachment of swivel adapter for endoscopic intubation via supraglottic airway","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Attachment of swivel adapter for endoscopic intubation via supraglottic airway</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110719_Swiveladaptervid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:612px; height:612px;\" src=\"images/EM/110719_Swiveladapterimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use of a swivel adapter while performing endoscopic intubation via a supraglottic airway enables continuous oxygenation and ventilation of the patient while the procedure is performed. Attachment of the adapter is shown in this video clip.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110719 Version 1.0</div></div></div>"},"110720":{"type":"graphic_movie","displayName":"Endoscopic intubation via supraglottic airway","title":"Intubation using a flexible endoscope via a supraglottic airway","html":"<div class=\"graphic normal\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Intubation using a flexible endoscope via a supraglottic airway</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/110720_Endointubsupraglotticvid.mp4\" style=\"width:464px;height:720px\"></div><img style=\"width:409px; height:612px;\" src=\"images/EM/110720_Endointubsupraglotticimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A flexible endoscope can be used to perform tracheal intubation via a supraglottic airway under direct visualization. This procedure is shown in the video clip.</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110720 Version 1.0</div></div></div>"},"110723":{"type":"graphic_table","displayName":"Dis prog small int GIST AJCC 2017","title":"2017 AJCC disease progression in small intestinal GISTs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2017 AJCC disease progression in small intestinal GISTs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Stage</td> <td class=\"subtitle1_left\">Tumor size (cm)</td> <td class=\"subtitle1_left\">Mitotic rate</td> <td class=\"subtitle1_left\">Observed rate of progressive disease</td> </tr> <tr class=\"divider_top\"> <td>Stage IA</td> <td>&#8804;5</td> <td>Low</td> <td>0 to 4%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>Stage II</td> <td>&#62;5 to 10</td> <td>Low</td> <td>24%</td> </tr> <tr> <td rowspan=\"2\">Stage IIIA</td> <td>&#62;10</td> <td>Low</td> <td>52%</td> </tr> <tr> <td>&#8804;2</td> <td>High</td> <td>50%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td rowspan=\"3\">Stage IIIB</td> <td>&#62;2 to 5</td> <td>High</td> <td>73%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>&#62;5 to 10</td> <td>High</td> <td>85%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>&#62;10</td> <td>High</td> <td>90%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; GIST: gastrointestinal stromal tumors.</div><div class=\"graphic_reference\">Original figure modified for this publication. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110723 Version 1.0</div></div></div>"},"110724":{"type":"graphic_table","displayName":"Dis prog gastric GIST AJCC 2017","title":"2017 AJCC disease progression in gastric GISTs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2017 AJCC disease progression in gastric GISTs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Stage</td> <td class=\"subtitle1_left\">Tumor size (cm)</td> <td class=\"subtitle1_left\">Mitotic rate</td> <td class=\"subtitle1_left\">Observed rate of progressive disease</td> </tr> <tr class=\"divider_top\"> <td>Stage IA</td> <td>&#8804;5</td> <td>Low</td> <td>0 to 2%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>Stage IB</td> <td>&#62;5 to 10</td> <td>Low</td> <td>3 to 4%</td> </tr> <tr> <td rowspan=\"3\">Stage II</td> <td>&#8804;2</td> <td>High</td> <td>Insufficient data</td> </tr> <tr> <td>&#62;2 to 5</td> <td>High</td> <td>16%</td> </tr> <tr> <td>&#62;10</td> <td>Low</td> <td>12%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>Stage IIIA</td> <td>&#62;5 to 10</td> <td>High</td> <td>55%</td> </tr> <tr> <td>Stage IIIB</td> <td>&#62;10</td> <td>High</td> <td>86%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AJCC: American Joint Committee on Cancer; GIST: gastrointestinal stromal tumors.</div><div class=\"graphic_reference\">Original figure modified for this publication. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110724 Version 1.0</div></div></div>"},"110725":{"type":"graphic_table","displayName":"Dis prog rectal GIST AJCC 2017","title":"Disease progression in rectal GISTs according to AJCC 2017 stage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease progression in rectal GISTs according to AJCC 2017&nbsp;stage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Stage</td> <td class=\"subtitle1_left\">Tumor size (cm)</td> <td class=\"subtitle1_left\">Mitotic rate</td> <td class=\"subtitle1_left\">Observed rate of progressive disease</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Stage IA</td> <td>&#8804;2 cm</td> <td>Low</td> <td>0%</td> </tr> <tr> <td>&#62;2 to 5</td> <td>Low</td> <td>8.5%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>Stage II</td> <td>&#62;5 to 10</td> <td>Low</td> <td>NR</td> </tr> <tr> <td rowspan=\"2\">Stage IIIA</td> <td>&#62;10</td> <td>Low</td> <td>57%</td> </tr> <tr> <td>&#8804;2</td> <td>High</td> <td>54%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td rowspan=\"3\">Stage IIIB</td> <td>&#62;2 to 5</td> <td>High</td> <td>52%</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>&#62;5 to 10</td> <td>High</td> <td>NR</td> </tr> <tr style=\"background-color: #eafaf1;\"> <td>&#62;10</td> <td>High</td> <td>71%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GIST: gastrointestinal stromal tumor; AJCC: American Joint Committee on Cancer;&nbsp;NR: not reported.</div><div class=\"graphic_reference\">Original figure modified for this publication. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110725 Version 2.0</div></div></div>"},"110726":{"type":"graphic_table","displayName":"Combination oral contraceptive (COC) options and risks","title":"Common combination oral contraceptive (COC) options and risks","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common combination oral contraceptive (COC) options and risks</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"65%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Progestin</td> <td class=\"subtitle1\" colspan=\"2\">Progestin</td> <td class=\"subtitle1\" rowspan=\"2\">Progestin <br /> relative<br /> VTE risk*<sup>[1]</sup></td> <td class=\"subtitle1\" rowspan=\"2\">Typical formulations<br /> (progestin mg/ethinyl estradiol mcg)</td> </tr> <tr> <td class=\"subtitle2\">Generation</td> <td class=\"subtitle2\">Androgenicity</td> </tr> <tr> <td>Norethisterone</td> <td class=\"centered\">1</td> <td class=\"centered\">Weak</td> <td class=\"centered\">2.6</td> <td>Loestrin (0.5/20); Estrostep (1.0/30)</td> </tr> <tr> <td>Levonorgestrel</td> <td class=\"centered\">2</td> <td class=\"centered\">Weak</td> <td class=\"centered\">2.4</td> <td>Alesse (0.1/20); Levora (0.15/30)</td> </tr> <tr> <td>Norgestimate</td> <td class=\"centered\">2-3</td> <td class=\"centered\">Weak-Neutral</td> <td class=\"centered\">2.5</td> <td>Tri-Sprintec (0.18/35); Ortho-Cyclen (0.25/35)</td> </tr> <tr> <td>Gestodene (UK)</td> <td class=\"centered\">3</td> <td class=\"centered\">Neutral</td> <td class=\"centered\">3.6</td> <td>Sunya (0.075/20); Femodene (0.075/30)</td> </tr> <tr> <td>Desogestrel</td> <td class=\"centered\">3</td> <td class=\"centered\">Neutral</td> <td class=\"centered\">4.3</td> <td>Mircette (0.15/20); Desogen (0.15/30)</td> </tr> <tr> <td>Drospirenone</td> <td class=\"centered\">4</td> <td class=\"centered\">Antiandrogen</td> <td class=\"centered\">4.1</td> <td>Yaz (3/20); Yasmin (3/30)</td> </tr> <tr> <td>Cyproterone acetate (UK)</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">Antiandrogen</td> <td class=\"centered\">4.3</td> <td>Diane (2/35)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COC: combination oral contraceptive; VTE: venous thromboembolism; UK: United Kingdom.<br />* Relative VTE risk is compared&nbsp;with patients who are not using&nbsp;oral contraceptives.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350:h2135.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Robert L Rosenfield, MD.</div><div id=\"graphicVersion\">Graphic 110726 Version 1.0</div></div></div>"},"110727":{"type":"graphic_table","displayName":"Cancer of the penis TNM 2017","title":"Cancer of the penis TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer of the penis TNM staging AJCC UICC&nbsp;2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em> (penile intraepithelial neoplasia [PeIN])</td> </tr> <tr> <td class=\"indent1\">Ta</td> <td colspan=\"3\">Noninvasive localized squamous cell carcinoma</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Glans: Tumor invades lamina propria.<br /> Foreskin: Tumor invades dermis, lamina propria, or dartos fascia.<br /> Shaft: Tumor invades connective tissue between epidermis and corpora regardless of location.<br /> All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade.</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor is without lymphovascular invasion or perineural invasion and is not high grade (ie, grade 3 or sarcomatoid)</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor exhibits lymphovascular invasion and/or perinerual invasion or is high grade (ie, grade 3 or sarcomatoid)</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades into corpa cavernosum (including tunica albuginea) with or without urethral invasion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades into adjacent structures (ie, scrotum, prostate, pubic bone)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>cN category</strong></td> <td colspan=\"3\"><strong>cN criteria</strong></td> </tr> <tr> <td class=\"indent2\">cNX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">cN0</td> <td colspan=\"3\">No palpable or visibly enlarged inguinal lymph nodes</td> </tr> <tr> <td class=\"indent2\">cN1</td> <td colspan=\"3\">Palpable mobile unilateral inguinal lymph node</td> </tr> <tr> <td class=\"indent2\">cN2</td> <td colspan=\"3\">Palpable mobile &#8805;2 unilateral inguinal nodes or bilateral inguinal lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">cN3</td> <td colspan=\"3\">Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>pN category</strong></td> <td colspan=\"3\"><strong>pN criteria</strong></td> </tr> <tr> <td class=\"indent2\">pNX</td> <td colspan=\"3\">Lymph node metastasis cannot be established</td> </tr> <tr> <td class=\"indent2\">pN0</td> <td colspan=\"3\">No lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">pN1</td> <td colspan=\"3\">&#8804;2 unilateral inguinal metastases, no ENE</td> </tr> <tr> <td class=\"indent2\">pN2</td> <td colspan=\"3\">&#8805;3 unilateral inguinal metastases or bilateral metastases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">pN3</td> <td colspan=\"3\">ENE of lymph node metastases or pelvic lymph node metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis present</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0is</td> </tr> <tr> <td class=\"indent1\">Ta</td> <td>N0</td> <td>M0</td> <td>0a</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T1-3</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1-3</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110727 Version 2.0</div></div></div>"},"110728":{"type":"graphic_table","displayName":"Prostate cancer TNM 2017","title":"Prostate cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prostate cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"3\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"3\">Clinical T (cT)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"2\">Clinically inapparent tumor that is not palpable</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td colspan=\"2\">Tumor incidental histologic finding in 5% or less of tissue resected</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td colspan=\"2\">Tumor incidental histologic finding in more than 5% of tissue resected</td> </tr> <tr> <td class=\"indent3\">T1c</td> <td colspan=\"2\">Tumor identified by needle biopsy found in one or both sides, but not palpable</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"2\">Tumor is palpable and confined within prostate</td> </tr> <tr> <td class=\"indent3\">T2a</td> <td colspan=\"2\">Tumor involves one-half of one side or less</td> </tr> <tr> <td class=\"indent3\">T2b</td> <td colspan=\"2\">Tumor involves more than one-half of one side but not both sides</td> </tr> <tr> <td class=\"indent3\">T2c</td> <td colspan=\"2\">Tumor involves both sides</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"2\">Extraprostatic tumor that is not fixed or does not invade adjacent structures</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td colspan=\"2\">Extraprostatic extension (unilateral or bilateral)</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td colspan=\"2\">Tumor invades seminal vesicle(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td colspan=\"2\">Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"3\">Pathological T (pT)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"2\">Organ confined</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"2\">Extraprostatic extension</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td colspan=\"2\">Extraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td colspan=\"2\">Tumor invades seminal vesicle(s)</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"2\">Tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"3\"><em>NOTE:</em> There is no pathological T1 classification.<br /> <em>NOTE:</em> Positive surgical margin should be indicated by an R1 descriptor, indicating residual microscopic disease.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"2\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"2\">Regional nodes were not assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"2\">No positive regional nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"2\">Metastases in regional node(s)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"2\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"2\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"2\">Nonregional lymph node(s)</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td colspan=\"2\">Bone(s)</td> </tr> <tr> <td class=\"indent2\">M1c</td> <td colspan=\"2\">Other site(s) with or without bone disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\"><em>NOTE:</em> When more than one site of metastasis is present, the most advanced category is used. M1c is most advanced.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Prostate-specific antigen (PSA)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">PSA values are used to assign this category.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\" colspan=\"3\"><strong>PSA values</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">&#60;10</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">&#8805;10 &#60;20</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">&#60;20</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\">&#8805;20</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"3\">Any value</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"3\">Histologic grade group (G)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Recently, the Gleason system has been compressed into so-called Grade Groups.</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>Grade Group</strong></td> <td><strong>Gleason score</strong></td> <td><strong>Gleason pattern</strong></td> </tr> <tr> <td class=\"indent2\">1</td> <td>&#8804;6</td> <td>&#8804;3+3</td> </tr> <tr> <td class=\"indent2\">2</td> <td>7</td> <td>3+4</td> </tr> <tr> <td class=\"indent2\">3</td> <td>7</td> <td>4+3</td> </tr> <tr> <td class=\"indent2\">4</td> <td>8</td> <td>4+4, 3+5, 5+3</td> </tr> <tr> <td class=\"indent2\">5</td> <td>9 or 10</td> <td>4+5, 5+4, or 5+5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110728 Version 2.0</div></div></div>"},"110729":{"type":"graphic_table","displayName":"Prostate cancer TNM 2017 prognostic stage groups","title":"Prostate cancer TNM prognostic stage groups AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prostate cancer TNM prognostic stage groups AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"subtitle1_left\">When T is...</td> <td class=\"subtitle1_left\">And N is...</td> <td class=\"subtitle1_left\">And M is...</td> <td class=\"subtitle1_left\">And PSA is...</td> <td class=\"subtitle1_left\">And Grade Group is...</td> <td class=\"subtitle1_left\">Then the stage group is...</td> </tr> <tr> <td>cT1a-c, cT2a</td> <td>N0</td> <td>M0</td> <td>&#60;10</td> <td>1</td> <td>I</td> </tr> <tr> <td>pT2</td> <td>N0</td> <td>M0</td> <td>&#60;10</td> <td>1</td> <td>I</td> </tr> <tr> <td>cT1a-c, cT2a, pT2</td> <td>N0</td> <td>M0</td> <td>&#8805;10 &#60;20</td> <td>1</td> <td>IIA</td> </tr> <tr> <td>cT2b-c</td> <td>N0</td> <td>M0</td> <td>&#60;20</td> <td>1</td> <td>IIA</td> </tr> <tr> <td>T1-2</td> <td>N0</td> <td>M0</td> <td>&#60;20</td> <td>2</td> <td>IIB</td> </tr> <tr> <td>T1-2</td> <td>N0</td> <td>M0</td> <td>&#60;20</td> <td>3</td> <td>IIC</td> </tr> <tr> <td>T1-2</td> <td>N0</td> <td>M0</td> <td>&#60;20</td> <td>4</td> <td>IIC</td> </tr> <tr> <td>T1-2</td> <td>N0</td> <td>M0</td> <td>&#8805;20</td> <td>1-4</td> <td>IIIA</td> </tr> <tr> <td>T3-4</td> <td>N0</td> <td>M0</td> <td>Any</td> <td>1-4</td> <td>IIIB</td> </tr> <tr> <td>Any T</td> <td>N0</td> <td>M0</td> <td>Any</td> <td>5</td> <td>IIIC</td> </tr> <tr> <td>Any T</td> <td>N1</td> <td>M0</td> <td>Any</td> <td>Any</td> <td>IVA</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> <td>Any</td> <td>Any</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><em>NOTE:</em> When either PSA or Grade Group is not available, grouping should be determined by T category and/or either PSA or Grade Group as available.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; PSA: prostate-specific antigen.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110729 Version 3.0</div></div></div>"},"110731":{"type":"graphic_table","displayName":"Testicular cancer TNM 2017","title":"Testicular cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Testicular cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Clinical T (cT)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>cT category</strong></td> <td><strong>cT criteria</strong></td> </tr> <tr> <td class=\"indent2\">cTX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">cT0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">cTis</td> <td>Germ cell neoplasia <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">cT4</td> <td>Tumor invades scrotum with or without vascular/lymphatic invasion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\"><em>NOTE:</em> Except for Tis confirmed by biopsy and T4, the extent of the primary tumor is classified by radical orchiectomy. TX may be used for other categories for clinical staging.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Pathological T (pT)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>pT category</strong></td> <td><strong>pT criteria</strong></td> </tr> <tr> <td class=\"indent2\">pTX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">pT0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">pTis</td> <td>Germ cell neoplasia <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">pT1</td> <td>Tumor limited to testis (including rete testis invasion) without lymphovascular invasion</td> </tr> <tr> <td class=\"indent3\">pT1a*</td> <td>Tumor smaller than 3 cm in size</td> </tr> <tr> <td class=\"indent3\">pT1b*</td> <td>Tumor 3 cm or larger in size</td> </tr> <tr> <td class=\"indent2\">pT2</td> <td>Tumor limited to testis (including rete testis invasion) with lymphovascular invasion <strong>or</strong><br /> Tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion</td> </tr> <tr> <td class=\"indent2\">pT3</td> <td>Tumor invades spermatic cord with or without lymphovascular invasion</td> </tr> <tr> <td class=\"indent2\">pT4</td> <td>Tumor invades scrotum with or without lymphovascular invasion</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\">* Subclassification of pT1 applies only to pure seminoma.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>cN category</strong></td> <td><strong>cN criteria</strong></td> </tr> <tr> <td class=\"indent2\">cNX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">cN0</td> <td>No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">cN1</td> <td>Metastases with a lymph node mass 2 cm or smaller in greatest dimension <strong>or</strong><br /> Multiple lymph nodes, none larger than 2 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">cN2</td> <td>Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension <strong>or</strong><br /> Multiple lymph nodes, any one mass larger than 2 cm but not larger than 5 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">cN3</td> <td>Metastasis with a lymph node mass larger than 5 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>pN category</strong></td> <td><strong>pN criteria</strong></td> </tr> <tr> <td class=\"indent2\">pNX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">pN0</td> <td>No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">pN1</td> <td>Metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">pN2</td> <td>Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">pN3</td> <td>Metastasis with a lymph node mass larger than 5 cm in greatest dimension</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No distant metastases</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>Distant metastases</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td>Non-retroperitoneal nodal or pulmonary metastases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1b</td> <td>Non-pulmonary visceral metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Serum markers (S)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>S category</strong></td> <td><strong>S criteria</strong></td> </tr> <tr> <td class=\"indent1\">SX</td> <td>Marker studies not available or not performed</td> </tr> <tr> <td class=\"indent1\">S0</td> <td>Marker study levels within normal limits</td> </tr> <tr> <td class=\"indent1\">S1</td> <td>LDH &#60;1.5 x N<sup>&#182;</sup> <strong>and</strong> hCG (mIU/mL) &#60;5000 <strong>and</strong> AFP (ng/mL) &#60;1000</td> </tr> <tr> <td class=\"indent1\">S2</td> <td>LDH 1.5-10 x N<sup>&#182;</sup> <strong>or</strong> hCG (mIU/mL) 5000-50,000 <strong>or</strong> AFP (ng/mL) 1000-10,000</td> </tr> <tr> <td class=\"indent1\">S3</td> <td>LDH &#62;10 x N<sup>&#182;</sup> <strong>or</strong> hCG (mIU/mL) &#62;50,000 <strong>or</strong> AFP (ng/mL) &#62;10,000</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#182; N indicates the upper limit of normal for the LDH assay.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; LDH: lactate dehydrogenase; hCG: human chorionic gonadotropin; AFP: alpha-fetoprotein.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110731 Version 2.0</div></div></div>"},"110732":{"type":"graphic_table","displayName":"Testicular cancer TNM 2017 prognostic stage groups","title":"Testicular cancer TNM prognostic stage groups AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Testicular cancer TNM prognostic stage groups AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">When T is...</td> <td class=\"subtitle1_left\">And N is...</td> <td class=\"subtitle1_left\">And M is...</td> <td class=\"subtitle1_left\">And S is...</td> <td class=\"subtitle1_left\">Then the stage group is...</td> </tr> <tr class=\"divider_top\"> <td>pTis</td> <td>N0</td> <td>M0</td> <td>S0</td> <td>0</td> </tr> <tr> <td>pT1-T4</td> <td>N0</td> <td>M0</td> <td>SX</td> <td>I</td> </tr> <tr> <td>pT1</td> <td>N0</td> <td>M0</td> <td>S0</td> <td>IA</td> </tr> <tr> <td>pT2</td> <td>N0</td> <td>M0</td> <td>S0</td> <td>IB</td> </tr> <tr> <td>pT3</td> <td>N0</td> <td>M0</td> <td>S0</td> <td>IB</td> </tr> <tr> <td>pT4</td> <td>N0</td> <td>M0</td> <td>S0</td> <td>IB</td> </tr> <tr> <td>Any pT/TX</td> <td>N0</td> <td>M0</td> <td>S1-3</td> <td>IS</td> </tr> <tr> <td>Any pT/TX</td> <td>N1-3</td> <td>M0</td> <td>SX</td> <td>II</td> </tr> <tr> <td>Any pT/TX</td> <td>N1</td> <td>M0</td> <td>S0</td> <td>IIA</td> </tr> <tr> <td>Any pT/TX</td> <td>N1</td> <td>M0</td> <td>S1</td> <td>IIA</td> </tr> <tr> <td>Any pT/TX</td> <td>N2</td> <td>M0</td> <td>S0</td> <td>IIB</td> </tr> <tr> <td>Any pT/TX</td> <td>N2</td> <td>M0</td> <td>S1</td> <td>IIB</td> </tr> <tr> <td>Any pT/TX</td> <td>N3</td> <td>M0</td> <td>S0</td> <td>IIC</td> </tr> <tr> <td>Any pT/TX</td> <td>N3</td> <td>M0</td> <td>S1</td> <td>IIC</td> </tr> <tr> <td>Any pT/TX</td> <td>Any N</td> <td>M1</td> <td>SX</td> <td>III</td> </tr> <tr> <td>Any pT/TX</td> <td>Any N</td> <td>M1a</td> <td>S0</td> <td>IIIA</td> </tr> <tr> <td>Any pT/TX</td> <td>Any N</td> <td>M1a</td> <td>S1</td> <td>IIIA</td> </tr> <tr> <td>Any pT/TX</td> <td>N1-3</td> <td>M0</td> <td>S2</td> <td>IIIB</td> </tr> <tr> <td>Any pT/TX</td> <td>Any N</td> <td>M1a</td> <td>S2</td> <td>IIIB</td> </tr> <tr> <td>Any pT/TX</td> <td>N1-3</td> <td>M0</td> <td>S3</td> <td>IIIC</td> </tr> <tr> <td>Any pT/TX</td> <td>Any N</td> <td>M1a</td> <td>S3</td> <td>IIIC</td> </tr> <tr> <td>Any pT/TX</td> <td>Any N</td> <td>M1b</td> <td>Any S</td> <td>IIIC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110732 Version 2.0</div></div></div>"},"110735":{"type":"graphic_table","displayName":"Kidney cancer TNM 2017","title":"Kidney cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kidney cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;7 cm in greatest dimension, limited to the kidney</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor &#8804;4 cm in greatest dimension, limited to the kidney</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor &#62;4 cm but &#8804;7 cm in greatest dimension, limited to the kidney</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#62;7 cm in greatest dimension, limited to the kidney</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td colspan=\"3\">Tumor &#62;7 cm but &#8804;10 cm in greatest dimension, limited to the kidney</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td colspan=\"3\">Tumor &#62;10 cm, limited to the kidney</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td colspan=\"3\">Tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota's fascia</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td colspan=\"3\">Tumor extends into the vena cava below the diaphragm</td> </tr> <tr> <td class=\"indent2\">T3c</td> <td colspan=\"3\">Tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"3\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in regional lymph node(s)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"3\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>NX, N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110735 Version 2.0</div></div></div>"},"110737":{"type":"graphic_table","displayName":"Bone sarcoma TNM 2017","title":"Bone sarcomas TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bone sarcomas TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Appendicular skeleton, trunk, skull, and facial bones</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"4\">Tumor &#8804;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"4\">Tumor &#62;8 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T3</td> <td colspan=\"4\">Discontinuous tumors in the primary bone site</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Spine</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"4\">Tumor confined to one vertebral segment or two adjacent vertebral segments</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"4\">Tumor confined to three adjacent vertebral segments</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"4\">Tumor confined to four or more adjacent vertebral segments, or any nonadjacent vertebral segments</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"4\">Extension into the spinal canal or great vessels</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"4\">Extension into the spinal canal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"4\">Evidence of gross vascular invasion or tumor thrombus in the great vessels</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Pelvis</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"4\">Tumor confined to one pelvic segment with no extraosseous extension</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td colspan=\"4\">Tumor &#8804;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td colspan=\"4\">Tumor &#62;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"4\">Tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension</td> </tr> <tr> <td class=\"indent3\">T2a</td> <td colspan=\"4\">Tumor &#8804;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent3\">T2b</td> <td colspan=\"4\">Tumor &#62;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"4\">Tumor spanning two pelvic segments with extraosseous extension</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td colspan=\"4\">Tumor &#8804;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td colspan=\"4\">Tumor &#62;8 cm in greatest dimension</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"4\">Tumor spanning three pelvic segments or crossing the sacroiliac joint</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"4\">Tumor involves sacroiliac joint and extends medial to the sacral neuroforamen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"4\">Tumor encasement of external iliac vessels or presence of gross tumor thrombus in major pelvic vessels</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"4\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"4\"> <p>Regional lymph nodes cannot be assessed.</p> Because of the rarity of lymph node involvement in bone sarcomas, the designation NX may not be appropriate, and cases should be considered N0 unless clinical node involvement clearly is evident.</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"4\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"4\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"4\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"4\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"4\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"4\">Lung</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1b</td> <td colspan=\"4\">Bone or other distant sites</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Histologic grade (G)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">G</td> <td class=\"subtitle2_left\" colspan=\"5\">G definition</td> </tr> <tr> <td class=\"indent1\">GX</td> <td colspan=\"4\">Grade cannot be assessed</td> </tr> <tr> <td class=\"indent1\">G1</td> <td colspan=\"4\">Well differentiated, low grade</td> </tr> <tr> <td class=\"indent1\">G2</td> <td colspan=\"4\">Moderately differentiated, high grade</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">G3</td> <td colspan=\"4\">Poorly differentiated, high grade</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Appendicular skeleton, trunk, skull, and facial bones</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>And grade is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>G1 or GX</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>G1 or GX</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>G1 or GX</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>G2 or G3</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>G2 or G3</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>G2 or G3</td> <td>III</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N0</td> <td>M1a</td> <td>Any G</td> <td>IVA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N1</td> <td>Any M</td> <td>Any G</td> <td>IVB</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1b</td> <td>Any G</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110737 Version 3.0</div></div></div>"},"110739":{"type":"graphic_table","displayName":"STS abd and thor viscera TNM 2017","title":"Soft tissue sarcomas arising in the abdominal and thoracic viscera TNM staging AJCC UICC 2017*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Soft tissue sarcomas arising in the abdominal and thoracic viscera TNM staging AJCC UICC 2017*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Organ confined</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>Tumor extension into tissue beyond organ</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td>Invades serosa or visceral peritoneum</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td>Extension beyond serosa (mesentery)</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Invades another organ</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Multifocal involvement</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>Multifocal (two sites)</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>Multifocal (three to five sites)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4c</td> <td>Multifocal (&#62;5 sites)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\">N criteria</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No lymph node involvement or unknown lymph node status</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td>Lymph node involvement present</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No metastases</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>Metastases present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.<br />* There is no recommended prognostic stage grouping at this time.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110739 Version 4.0</div></div></div>"},"110756":{"type":"graphic_table","displayName":"Vaccination in primary immunodeficiency disorders","title":"Vaccination in primary immunodeficiency disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaccination in primary immunodeficiency disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" colspan=\"2\">Combined immunodeficiency syndromes</td> <td class=\"subtitle1\" colspan=\"2\">Antibody deficiency</td> <td class=\"subtitle1\" colspan=\"2\">Patients receiving IgG</td> <td class=\"subtitle1\" rowspan=\"2\">Diseases of immune dysregulation</td> <td class=\"subtitle1\" colspan=\"2\">Phagocytic cell disorders</td> <td class=\"subtitle1\" colspan=\"3\">Diseases of innate immunity</td> <td class=\"subtitle1\" rowspan=\"2\">Autoinflammatory disorders</td> <td class=\"subtitle1\" rowspan=\"2\">Complement deficiency</td> <td class=\"subtitle1\" rowspan=\"2\">Phenocopies</td> <td class=\"subtitle1\" rowspan=\"2\">Immunosuppression<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">Severe</td> <td class=\"subtitle2\">Mild*</td> <td class=\"subtitle2\">Severe</td> <td class=\"subtitle2\">Mild</td> <td class=\"subtitle2\">Replacement</td> <td class=\"subtitle2\">Immuno<br /> modulatory</td> <td class=\"subtitle2\">CGD and neutropenia</td> <td class=\"subtitle2\">LAD and cytotoxic granule defects</td> <td class=\"subtitle2\">Invasive bacterial infections</td> <td class=\"subtitle2\">Invasive viral infections</td> <td class=\"subtitle2\">Mycobacterial infections</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Inactivated/subunit</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">DTaP</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">HAV</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">HBV</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">HIB</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A<sup>&#916;</sup></td> <td class=\"centered\">B</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">HPV</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Influenza (IM/SC)</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Meningococcal</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A<sup>&#916;</sup></td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Serogroup B meningococcal vaccine</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A<sup>&#916;</sup></td> <td class=\"centered\">B</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Pneumococcal conjugate</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A<sup>&#916;</sup></td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Pneumococcal polysaccharide</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">E</td> <td class=\"centered\">A<sup>&#916;</sup></td> <td class=\"centered\">B</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Polio (IM)</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Anthrax</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">JE</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr> <td class=\"indent1\">Typhoid (IM)</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">B</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\">Rabies<sup>&#9674;</sup></td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"17\">Live-attenuated</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Influenza</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">MMR</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Polio (oral)</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">Rotavirus</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Varicella</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">B</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Adenovirus</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">Smallpox<sup>&#165;</sup></td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">Typhoid</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr> <td class=\"indent1\">Yellow fever</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">D</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"indent1\">BCG</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">D</td> <td class=\"centered\">D</td> <td class=\"centered\">D</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">C</td> <td class=\"centered\">D</td> <td class=\"centered\">D</td> <td class=\"centered\">C</td> <td class=\"centered\">A</td> <td class=\"centered\">A</td> <td class=\"centered\">D<sup>&#167;</sup></td> <td class=\"centered\">C</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A: No possibility of harm; benefit possible; administration recommended; use according to routine schedule.<br />B: No possibility of harm; benefit unlikely; administration not recommended.<br />C: Possibility of harm (significant); benefit unlikely; administration not recommended.<br />D: Possibility of harm (small); benefit likely; administration recommended.<br />E: Administration recommended for therapeutic benefit.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; CGD: chronic granulomatous disease; LAD: leukocyte-adhesion deficiency; DTaP:&nbsp;diphtheria, tetanus toxoids, and acellular pertussis vaccine; HAV: hepatitis A virus; HBV: hepatitis B virus; HIB: <EM>Haemophilus influenzae</EM> type B; HPV: human papilloma virus; IM: intramuscular; SC: subcutaneous; JE: Japanese encephalitis; MMR: measles-mumps-rubella; BCG: Bacille Calmette-Guérin; MMRV: measles-mumps-rubella-varicella.<br />* Patients with partial defects (eg, most patients with DiGeorge syndrome, hyperimmunoglobulin M syndrome, Wiskott-Aldrich syndrome, and others). Patients with ≥500 CD3+ T lymphocytes/mm<SUP>3</SUP> ≥200 CD8+ T lymphocytes/mm<SUP>3</SUP>, and normal mitogen response should receive MMR and varicella vaccine (but not MMRV).<br />¶ High-level immunosuppression.<br />Δ Patients with atypical hemolytic uremic syndrome who receive eculizumab should receive the same schedule of pneumococcal, HIB, and meningococcal vaccines as patients with primary complement deficiency and asplenia.<br /><FONT class=lozenge>◊</FONT> All patients should receive postexposure regimen of rabies vaccine, and patients with severe immunosuppression should be assessed for antibody response.<br />§ Patients with Mendelian susceptibility to mycobacterial disease due to autoantibodies to interferon-gamma should not receive live bacterial vaccines. Patients with autoantibodies to type 1 interferon should not receive live viral vaccines.<br /><SPAN style=\"COLOR: black\">¥ These recommendations are for pre-exposure, if indicated; however, no absolute contraindication for smallpox vaccine in postexposure settings.</SPAN></div><div class=\"graphic_reference\">Reproduced from: Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Allergy Clin Immunol Pract 2016; 4:1066. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110756 Version 2.0</div></div></div>"},"110759":{"type":"graphic_algorithm","displayName":"Management of psychosis in PD","title":"Management of psychosis in Parkinson disease","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Management of psychosis in Parkinson disease</div><div class=\"cntnt\"><img style=\"width:688px; height:672px;\" src=\"images/NEURO/110759_Mgmt_psychosis_PD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PD: Parkinson disease; MAO-B: monoamine oxidase type B; COMT: catechol-O-methyl transferase.</div><div id=\"graphicVersion\">Graphic 110759 Version 1.0</div></div></div>"},"110761":{"type":"graphic_figure","displayName":"Outcomes for extremity trunk STS according to tumor size","title":"Impact of primary tumor size on local recurrence-free survival, overall recurrence-free survival, and disease-specific survival in a series of 5267 patients with soft tissue sarcoma of the extremities or trunk","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Impact of primary tumor size on local recurrence-free survival, overall recurrence-free survival, and disease-specific survival in a series of 5267 patients with soft tissue sarcoma of the extremities or trunk</div><div class=\"cntnt\"><img style=\"width:752px; height:374px;\" src=\"images/ONC/110761_OtcmsextrmtySTStumrsize.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Local recurrence-free survival, overall recurrence-free survival, and disease-specific survival by size category, &le;5, 5-10, 10-15, and &gt;15 cm.<br />(A) Local recurrence-free survival (time from primary surgery to first local recurrence), n = 5267 patients, excludes 75 patients with unknown size categories; log rank, p&lt;0.001.<br />(B) Recurrence-free survival (time from primary surgery to first local or distant recurrence), n = 5267, excludes 75 patients with unknown size categories; log rank, p&lt;0.001.<br />(C) Disease-specific survival (time from primary surgery to death from disease), n = 5267, excludes 75 patients with unknown size categories; log rank, p&lt;0.001; log rank, p value = 0.91 comparing &gt;10-15 and &gt;15 cm groups.</div><div class=\"graphic_reference\">Annals of Surgical Oncology, Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7, Vol. 20, 2013, p. 3377, Maki RG, Moraco N, Antonescu CR, et al, &copy; Society of Surgical Oncology 2013, with permission of Springer.</div><div id=\"graphicVersion\">Graphic 110761 Version 2.0</div></div></div>"},"110762":{"type":"graphic_table","displayName":"Renal pelvis and ureter TNM 2017","title":"Tumors of the renal pelvis and ureter TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tumors of the renal pelvis and ureter TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Ta</td> <td colspan=\"3\">Papillary noninvasive carcinoma</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades subepithelial connective tissue</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the muscularis</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma.<br /> For ureter only: Tumor invades beyond muscularis into periureteric fat.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades adjacent organs, or through the kidney into the perinephric fat</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in a single lymph node, &#8804;2 cm in greatest dimension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in a single lymph node, &#62;2 cm; or multiple lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Ta</td> <td>N0</td> <td>M0</td> <td>0a</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0is</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>NX, N0</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110762 Version 2.0</div></div></div>"},"110763":{"type":"graphic_table","displayName":"Bladder cancer TNM 2017","title":"Bladder cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bladder cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Ta</td> <td colspan=\"3\">Noninvasive papillary carcinoma</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Urothelial carcinoma in situ: \"Flat tumor\"</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades lamina propria (subepithelial connective tissue)</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades muscularis propria</td> </tr> <tr> <td class=\"indent2\">pT2a</td> <td colspan=\"3\">Tumor invades superficial muscularis propria (inner half)</td> </tr> <tr> <td class=\"indent2\">pT2b</td> <td colspan=\"3\">Tumor invades deep muscularis propria (outer half)</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades perivesical soft tissue</td> </tr> <tr> <td class=\"indent2\">pT3a</td> <td colspan=\"3\">Microscopically</td> </tr> <tr> <td class=\"indent2\">pT3b</td> <td colspan=\"3\">Macroscopically (extravesical mass)</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Extravesical tumor directly invades any of the following: Prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Extravesical tumor invades directly into prostatic stroma, uterus, vagina</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Extravesical tumor invades pelvic wall, abdominal wall</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node)</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N3</td> <td colspan=\"3\">Lymph node metastasis to the common iliac lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Distant metastasis limited to lymph nodes beyond the common iliacs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Non-lymph-node distant metastases</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Ta</td> <td>N0</td> <td>M0</td> <td>0a</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0is</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3a, T3b, T4a</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1-T4a</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1-T4a</td> <td>N2, N3</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1a</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110763 Version 3.0</div></div></div>"},"110764":{"type":"graphic_table","displayName":"Conjunctival melanoma TNM 2017","title":"Conjunctival melanoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conjunctival melanoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Clinical tumor (cT)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>cT category</strong></td> <td><strong>cT criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>Tumor of the bulbar conjunctiva</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td>&#60;1 quadrant</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td>&#8805;1 to &#60;2 quadrants</td> </tr> <tr> <td class=\"indent3\">T1c</td> <td>&#8805;2 to &#60;3 quadrants</td> </tr> <tr> <td class=\"indent3\">T1d</td> <td>&#8805;3 quadrants</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>Tumor of the nonbulbar (forniceal, palpebral, tarsal) conjunctiva, and tumor involving the caruncle</td> </tr> <tr> <td class=\"indent3\">T2a</td> <td>Noncaruncular, and &#8804;1 quadrant of the nonbulbar conjunctiva involved</td> </tr> <tr> <td class=\"indent3\">T2b</td> <td>Noncaruncular, and &#62;1 quadrant of the nonbulbar conjunctiva involved</td> </tr> <tr> <td class=\"indent3\">T2c</td> <td>Caruncular, and &#8804;1 quadrant of the nonbulbar conjunctiva involved</td> </tr> <tr> <td class=\"indent3\">T2d</td> <td>Caruncular, and &#62;1 quadrant of the nonbulbar conjunctiva involved</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>Tumor of any size with local invasion</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td>Globe</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td>Eyelid</td> </tr> <tr> <td class=\"indent3\">T3c</td> <td>Orbit</td> </tr> <tr> <td class=\"indent3\">T3d</td> <td>Nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td>Tumor of any size with invasion of the central nervous system</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"2\">Pathological tumor (pT)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>pT category</strong></td> <td><strong>pT criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>Melanoma confined to the conjunctival epithelium</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>Tumor of the bulbar conjunctiva</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td>Tumor of the bulbar conjunctiva with invasion of the substantia propria, not more than 2.0 mm in thickness</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td>Tumor of the bulbar conjunctiva with invasion of the substantia propria, more than 2.0 mm in thickness</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>Tumor of the nonbulbar (forniceal, palpebral, tarsal) conjunctiva, and tumor involving the caruncle</td> </tr> <tr> <td class=\"indent3\">T2a</td> <td>Tumor of the nonbulbar conjunctiva with invasion of the substantia propria, not more than 2.0 mm in thickness</td> </tr> <tr> <td class=\"indent3\">T2b</td> <td>Tumor of the nonbulbar conjunctiva with invasion of the substantia propria, more than 2.0 mm in thickness</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>Tumor of any size with local invasion</td> </tr> <tr> <td class=\"indent3\">T3a</td> <td>Globe</td> </tr> <tr> <td class=\"indent3\">T3b</td> <td>Eyelid</td> </tr> <tr> <td class=\"indent3\">T3c</td> <td>Orbit</td> </tr> <tr> <td class=\"indent3\">T3d</td> <td>Nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td>Tumor of any size with invasion of the central nervous system</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td>Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td>Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Prognostic stage groups</td> </tr> <tr> <td colspan=\"2\">There is no proposal for anatomic stage and prognostic groups for conjunctival melanoma.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110764 Version 2.0</div></div></div>"},"110765":{"type":"graphic_table","displayName":"Iris melanoma TNM 2017","title":"Iris melanoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Iris melanoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>Tumor limited to the iris</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>Tumor limited to the iris, not more than 3 clock hours in size</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>Tumor limited to the iris, more than 3 clock hours in size</td> </tr> <tr> <td class=\"indent2\">T1c</td> <td>Tumor limited to the iris with secondary glaucoma</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>Tumor confluent with or extending into the ciliary body, choroid, or both</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td>Tumor confluent with or extending into the ciliary body, without secondary glaucoma</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td>Tumor confluent with or extending into the ciliary body and choroid, without secondary glaucoma</td> </tr> <tr> <td class=\"indent2\">T2c</td> <td>Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Tumor with extrascleral extension</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>Tumor with extrascleral extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td>Tumor with extrascleral extension &#62;5 mm in largest diameter</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"><em>NOTE:</em> Iris melanomas originate from, and are predominately located in, this region of the uvea. If less than half the tumor volume is located within the iris, the tumor may have originated in the ciliary body, and consideration should be given to classifying it accordingly.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional lymph node involvement</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>Regional lymph node metastases or discrete tumor deposits in the orbit</td> </tr> <tr> <td class=\"indent2\">N1a</td> <td>Metastasis in one or more regional lymph node(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N1b</td> <td>No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye (choroidal and ciliary body)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No distant metastasis by clinical classification</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>Distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td>Largest diameter of the largest metastasis &#8804;3.0 cm</td> </tr> <tr> <td class=\"indent2\">M1b</td> <td>Largest diameter of the largest metastasis 3.1-8.0 cm</td> </tr> <tr> <td class=\"indent2\">M1c</td> <td>Largest diameter of the largest metastasis &#8805;8.1 cm</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110765 Version 2.0</div></div></div>"},"110766":{"type":"graphic_table","displayName":"Choroidal and ciliary body melanoma TNM 2017","title":"Choroidal and ciliary body melanoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choroidal and ciliary body melanoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"8\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>T category</strong></td> <td colspan=\"6\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">TX</td> <td colspan=\"6\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T0</td> <td colspan=\"6\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T1</td> <td colspan=\"6\">Tumor size category 1</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T1a</td> <td colspan=\"6\">Tumor size category 1 without ciliary body involvement and extraocular extension</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T1b</td> <td colspan=\"6\">Tumor size category 1 with ciliary body involvement</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T1c</td> <td colspan=\"6\">Tumor size category 1 without ciliary body involvement but with extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T1d</td> <td colspan=\"6\">Tumor size category 1 with ciliary body involvement and extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T2</td> <td colspan=\"6\">Tumor size category 2</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T2a</td> <td colspan=\"6\">Tumor size category 2 without ciliary body involvement and extraocular extension</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T2b</td> <td colspan=\"6\">Tumor size category 2 with ciliary body involvement</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T2c</td> <td colspan=\"6\">Tumor size category 2 without ciliary body involvement but with extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T2d</td> <td colspan=\"6\">Tumor size category 2 with ciliary body involvement and extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T3</td> <td colspan=\"6\">Tumor size category 3</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T3a</td> <td colspan=\"6\">Tumor size category 3 without ciliary body involvement and extraocular extension</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T3b</td> <td colspan=\"6\">Tumor size category 3 with ciliary body involvement</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T3c</td> <td colspan=\"6\">Tumor size category 3 without ciliary body involvement but with extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T3d</td> <td colspan=\"6\">Tumor size category 3 with ciliary body involvement and extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T4</td> <td colspan=\"6\">Tumor size category 4</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T4a</td> <td colspan=\"6\">Tumor size category 4 without ciliary body involvement and extraocular extension</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T4b</td> <td colspan=\"6\">Tumor size category 4 with ciliary body involvement</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T4c</td> <td colspan=\"6\">Tumor size category 4 without ciliary body involvement but with extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T4d</td> <td colspan=\"6\">Tumor size category 4 with ciliary body involvement and extraocular extension &#8804;5 mm in largest diameter</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">T4e</td> <td colspan=\"6\">Any tumor size category with extraocular extension &#62;5 mm in largest diameter</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"8\"><em>NOTES:</em> <ol> <li>Primary ciliary body and choroidal melanomas are classified according to the four tumor size categories defined in figure entitled \"Classification for ciliary body and choroid uveal melanoma based on thickness and diameter.\" </li> <li>In clinical practice, the largest tumor basal diameter may be estimated in optic disc diameters (DD; average: 1 DD = 1.5 mm), and tumor thickness may be estimated in diopters (average: 2.5 diopters = 1 mm). Ultrasonography and fundus photography are used to provide more accurate measurements. </li> <li>When histopathologic measurements are recorded after fixation, tumor diameter and thickness may be underestimated because of tissue shrinkage. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle1_left\" colspan=\"8\">Classification for ciliary body and choroid uveal melanoma based on thickness and diameter</td> </tr> <tr> <td class=\"subtitle2_left\">&nbsp;</td> <td class=\"subtitle2_left\" colspan=\"7\">Largest basal diameter (mm)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">Thickness (mm)</td> <td class=\"highlight_gray_text centered\"><strong>&#8804;3.0</strong></td> <td class=\"highlight_gray_text centered\"><strong>3.1 to 6.0</strong></td> <td class=\"highlight_gray_text centered\"><strong>6.1 to 9.0</strong></td> <td class=\"highlight_gray_text centered\"><strong>9.1 to 12.0</strong></td> <td class=\"highlight_gray_text centered\"><strong>12.1 to 15.0</strong></td> <td class=\"highlight_gray_text centered\"><strong>15.1 to 18.0</strong></td> <td class=\"highlight_gray_text centered\"><strong>&#62;18.0</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>&#62;15.0</strong></td> <td class=\"centered\" style=\"background-color: #bee0f2;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>12.1 to 15.0</strong></td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>9.1 to 12.0</strong></td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">&nbsp;</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>6.1 to 9.0</strong></td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>3.1 to 6.0</strong></td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f8d5ae;\">3</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"highlight_gray_text\"><strong>&#8804;3.0</strong></td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #a4a3c8;\">1</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #f3b8cd;\">2</td> <td class=\"centered\" style=\"background-color: #bee0f2;\">4</td> </tr> <tr class=\"divider_top\"> <td class=\"small divider_bottom\" colspan=\"8\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"8\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>N category</strong></td> <td colspan=\"6\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">NX</td> <td colspan=\"6\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">N0</td> <td colspan=\"6\">No regional lymph node involvement</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">N1</td> <td colspan=\"6\">Regional lymph node metastases or discrete tumor deposits in the orbit</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">N1a</td> <td colspan=\"6\">Metastasis in one or more regional lymph node(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\">N1b</td> <td colspan=\"6\">No regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye (choroidal and ciliary body)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"8\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>M category</strong></td> <td colspan=\"6\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">M0</td> <td colspan=\"6\">No distant metastasis by clinical classification</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">M1</td> <td colspan=\"6\">Distant metastasis</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">M1a</td> <td colspan=\"6\">Largest diameter of the largest metastasis &#8804;3.0 cm</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">M1b</td> <td colspan=\"6\">Largest diameter of the largest metastasis 3.1-8.0 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"2\">M1c</td> <td colspan=\"6\">Largest diameter of the largest metastasis &#8805;8.1 cm</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"8\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>When T is...</strong></td> <td colspan=\"2\"><strong>And N is...</strong></td> <td colspan=\"2\"><strong>And M is...</strong></td> <td colspan=\"2\"><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T1a</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">I</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T1b-d</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIA</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T2a</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIA</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T2b</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIB</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T3a</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIB</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T2c-d</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T3b-c</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T4a</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIA</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T3d</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T4b-c</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIB</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">T4d-e</td> <td colspan=\"2\">N0</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IIIC</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Any T</td> <td colspan=\"2\">N1</td> <td colspan=\"2\">M0</td> <td colspan=\"2\">IV</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Any T</td> <td colspan=\"2\">Any N</td> <td colspan=\"2\">M1a-c</td> <td colspan=\"2\">IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110766 Version 3.0</div></div></div>"},"110767":{"type":"graphic_table","displayName":"Lip and oral cavity cancer TNM 2017","title":"Cancer of the lip and oral cavity TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer of the lip and oral cavity TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor &#8804;2 cm, &#8804;5 mm depth of invasion (DOI).<br /> DOI is depth of invasion and not tumor thickness.</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor &#8804;2 cm, DOI &#62;5 mm and &#8804;10 mm; <strong>or</strong><br /> Tumor &#62;2 cm but &#8804;4 cm, and &#8804;10 mm DOI</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor &#62;4 cm; <strong>or</strong><br /> Any tumor &#62;10 mm DOI</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced local disease</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> <strong>LIP:</strong> Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (ie, chin or nose).<br /> <strong>ORAL CAVITY:</strong> Tumor invades adjacent structures only (eg, through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of the face).<br /> <em>NOTE:</em> Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension, and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in any node(s) and clinically overt ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) and clinically overt ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension, ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110767 Version 2.0</div></div></div>"},"110768":{"type":"graphic_table","displayName":"Nasal cavity and paranasal sinuses TNM 2017","title":"Cancer of the nasal cavity and paranasal sinuses TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer of the nasal cavity and paranasal sinuses TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Maxillary sinus</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor invades any of the following: Bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced local disease</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades any of the following: Orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal verve (V2), nasopharynx, or clivus.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Nasal cavity and ethmoid sinus</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor restricted to any one subsite, with or without bony invasion</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced local disease</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades any of the following: Anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades any of the following: Orbital apex, dura, brain, middle cranial fossa, cranial nerves other than (V2), nasopharynx, or clivus.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in any node(s) with clinically overt ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) with clinically overt ENE (ENE<sub>c</sub>)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension, ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); <strong>or</strong><br /> A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis (no pathologic M0; use clinical M to complete stage group)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110768 Version 2.0</div></div></div>"},"110769":{"type":"graphic_table","displayName":"Larynx cancer TNM 2017","title":"Cancer of the larynx TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer of the larynx TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Supraglottis</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor limited to one subsite of supraglottis with normal vocal cord mobility</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor limited to larynx with vocal cord fixation and/or invades any of the following: Postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Glottis</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility</td> </tr> <tr> <td class=\"indent3\">T1a</td> <td colspan=\"3\">Tumor limited to one vocal cord</td> </tr> <tr> <td class=\"indent3\">T1b</td> <td colspan=\"3\">Tumor involves both vocal cords</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Subglottis</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor limited to the subglottis</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor extends to vocal cord(s) with normal or impaired mobility</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor limited to larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage</td> </tr> <tr> <td class=\"indent2\">T4</td> <td colspan=\"3\">Moderately advanced or very advanced</td> </tr> <tr> <td class=\"indent3\">T4a</td> <td colspan=\"3\">Moderately advanced local disease.<br /> Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">T4b</td> <td colspan=\"3\">Very advanced local disease.<br /> Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in any lymph node(s) with clinically overt ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any lymph node(s) with clinically overt ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4a</td> <td>N0, N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T1, T2, T3, T4a</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">T4b</td> <td>Any N</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVC</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110769 Version 2.0</div></div></div>"},"110771":{"type":"graphic_table","displayName":"ECG effects of anesthetic agents","title":"ECG effects of anesthetic agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG effects of anesthetic agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anesthetic agent*</td> <td class=\"subtitle1\">ECG effects</td> </tr> <tr class=\"divider_bottom\"> <td>Volatile inhaled agents</td> <td>QT interval: Slight prolongation</td> </tr> <tr class=\"divider_bottom\"> <td>Dexmedetomidine</td> <td> <p>QT interval: Slight prolongation</p> SA and AV nodes: Slight depression in function</td> </tr> <tr> <td colspan=\"2\">Opioids:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sufentanil </li> </ul> </td> <td>QT interval: Slight prolongation</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Fentanyl </li> </ul> </td> <td>QT interval: Slight prolongation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Remifentanil </li> </ul> </td> <td>SA node: Depression in function with possible bradycardia</td> </tr> <tr class=\"divider_bottom\"> <td>Midazolam</td> <td>QT interval: Slight prolongation</td> </tr> <tr class=\"divider_bottom\"> <td>Etomidate</td> <td>QT interval: Slight prolongation or no effect</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine</td> <td>QT interval: Variability in duration</td> </tr> <tr> <td>Bupivacaine</td> <td>QT interval: Slight increase</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SA: sinoatrial; AV: atrioventricular.<br />* Propofol and neuromuscular blocking agents have no known effects on the ECG.</div><div id=\"graphicVersion\">Graphic 110771 Version 1.0</div></div></div>"},"110777":{"type":"graphic_picture","displayName":"Histopathology of pancreatic transplant rejection","title":"Histopathology of pancreatic transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Histopathology of pancreatic transplant rejection</div><div class=\"cntnt\"><img style=\"width:764px; height:578px;\" src=\"images/NEPH/110777_Hstpthlgy_pncrtc_trsplt_rjn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Septal lymphocytic and eosinophilic inflammation (arrows) is common in acute cellular rejection of pancreas allografts. Pancreatic acini are seen in the lower left (asterisk; H&amp;E 200x).<br />(B) The small artery seen in the center of the field shows prominent intimal arteritis (arrow). This finding is associated with more severe forms of both acute cellular rejection and antibody-mediated rejection of the pancreas allograft (H&amp;E 400x).<br />(C) Lymphocytic and eosinophilic acinar inflammation (arrows) with associated acinar cell injury in acute cellular rejection (asterisks; H&amp;E 400x).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin stain.</div><div class=\"graphic_reference\">Courtesy of Joseph Gaut, MD, Department of Pathology and Immunology, Washington University of St. Louis.</div><div id=\"graphicVersion\">Graphic 110777 Version 1.0</div></div></div>"},"110782":{"type":"graphic_picture","displayName":"Reticular erythematous mucinosis","title":"Reticular erythematous mucinosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Reticular erythematous mucinosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/110782_Reticular_erythemats_mucnss.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110782 Version 1.0</div></div></div>"},"110783":{"type":"graphic_table","displayName":"Inheritable forms of impaired sensitivity to thyroid hormone","title":"Inheritable forms of impaired sensitivity to thyroid hormone","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inheritable forms of impaired sensitivity to thyroid hormone</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Commonly used name</td> <td class=\"subtitle1\" rowspan=\"2\">Synonyms</td> <td class=\"subtitle1\" rowspan=\"2\">Gene involved and inheritance (OMIM)</td> <td class=\"subtitle1\" colspan=\"2\">Phenotype</td> </tr> <tr> <td class=\"subtitle2\">Consistent<br /> (pathognomonic)</td> <td class=\"subtitle2\">Common</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Thyroid hormone cell membrane transport defects (THCMTD)</td> </tr> <tr> <td class=\"indent1\">Monocarboxylate transporter 8 (MCT8) defect</td> <td>Allan-Herndon-Dudley syndrome</td> <td> <ul> <li><em>MCT8 (SLC16A2)</em><br /> gene (MIM #300095) </li> <li>X-chromosome linked </li> </ul> </td> <td>High T<sub>3</sub>, low rT<sub>3</sub> and T<sub>4</sub>, normal or slightly elevated TSH; low BMI; hypotonia, spastic quadriplegia; not walking or rarely ataxic gait; no speech or dysarthria, mental retardation</td> <td>Hypermetabolism, paroxysmal dyskinesia, reduced muscle mass, seizures, poor head control, difficulty sitting independently</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Idiopathic and other THCMTDs</td> <td>&nbsp;</td> <td> <ul> <li>To be determined </li> </ul> </td> <td>Unknown</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Thyroid hormone metabolism defects (THMD)</td> </tr> <tr> <td class=\"indent1\">Selenocysteine insertion sequence binding protein 2 (SBP2) defect</td> <td>&nbsp;</td> <td> <ul> <li><em>SBP2 (SECISBP2)</em><br /> gene (MIM #607693) </li> <li>Recessive </li> </ul> </td> <td>High T<sub>4</sub> and rT<sub>3</sub>, low T<sub>3</sub>, normal or slightly elevated TSH; growth retardation</td> <td>Azoospermia, immunodeficiency, photosensitivity, delayed bone maturation, myopathy, hearing impairment, delayed developmental milestones</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Idiopathic and other THMDs</td> <td>&nbsp;</td> <td> <ul> <li>To be determined </li> </ul> </td> <td>Unknown</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Thyroid hormone action defects (THAD): Nuclear receptor and other</td> </tr> <tr> <td class=\"indent1\">Resistance to thyroid hormone (RTH)*</td> <td>Thyroid hormone unresponsiveness, generalized RTH, RTH beta; Refetoff syndrome</td> <td> <ul> <li><em>THRB</em><br /> gene (MIM #190160) </li> <li>Dominant negative (rarely recessive) </li> </ul> </td> <td>High serum FT<sub>4</sub> and non suppressed TSH</td> <td>High serum FT<sub>3</sub> and rT<sub>3</sub>, high thyroglobulin, goiter, attention deficit hyperactivity disorder (ADHD), tachycardia</td> </tr> <tr> <td class=\"indent1\">nonTR-RTH<sup>&#182;</sup></td> <td>&nbsp;</td> <td> <ul> <li>Unknown </li> </ul> </td> <td>Same as above</td> <td>Same as above</td> </tr> <tr> <td class=\"indent1\">RTH alpha-1<sup>&#916;</sup></td> <td>Congenital nongoitrous hypothyroidism 6</td> <td> <ul> <li><em>THRA</em><br /> gene (MIM #190120) </li> <li>Dominant negative </li> </ul> </td> <td>Low serum T<sub>4</sub>/T<sub>3</sub> and T<sub>3</sub>/T<sub>4</sub> ratios; cognitive impairment, short lower limbs, delayed closure of skull sutures, bone and dental development, skeletal dysplasia; constipation; anemia</td> <td>Macrocephaly, seizures, placid behavior</td> </tr> <tr> <td class=\"indent1\">Hypersensitivity to thyroid hormone (HTH)</td> <td>&nbsp;</td> <td> <ul> <li>Unknown </li> </ul> </td> <td>Low FT<sub>4</sub> and FT<sub>3</sub> with normal TSH and no serum transport defects</td> <td>Normal thyroid gland</td> </tr> <tr> <td class=\"indent1\">Idiopathic and other THADs</td> <td>&nbsp;</td> <td> <ul> <li>To be determined </li> </ul> </td> <td>Unknown</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OMIM: on-line Mendelian inheritance in man; THCMTD: thyroid hormone cell membrane transport defects; MCT8: monocarboxylate transporter 8; MIM: Mendelian inheritance in man; TSH: thyroid-stimulating hormone; BMI: body mass index; THMD: thyroid hormone metabolism; SBP2: selenocysteine insertion sequence binding protein 2; THAD: thyroid hormone action defects; RTH: resistance to thyroid hormone; THRB: thyroid hormone receptor beta; ADHD: attention deficit hyperactivity disorder; THRA: thyroid hormone receptor alpha; HTH: hypersensitivity to thyroid hormone.<br />* Proposed future terminology: RTH beta.<br />&para; RTH without mutations in the <em>THRB</em> gene.<br />&Delta; Mutations in TR alpha 2 do not produce a phenotype, because this receptor does not bind thyroid hormone.</div><div class=\"graphic_reference\">Reference (published simultaneously in these journals):&#xD;&#xA;<ol>&#xD;&#xA;    <li>Refetoff S, Bassett JHD, Beck-Peccoz P, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. Thyroid 2014; 24:407.</li>&#xD;&#xA;    <li>Refetoff S, Bassett JHD, Beck-Peccoz P, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. J Clin Endocrinol Metab 2014; 99:768.</li>&#xD;&#xA;    <li>Refetoff S, Bassett JHD, Beck-Peccoz P, et al. Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism. Eur Thyroid J 2014; 3:7.</li>&#xD;&#xA;</ol>&#xD;&#xA;Republished with permission of The Endocrine Society. Copyright &copy; 2014. Permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 110783 Version 1.0</div></div></div>"},"110785":{"type":"graphic_table","displayName":"Small intestine adenoCA TNM 2017","title":"Small intestine adenocarcinoma TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Small intestine adenocarcinoma TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">High-grade dysplasia/carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the lamina propria or submucosa</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor invades the lamina propria</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor invades the submucosa</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the muscularis propria</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades through the muscularis propria into the subserosa, or extends into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration*</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor perforates the visceral peritoneum or directly invades other organs or structures (eg, other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* <em>NOTE:</em> For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">N category</td> <td class=\"subtitle2_left\" colspan=\"3\">N criteria</td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in one or two regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in three or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">M category</td> <td class=\"subtitle2_left\" colspan=\"3\">M criteria</td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis present</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Adenocarcinoma</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent2\">T1-2</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110785 Version 3.0</div></div></div>"},"110788":{"type":"graphic_table","displayName":"STRONGkids nutritional screening tool","title":"STRONGkids screening tool for assessment of nutritional risk in hospitalized children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">STRONGkids screening tool for assessment of nutritional risk in hospitalized children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td colspan=\"3\"><strong>1. High risk disease (Yes = 2 points)</strong> <ul class=\"decimal_heading\"> <li>Is there an underlying illness with a risk of malnutrition* or expected major surgery? <ul> <li>Subjective clinical assessment (1 point) </li> <li>Is the patient in a poor nutritional status judged by subjective clinical assessment (diminished subcutaneous fat and/or muscle mass and/or hollow face)? </li> </ul> </li> </ul> </td> </tr> <tr> <td colspan=\"3\"><strong>2. Nutritional intake and losses (Yes = 1 point)</strong> <ul class=\"decimal_heading\"> <li>Are one of the following items present? <ul> <li>Excessive diarrhea (&#8805;5 per day) and/or vomiting (&#62;3 times/day) the last few days? </li> <li>Reduced food intake during the last few days before admission (not including fasting for an elective procedure or surgery)? </li> <li>Pre-existing dietetically advised nutritional intervention? </li> <li>Inability to consume adequate intake because of pain? </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>3. Weight loss or poor weight gain? (Yes = 1 point)</strong> <ul class=\"decimal_heading\"> <li>Is there weight loss or no weight gain (infants &#60;year) during the last few weeks/months? </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left highlight_gray_text\" colspan=\"3\">Interpretation: Risk for malnutrition and need for intervention (per Hulst et al, 2010)</td> </tr> <tr> <td class=\"centered\">4 to 5 points</td> <td class=\"centered\">High risk</td> <td>Consult doctor and dietician for full diagnosis and individual nutritional advice and follow-up. Start prescribing sip feeds until further diagnosis.</td> </tr> <tr> <td class=\"centered\">1 to 3 points</td> <td class=\"centered\">Medium risk</td> <td>Consult doctor for full diagnosis; consider nutritional intervention with dietician. Check weight twice a week and evaluate the nutritional risk after one week.</td> </tr> <tr> <td class=\"centered\">0 points</td> <td class=\"centered\">Low risk</td> <td>No intervention necessary. Check weight regularly&nbsp;per hospital policy, and evaluate the nutritional risk after one week.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* High risk disease includes anorexia nervosa, burns, bronchopulmonary dysplasia (maximum age two years), celiac disease, cystic fibrosis, dysmaturity/prematurity (up to corrected age six months), cardiac disease (chronic), infectious disease (eg, AIDS), inflammatory bowel disease, cancer, liver disease (chronic), kidney disease (chronic), pancreatitis, short bowel syndrome, muscle disease, metabolic disease, trauma, intellectual disability, expected major surgery, not specified (classified by doctor).</div><div class=\"graphic_reference\">Reproduced from: Hult JM, Zwart H, Hop WC, Joosten KFM. Dutch national survey to test the STRONGkids nutritional risk screening tool in hospitalized children. Clinical Nutrition 2010; 29:106. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110788 Version 1.0</div></div></div>"},"110789":{"type":"graphic_figure","displayName":"Arm support supine position","title":"Arm support supine position","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Arm support supine position</div><div class=\"cntnt\"><img style=\"width:536px; height:469px;\" src=\"images/ANEST/110789_Arm_support_supine_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the arms are abducted, the padded arm board should support the upper arm at the same level as the operating table mattress, with the forearm flexed slightly, as in figure B. In figure A, the arm is positioned incorrectly, causing impingement of the upper arm, and hyperextension at the elbow.</div><div id=\"graphicVersion\">Graphic 110789 Version 1.0</div></div></div>"},"110790":{"type":"graphic_figure","displayName":"Approach to control asthma symptoms and minimize risk","title":"Stepwise approach to control asthma symptoms and minimize future risk","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Stepwise approach to control asthma symptoms and minimize future risk</div><div class=\"cntnt\"><img style=\"width:764px; height:504px;\" src=\"images/ALLRG/110790_Cntrl_asthm_symptms_min_rsk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ICS: inhaled corticosteroids; LABA: long-acting beta<SUB>2</SUB>-agonist; OCS: oral corticosteroids.<br />* For children 6 to 11 years, the preferred Step 3 treatment is medium-dose ICS.<br />¶ Not for children &lt;12 years.<br />Δ Tiotropium by mist inhaler is an add-on treatment for patients with a history of exacerbations; it is not indicated in children &lt;12 years.<br /><FONT class=lozenge>◊</FONT> Low-dose ICS/formoterol is the reliever medication for patients prescribed low-dose budesonide/formoterol or low-dose beclometasone/formoterol maintenance and reliever therapy.</div><div class=\"graphic_reference\">Reproduced with permission from: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: <A href=\"http://www.ginasthma.org/\" target=_blank>www.ginasthma.org</A> (accessed on November 15, 2016).</div><div id=\"graphicVersion\">Graphic 110790 Version 2.0</div></div></div>"},"110804":{"type":"graphic_figure","displayName":"MCC overall survival with local disease only","title":"Merkel cell carcinoma overall survival with local disease only","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma overall survival with local disease only</div><div class=\"cntnt\"><img style=\"width:636px; height:854px;\" src=\"images/ONC/110804_MerkelcellsurvAJCC2017A.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Five-year OS of 6127 patients with local Merkel cell carcinoma only (clinically and, if known, pathologically node negative) in the NCDB, stratified by T category (&le;2 cm, T1; &gt;2 cm, T2/3; involving fascia, muscle, cartilage, or bone, T4). Eleven patients with <em>in situ</em> disease (Tis) were excluded. Categories T2 (n = 1511) and T3 (n = 311) were combined because of overlapping survival curves.<br />(B) Five-year OS of 2013 patients with Merkel cell carcinoma in the NCDB with clinical staging only for local disease (cN0 pNx; ie, pathological nodal staging was not performed). Of these patients, 1272 presented with clinical stage I, 675 presented with clinical stage IIA, and 66 presented with clinical stage IIB. Survival rates of clinically staged nodal and distant metastases are not depicted; refer to Additional Factors Recommended for Clinical Care for details.</div><div class=\"graphic_footnotes\">OS: overall survival; NCDB: National Cancer Database.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110804 Version 2.0</div></div></div>"},"110807":{"type":"graphic_table","displayName":"Urethral cancer TNM 2017","title":"Urethral cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urethral cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Male penile urethra and female urethra</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent2\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent2\">Ta</td> <td colspan=\"3\">Non-invasive papillary carcinoma</td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor invades subepithelial connective tissue</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor invades any of the following: Corpus spongiosum, periurethral muscle</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor invades any of the following: Corpus cavernosum, anterior vagina</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td colspan=\"3\">Tumor invades other adjacent organs (eg, invasion of the bladder wall)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Prostatic urethra</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em> involving the prostatic urethra or periurethral or prostatic ducts without stromal invasion</td> </tr> <tr> <td class=\"indent2\">T1</td> <td colspan=\"3\">Tumor invades urethral subepithelial connective tissue immediately underlying the urothelium</td> </tr> <tr> <td class=\"indent2\">T2</td> <td colspan=\"3\">Tumor invades the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts</td> </tr> <tr> <td class=\"indent2\">T3</td> <td colspan=\"3\">Tumor invades the periprostatic fat</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4</td> <td colspan=\"3\">Tumor invades other adjacent organs (eg, extraprostatic invasion of the bladder wall, rectal wall)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"4\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Single regional lymph node metastasis in the inguinal region or true pelvis (perivesical, obturator, internal [hypogastric] and external iliac), or presacral lymph node</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Multiple regional lymph node metastasis in the inguinal region or true pelvis (perivesical, obturator, internal [hypogastric] and external iliac), or presacral lymph node</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"4\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0is</td> </tr> <tr> <td class=\"indent1\">Ta</td> <td>N0</td> <td>M0</td> <td>0a</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110807 Version 2.0</div></div></div>"},"110810":{"type":"graphic_table","displayName":"Mucosal melanoma head and neck TNM 2017","title":"Mucosal melanoma of the head and neck TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mucosal melanoma of the head and neck TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\" subtitle1_left\" colspan=\"2\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Moderately advanced or very advanced</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td>Moderately advanced disease.<br /> Tumor involving deep soft tissue, cartilage, bone, or overlying skin.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">T4b</td> <td>Very advanced disease.<br /> Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures.</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"2\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>No regional lymph node metastases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td>Regional lymph node metastases present</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"2\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>No distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td>Distant metastasis present</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110810 Version 2.0</div></div></div>"},"110814":{"type":"graphic_table","displayName":"Vulvar cancer TNM 2017","title":"Vulvar cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vulvar cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">The definitions of the T categories correspond to the stages accepted by the F&#233;d&#233;ration Internationale de Gyn&#233;cologie et d'Obst&#233;trique (FIGO). Both systems are included for comparison.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>I</td> <td colspan=\"2\">Tumor confined to the vulva and/or perineum.<br /> Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage.<br /> Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>IA</td> <td colspan=\"2\">Lesions 2 cm or less, confined to the vulva and/or perineum, and with stromal invasion of 1 mm or less</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>IB</td> <td colspan=\"2\">Lesions more than 2 cm, or any size with stromal invasion of more than 1 mm, confined to the vulva and/or perineum</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>II</td> <td colspan=\"2\">Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T3</td> <td>IVA</td> <td colspan=\"2\">Tumor of any size with extension to any of the following&#8212;upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa&#8212;or fixed to the pelvic bone</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N0(i+)</td> <td>&nbsp;</td> <td colspan=\"2\">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr> <td class=\"indent1\">N1</td> <td>III</td> <td colspan=\"2\">Regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis greater than or equal to 5 mm</td> </tr> <tr> <td class=\"indent2\">N1a*</td> <td>IIIA</td> <td colspan=\"2\">One or two lymph node metastases each less than 5 mm</td> </tr> <tr> <td class=\"indent2\">N1b</td> <td>IIIA</td> <td colspan=\"2\">One lymph node metastasis equal to 5 mm</td> </tr> <tr> <td class=\"indent1\">N2</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph node metastasis with three or more lymph node metastases each less than 5 mm, or two or more lymph node metastases equal to 5 mm, or lymph node(s) with extranodal extension</td> </tr> <tr> <td class=\"indent2\">N2a*</td> <td>IIIB</td> <td colspan=\"2\">Three or more lymph node metastases each less than 5 mm</td> </tr> <tr> <td class=\"indent2\">N2b</td> <td>IIIB</td> <td colspan=\"2\">Two or more lymph node metastases equal to 5 mm</td> </tr> <tr> <td class=\"indent2\">N2c</td> <td>IIIC</td> <td colspan=\"2\">Lymph node(s) with extranodal extension</td> </tr> <tr> <td class=\"indent1\">N3</td> <td>IVA</td> <td colspan=\"2\">Fixed or ulcerated regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><em>NOTE:</em> The site, size, and laterality of lymph node metastases should be recorded.<br /> * Includes micrometastasis, N1mi and N2mi.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis (no pathological M0; use clinical M to complete stage group)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis (including pelvic lymph node metastasis)</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N1-N2c</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N2a, N2b</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N2c</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">T1-T3</td> <td>N3</td> <td>M0-M1</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td>N3</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Vulvar melanoma is not included in this staging system; it is staged with the melanoma staging system.<br /><br />Classification of p16 status will be included if obtained but is not required.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control. </div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110814 Version 3.0</div></div></div>"},"110815":{"type":"graphic_table","displayName":"Vagina TNM 2017","title":"Cancer of the vagina TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer of the vagina TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">The definitions of the T categories correspond to the stages accepted by the F&#233;d&#233;ration Internationale de Gyn&#233;cologie et d'Obst&#233;trique (FIGO). Both systems are included for comparison.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td>&nbsp;</td> <td colspan=\"2\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td>&nbsp;</td> <td colspan=\"2\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>I</td> <td colspan=\"2\">Tumor confined to the vagina</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td>I</td> <td colspan=\"2\">Tumor confined to the vagina, measuring &#8804;2.0 cm</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td>I</td> <td colspan=\"2\">Tumor confined to the vagina, measuring &#62;2.0 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>II</td> <td colspan=\"2\">Tumor invading paravaginal tissues but not to pelvic sidewall</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td>II</td> <td colspan=\"2\">Tumor invading paravaginal tissues but not to pelvic wall, measuring &#8804;2.0 cm</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td>II</td> <td colspan=\"2\">Tumor invading paravaginal tissues but not to pelvic wall, measuring &#62;2.0 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>III</td> <td colspan=\"2\">Tumor extending to the pelvic sidewall* and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>IVA</td> <td colspan=\"2\">Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* \"Pelvic sidewall\" is defined as the muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis. On rectal examination, there is no cancer-free space between the tumor and pelvic sidewall.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td>&nbsp;</td> <td colspan=\"2\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td>&nbsp;</td> <td colspan=\"2\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N0(i+)</td> <td>&nbsp;</td> <td colspan=\"2\">Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td>III</td> <td colspan=\"2\">Pelvic or inguinal lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td><strong>FIGO stage</strong></td> <td colspan=\"2\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td>&nbsp;</td> <td colspan=\"2\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td>IVB</td> <td colspan=\"2\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T1-T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110815 Version 3.0</div></div></div>"},"110820":{"type":"graphic_table","displayName":"Treatment of bleeding in hemophilia","title":"Treatment of bleeding in hemophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of bleeding in hemophilia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Hemophilia A</td> <td class=\"subtitle1\">Hemophilia B</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Major/severe bleeding*</strong></p> Raise factor level to 80 to 100%</td> <td>Factor VIII dose of approximately 50 units/kg</td> <td>Factor IX dose of approximately 100 to 120 units/kg</td> </tr> <tr> <td> <p><strong>Hemarthrosis</strong></p> Raise factor level to 40 to 50%</td> <td>Factor VIII dose of approximately 25 units/kg</td> <td>Factor IX dose of approximately 50 to 60 units/kg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This&nbsp;table is a&nbsp;general guide and does not replace clinical judgment in determining the severity of bleeding, risk of morbidity, factor dosing, and need for other treatments. Mucosal bleeding can be treated with antifibrinolytics or local hemostatic therapies concomitantly with factor infusion. Patients with mild hemophilia A and minor bleeding may be treated with DDAVP if they have previously demonstrated a response. Patients with inhibitors may require a bypassing agent such as recombinant activated factor VII (rFVIIa) or FEIBA. Do not use antifibrinolytics with FEIBA concomitantly.&nbsp;Refer to UpToDate for additional&nbsp;information about management of bleeding in patients with hemophilia.</div><div class=\"graphic_footnotes\">FEIBA: Factor eight inhibitor bypassing agent.<br />* Examples of major bleeding include bleeding affecting the central nervous system, airway, hip, deep muscle with neurovascular injury, or abdomen; bleeding that cannot be controlled with local therapies, or bleeding necessitating transfusion.</div><div id=\"graphicVersion\">Graphic 110820 Version 1.0</div></div></div>"},"110821":{"type":"graphic_figure","displayName":"Celiac axis anatomy","title":"Celiac axis anatomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Celiac axis anatomy</div><div class=\"cntnt\"><img style=\"width:538px; height:470px;\" src=\"images/SURG/110821_Celiac_axis_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The celiac axis originates from the abdominal aorta, dividing shortly thereafter into the splenic artery and common hepatic arteries. It provides blood flow to the structures arising from the primitive foregut, including the stomach (rotated to show its posterior aspect), duodenum, spleen, and&nbsp;pancreas. </div><div class=\"graphic_footnotes\">Ant.: anterior; post.: posterior. </div><div id=\"graphicVersion\">Graphic 110821 Version 1.0</div></div></div>"},"110834":{"type":"graphic_figure","displayName":"Prognosis HCC according to size and MVI","title":"Prognostic influence of tumor size and microvascular invasion on prognosis of HCC after surgical resection, using the revised primary tumor (T) stages from the 8th edition AJCC/UICC TNM classification, 2017","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Prognostic influence of tumor size and microvascular invasion on prognosis of HCC after surgical resection, using the revised primary tumor (T) stages from the 8th edition AJCC/UICC TNM classification, 2017</div><div class=\"cntnt\"><img style=\"width:640px; height:466px;\" src=\"images/ONC/110834_ProgHCCaccordingsizeMVI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival of patients with solitary HCC according to tumor size and microvascular invasion, and new classification of HCC. Proposed new classification by stage.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; TNM: tumor, node, metastasis.</div><div class=\"graphic_reference\">Annals of Surgical Oncology, Microvascular Invasion Does Not Predict Long-Term Survival in Hepatocellular Carcinoma up to 2 cm: Reappraisal of the Staging System for Solitary Tumors, Vol. 20, 2013, p. 1223, Shindoh J, Andreou A, Aloia TA, et al, &copy; Society of Surgical Oncology 2012, with permission of Springer.</div><div id=\"graphicVersion\">Graphic 110834 Version 2.0</div></div></div>"},"110835":{"type":"graphic_table","displayName":"Hepatocellular CA TNM 2017","title":"Hepatocellular cancer TNM staging AJCC UICC 2017 ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hepatocellular cancer TNM staging AJCC UICC 2017 </div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Solitary tumor &#8804;2 cm, or &#62;2 cm without vascular invasion</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Solitary tumor &#8804;2 cm</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Solitary tumor &#62;2 cm without vascular invasion</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Solitary tumor &#62;2 cm with vascular invasion, or multiple tumors, none &#62;5 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Multiple tumors, at least one of which is &#62;5 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, Mmtastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110835 Version 2.0</div></div></div>"},"110840":{"type":"graphic_table","displayName":"Laboratories by country providing full complement workup","title":"Non-exhaustive list of laboratories providing full complement workup","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Non-exhaustive list of laboratories providing full complement workup</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Country</td> <td class=\"subtitle1\">Laboratory details</td> <td class=\"subtitle1\">Address</td> <td class=\"subtitle1\">Contact(s)</td> </tr> <tr class=\"divider_bottom\"> <td>Austria</td> <td>Division of Hygiene &#38; Medical Microbiology, Innsbruck Medical University</td> <td>Fritz-Pregl-Str. 3 A-6020, Innsbruck</td> <td>Contact: Dr. Reinhard W&#252;rzner<br /> Email: reinhard.wuerzner&#64;i-med.ac.at</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Belgium</td> <td>Clinique d'Immunobiologie, H&#244;pital Erasme, Universit&#233; Libre de Bruxelles (biochemical analysis)</td> <td>808 route de Lennik, 1070, Brussels</td> <td> <p>Contact: Dr. Patrick Stordeur<br /> Email: Patrick.Stordeur&#64;ulb.ac.be</p> Contact: Dr. F. Mascart<br /> Email: Francoise.Mascart&#64;erasme.ulb.ac.be</td> </tr> <tr class=\"divider_bottom\"> <td>Centre de G&#233;n&#233;tique Humaine, Institut de Pathologie et de G&#233;n&#233;tique (IPG) (genetic analysis)</td> <td>25 Avenue Georges Lema&#238;tre, 6041, Gosselies</td> <td> <p>Contact: Dr. Karin Dahan<br /> Email: karin.dahan&#64;ipg.be</p> Contact: Val&#233;rie Benoit<br /> Email: valerie.benoit&#64;ipg.be</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Brazil</td> <td>Immunochemistry Laboratory, Butantan Institute</td> <td>Av. Vital Brasil, 1500 - Butant&#227;, 05503-900, S&#227;o Paulo, SP</td> <td>Contact: Dr. Denise V. Tambourgi<br /> Email: denise.tambourgi&#64;butantan.gov.br</td> </tr> <tr class=\"divider_bottom\"> <td>Laboratory of Complement, Institute of Biomedical Sciences, University of S&#227;o Paulo</td> <td>Av. Prof. Lineu Prestes 1730 Cidade Universit&#225;ria, 05508-900, S&#227;o Paulo, SP</td> <td>Contact: Dr. Lourdes Isaac<br /> Email: louisaac&#64;icb.usp.br</td> </tr> <tr class=\"divider_bottom\"> <td>Canada</td> <td>Licht Lab, The Hospital for Sick Children, Research Institute, Peter Gilgan Centre for Research and Learning</td> <td>686 Bay Street, Rm. 19.9420, Bench EE-FF West, Toronto, ON M5G 0A4</td> <td>Contact: Dr. Christoph Licht<br /> Email: clicht.lab&#64;sickkids.ca</td> </tr> <tr class=\"divider_bottom\"> <td>Denmark</td> <td>Department of Biomedicine, University of Aarhus</td> <td>Bartholins All&#233; 6, 8000, Aarhus C</td> <td>Contact: Dr. Steffen Thiel<br /> Email: st&#64;microbiology.au.dk</td> </tr> <tr class=\"divider_bottom\"> <td>Finland</td> <td>Department of Bacteriology and Immunology, Haartman Institute</td> <td>Haartmaninkatu 3 (P.O. Box 21) FIN-00014 University of Helsinki, Helsinki</td> <td>Contact: Dr. Seppo Meri<br /> Email: seppo.meri&#64;helsinki.fi</td> </tr> <tr class=\"divider_bottom\"> <td>France</td> <td>H&#244;pital Europ&#233;en Georges Pompidou, Laboratoire d'Immunologie</td> <td>20-40 rue Leblanc, 75908 Paris Cedex 15, Paris</td> <td>Contact: Dr. Veronique Fremeaux-Bacchi<br /> Email: veronique.fremeaux-bacchi&#64;aphp.fr</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Germany</td> <td>Institute of Immunology, University of Heidelberg</td> <td>Im Neuenheimer Feld 305, 69120, Heidelberg</td> <td>Contact: Dr. Michael Kirschfink<br /> Email: kirschfink&#64;uni-hd.de</td> </tr> <tr class=\"divider_bottom\"> <td>Leibniz Institute for Natural Product Research and Infection Biology</td> <td>Adolf-Reichwein Strasse 23, D- 07745, Jena</td> <td> <p>Contact: Dr. Peter F. Zipfel<br /> Email: peter.zipfel&#64;leibniz-hki.de</p> Contact: Prof. Christine Skerka<br /> Email: christine.skerka&#64;leibniz-hki.de</td> </tr> <tr class=\"divider_bottom\"> <td>Hungary</td> <td>Institute of Enzymology, Biological Research Center</td> <td>Hungarian Academy of Sciences, Budapest, H-1518</td> <td>Contact: Dr. P&#233;ter G&#225;l<br /> Email: gal&#64;enzim.hu</td> </tr> <tr class=\"divider_bottom\"> <td>Israel</td> <td>Department of Cell &#38; Developmental Biology, Sackler School of Medicine</td> <td>Tel Aviv University, Chaim Levanon Street, Tel Aviv, 69978</td> <td>Contact: Dr. Zvi Fishelson<br /> Email: lifish&#64;post.tau.ac.il</td> </tr> <tr class=\"divider_bottom\"> <td>Italy</td> <td>Mario Negri Institute for Pharmacological Research</td> <td>Via Gavazzeni 11, 24125, Bergamo</td> <td> <p>Contact: Dr. Giuseppe Remuzzi<br /> Email: gremuzzi&#64;marionegri.it</p> Contact: Dr. Marina Noris<br /> Email: noris&#64;marionegri.it</td> </tr> <tr class=\"divider_bottom\"> <td>Japan</td> <td>Division of Nephrology and Endocrinology, the University of Tokyo Graduate School of Medicine/Working group of aHUS in Japan (biochemical and genetic analysis)</td> <td>7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655</td> <td>Contact: Dr. Masaomi Nangaku and Dr. Hideki Kato<br /> Email: ahus-office&#64;umin.ac.jp</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">The Netherlands</td> <td>Department of Rheumatology, C1-R</td> <td>Leiden University Medical Center, Postbus 9600, 2300 RC Leiden</td> <td>Contact: Dr. Leendert Trouw<br /> Email: L.A.Trouw&#64;lumc.nl</td> </tr> <tr class=\"divider_bottom\"> <td>Clinical Genetics Centre Nijmegen, Unit Complement-Mediated Disorders</td> <td>Radboud University Medical Center, Translational Metabolic Laboratory (830), Geert Grooteplein Zuid 10, 6525 GA, Nijmegen</td> <td> <p>Contact: Dr. Lambertus P. van den Heuvel<br /> Email: Bert.vandenHeuvel&#64;radboudumc.nl</p> Contact: Dr. Elena B. Volokhina<br /> Email: Elena.Volokhina&#64;radboudumc.nl</td> </tr> <tr class=\"divider_bottom\"> <td>Norway</td> <td>Department of Immunology, Oslo University Hospital</td> <td>Rikshospitalet, NO-0027, Oslo</td> <td>Contact: Dr. Tom E. Mollnes<br /> Email: t.e.mollnes&#64;medisin.uio.no</td> </tr> <tr class=\"divider_bottom\"> <td>South Africa</td> <td>NHLS Immunology Unit Tygerberg, Stellenbosch University</td> <td>P.O. Box 19063 Tygerberg 7505, Faculty of Medicine and Health Sciences Stellenbosch University (Tygerberg Campus), Francie Van Zijl Avenue, Parow, Western Cape</td> <td>Contact: Dr. Monika Esser<br /> Email: monika&#64;sun.ac.za</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Spain</td> <td>Laboratory of Complement Genetics and Molecular Pathology, Centro de Investigaciones Biologicas</td> <td>Department of Cellular and Molecular Medicine, Centro de Investigaciones Biologicas, Ramiro de Maeztu 9, 28040, Madrid</td> <td> <p>Contact: Dr. Santiago Rodriguez de Cordoba<br /> Email: srdecordoba&#64;cib.csic.es</p> Contact: Emi Arjona<br /> Email: earjona&#64;cib.csic.es</td> </tr> <tr class=\"divider_bottom\"> <td>Unidad de Inmunolog&#237;a, Hospital Universitario La Paz</td> <td>Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid</td> <td>Contact: Dr. Margarita L&#243;pez Trascasa<br /> Email: mltrascasa&#64;salud.madrid.org</td> </tr> <tr class=\"divider_bottom\"> <td>Sweden</td> <td>Department of Immunology, Genetics and Pathology, Clinical Immunology</td> <td>Rudbecklaboratoriet, Dag Hammarskj&#246;lds v&#228;g 20, 752 37, Uppsala</td> <td>Contact: Dr. Bo Nilsson<br /> Email: bo.nilsson&#64;igp.uu.se</td> </tr> <tr class=\"divider_bottom\"> <td>Switzerland</td> <td>Department of Biomedicine, University Hospital Basel</td> <td>Hebelstrasse 20 CH - 4031, Basel</td> <td>Contact: Dr. Marten Trendelenburg<br /> Email: marten.trendelenburg&#64;unibas.ch</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">United Kingdom</td> <td>Centre for Complement and Inflammation Research, Imperial College</td> <td>Hammersmith Campus, Du Cane Road, London, W12 0NN</td> <td>Contact: Dr. Matthew Pickering<br /> Email: matthew.pickering&#64;imperial.ac.uk</td> </tr> <tr> <td>Department of Infection of Immunity, Imperial College Healthcare NHS Trust</td> <td>Charing Cross Hospital, Fulham Palace Road, London, W6 8RF</td> <td> <p>Contact: Dr. Pantelidis Panagiotis<br /> Email: Panagiotis.Pantelidis2&#64;imperial.nhs.uk</p> Contact: Dr. Peter Kelleher<br /> Email: william.kelleher&#64;imperial.nhs.uk</td> </tr> <tr class=\"divider_bottom\"> <td>Northern Genetic Service, National Health Service</td> <td>Central Parkway, Newcastle upon Tyne, Tyne and Wear, NE1 3BZ</td> <td>Contact: Dr. Tim H. J. Goodship<br /> Email: t.h.j.goodship&#64;ncl.ac.uk</td> </tr> <tr> <td rowspan=\"4\">United States</td> <td>Molecular Otolaryngology Research Laboratories (MORL)</td> <td>Department of Otolaryngology, 200 Hawkins Dr., 21151-A PFP, Iowa City, IA 52242-1078</td> <td> <p>Contact: Dr. Richard J. H. Smith<br /> Email: richard-smith&#64;uiowa.edu</p> Contact: Amy Weaver<br /> Email: amy-weaver&#64;uiowa.edu</td> </tr> <tr> <td>Mayo Clinic, Clinical Biochemistry</td> <td>200 First St. SW, Rochester, MN 55905</td> <td>Contact: Dr. David L. Murray<br /> Email: Murray.David&#64;mayo.edu</td> </tr> <tr> <td>National Jewish Health</td> <td>1400 Jackson Street, Denver, CO 80206</td> <td>Contact: Dr. Patricia C. Giclas<br /> Email: giclasp&#64;njc.org</td> </tr> <tr> <td>Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center (CCHMC)</td> <td>Attn Lab processing, B-4 (HT-4), 3333 Burnet Ave, Cincinnati, OH 45229</td> <td>Contact: Dr. Prasad Devarajan<br /> Email: Prasad.Devarajan&#64;cchmc.org</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 110840 Version 1.0</div></div></div>"},"110841":{"type":"graphic_table","displayName":"Intrapartum management and infant prophylaxis","title":"Intrapartum management and infant prophylaxis for HIV-infected pregnant women in resource-rich settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intrapartum management and infant prophylaxis for HIV-infected pregnant women in resource-rich settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Treatment and viral load status of the mother</td> <td class=\"subtitle1\" colspan=\"3\">Received antepartum ART</td> <td class=\"subtitle1\" rowspan=\"2\">No antepartum ART*</td> </tr> <tr> <td class=\"subtitle2\">Undetectable VL near time of delivery</td> <td class=\"subtitle2\">Detectable but &#8804;1000 copies/mL near time of delivery</td> <td class=\"subtitle2\">&#62;1000 copies/mL near time of delivery</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Risk for HIV transmission</strong></td> <td>Lowest risk</td> <td>Low risk</td> <td>High risk</td> <td>High risk</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Preferred delivery mode</strong></td> <td>Determined by obstetric indications</td> <td>Determined by obstetric indications</td> <td>Scheduled cesarean delivery at 38 weeks</td> <td>Cesarean delivery, if possible<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intrapartum antiretrovirals</strong></td> <td>Continue baseline ART regimen<sup>&#916;</sup></td> <td>Continue baseline ART regimen<sup>&#916;</sup></td> <td>Continue baseline ART regimen plus intravenous zidovudine<sup>&#9674;</sup></td> <td>Intravenous zidovudine<sup>&#9674;</sup></td> </tr> <tr> <td><strong>Infant antiretroviral prophylaxis<sup>&#167;</sup></strong></td> <td>4 to 6 weeks of zidovudine</td> <td>4 to 6 weeks of zidovudine or combination prophylaxis<sup>&#165;</sup></td> <td>Combination prophylaxis</td> <td>Combination prophylaxis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table reflects the general principles of intrapartum management and infant antiretroviral prophylaxis for HIV-infected pregnant women.</div><div class=\"graphic_footnotes\">ART: antiretroviral therapy.<br />* Women who present in labor with unknown HIV status (or a prior negative test with subsequent risk factors for HIV infection) should undergo rapid combination antibody/antigen HIV testing. If this test is positive, the woman and her infant should be managed as high risk for HIV transmission (having had&nbsp;no antepartum ART) while awaiting confirmatory testing.<br />¶ For women who did not receive ART and present in labor or with ruptured membranes, management delivery must be individualized and take into account the duration of the rupture of membranes/labor and HIV RNA level, if known.<br />Δ Clinicians may reasonably add intrapartum zidovudine for such patients, particularly if there were concerns about adherence to ART during pregnancy.<br /><FONT class=lozenge>◊</FONT> Intrapartum zidovudine is administered intravenously with a 2 mg/kg dose followed by a continuous infusion of 1 mg/kg/hour until delivery. For women undergoing scheduled cesarean delivery, zidovudine is initiated three hours before the procedure. For women who present in labor and have not received antepartum ART, intravenous zidovudine should be administered immediately.<br />§ Refer to other UpToDate content&nbsp;for specifics on regimens and dosing for infant antiretroviral prophylaxis.<br />¥ The decision to use zidovudine or combination infant prophylaxis in this setting depends on individual circumstances and the presence of other features that might increase the risk of HIV transmission. Data informing this decision are limited.</div><div id=\"graphicVersion\">Graphic 110841 Version 1.0</div></div></div>"},"110845":{"type":"graphic_figure","displayName":"RETREAT score to estimate recurrence risk HCC liver transplant","title":"RETREAT (Risk Estimation of Tumor Recurrence After Transplant) score for hepatocellular carcinoma recurrence after liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">RETREAT (Risk Estimation of Tumor Recurrence After Transplant) score for hepatocellular carcinoma recurrence after liver transplantation</div><div class=\"cntnt\"><img style=\"width:711px; height:614px;\" src=\"images/ONC/110845_RETREAT_score_HCC_liver_trn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For panel B and panel C, the C statistic was 0.77 for the development cohort and 0.82 for the validation cohort.</div><div class=\"graphic_footnotes\">HR: hazard ratio; AFP: alpha-fetoprotein level; LT: liver transplant; NA: not applicable.<br />* The RETREAT score is obtained by adding the total number of points scored in each of the three variables (range: 0 to 8). RETREAT score = 0, if a patient has an AFP of 0 to 20 ng/mL at LT, no microvascular invasion, and no viable tumor in the explant.<br />¶ For example, if there are three lesions on the explant, two viable lesions measuring 4 cm and 3 cm, and a single completely necrotic lesion measuring 5 cm, the completely necrotic lesion is not counted, and the sum of the largest diameter of the viable tumor (cm) and the number of viable tumors would be 6 (4 [diameter of largest lesion] + 2 [number of viable tumors]). Explant largest viable tumor diameter + number = 0, if no viable tumor is identified.</div><div class=\"graphic_reference\">Reproduced with permission from: Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol 2016. DOI:10.1001/jamaoncol.2016.5116. Copyright © 2016 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110845 Version 2.0</div></div></div>"},"110846":{"type":"graphic_figure","displayName":"Pediatric suicide safety plan","title":"Pediatric suicide safety plan","html":"<div class=\"graphic\"><div style=\"width: 718px\" class=\"figure\"><div class=\"ttl\">Pediatric suicide safety plan</div><div class=\"cntnt\"><img style=\"width:698px; height:570px;\" src=\"images/PSYCH/110846_Pedssuicidesafetyplan.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Patient safety plan template. ​Available at: <A href=\"http://www.sprc.org/sites/default/files/Brown_StanleySafetyPlanTemplate.pdf\">http://www.sprc.org/sites/default/files/Brown_StanleySafetyPlanTemplate.pdf</A> (Accessed on November 29, 2017).</LI>&#xD;&#xA;<LI>Samra J, Bilsker D. Coping with suicidal thoughts. Consortium for Organizational Mental Health 2007. Available at: <A href=\"http://www.comh.ca/publications/resources/pub_cwst/cwst.pdf\" target=_blank>http://www.comh.ca/publications/resources/pub_cwst/cwst.pdf</A> (Accessed on November 16, 2016).</LI>&#xD;&#xA;<LI>Stanley B, Brown G, Brent DA, et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 2009; 48:1005.</LI></OL></div><div id=\"graphicVersion\">Graphic 110846 Version 3.0</div></div></div>"},"110847":{"type":"graphic_table","displayName":"GIST TNM 2017","title":"GIST TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GIST TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"5\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"4\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"4\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"4\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"4\">Tumor 2 cm or less</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"4\">Tumor more than 2 cm but not more than 5 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"4\">Tumor more than 5 cm but not more than 10 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"4\">Tumor more than 10 cm in greatest dimension</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"4\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"4\">No regional lymph node metastasis or unknown lymph node status</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"4\">Regional lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"4\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"4\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"4\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Mitotic rate</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Mitotic rate</strong></td> <td colspan=\"4\"><strong>Definition</strong></td> </tr> <tr> <td class=\"indent1\">Low</td> <td colspan=\"4\">Five or fewer mitoses per 5 mm<sup>2</sup>, or per 50 HPF</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">High</td> <td colspan=\"4\">Over five mitoses per 5 mm<sup>2</sup>, or per 50 HPF</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Gastric and omental GIST</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>And mitotic rate is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1 or T2</td> <td>N0</td> <td>M0</td> <td>Low</td> <td>IA</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>Low</td> <td>IB</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>High</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>High</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>Low</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>High</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>High</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N1</td> <td>M0</td> <td>Any rate</td> <td>IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>Any rate</td> <td>IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"5\">Small intestinal, esophageal, colorectal, mesenteric, and peritoneal GIST</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>And mitotic rate is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">T1 or T2</td> <td>N0</td> <td>M0</td> <td>Low</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>Low</td> <td>II</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>High</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>Low</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T2</td> <td>N0</td> <td>M0</td> <td>High</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T3</td> <td>N0</td> <td>M0</td> <td>High</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>High</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>N1</td> <td>M0</td> <td>Any rate</td> <td>IV</td> </tr> <tr> <td class=\"indent2\">Any T</td> <td>Any N</td> <td>M1</td> <td>Any rate</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GIST: gastrointestinal stromal tumor; TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; HPF: high-power field.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110847 Version 2.0</div></div></div>"},"110848":{"type":"graphic_table","displayName":"Breast carcinoma TNM anatomic stage groups 2017","title":"Breast carcinoma TNM anatomic stage group AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast carcinoma TNM anatomic stage group AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">When T is...</td> <td class=\"subtitle1\">And N is...</td> <td class=\"subtitle1\">And M is...</td> <td class=\"subtitle1\">Then the stage group is...</td> </tr> <tr class=\"divider_bottom\"> <td>Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>T1</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>T0</td> <td>N1mi</td> <td>M0</td> <td>IB</td> </tr> <tr class=\"divider_bottom\"> <td>T1</td> <td>N1mi</td> <td>M0</td> <td>IB</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>T0</td> <td>N1</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td>T1</td> <td>N1</td> <td>M0</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>T2</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>T2</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>T3</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>T0</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td>T1</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td>T2</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>T3</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td>T4</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>T4</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Any T</td> <td>N3</td> <td>M0</td> <td>IIIC</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>The anatomic stage group table should only be used in global regions where biomarker tests are not routinely available.</li>&#xD;&#xA;    <li>Cancer registries in the US must use the prognostic stage group table for case reporting.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110848 Version 3.0</div></div></div>"},"110850":{"type":"graphic_table","displayName":"Risk profile and associated survival outcomes","title":"Risk profile and associated survival outcomes, MD Anderson validation of biomarkers in TNM eighth edition staging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk profile and associated survival outcomes, MD Anderson validation of biomarkers in TNM eighth edition staging</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Five-year DSS<br /> (%)</td> <td class=\"subtitle1\" colspan=\"2\">Univariate analysis</td> <td class=\"subtitle1\" colspan=\"2\">Multivariate analysis 2</td> <td class=\"subtitle1\" rowspan=\"2\">Assigned points</td> </tr> <tr> <td class=\"subtitle2\">HR</td> <td class=\"subtitle2\"><em>p</em></td> <td class=\"subtitle2\">HR</td> <td class=\"subtitle2\"><em>p</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"7\">Pathological stage</td> </tr> <tr> <td class=\"indent1\">I</td> <td>99.1</td> <td>Referent</td> <td>&nbsp;</td> <td>Referent</td> <td>&nbsp;</td> <td>0</td> </tr> <tr> <td class=\"indent1\">IIA</td> <td>98.0</td> <td>2.8</td> <td>0.002</td> <td>2.3</td> <td>0.01</td> <td>1</td> </tr> <tr> <td class=\"indent1\">IIB</td> <td>95.6</td> <td>4.8</td> <td>&#60;0.0001</td> <td>4.0</td> <td>&#60;0.0001</td> <td>2</td> </tr> <tr> <td class=\"indent1\">IIIA</td> <td>95.4</td> <td>6.8</td> <td>&#60;0.0001</td> <td>7.2</td> <td>&#60;0.0001</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">IIIC</td> <td>79.5</td> <td>26.6</td> <td>&#60;0.0001</td> <td>19.9</td> <td>&#60;0.0001</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"7\">Nuclear grade</td> </tr> <tr> <td class=\"indent1\">I</td> <td>99.8</td> <td>Referent</td> <td>&nbsp;</td> <td>Referent</td> <td>&nbsp;</td> <td>0</td> </tr> <tr> <td class=\"indent1\">II</td> <td>98.9</td> <td>5.0</td> <td>0.1</td> <td>4.0</td> <td>0.2</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">III</td> <td>95.3</td> <td>25.0</td> <td>0.001</td> <td>13.1</td> <td>0.01</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"7\">ER status</td> </tr> <tr> <td class=\"indent1\">Positive</td> <td>98.8</td> <td>Referent</td> <td>&nbsp;</td> <td>Referent</td> <td>&nbsp;</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Negative</td> <td>92.9</td> <td>4.9</td> <td>&#60;0.0001</td> <td>2.5</td> <td>0.001</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"7\">PR status</td> </tr> <tr> <td class=\"indent1\">Positive</td> <td>98.8</td> <td>Referent</td> <td>&nbsp;</td> <td>Referent</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Negative</td> <td>95.2</td> <td>4.0</td> <td>&#60;0.0001</td> <td>&nbsp;</td> <td>NS</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"7\">HER2 status</td> </tr> <tr> <td class=\"indent1\">Positive</td> <td>97.5</td> <td>Referent</td> <td>&nbsp;</td> <td>Referent</td> <td>&nbsp;</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Negative</td> <td>98.0</td> <td>0.8</td> <td>0.5</td> <td>2.2</td> <td>0.04</td> <td>1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\" colspan=\"3\">0 points</td> <td class=\"subtitle1\" colspan=\"3\">1 point</td> </tr> <tr> <td>Grade</td> <td colspan=\"3\">Grade 1/2</td> <td colspan=\"3\">Grade 3</td> </tr> <tr> <td>ER status</td> <td colspan=\"3\">ER positive</td> <td colspan=\"3\">ER negative</td> </tr> <tr class=\"divider_bottom\"> <td>HER2 status</td> <td colspan=\"3\">HER2 positive</td> <td colspan=\"3\">HER2 negative</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Risk profile</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Five-year DSS<br /> (%)</td> <td class=\"subtitle1\">95% CI</td> <td class=\"subtitle1\">Five-year OS<br /> (%)</td> <td class=\"subtitle1\">95% CI</td> </tr> <tr> <td rowspan=\"4\">I (IA and IB)</td> <td>0</td> <td>36</td> <td>100</td> <td>&nbsp;</td> <td>97</td> <td>80.4-99.6</td> </tr> <tr> <td>1</td> <td>1173</td> <td>99.4</td> <td>98.7-99.7</td> <td>96.7</td> <td>95.4-97</td> </tr> <tr> <td>2</td> <td>274</td> <td>98.8</td> <td>96.4-99.6</td> <td>94.6</td> <td>91-96.8</td> </tr> <tr> <td>3</td> <td>119</td> <td>96.6</td> <td>91.1-98.7</td> <td>93.8</td> <td>87.5-97</td> </tr> <tr> <td rowspan=\"4\">IIA</td> <td>0</td> <td>31</td> <td>100</td> <td>&nbsp;</td> <td>96.8</td> <td>79.2-99.5</td> </tr> <tr> <td>1</td> <td>634</td> <td>99.4</td> <td>97.5-99.8</td> <td>97.1</td> <td>94.7-98.4</td> </tr> <tr> <td>2</td> <td>236</td> <td>97.5</td> <td>93.2-99.1</td> <td>94.1</td> <td>88.7-97</td> </tr> <tr> <td>3</td> <td>98</td> <td>91</td> <td>81.8-95.7</td> <td>88.2</td> <td>78.5-93.8</td> </tr> <tr> <td rowspan=\"4\">IIB</td> <td>0</td> <td>11</td> <td>100</td> <td>&nbsp;</td> <td>100</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>309</td> <td>96.9</td> <td>92.6-98.8</td> <td>94.6</td> <td>89.6-97.2</td> </tr> <tr> <td>2</td> <td>107</td> <td>92.9</td> <td>83.6-97.1</td> <td>89.3</td> <td>80.1-94.4</td> </tr> <tr> <td>3</td> <td>40</td> <td>91.5</td> <td>75.6-97.2</td> <td>91.5</td> <td>75.6-97.2</td> </tr> <tr> <td rowspan=\"4\">IIIA</td> <td>0</td> <td>3</td> <td>100</td> <td>&nbsp;</td> <td>100</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>134</td> <td>98.3</td> <td>88.2-99.8</td> <td>91.5</td> <td>82.6-96</td> </tr> <tr> <td>2</td> <td>50</td> <td>92.2</td> <td>77.2-97.5</td> <td>90.3</td> <td>75.7-96.3</td> </tr> <tr> <td>3</td> <td>7</td> <td>68.6</td> <td>21.3-91.2</td> <td>68.6</td> <td>21.3-91.2</td> </tr> <tr> <td rowspan=\"4\">IIIC</td> <td>0</td> <td>0</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>1</td> <td>39</td> <td>92.2</td> <td>72.1-98.0</td> <td>84.4</td> <td>63.7-93.9</td> </tr> <tr> <td>2</td> <td>16</td> <td>80.8</td> <td>51.4-93.4</td> <td>80.8</td> <td>51.4-93.4</td> </tr> <tr> <td>3</td> <td>10</td> <td>33.3</td> <td>6.3-64.6</td> <td>33.3</td> <td>6.3-64.6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110850 Version 4.0</div></div></div>"},"110851":{"type":"graphic_table","displayName":"Breast carcinoma TNM prognostic stage groups 2017","title":"Breast carcinoma TNM prognostic stage group AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breast carcinoma TNM prognostic stage group AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">When TNM is...</td> <td class=\"subtitle1\">And grade is...</td> <td class=\"subtitle1\">And HER2 status is...</td> <td class=\"subtitle1\">And ER status is...</td> <td class=\"subtitle1\">And PR status is...</td> <td class=\"subtitle1\">Then the clinical prognostic stage group is...</td> </tr> <tr class=\"divider_bottom\"> <td>Tis N0 M0</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>0</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T1* N0 M0</p> <p>T0 N1mi M0</p> T1* N1mi M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T1* N0 M0</p> <p>T0 N1mi M0</p> T1* N1mi M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <t /> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T1* N0 M0</p> <p>T0 N1mi M0</p> T1* N1mi M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IA</td> </tr> <tr> <td>Negative</td> <td>IB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IB</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T0 N1<sup>&#182;</sup> M0</p> <p>T1* N1<sup>&#182;</sup> M0</p> T2 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T0 N1<sup>&#182;</sup> M0</p> <p>T1* N1<sup>&#182;</sup> M0</p> T2 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <t /> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T0 N1<sup>&#182;</sup> M0</p> <p>T1* N1<sup>&#182;</sup> M0</p> T2 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T2 N1<sup>&#916;</sup> M0</p> T3 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T2 N1<sup>&#916;</sup> M0</p> T3 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <t /> <tr> <td>Negative</td> <td>IIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T2 N1<sup>&#916;</sup> M0</p> T3 N0 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IB</td> </tr> <tr> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIB</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T0 N2 M0</p> <p>T1* N2 M0</p> <p>T2 N2 M0</p> <p>T3 N1<sup>&#916;</sup> M0</p> T3 N2 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T0 N2 M0</p> <p>T1* N2 M0</p> <p>T2 N2 M0</p> <p>T3 N1<sup>&#916;</sup> M0</p> T3 N2 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <t /> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIA</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T0 N2 M0</p> <p>T1* N2 M0</p> <p>T2 N2 M0</p> <p>T3 N1<sup>&#916;</sup> M0</p> T3 N2 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIB</td> </tr> <tr> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIA</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIA</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T4 N0 M0</p> <p>T4 N1<sup>&#916;</sup> M0</p> <p>T4 N2 M0</p> Any T N3 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G1</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIB</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T4 N0 M0</p> <p>T4 N1<sup>&#916;</sup> M0</p> <p>T4 N2 M0</p> Any T N3 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G2</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIA</td> </tr> <t /> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIB</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"> <p>T4 N0 M0</p> <p>T4 N1<sup>&#916;</sup> M0</p> <p>T4 N2 M0</p> Any T N3 M0</td> <td class=\"divider_bottom\" rowspan=\"8\">G3</td> <td class=\"divider_bottom\" rowspan=\"4\">Positive</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIB</td> </tr> <tr> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIB</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Negative</td> <td rowspan=\"2\">Positive</td> <td>Positive</td> <td>IIIB</td> </tr> <tr> <td>Negative</td> <td>IIIC</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Negative</td> <td>Positive</td> <td>IIIC</td> </tr> <tr class=\"divider_bottom\"> <td>Negative</td> <td>IIIC</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"small divider_bottom\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td>Any T Any N M1</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>Any</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><EM>NOTES:</EM> &#xD;&#xA;<OL>&#xD;&#xA;<LI>Because N1mi categorization requires evaluation of the entire node, and cannot be assigned on the basis of an FNA or core biopsy, N1mi can only be used with the clinical prognostic staging when clinical staging is based on a resected lymph node in the absence of resection of the primary cancer, such as the situation where sentinel node biopsy is performed prior to receipt of neoadjuvant chemotherapy or endocrine therapy.</LI>&#xD;&#xA;<LI>For cases with lymph node involvement with no evidence of primary tumor (eg, T0 N1, etc) or with breast ductal carcinoma <EM>in situ</EM> (eg, Tis N1, etc), the grade, HER2, ER, and PR information from the tumor in the lymph node should be used for assigning stage group.</LI>&#xD;&#xA;<LI>For cases where HER2 is determined to be \"equivocal\" by ISH (FISH or CISH) testing under the 2013 ASCO/CAP HER2 testing guidelines, the HER2 \"negative\" category should be used for staging in the clinical prognostic stage group table.</LI>&#xD;&#xA;<LI>The prognostic value of these prognostic stage groups is based on populations of persons with breast cancer that have been offered and mostly treated with appropriate endocrine and/or systemic chemotherapy (including anti-HER2 therapy).</LI></OL></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.<br />* T1 includes T1mi.<br />&para; N1 does not include N1mi. T1 N1mi M0 and T0 N1mi M0 cancers are included for prognostic staging with T1 N0 M0 cancers of the same prognostic factor status.<br />&Delta; N1 includes N1mi. T2, T3, and T4 cancers and N1mi are included for prognostic staging with T2 N1, T3 N1, and T4 N1, respectively.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Corrected at 3rd printing, 2017.</div><div id=\"graphicVersion\">Graphic 110851 Version 4.0</div></div></div>"},"110852":{"type":"graphic_table","displayName":"Dindo-Clavien classification of surgical complications","title":"Dindo-Clavien classification of surgical complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dindo-Clavien classification of surgical complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td class=\"centered\">Grade I</td> <td>Any deviation from the normal postoperative course without the need for pharmacologic treatment or surgical, endoscopic, and radiological interventions. <ul class=\"decimal_heading\"> <li>Allowed therapeutic regimens are drugs as antiemetics, antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. </li> <li>This grade also includes wound infections opened at the bedside. </li> </ul> </td> </tr> <tr> <td class=\"centered\">Grade II</td> <td>Requiring pharmacologic treatment with drugs other than such allowed for grade I complications. <ul class=\"decimal_heading\"> <li>Blood transfusions and total parenteral nutrition are also included. </li> </ul> </td> </tr> <tr> <td class=\"centered\">Grade IIIa</td> <td>Requiring surgical, endoscopic, or radiological intervention <strong>not</strong> under general anesthesia.</td> </tr> <tr> <td class=\"centered\">Grade IIIb</td> <td>Requiring surgical, endoscopic, or radiological intervention under general anesthesia.</td> </tr> <tr> <td class=\"centered\">Grade IVa</td> <td>Life-threatening complication (including CNS complications)* requiring IC/ICU management, single organ dysfunction (including dialysis).</td> </tr> <tr> <td class=\"centered\">Grade IVb</td> <td>Life-threatening complication (including CNS complications)* requiring IC/ICU management, multiorgan dysfunction.</td> </tr> <tr> <td class=\"centered\">Grade V</td> <td>Death.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; IC: intermediate care; ICU: intensive care unit.<br />​* Brain hemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding transient ischemic attacks.</div><div class=\"graphic_reference\">From: Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205. Copyright © 2004 American Surgical Association and European Surgical Association. Modified with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110852 Version 1.0</div></div></div>"},"110853":{"type":"graphic_table","displayName":"Medications treatment of lower urinary symptoms in BPH","title":"Medications used to treat lower urinary symptoms attributed to benign prostatic hyperplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications used to treat lower urinary symptoms attributed to benign prostatic hyperplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Medication</td> </tr> <tr class=\"divider_bottom\"> <td>Alpha-1 blockers (ABs)</td> <td> <ul> <li>Silodosin (Rapaflo) </li> <li>Terazosin (Hytrin) </li> <li>Alfuzosin (Uroxatral) </li> <li>Doxazosin (Cardura) </li> <li>Tamsulosin (Flomax) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>5-alpha-reductase inhibitors (5-ARIs)</td> <td> <ul> <li>Finasteride (Proscar) </li> <li>Dutasteride (Avodart) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Anticholinergic agents</td> <td> <ul> <li>Oxybutynin (Oxytrol) </li> <li>Fesoterodine (Toviaz) </li> <li>Darifenacin (Enablex) </li> <li>Tolterodine (Detrol, Detrol LA) </li> <li>Solifenacin (VESIcare) </li> <li>Trospium (Sanctura) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Beta-3 adrenergic agonist</td> <td> <ul> <li>Mirabegron (Myrbetriq) </li> </ul> </td> </tr> <tr> <td>Phosphodiesterase type 5 (PDE-5) inhibitors</td> <td> <ul> <li>Tadalafil (Cialis) </li> <li>Sildenafil (Viagra) </li> <li>Avanafil (Stendra) </li> <li>Vardenafil (Staxyn, Levitra) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Brasure M, MacDonald R, Dahm P, et al. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: A review. Comparative Effectiveness Review No. 178, AHRQ Publication No. 16-EHC024-EF, Agency for Healthcare Research and Quality, Rockville, MD 2016.</div><div id=\"graphicVersion\">Graphic 110853 Version 2.0</div></div></div>"},"110855":{"type":"graphic_picture","displayName":"Skin lesion associated with coccidioidomycosis","title":"Skin lesion associated with coccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Skin lesion associated with coccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/ID/110855_Skin_lesion_coccidioidomycs.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Joanne N. Engel, MD, Ph.D.</div><div id=\"graphicVersion\">Graphic 110855 Version 1.0</div></div></div>"},"110856":{"type":"graphic_diagnosticimage","displayName":"Acute cholestatic hepatitis biopsy","title":"Acute cholestatic hepatitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acute cholestatic hepatitis</div><div class=\"cntnt\"><img style=\"width:756px; height:487px;\" src=\"images/GAST/110856_Acute_cholestatic_hep_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An arrow points to a dilated canaliculus that contains inspissated bile. There is extensive feathery degeneration of hepatocytes (delineated by asterisks).</div><div id=\"graphicVersion\">Graphic 110856 Version 1.0</div></div></div>"},"110857":{"type":"graphic_picture","displayName":"Idiopathic noncirrhotic portal hypertension biopsy","title":"Idiopathic noncirrhotic portal hypertension","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Idiopathic noncirrhotic portal hypertension</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/GAST/110857_Idpthc_noncirrhtc_hypertnsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reticulin stain delineates condensed reticulin fibers (arrows) that represent the atrophic hepatocyte plates. These atrophic plates surround the regenerating hepatocytes in the center, resulting in the formation of a nodule, but without fibrosis.</div><div id=\"graphicVersion\">Graphic 110857 Version 1.0</div></div></div>"},"110858":{"type":"graphic_diagnosticimage","displayName":"Hemochromatosis sarcoidosis biopsy","title":"Hemochromatosis and sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Hemochromatosis and sarcoidosis</div><div class=\"cntnt\"><img style=\"width:756px; height:561px;\" src=\"images/GAST/110858_Hemochromatosis_srcdss_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy showing an epithelioid granuloma (thick arrow). The arrow points at several sclerotic granulomas as represented by dense collagen tissue with rounded borders. Fibrosis is also seen (thin arrow). Schaumman bodies within multinucleated cells are present. Note that there is also mild steatosis in the background.</div><div id=\"graphicVersion\">Graphic 110858 Version 1.0</div></div></div>"},"110859":{"type":"graphic_picture","displayName":"Cutaneous polyarteritis nodosa histopathology","title":"Cutaneous polyarteritis nodosa","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Cutaneous polyarteritis nodosa</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/110859_Ctns_plyartrts_nodosa_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrinoid necrosis of a medium-sized muscular artery in the deep dermis with disruption of the internal elastic lamina, neutrophilic inflammation, and leukocytoclasis.</div><div class=\"graphic_reference\">Courtesy of Robert G. Micheletti, MD.</div><div id=\"graphicVersion\">Graphic 110859 Version 1.0</div></div></div>"},"110869":{"type":"graphic_figure","displayName":"Map - cutaneous leishmaniasis","title":"Geographic distribution of cutaneous leishmaniasis","html":"<div class=\"graphic\"><div style=\"width: 907px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of cutaneous leishmaniasis</div><div class=\"cntnt\"><img style=\"width:887px; height:860px;\" src=\"images/ID/110869_Map_cutaneous_leishmaniasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maps of the geographic distribution of cutaneous leishmaniasis (CL). Not all <EM>Leishmania</EM> species that cause CL are included in this map (eg, <EM>L. amazonensis</EM> in South America).</div><div class=\"graphic_reference\">Magill A. Leishmania species. Chapter 277. In: Principles and practice of infectious diseases, 8th ed, Bennett JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2015.</div><div id=\"graphicVersion\">Graphic 110869 Version 1.0</div></div></div>"},"110870":{"type":"graphic_figure","displayName":"Map - visceral leishmaniasis","title":"Geographic distribution of visceral leishmaniasis","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Geographic distribution of visceral leishmaniasis</div><div class=\"cntnt\"><img style=\"width:872px; height:885px;\" src=\"images/ID/110870_Mapvisceralleishmaniasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63(12):1539-1557, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2016. Available at: <A spellcheck=true href=\"http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_By_Organism-28143/Parasites/Leishmaniasis/\" target=_blank>http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infections_By_Organism-28143/Parasites/Leishmaniasis/</A>. </div><div id=\"graphicVersion\">Graphic 110870 Version 2.0</div></div></div>"},"110871":{"type":"graphic_picture","displayName":"Bronchoscope swivel adapter","title":"Bronchoscope swivel adapter","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Bronchoscope swivel adapter</div><div class=\"cntnt\"><img style=\"width:764px; height:527px;\" src=\"images/EM/110871_Bronchoscope_swivel_adapter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bronchoscope swivel adapter (pictured above) can be placed on&nbsp;an endotracheal tube&nbsp;to allow oxygenation and ventilation to continue while flexible endoscopy&nbsp;and intubation are&nbsp;performed via a supraglottic airway.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Erik Laurin, MD.</div><div id=\"graphicVersion\">Graphic 110871 Version 1.0</div></div></div>"},"110872":{"type":"graphic_table","displayName":"Ampulla of Vater cancer TNM 2017","title":" Ampulla of Vater cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">&nbsp;Ampulla of Vater cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor limited to ampulla of Vater or sphincter of Oddi or tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor limited to ampulla of Vater or sphincter of Oddi</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades into the muscularis propria of the duodenum</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor directly invades the pancreas (up to 0.5 cm) or tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery</td> </tr> <tr> <td class=\"indent2\">T3a</td> <td colspan=\"3\">Tumor directly invades pancreas (up to 0.5 cm)</td> </tr> <tr> <td class=\"indent2\">T3b</td> <td colspan=\"3\">Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph nodes metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis to one to three regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis to four or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T3a</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3b</td> <td>N1</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110872 Version 2.0</div></div></div>"},"110878":{"type":"graphic_figure","displayName":"PHACE facial hemangioma distribution","title":"Segmental distribution of hemangiomas in PHACE syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Segmental distribution of hemangiomas in PHACE syndrome</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/DERM/110878_PHACEfacialhmngmdstrbtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four segmental patterns were extracted from image analysis of large facial hemangiomas: segment 1 (frontotemporal), segment 2 (maxillary), segment 3 (mandibular), and segment 4 (frontonasal).</div><div class=\"graphic_footnotes\">PHACE: posterior fossa anomalies, hemangiomas, arterial anomalies, cardiac anomalies, and eye anomalies.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 117, Pages 698-703, Copyright © 2006 by the AAP.</div><div id=\"graphicVersion\">Graphic 110878 Version 2.0</div></div></div>"},"110879":{"type":"graphic_diagnosticimage","displayName":"Cephalocele 3D","title":"Posterior cephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior cephalocele</div><div class=\"cntnt\"><img style=\"width:283px; height:360px;\" src=\"images/OBGYN/110879_Cephalocele_3D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional surface rendering of the posterior cephalocele (arrows).</div><div id=\"graphicVersion\">Graphic 110879 Version 1.0</div></div></div>"},"110880":{"type":"graphic_diagnosticimage","displayName":"Posterior cephalocele 2","title":"Posterior cephalocele","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Posterior cephalocele</div><div class=\"cntnt\"><img style=\"width:543px; height:435px;\" src=\"images/OBGYN/110880_Posterior_cephalocele_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of a large posterior cephalocele at 19<SUP>1/7th</SUP> weeks of gestation showing brain extending into the cephalocele sac (arrow).</div><div id=\"graphicVersion\">Graphic 110880 Version 1.0</div></div></div>"},"110881":{"type":"graphic_diagnosticimage","displayName":"Posterior cephalocele","title":"Posterior cephalocele","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Posterior cephalocele</div><div class=\"cntnt\"><img style=\"width:646px; height:439px;\" src=\"images/OBGYN/110881_Posterior_cephalocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial view of the posterior cephalocele showing the sac protruding through the cranial defect (arrows) and the brain within the sac.</div><div id=\"graphicVersion\">Graphic 110881 Version 1.0</div></div></div>"},"110882":{"type":"graphic_diagnosticimage","displayName":"Cephalocele in 3D","title":"Cephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cephalocele</div><div class=\"cntnt\"><img style=\"width:431px; height:392px;\" src=\"images/OBGYN/110882_Cephalocele_in_3D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional surface rendering of a cephalocele (arrows).</div><div id=\"graphicVersion\">Graphic 110882 Version 2.0</div></div></div>"},"110883":{"type":"graphic_table","displayName":"PHACE risk stratification","title":"Risk stratification in patients with PHACE syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk stratification in patients with PHACE syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Surveillance</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Low risk</strong></td> <td> <ul> <li>Anomalous origin of arteries </li> <li>Variants in the circle of Willis </li> <li>Persistent fetal vessels </li> </ul> </td> <td> <ul> <li>Baseline scan only. Repeat imaging as needed for new symptoms. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Intermediate risk</strong></td> <td> <ul> <li>Narrowing proximal to the circle of Willis* </li> <li>Stenosis of the proximal ICA if there is normal collateral flow in ACA and PCA </li> </ul> </td> <td> <ul> <li>Referral to neurologist. </li> <li>Repeat imaging when sedation no longer needed or sooner for new signs or symptoms. </li> <li>May be at increased risk later in life if additional risk factors arise (atherosclerosis or traumatic injury). </li> <li>Avoid contact sports and sports with extreme neck positions. </li> </ul> </td> </tr> <tr> <td><strong>High risk</strong></td> <td> <ul> <li>&#62;25% narrowing of principal cerebral vessels </li> <li>In association with an incomplete circle of Willis </li> <li>Tandem stenosis that causes a risk of diminished cerebral perfusion </li> <li>Signs of chronic or silent <ul> <li>Ischemia </li> <li>Existing infarction </li> <li>Border zone ischemic changes </li> <li>Presence of lenticulostriate collateral dilation </li> <li>Pial collaterals </li> </ul> </li> </ul> </td> <td> <ul> <li>Referral to neurology. </li> <li>Repeat imaging at six months and one year. Then to be determined based on symptoms and progression. </li> <li>Avoid contact sports and sports with extreme neck positions. </li> <li>Aspirin 4 to 5 mg/kg/day up to 81 mg per day. </li> <li>If progressive moyamoya, refer to tertiary care center with experienced neurologist and neurosurgeon. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PHACE: posterior fossa anomalies, hemangiomas, arterial anomalies, cardiac anomalies, and eye anomalies; ICA: internal carotid artery; ACA: anterior cerebral artery; PCA: posterior cerebral artery.<br />* Must have intact circle of Willis.</div><div class=\"graphic_reference\">Adapted from: Garzon MC, Epstein LG, Heyer GL, et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr 2016; 178:24.</div><div id=\"graphicVersion\">Graphic 110883 Version 3.0</div></div></div>"},"110884":{"type":"graphic_figure","displayName":"Take-home practice HOTV test","title":"The HOTV test for visual acuity in children","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">The HOTV test for visual acuity in children</div><div class=\"cntnt\"><img style=\"width:794px; height:614px;\" src=\"images/PEDS/110884_Take-home_practice_HOTVtest.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 110884 Version 1.0</div></div></div>"},"110890":{"type":"graphic_table","displayName":"Gallbladder cancer TNM 2017","title":"Gallbladder cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gallbladder cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the lamina propria or muscular layer</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor invades the lamina propria</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor invades the muscular layer</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum).<br /> Or tumor invades the perimuscular connective tissue on the hepatic side, with no extension into the liver.</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td colspan=\"3\">Tumor invades the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum)</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td colspan=\"3\">Tumor invades the perimuscular connective tissue on the hepatic side, with no extension into the liver</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades the main portal vein or hepatic artery or invades two or more extrahepatic organs or structures</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastases to one or three regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastases to four or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2a</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2b</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T1-3</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0-1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110890 Version 2.0</div></div></div>"},"110891":{"type":"graphic_figure","displayName":"Survival after resection of GBC, stratified by AJCC stage","title":"Survival after resection of gallbladder cancer, stratified by stage according to the 2017 TNM staging criteria","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Survival after resection of gallbladder cancer, stratified by stage according to the 2017 TNM staging criteria</div><div class=\"cntnt\"><img style=\"width:712px; height:362px;\" src=\"images/ONC/110891_Surv_aftr_resect_GBC_AJCC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of survival according to conventional TNM classification with subclassification of T2 tumors by tumor location. N factor and M factor were clinically determined on the basis of either histopathologic findings or radiographic evaluation.</div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis.</div><div class=\"graphic_reference\">From: Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg 2015; 261:733. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2015&amp;issue=04000&amp;article=00018&amp;type=abstract\" target=\"_blank\">10.1097/SLA.0000000000000728</a>. Copyright &copy; 2015 American Surgical Association and European Surgical Association. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 110891 Version 1.0</div></div></div>"},"110892":{"type":"graphic_table","displayName":"Stages of obstetric hemorrhage","title":"Stages of obstetric hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of obstetric hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr class=\"divider_bottom\"> <td>Stage 0</td> <td>Observation period following delivery of the neonate for signs of abnormal bleeding*</td> <td> <ul> <li>All births </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Stage 1</td> <td>First sign of abnormal bleeding</td> <td> <ul> <li>Blood loss &#62;500 mL VD or &#62;1000 mL CD and &#60;1500 mL </li> <li>Brisk bleeding, large gush, large or multiple clots </li> <li>Boggy uterus </li> <li>Vital sign change &#62;15 percent; or heart rate &#8805;110 beats/min, BP &#8804;85/45 mmHg, or O<sub>2</sub> saturation &#60;95 percent </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Stage 2</td> <td>Bleeding that continues despite initial bedside interventions</td> <td> <ul> <li>Continued bleeding or unstable VS, or symptomatic AND </li> <li>Total blood loss &#60;1500 mL </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Stage 3</td> <td>Major postpartum hemorrhage</td> <td> <ul> <li>Cumulative blood loss &#8805;1500 mL or </li> <li>&#62;2 units packed red cells transfused or </li> <li>Coagulopathy suspected </li> </ul> </td> </tr> <tr> <td>Stage 4</td> <td>Catastrophic postpartum hemorrhage</td> <td> <ul> <li>Hypovolemic shock or </li> <li>Disseminated intravascular coagulopathy confirmed or </li> <li>Amniotic fluid embolism suspected </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There is no national consensus on the definitions of the stages of obstetric hemorrhage. However, there is consensus that clinicians should create common terminology at the institutional level, and that care providers should communicate and manage hemorrhage in terms of stages. This table shows an example of such a stage-based approach to obstetric hemorrhage, with criteria for assigning the various stages.</div><div class=\"graphic_footnotes\">VD: vaginal delivery; CD: cesarean delivery; BP: blood pressure; O<sub>2</sub>: oxygen; VS: vital signs.<br />* The Association of Women's Health Obstetric and Neonatal Nurses recommends a period of two hours following vaginal or cesarean birth to observe for abnormal postpartum bleeding.<sup>[1]</sup></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Perioperative care of the pregnant woman. Evidence-based clinical practice guideline. Association of Women's Health Obstetric, and Neonatal Nurses, 2011.</LI></OL>Modified from: Lyndon A, Lagrew D, Shields L, et al. Improving Health Care Response to Obstetric Hemorrhage (California Maternal Quality Care Collaborative Toolkit to Transform Maternity Care). Developed under contract #11-10006 with the California Department of Public Health; Maternal, Child and Adolescent Health Division; Published by the California Maternal Quality Care Collaborative, 2015. Available at: <A href=\"http://www.cmqcc.org/\" target=_blank>www.cmqcc.org</A> (accessed on November 18, 2016).</div><div id=\"graphicVersion\">Graphic 110892 Version 2.0</div></div></div>"},"110924":{"type":"graphic_algorithm","displayName":"Approach to heparin resistance during anticoagulation for CPB","title":"Approach to heparin resistance during systemic anticoagulation for CPB*","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Approach to heparin resistance during systemic anticoagulation for CPB*</div><div class=\"cntnt\"><img style=\"width:580px; height:646px;\" src=\"images/ANEST/110924_AprhprnrstncantcgltnCPB.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPB: cardiopulmonary bypass; ACT: activated whole blood clotting time; ATIII: antithrombin III cofactor; FFP: fresh frozen plasma.<br />* Refer to UpToDate content on management of CPB for details regarding heparin administration and monitoring, and management of heparin resistance.<br />¶ Wait three minutes after each heparin dose to obtain blood to check ACT value.<br />Δ Fixed dosing regimen for heparin administration during CPB:100 to 150 units/kg per hour (or 50 units/kg every 30 minutes if duration of CPB will be brief).</div><div id=\"graphicVersion\">Graphic 110924 Version 1.0</div></div></div>"},"110925":{"type":"graphic_figure","displayName":"Prothrombin G20210A","title":"Prothrombin G20210A mutation","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Prothrombin G20210A mutation</div><div class=\"cntnt\"><img style=\"width:814px; height:404px;\" src=\"images/HEME/110925_20210GA_muttn_prthrmbn_gen.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prothrombin G20210A mutation is a single G-to-A point mutation at position 20210 in the 3' untranslated region of the prothrombin (factor II) gene. The mutation does not affect the protein-coding region (exons)&nbsp;of the gene. Refer to the UpToDate topics on the prothrombin G20210A mutation and management of patients&nbsp;with inherited thrombophilias&nbsp;for further information.</div><div class=\"graphic_footnotes\">3' UT: Three-prime untranslated region.</div><div class=\"graphic_reference\">Illustration reproduced with permission from Marie Dauenheimer. Illustration published in: Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19.</div><div id=\"graphicVersion\">Graphic 110925 Version 1.0</div></div></div>"},"110927":{"type":"graphic_figure","displayName":"Angle of progression","title":"Angle of progression","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Angle of progression</div><div class=\"cntnt\"><img style=\"width:519px; height:304px;\" src=\"images/OBGYN/110927_Angle_of_progression.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The angle of progression is the angle between a straight line drawn along the longitudinal axis of the pubic bone and a line&nbsp;drawn from at&nbsp;the&nbsp;inferior edge of the pubic bone to the leading edge of the fetal cranium.</div><div class=\"graphic_reference\">Data from: Kalache KD, Dückelmann AM, Michaelis SA, et al. Transperineal ultrasound imaging in prolonged second stage of labor with occipitoanterior presenting fetuses: how well does the 'angle of progression' predict the mode of delivery? Ultrasound Obstet Gynecol 2009; 33:326.</div><div id=\"graphicVersion\">Graphic 110927 Version 1.0</div></div></div>"},"110928":{"type":"graphic_table","displayName":"PACU admission report","title":"PACU admission report","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PACU admission report</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preoperative history/procedures</td> </tr> <tr> <td class=\"indent1 divider_bottom\"> <ul> <li>Medication allergies or reactions </li> <li>Pertinent earlier surgical procedures </li> <li>Underlying medical illness </li> <li>Chronic medications </li> <li>Acute problems (eg, ischemia, acid-base status, dehydration) </li> <li>Premedications (eg, antibiotics and time given, beta-adrenergic blockers, antiemetics) </li> <li>Preoperative pain control (eg, nerve blocks, adjunct medications, narcotics) </li> <li>Preoperative pain assessment (chronic and acute pain scores) </li> <li>NPO status </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative factors</td> </tr> <tr> <td class=\"indent1 divider_bottom\"> <ul> <li>Surgical procedure </li> <li>Type of anesthetic </li> <li>Type and difficulty of airway management </li> <li>Relaxant/reversal status </li> <li>Time and amount of opioids administered </li> <li>Type and amount of intravenous fluids administered </li> <li>Estimated blood loss </li> <li>Urine output </li> <li>Unexpected surgical or anesthetic events </li> <li>Intraoperative vital sign ranges </li> <li>Intraoperative laboratory findings </li> <li>Drugs given (eg, steroids, diuretics, antibiotics, vasoactive medications, antiemetics) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Assessment and report of current status</td> </tr> <tr> <td class=\"indent1 divider_bottom\"> <ul> <li>Airway patency </li> <li>Ventilatory adequacy </li> <li>Level of consciousness </li> <li>Level of pain </li> <li>Heart rate and heart rhythm </li> <li>Endotracheal tube position </li> <li>Systemic pressure </li> <li>Intravascular volume status </li> <li>Function of invasive monitors </li> <li>Size and location of intravenous catheters </li> <li>Anesthetic equipment (eg, epidural catheters, peripheral nerve catheters) </li> <li>Overall impression </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative instructions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Expected airway and ventilatory status </li> <li>Acceptable vital sign ranges </li> <li>Acceptable urine output and blood loss </li> <li>Surgical instructions (eg, positioning, wound care) </li> <li>Anticipated cardiovascular problems </li> <li>Orders for therapeutic interventions </li> <li>Diagnostic tests to be secured </li> <li>Therapeutic goals and end points before discharge </li> <li>Location of responsible physician </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PACU: post-anesthesia care unit; NPO: nothing by mouth.</div><div class=\"graphic_reference\">Reproduced with permission from: Fowler MA, Spiess BD. Postanesthesia recovery. In: Clinical Anesthesia, 7th ed, Barash PG (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 110928 Version 1.0</div></div></div>"},"110935":{"type":"graphic_picture","displayName":"Erythromelalgia feet","title":"Erythromelalgia","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/110935_Erythromelalgia_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red, hot feet.</div><div id=\"graphicVersion\">Graphic 110935 Version 1.0</div></div></div>"},"110936":{"type":"graphic_picture","displayName":"Erythromelalgia hands","title":"Erythromelalgia","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/110936_Erythromelalgia_hands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red, hot hands.</div><div id=\"graphicVersion\">Graphic 110936 Version 1.0</div></div></div>"},"110937":{"type":"graphic_picture","displayName":"Erythromelalgia feet 2","title":"Erythromelalgia","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/110937_Erythromelalgia_feet_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red, hot feet.</div><div id=\"graphicVersion\">Graphic 110937 Version 1.0</div></div></div>"},"110938":{"type":"graphic_picture","displayName":"Erythromelalgia plantar feet","title":"Erythromelalgia","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/110938_Erythromelalgia_plantr_feet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red, hot soles of feet.</div><div id=\"graphicVersion\">Graphic 110938 Version 1.0</div></div></div>"},"110939":{"type":"graphic_picture","displayName":"Erythromelalgia hands 2","title":"Erythromelalgia","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/110939_Erythromelalgia_hands_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red, hot hands.</div><div id=\"graphicVersion\">Graphic 110939 Version 1.0</div></div></div>"},"110940":{"type":"graphic_picture","displayName":"Acrocyanosis in erythromelalgia","title":"Acrocyanosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Acrocyanosis</div><div class=\"cntnt\"><img style=\"width:756px; height:504px;\" src=\"images/DERM/110940_Acrocyanosis_erythromelalgi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acrocyanosis occurring between episodes of erythromelalgia.</div><div id=\"graphicVersion\">Graphic 110940 Version 1.0</div></div></div>"},"110941":{"type":"graphic_figure","displayName":"Surveillance benefit arteriovenous graft","title":"Surveillance benefit arteriovenous graft","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Surveillance benefit arteriovenous graft</div><div class=\"cntnt\"><img style=\"width:577px; height:573px;\" src=\"images/SURG/110941_Srvllnc_arteriovens_fistula.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nonrandomized studies that reported graft thrombosis rates during a historical control period and after implementing monitoring or surveillance. All studies reported that thrombosis decreased during monitoring or surveillance.<br />(B) Rates of graft thrombosis in graft surveillance group and control group in randomized controlled trials. Thrombosis rates were not significantly different between groups.</div><div class=\"graphic_footnotes\">DVP: dynamic venous pressure; SVP: static dialysis venous pressure; CM: clinical monitoring; FM: flow monitoring; US: duplex ultrasound.</div><div class=\"graphic_reference\">Reproduced with permission from: Allon M. Do we really need periodic monitoring of vascular access for hemodialysis? NephSap 2007; 6:111. Copyright © 2007 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 110941 Version 1.0</div></div></div>"},"110942":{"type":"graphic_picture","displayName":"Erythromelalgia complications","title":"Erythromelalgia","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Erythromelalgia</div><div class=\"cntnt\"><img style=\"width:765px; height:573px;\" src=\"images/DERM/110942_Erythromelalgia_complications.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chronic appearance of lower extremities in a patient with erythromelalgia who has been soaking feet in ice water. Erythema, swelling, and ulcerations are present.<br />(B) After stopping ice water soaks.</div><div id=\"graphicVersion\">Graphic 110942 Version 1.0</div></div></div>"},"110943":{"type":"graphic_table","displayName":"Distal bile duct cancer TNM 2017","title":"Distal bile duct cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distal bile duct cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em>/high-grade dysplasia</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor invades the bile duct wall with a depth less than 5 mm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades the bile duct wall with a depth of 5 to 12 mm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades the bile duct wall with a depth greater than 12 mm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in one to three regional lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in four or more regional lymph nodes</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N2</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N2</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110943 Version 2.0</div></div></div>"},"110944":{"type":"graphic_table","displayName":"Perihilar bile duct cancer TNM 2017","title":"Perihilar bile duct cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perihilar bile duct cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em>/high-grade dysplasia</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor invades beyond the wall of the bile duct to surrounding adipose tissue, or tumor invades adjacent hepatic parenchyma</td> </tr> <tr> <td class=\"indent2\">T2a</td> <td colspan=\"3\">Tumor invades beyond the wall of the bile duct to surrounding adipose tissue</td> </tr> <tr> <td class=\"indent2\">T2b</td> <td colspan=\"3\">Tumor invades adjacent hepatic parenchyma</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor invades unilateral branches of the portal vein or hepatic artery</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor invades the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N2</td> <td colspan=\"3\">Four or more positive lymph nodes from the sites described for N1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2a-b</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IIIC</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110944 Version 2.0</div></div></div>"},"110945":{"type":"graphic_table","displayName":"Intrahepatic bile duct cancer TNM 2017","title":"Intrahepatic bile duct cancer TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intrahepatic bile duct cancer TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em> (intraductal tumor)</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Solitary tumor without vascular invasion, &#8804;5 cm or &#62;5 cm</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Solitary tumor &#8804;5 cm without vascular invasion</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Solitary tumor &#62;5 cm without vascular invasion</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Solitary tumor with intrahepatic vascular invasion or multiple tumors, with or without vascular invasion</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor perforating the visceral peritoneum</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor involving local extrahepatic structures by direct invasion</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">N1</td> <td colspan=\"3\">Regional lymph node metastasis present</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis present</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1a</td> <td>N0</td> <td>M0</td> <td>IA</td> </tr> <tr> <td class=\"indent1\">T1b</td> <td>N0</td> <td>M0</td> <td>IB</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110945 Version 2.0</div></div></div>"},"110946":{"type":"graphic_table","displayName":"Squamous cell CA head and neck TNM 2017","title":"Cutaneous squamous cell carcinoma of the head and neck TNM staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous squamous cell carcinoma of the head and neck TNM staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T criteria</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\">Carcinoma <em>in situ</em></td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor smaller than 2 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor 4 cm or larger in maximum dimension or minor bone erosion or perineural invasion or deep invasion*</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion</td> </tr> <tr> <td class=\"indent2\">T4a</td> <td colspan=\"3\">Tumor with gross cortical bone/marrow invasion</td> </tr> <tr> <td class=\"indent2\">T4b</td> <td colspan=\"3\">Tumor with skull base invasion and/or skull base foramen involvement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* Deep invasion is defined as invasion beyond the subcutaneous fat or &#62;6 mm (as measured from the granular layer of adjacent normal epidermis to the base of the tumor); perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical N (cN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastasis in any node(s) and clinically overt ENE [ENE(+)]</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in any node(s) and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological N (pN)</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"3\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> Larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension, ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2a</td> <td colspan=\"3\">Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); <strong>or</strong><br /> A single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2b</td> <td colspan=\"3\">Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N2c</td> <td colspan=\"3\">Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent2\">N3</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;); <strong>or</strong><br /> In a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr> <td class=\"indent3\">N3a</td> <td colspan=\"3\">Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(&ndash;)</td> </tr> <tr> <td class=\"indent3\">N3b</td> <td colspan=\"3\">Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); <strong>or</strong><br /> Multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); <strong>or</strong><br /> A single contralateral node 3 cm or smaller and ENE(+)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\" colspan=\"4\"><em>NOTE:</em> A designation of \"U\" or \"L\" may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L).<br /> Similarly, clinical and pathological ENE should be recorded as ENE(&ndash;) or ENE(+).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No distant metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">M1</td> <td colspan=\"3\">Distant metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\" subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N1</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent1\">T1</td> <td>N2</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N2</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N2</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N3</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>Any N</td> <td>M0</td> <td>IV</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; ENE: extranodal extension.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110946 Version 2.0</div></div></div>"},"110947":{"type":"graphic_algorithm","displayName":"Herniation or increased ICP in children","title":"Treatment of acute brain herniation or symptomatic intracranial hypertension (ICP >20 mmHg [27 cm H<SUB>2</SUB>0]) in children*","html":"<div class=\"graphic\"><div style=\"width: 923px\" class=\"figure\"><div class=\"ttl\">Treatment of acute brain herniation or symptomatic intracranial hypertension (ICP &gt;20 mmHg [27 cm H<SUB>2</SUB>0]) in children*</div><div class=\"cntnt\"><img style=\"width:903px; height:1180px;\" src=\"images/EM/110947_HerniationincrsdICPchild.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RSI: rapid sequence intubation; GCS: Glasgow coma scale; ICP: intracranial pressure.<br />* This algorithm is intended for children in whom increased ICP is diagnosed based upon neuroimaging or intracranial monitoring, or in whom it is strongly suspected based upon signs of brain herniation. Refer to UpToDate topics on elevated ICP in children.<br />¶ A large diuresis is expected with mannitol and may require normal saline boluses to prevent hypotension. Thus, placement of a urinary Foley catheter is suggested. Monitoring of serum osmolal gap is necessary to avoid complications. Refer to UpToDate topics on the management of elevated ICP in children.<br />Δ When administering 3% saline, the expected serum sodium rise is 1 mEq/L for every 1 mL/kg bolus, and 1 mEq/L/hour for every 1 mL/kg/hour of continuous infusion. Monitoring of serum sodium is necessary to avoid complications. Patients with a serum sodium level &gt;160 mEq/L are unlikely to benefit from hypertonic saline administration. Refer to UpToDate topics on management of elevated ICP in children.<br /><FONT class=lozenge>◊</FONT> Temporary therapeutic hyperventilation (PaCO<SUB>2</SUB> 30 to 35 mmHg) may be initiated under direction by a neurosurgeon for patients with signs of impending herniation in whom surgical intervention is planned. If used, avoid hyperventilation for longer than 2 hours.<br />§ Monitor total dose of lidocaine administered to avoid lidocaine toxicity.</div><div class=\"graphic_reference\">Adapted from: Stevens RD, Shoykhet M, Cadena R. Emergency Neurological Life Support: Intracranial Hypertension and Herniation. Neurocrit Care 2015; 23 Suppl 2:S76.</div><div id=\"graphicVersion\">Graphic 110947 Version 4.0</div></div></div>"},"110948":{"type":"graphic_diagnosticimage","displayName":"TEE assessment of LV diastolic dysfunction","title":"TEE assessment of LV diastolic dysfunction using pulsed wave tissue Doppler of the mitral annulus (center panels) and pulsed wave Doppler of the mitral inflow (right panels)","html":"<div class=\"graphic\"><div style=\"width: 971px\" class=\"figure\"><div class=\"ttl\">TEE assessment of LV diastolic dysfunction using pulsed wave tissue Doppler of the mitral annulus (center panels) and pulsed wave Doppler of the mitral inflow (right panels)</div><div class=\"cntnt\"><img style=\"width:951px; height:1083px;\" src=\"images/ANEST/110948_TEE_LV_diastolic_dysfunctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Accurate identification of each Doppler spectral peak requires an accompanying electrocardiographic tracing. Conditions such as atrial fibrillation, mitral annular calcification, mitral valve surgery, or extracorporeal circulatory support generally preclude using these Doppler techniques.</div><div class=\"graphic_footnotes\">A: late mitral inflow velocity resulting from atrial contraction; E: early mitral inflow velocity; e′: early mitral annular velocity recorded from the lateral mitral annulus.</div><div class=\"graphic_reference\">From: Maxwell C, Konoske R, Mark J. Emerging concepts in transesophageal echocardiography. F1000Research 2016; 5:340. DOI: <A href=\"https://f1000research.com/articles/5-340/v1\" target=_blank>10.12688/f1000research.7169.1</A>. Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/4.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 110948 Version 2.0</div></div></div>"},"110952":{"type":"graphic_diagnosticimage","displayName":"3D CT severe rib fractures","title":"3D CT severe rib fractures","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">3D CT severe rib fractures</div><div class=\"cntnt\"><img style=\"width:527px; height:704px;\" src=\"images/EM/110952_3D_CT_severe_rib_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows chest CT 3D reconstruction of a flail chest in a patient in her late thirties who was ejected off a motorcycle. She arrived with complaints of severe chest pain precluding her ability to speak in full sentences or take a deep breath. The CT scan confirmed displaced fractures of nearly all the ribs on the right side. She underwent operative rib fixation of ribs 5 through 9 on postinjury day 1 and was extubated the following day.</div><div class=\"graphic_footnotes\">CT: computed tomography; 3D: three-dimensional.</div><div id=\"graphicVersion\">Graphic 110952 Version 3.0</div></div></div>"},"110953":{"type":"graphic_diagnosticimage","displayName":"3D reconstruction of flail chest from collision at eight months","title":"3D reconstruction of flail chest from collision at eight months","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">3D reconstruction of flail chest from collision at eight months</div><div class=\"cntnt\"><img style=\"width:748px; height:541px;\" src=\"images/SURG/110953_3D_flail_chest_cllsn_8mths.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">3D reconstruction of the chest wall of a patient involved in a motorcycle collision eight months following injury. The patient presented with severe, constant pain. On the right, there are multiple areas of nonunion as well as several areas of malunion with perifracture callous.</div><div class=\"graphic_footnotes\">3D: three-dimensional.</div><div id=\"graphicVersion\">Graphic 110953 Version 1.0</div></div></div>"},"110954":{"type":"graphic_diagnosticimage","displayName":"U-plate stabilization of flail chest","title":"U-plate stabilization of flail chest","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">U-plate stabilization of flail chest</div><div class=\"cntnt\"><img style=\"width:530px; height:629px;\" src=\"images/SURG/110954_Chest_radiograph_Uplates.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The chest radiograph shows U-plates in situ, which were used to stabilize a three-segment flail chest. This patient in his late fifties fell in his bathtub, landing on his left chest. He presented with severe chest pain and complained of hearing a \"click\" when he breathed. Chest imaging confirmed fracture of ribs 8 to 11 anteriorly and 6 to 10 posteriorly. Pain severely limited his movement&nbsp;despite him&nbsp;receiving&nbsp;systemic and regional analgesia. He underwent operative fixation of ribs 6 and 7 anteriorly and 8 to 9 posteriorly. Following rib fixation, he was able to get out of bed into a chair on postoperative day 1 and ambulate on postoperative day 2. </div><div id=\"graphicVersion\">Graphic 110954 Version 2.0</div></div></div>"},"110955":{"type":"graphic_table","displayName":"Müllerian anomalies and impact on fertility","title":"Müllerian anomalies and impact on fertility","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Müllerian anomalies and impact on fertility</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.3%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">% among M&#252;llerian malformations</td> <td class=\"subtitle1\">Impact on fertility</td> </tr> <tr> <td>Septate uterus</td> <td class=\"centered\">&#62;30%</td> <td>Approximately 40% miscarriage rate</td> </tr> <tr> <td>Bicornuate uterus</td> <td class=\"centered\">25%</td> <td>35% miscarriage rate</td> </tr> <tr> <td>Unicornuate uterus</td> <td class=\"centered\">20%</td> <td>30% miscarriage rate<br /> 50% reduction in LBR</td> </tr> <tr> <td>Didelphys uterus</td> <td class=\"centered\">20%</td> <td>30% miscarriage rate<br /> 50% reduction in LBR</td> </tr> <tr> <td>T-shaped uterus and hypoplastic uterus</td> <td class=\"centered\">&#60;5%</td> <td>80 to 90% reduction in LBR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LBR: live birth rate.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Grimbizis GF, Camus M, Tarlatzis BC, et al. Clinical implications of uterine malformations and hysteroscopic treatment results. Hum Reprod Update 2001; 7:161.</LI>&#xD;&#xA;<LI>Saravelos SH, Cocksedge KA, Li TC. Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal. Hum Reprod Update 2008; 14:415.</LI>&#xD;&#xA;<LI>Taylor E, Gomel V. The uterus and fertility. Fertil Steril 2008; 89:1.</LI>&#xD;&#xA;<LI>Galliano D, Bellver J, Diaz-Garcia C, et al. ART and uterine pathology: How relevant is the maternal side for implantation? Hum Reprod Update 2015; 21:13.</LI>&#xD;&#xA;<LI>Kupesic S, Kurjak A, Skenderovic S, Bjelos D. Screening for uterine abnormalities by three-dimensional ultrasound improves perinatal outcome. J Perinat Med 2002; 30:9.</LI></OL></div><div id=\"graphicVersion\">Graphic 110955 Version 1.0</div></div></div>"},"110958":{"type":"graphic_algorithm","displayName":"Use of PFTs to diagnose asthma in adults and adolescents","title":"Use of PFTs to diagnose asthma in adults and adolescents","html":"<div class=\"graphic\"><div style=\"width: 942px\" class=\"figure\"><div class=\"ttl\">Use of PFTs to diagnose asthma in adults and adolescents</div><div class=\"cntnt\"><img style=\"width:922px; height:736px;\" src=\"images/PULM/110958_PFT_DX_asthma_adult_teen.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BD: bronchodilator; FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity; LLN: lower limit of normal.<br />* If spirometry pre- and post-BD or bronchoprovocation challenge is not available, serial peak flow measurements showing a variability of ≥20% that corresponds to symptoms is suggestive of asthma.<br />¶ Patients with borderline airflow limitation (FEV<SUB>1</SUB>/FVC &lt;70% or LLN, but FEV<SUB>1</SUB> ≥80% predicted) may have asthma, but will need further monitoring over time to confirm. Refer to UpToDate content on the diagnosis of asthma.<br />Δ Positive methacholine: A decrease in FEV<SUB>1</SUB> by ≥20% (PC20) after inhalation of 8 mg/mL or less is considered positive; a PC20 ≥16 mg/mL is considered negative. Positive mannitol: Decrease in FEV<SUB>1</SUB> by ≥15% after total cumulative dose of ≤635 mg. Positive exercise challenge; decrease in FEV<SUB>1</SUB> by ≥10%, although ≥15% is more diagnostic.<br /><FONT class=lozenge>◊</FONT> In selected patients, methacholine challenge may help identify airways hyperresponsiveness in patients with baseline mild-to-moderate airflow limitation, but no bronchodilator reversibility.</div><div id=\"graphicVersion\">Graphic 110958 Version 1.0</div></div></div>"},"110959":{"type":"graphic_figure","displayName":"US mumps cases","title":"Mumps cases in the United States, by year","html":"<div class=\"graphic\"><div style=\"width: 827px\" class=\"figure\"><div class=\"ttl\">Mumps cases in the United States, by year</div><div class=\"cntnt\"><img style=\"width:807px; height:335px;\" src=\"images/ID/110959_USmumpscases.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Case count is preliminary and subject to change.<br />&para; Cases as of December 30, 2017. Case count is preliminary and subject to change.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Mumps cases and outbreaks. Available at: <a href=\"https://www.cdc.gov/mumps/outbreaks.html\" target=\"_blank\">https://www.cdc.gov/mumps/outbreaks.html</a> (Accessed on January 12, 2018).</div><div id=\"graphicVersion\">Graphic 110959 Version 2.0</div></div></div>"},"110960":{"type":"graphic_table","displayName":"Preoperative evaluation of uterus recipient","title":"Preoperative evaluation of uterus recipient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative evaluation of uterus recipient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Surgical team review</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>History </li> <li>Examination </li> <li>Blood <ul> <li>Hematology <ul> <li>Full blood count, clotting, thrombophilia screen </li> </ul> </li> <li>Biochemistry <ul> <li>Urea and electrolytes, liver function tests </li> </ul> </li> <li>Microbiology/virology <ul> <li>HIV, hepatitis B and C, Epstein-Barr virus, TORCH, and syphilis </li> </ul> </li> </ul> </li> <li>Genitourinary medicine screen <ul> <li><em>Chlamydia</em>, <em>gonorrhoa</em> </li> </ul> </li> <li>Radiology <ul> <li>Chest radiograph, pelvic ultrasound, magnetic resonance image abdomen/pelvis </li> </ul> </li> <li>Electrocardiogram </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Clinical psychologist</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Initial interview and separate interview with partner </li> <li>Structured Clinical Interview for DSM (SCID-RV) </li> <li>Marital taxon interview measure </li> <li>The World Health Organization Quality of Life BREF (WHOQOL-BREF) </li> <li>Fertility quality of life tool (FertiQoL) </li> <li>Hospital Anxiety and Depression Scale (HADS) </li> <li>Dyadic Adjustment Scale (DAS) </li> <li>36-item Short-Form Health Survey (SF-36) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">IVF team review</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Blood <ul> <li>Follicle-stimulating hormone, luteinizing hormone, progesterone, anti-M&#252;llerian hormone, estradiol </li> </ul> </li> <li>Male partner semen analysis </li> <li>Egg collection and intracytoplasmic sperm injection </li> <li>Embryo freezing day 5 to 6 (Minimum number of ten sufficient quality needed) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Transplant team review</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Group and screen </li> <li>Tissue typing </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Partner testing</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Infection screen (HIV, hepatitis B and C, Epstein-Barr virus, TORCH, and syphilis), GUM screen </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; TORCH: toxoplasmosis, other (congenital syphilis and viruses), rubella, cytomegalovirus, and herpes simplex virus; DSM: Diagnostic and Statistical Manual of Mental Disorders; IVF: in vitro fertilization.</div><div class=\"graphic_reference\">From: Jones BP, Saso S, Yazbek J, Smitha JR. Uterine transplantation: Past, present and future. BJOG 2016; 123:1434. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/1471-0528.13963/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1111/1471-0528.13963/abstract</A>. Copyright © 2016 Royal College of Obstetricians and Gynaecologists. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\">permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 110960 Version 1.0</div></div></div>"},"110961":{"type":"graphic_figure","displayName":"Overview of uterus transplantation","title":"Overview of uterus transplantation","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Overview of uterus transplantation</div><div class=\"cntnt\"><img style=\"width:662px; height:550px;\" src=\"images/OBGYN/110961_Overview_uterus_transplantn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IVF: in vitro fertilization; CS: cesarean section.</div><div class=\"graphic_reference\">Reproduced from: Balayla J. Uterine transplants in the Canadian setting: A theoretical framework. J Obstet Gynaecol Can 2016; 38:955. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110961 Version 1.0</div></div></div>"},"110962":{"type":"graphic_table","displayName":"Preoperative medical testing of donor and recipient","title":"Preoperative medical testing of uterus transplantation donor and recipient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative medical testing of uterus transplantation donor and recipient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Radiology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>MRI (abdominal and pelvic) </li> <li>Chest radiograph </li> <li>Vaginal ultrasound scan </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Clinical</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>ECG </li> <li>Exercise ECG* </li> <li>Pap smear </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Blood chemistry</td> </tr> <tr> <td class=\"subtitle2_single\">Liver function</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Alanine transaminase </li> <li>Aspartate transaminase </li> <li>Alkaline phosphatase </li> <li>Albumin </li> <li>Total protein </li> <li>Bilirubin </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Kidney function</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Creatinine </li> <li>Urea </li> <li>Electrolytes </li> <li>Dissolved salts </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">General</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Hemoglobin </li> <li>White blood cells </li> <li>Prothrombin time </li> <li>Activated partial thromboplastin time </li> <li>Total particle concentration </li> <li>C-reactive protein </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Microbiology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Cytomegalovirus </li> <li>Epstein-Barr virus </li> <li>Human immunodeficiency virus </li> <li>Hepatitis A, B, C </li> <li>Chlamydia </li> <li>Human papilloma virus </li> <li>Gonorrhea </li> <li>Syphilis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Assessment by specialist in</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Gynecology </li> <li>Transplantation surgery </li> <li>Psychology </li> <li>Clinical immunology </li> <li>Anesthesiology </li> <li>Internal medicine </li> <li>Radiology </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; ECG: electrocardiography.<br />* Donors only.</div><div class=\"graphic_reference\">Reproduced from: Br&auml;nnstr&ouml;m M, Johannesson L, Dahm-K&auml;hler P, et al. First clinical uterus transplantation trial: A six month report. Fertil Steril 2014; 101:1228. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110962 Version 1.0</div></div></div>"},"110963":{"type":"graphic_algorithm","displayName":"Approach to the management of pneumatosis intestinalis in adults","title":"Approach to the management of pneumatosis intestinalis in adults","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Approach to the management of pneumatosis intestinalis in adults</div><div class=\"cntnt\"><img style=\"width:760px; height:732px;\" src=\"images/GAST/110963_Mgmt_pnmtss_intstnls_adult.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Abdominal rigidity, rebound tenderness, and/or pain that worsens when the examiner lightly bumps the stretcher.<br />¶ Mild symptoms include abdominal pain that does not interfere with functioning and the ability to perform activities of daily living. Moderate to severe symptoms include bleeding or abdominal pain that interferes with functioning and the ability to perform activities of daily living.<br />Δ Antibiotic options include metronidazole, ampicillin, tetracycline, and vancomycin.<br /><FONT class=lozenge>◊</FONT> Decision to recommend surgery depends on patient presentation, age, comorbidities, and extent of intestine involved.<br />§ Complications include bowel obstruction, perforation, peritonitis, and necrotic bowel.</div><div id=\"graphicVersion\">Graphic 110963 Version 1.0</div></div></div>"},"110964":{"type":"graphic_table","displayName":"Lung cancer stage grouping (eighth edition)","title":"Lung cancer stage grouping (eighth edition)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lung cancer stage grouping (eighth edition)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">T/M</td> <td class=\"subtitle1\" style=\"text-align: left;\">Label</td> <td class=\"subtitle1\">N0</td> <td class=\"subtitle1\">N1</td> <td class=\"subtitle1\">N2</td> <td class=\"subtitle1\">N3</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\"><strong>T1</strong></td> <td>T1a <em>&#8804;1</em></td> <td class=\"centered\" style=\"background-color: #d4efdf;\">IA1</td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> </tr> <tr> <td>T1b <em>&#62;1 to 2</em></td> <td class=\"centered\" style=\"background-color: #d4efdf;\">IA2</td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>T1c <em>&#62;2 to 3</em></td> <td class=\"centered\" style=\"background-color: #d4efdf;\">IA3</td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\"><strong>T2</strong></td> <td>T2a <em style=\"color: red;\"><span style=\"color: black;\">Cent, Visc Pl</span></em></td> <td class=\"centered\" style=\"background-color: #2ecc71;\">IB</td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> </tr> <tr> <td>T2a <em>&#62;3 to 4</em></td> <td class=\"centered\" style=\"background-color: #2ecc71;\">IB</td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> </tr> <tr class=\"divider_bottom\"> <td>T2b <em>&#62;4 to 5</em></td> <td class=\"centered\" style=\"background-color: #f39c12;\">IIA</td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\"><strong>T3</strong></td> <td>T3 <em>&#62;5 to 7</em></td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> <td class=\"centered\" style=\"background-color: #7e57c2;\">IIIC</td> </tr> <tr> <td>T3 <em>Inv</em></td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> <td class=\"centered\" style=\"background-color: #7e57c2;\">IIIC</td> </tr> <tr class=\"divider_bottom\"> <td>T3 <em>Satell</em></td> <td class=\"centered\" style=\"background-color: #fff176;\">IIB</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> <td class=\"centered\" style=\"background-color: #7e57c2;\">IIIC</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"3\"><strong>T4</strong></td> <td>T4 <em>&#62;7</em></td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> <td class=\"centered\" style=\"background-color: #7e57c2;\">IIIC</td> </tr> <tr> <td>T4 <em>Inv</em></td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> <td class=\"centered\" style=\"background-color: #7e57c2;\">IIIC</td> </tr> <tr class=\"divider_bottom\"> <td>T4 <em>Ipsi Nod</em></td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #80deea;\">IIIA</td> <td class=\"centered\" style=\"background-color: #2196f3;\">IIIB</td> <td class=\"centered\" style=\"background-color: #7e57c2;\">IIIC</td> </tr> <tr> <td class=\"centered\" rowspan=\"4\"><strong>M1</strong></td> <td>M1a <em>Contr Nod</em></td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> </tr> <tr> <td>M1a <em>Pl Dissem</em></td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> </tr> <tr> <td>M1b <em>Single</em></td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> <td class=\"centered\" style=\"background-color: #e6b0aa;\">IVA</td> </tr> <tr> <td>M1c <em>Multi</em></td> <td class=\"centered\" style=\"background-color: #e74c3c;\">IVB</td> <td class=\"centered\" style=\"background-color: #e74c3c;\">IVB</td> <td class=\"centered\" style=\"background-color: #e74c3c;\">IVB</td> <td class=\"centered\" style=\"background-color: #e74c3c;\">IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=red><SPAN style=\"COLOR: black\">Centr, Visc Pl: tumor involving main bronchus (not carina), atelectasis to hilum or visceral pleura; T3 Inv: tumor invading chest wall, pericardium, phrenic nerve;&nbsp;T3 Satell: separate tumor nodule(s) in the same lobe; T4 Inv: tumor invading mediastinum, diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine; T4 Ipsi Nod: tumor nodule in different ipsilateral lobe; M1a Contr Nod: separate tumor nodule(s) in contralateral lobe; M1a Pl Dissem: malignant pleural/pericardial effusion or pleural/pericardial nodules; M1b Single: single extrathoracic metastasis; M1c Multi: multiple extrathoracic metastases (1 or &gt;1 organ)</SPAN>.</FONT></div><div class=\"graphic_reference\">Original figure modified for this publication. Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest 2017; 151:193. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 110964 Version 2.0</div></div></div>"},"110966":{"type":"graphic_picture","displayName":"Physiologic breast hypertrophy","title":"Physiologic breast hypertrophy in a neonate","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Physiologic breast hypertrophy in a neonate</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PEDS/110966_Physiolgc_breast_hypertrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Symmetric enlargement of the breasts in a neonate without erythema, tenderness, or warmth.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 110966 Version 1.0</div></div></div>"},"110968":{"type":"graphic_algorithm","displayName":"Approach to selecting treatments for performance-only SAD","title":"Approach to selecting treatments for performance-only social anxiety disorder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to selecting treatments for performance-only social anxiety disorder</div><div class=\"cntnt\"><img style=\"width:236px; height:266px;\" src=\"images/PSYCH/110968_Apprch_trtmnts_perform_SAD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CBT: cognitive-behavioral therapy.<br />* Refer to topic for contraindications to beta-blocker use.</div><div id=\"graphicVersion\">Graphic 110968 Version 1.0</div></div></div>"},"110969":{"type":"graphic_picture","displayName":"Condylomata acuminata vulva child","title":"Condylomata acuminata of the vulva in a prepubertal child","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Condylomata acuminata of the vulva in a prepubertal child</div><div class=\"cntnt\"><img style=\"width:468px; height:596px;\" src=\"images/EM/110969_Condylm_accumint_vulv_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture demonstrates condylomata acuminata of the right vaginal wall and posterior fourchette in a prepubertal child caused by human papilloma virus. Transmission may be sexual or nonsexual. Consultation with a child abuse specialist is warranted to determine the need for further evaluation for sexual abuse. </div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ. Vulvovaginal problems in the prepubertal child. In: Emans, Laufer, and Goldstein's Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 110969 Version 1.0</div></div></div>"},"110971":{"type":"graphic_table","displayName":"Merkel cell carcinoma TNM 2017 clinical staging","title":"Merkel cell carcinoma TNM clinical staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma TNM clinical staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed (eg, curetted)</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\"><em>In situ</em> primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Maximum clinical tumor diameter &#8804;2 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Maximum clinical tumor diameter &#62;2 but &#8804;5 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Maximum clinical tumor diameter &#62;5 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Primary tumor invades fascia, muscle, cartilage, or bone</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical (N)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>N category</strong></td> <td colspan=\"5\"><strong>N criteria</strong></td> </tr> <tr> <td class=\"indent2\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be clinically assessed (eg, previously removed for another reason, or because of body habitus)</td> </tr> <tr> <td class=\"indent2\">N0</td> <td colspan=\"3\">No regional lymph node metastasis detected on clinical and/or radiologic examination</td> </tr> <tr> <td class=\"indent2\">N1</td> <td colspan=\"3\">Metastasis in regional lymph node(s)</td> </tr> <tr> <td class=\"indent2\">N2</td> <td colspan=\"3\">In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) <strong>without</strong> lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">N3</td> <td colspan=\"3\">In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) <strong>with</strong> lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical (M)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>M category</strong></td> <td colspan=\"4\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td colspan=\"3\">No distant metastasis detected on clinical and/or radiologic examination</td> </tr> <tr> <td class=\"indent2\">M1</td> <td colspan=\"3\">Distant metastasis detected on clinical and/or radiologic examination</td> </tr> <tr> <td class=\"indent3\">M1a</td> <td colspan=\"3\">Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s)</td> </tr> <tr> <td class=\"indent3\">M1b</td> <td colspan=\"3\">Metastasis to lung</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">M1c</td> <td colspan=\"3\">Metastasis to all other visceral sites</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Clinical stage group (cTNM)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T2-3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T0-4</td> <td>N1-3</td> <td>M0</td> <td>III</td> </tr> <tr> <td class=\"indent2\">T0-4</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110971 Version 6.0</div></div></div>"},"110972":{"type":"graphic_table","displayName":"Merkel cell carcinoma TNM 2017 pathologic staging","title":"Merkel cell carcinoma TNM pathologic staging AJCC UICC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Merkel cell carcinoma TNM pathologic staging AJCC UICC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\">T category</td> <td class=\"subtitle2_left\" colspan=\"3\">T criteria</td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed (eg, curetted)</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">Tis</td> <td colspan=\"3\"><em>In situ</em> primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Maximum clinical tumor diameter &#8804;2 cm</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Maximum clinical tumor diameter &#62;2 but &#8804;5 cm</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Maximum clinical tumor diameter &#62;5 cm</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">T4</td> <td colspan=\"3\">Primary tumor invades fascia, muscle, cartilage, or bone</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological (pN)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>pN category</strong></td> <td colspan=\"3\"><strong>pN criteria</strong></td> </tr> <tr> <td class=\"indent2\">pNX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed (eg, previously removed for another reason or <strong>not</strong> removed for pathological evaluation)</td> </tr> <tr> <td class=\"indent2\">pN0</td> <td colspan=\"3\">No regional lymph node metastasis detected on pathological evaluation</td> </tr> <tr> <td class=\"indent2\">pN1</td> <td colspan=\"3\">Metastasis in regional lymph node(s)</td> </tr> <tr> <td class=\"indent3\">pN1a(sn)</td> <td colspan=\"3\">Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy</td> </tr> <tr> <td class=\"indent3\">pN1a</td> <td colspan=\"3\">Clinically occult regional lymph node metastasis following lymph node dissection</td> </tr> <tr> <td class=\"indent3\">pN1b</td> <td colspan=\"3\">Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed</td> </tr> <tr> <td class=\"indent2\">pN2</td> <td colspan=\"3\">In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) <strong>without</strong> lymph node metastasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">pN3</td> <td colspan=\"3\">In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) <strong>with</strong> lymph node metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological (M)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>M category</strong></td> <td colspan=\"3\"><strong>M criteria</strong></td> </tr> <tr> <td class=\"indent2\">M0</td> <td colspan=\"3\">No distant metastasis detected on clinical and/or radiologic examination</td> </tr> <tr> <td class=\"indent2\">pM1</td> <td colspan=\"3\">Distant metastasis microscopically confirmed</td> </tr> <tr> <td class=\"indent3\">pM1a</td> <td colspan=\"3\">Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s), microscopically confirmed</td> </tr> <tr> <td class=\"indent3\">pM1b</td> <td colspan=\"3\">Metastasis to lung, microscopically confirmed</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">pM1c</td> <td colspan=\"3\">Metastasis to all other distant sites, microscopically confirmed</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"4\">Pathological stage group (pTNM)</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td class=\"indent1\"><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent2\">Tis</td> <td>N0</td> <td>M0</td> <td>0</td> </tr> <tr> <td class=\"indent2\">T1</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent2\">T2-3</td> <td>N0</td> <td>M0</td> <td>IIA</td> </tr> <tr> <td class=\"indent2\">T4</td> <td>N0</td> <td>M0</td> <td>IIB</td> </tr> <tr> <td class=\"indent2\">T1-4</td> <td>N1a(sn) or N1a</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T0</td> <td>N1b</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent2\">T1-4</td> <td>N1b-3</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent2\">T0-4</td> <td>Any N</td> <td>M1</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110972 Version 4.0</div></div></div>"},"110976":{"type":"graphic_figure","displayName":"Movement of thoracoscopic instrument in chest wall","title":"Movement of thoracoscopic instrument in chest wall","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Movement of thoracoscopic instrument in chest wall</div><div class=\"cntnt\"><img style=\"width:535px; height:417px;\" src=\"images/SURG/110976_Movement_of_thoracoscope_instrument_in_chest_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figures illustrate the limited movement between ribs in thick chest wall using standard video-assisted thoracoscopic instruments. An advantage of robotic surgery is that the robotic arm fulcrums the instrument around a fixed point. Once the trocars are in place, the thickness of the chest is less important for the mobility of the robotic instruments.</div><div class=\"graphic_footnotes\">VATS: video-assisted thoracoscopic surgery; RATS: robotic-assisted thoracic surgery.</div><div id=\"graphicVersion\">Graphic 110976 Version 1.0</div></div></div>"},"110984":{"type":"graphic_picture","displayName":"ETCO2 waveform demonstrating effects of phrenic nerve pacing","title":"ETCO<SUB>2</SUB> waveform demonstrating effects of phrenic nerve pacing","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">ETCO<SUB>2</SUB> waveform demonstrating effects of phrenic nerve pacing</div><div class=\"cntnt\"><img style=\"width:796px; height:432px;\" src=\"images/ANEST/110984_ETCO2_curve_phrenc_nrv_pcng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Leads II and V5 on the ECG are shown in green. The spike in the&nbsp;ECG (arrow) is representative of stimuli from phrenic nerve pacing. The capnogram is shown in white, with alterations in the ETCO<SUB>2</SUB> curve due to diaphragmatic contraction occurring with phrenic nerve pacing (circle).&nbsp;<FONT color=red><FONT color=black>Note that the capnogram tracing speed is slower than the standard sweep speed of the ECG and SpO<SUB>2</SUB> tracing.</FONT><EM innerHtml>&nbsp;</EM><FONT color=black>The plethysmogram from the pulse oximeter&nbsp;is shown in green and represents the&nbsp;SpO<SUB>2</SUB> value.</FONT></FONT></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ETCO<SUB>2</SUB>: end-tidal carbon dioxide; SpO<SUB>2</SUB>: peripheral arterial oxygen saturation.</div><div id=\"graphicVersion\">Graphic 110984 Version 2.0</div></div></div>"},"110986":{"type":"graphic_picture","displayName":"Typical ETCO2 tracing during high frequency jet ventilation","title":"Typical ETCO<SUB>2</SUB> tracing during high frequency jet ventilation","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Typical ETCO<SUB>2</SUB> tracing during high frequency jet ventilation</div><div class=\"cntnt\"><img style=\"width:788px; height:360px;\" src=\"images/ANEST/110986_Typcl_ETCO2_trcng_jet_vent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ETCO<SUB>2</SUB> waveform (in white) has the typical \"saw tooth\" pattern that is seen&nbsp;during intraoperative high frequency jet ventilation.</div><div class=\"graphic_footnotes\">ETCO<SUB>2</SUB>: End-tidal carbon dioxide</div><div id=\"graphicVersion\">Graphic 110986 Version 2.0</div></div></div>"},"110988":{"type":"graphic_figure","displayName":"Superficial arteries face","title":"Superficial arteries of the face","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Superficial arteries of the face</div><div class=\"cntnt\"><img style=\"width:532px; height:579px;\" src=\"images/DERM/110988_Superficial_arteries_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">A: artery; N: nerve; AA: arteries.</div><div id=\"graphicVersion\">Graphic 110988 Version 1.0</div></div></div>"},"110995":{"type":"graphic_algorithm","displayName":"Algorithm for HER2 testing in esophagogastric adenocarcinoma","title":"Algorithm for HER2 testing in advanced esophagogastric adenoocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">Algorithm for HER2 testing in advanced esophagogastric adenoocarcinoma</div><div class=\"cntnt\"><img style=\"width:810px; height:368px;\" src=\"images/ONC/110995_HER2_esophggstrc_adncrcnm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for pathologists.<br />Additional recommendations: Pathologists should ensure that biopsy or resection specimens used for HER2 testing are rapidly placed in fixative, ideally within 1 hour (cold ischemic time) and are fixed in 10% neutral buffered formalin for 6 to 72 hours. Routine histology processing and HER2 testing should be performed according to analytically validated protocols. Pathologists should identify areas of invasive adenocarcinoma and also mark areas with strongest intensity of HER2 expression by IHC in the GEA specimen for subsequent scoring when ISH is required.</div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor receptor 2; GEA: gastroesophageal adenocarcinoma; IHC: immunohistochemistry; ISH: in situ hybridization.<br />* Tumor cell cluster is defined as a cluster of 5 or more tumor cells.</div><div class=\"graphic_reference\">Reprinted from Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 2016; 140(12):1345-1363. From Archives of Pathology &amp; Laboratory Medicine. Copyright 2016 College of American Pathologists.</div><div id=\"graphicVersion\">Graphic 110995 Version 1.0</div></div></div>"},"110996":{"type":"graphic_table","displayName":"Scoring guidelines HER2 IHC esophagogastric CA","title":"Scoring guidelines for the interpretation of HER2 immunohistochemical staining (IHC) in esophagogastric adenocarcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scoring guidelines for the interpretation of HER2 immunohistochemical staining (IHC) in esophagogastric adenocarcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Surgical specimen-staining pattern</td> <td class=\"subtitle1\">Biopsy specimen-staining pattern</td> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">HER2 expression assessment</td> </tr> <tr> <td>No reactivity or membranous reactivity in &#60;10% of tumor cells</td> <td>No reactivity or no membranous reactivity in any tumor cell</td> <td class=\"centered\">0</td> <td class=\"centered\">Negative</td> </tr> <tr> <td>Faint/barely perceptible membranous reactivity in &#8805;10% of tumor cells; cells are reactive only in part of their membrane</td> <td>Tumor cell cluster* with a faint/barely perceptible membranous reactivity irrespective of percentage of tumor cells stained</td> <td class=\"centered\">1+</td> <td class=\"centered\">Negative</td> </tr> <tr> <td>Weak to moderate, complete, basolateral or lateral membranous reactivity in &#8805;10% of tumor cells</td> <td>Tumor cell cluster* with a weak to moderate, complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained</td> <td class=\"centered\">2+</td> <td class=\"centered\">Equivocal</td> </tr> <tr> <td>Strong, complete, basolateral or lateral membranous reactivity in &#8805;10% of tumor cells</td> <td>Tumor cell cluster* with a strong, complete, basolateral or lateral membranous reactivity irrespective of percentage of tumor cells stained</td> <td class=\"centered\">3+</td> <td class=\"centered\">Positive</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HER2: human epidermal growth factor&nbsp;receptor 2.<br />* Tumor cell cluster (5 neoplastic cells).</div><div class=\"graphic_reference\">Original table published in Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797. <a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2008.03028.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2008.03028.x/abstract</a>. Copyright &copy; 2008. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).<br />Modified table reprinted from Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 2016; 140(12):1345-1363. From Archives of Pathology &amp; Laboratory Medicine. Copyright 2016 College of American Pathologists.</div><div id=\"graphicVersion\">Graphic 110996 Version 1.0</div></div></div>"},"110997":{"type":"graphic_table","displayName":"Comparison of neuraxial anesthesia techniques","title":"Comparison of neuraxial anesthesia techniques","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of neuraxial anesthesia techniques</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr class=\"divider_bottom\"> <td>Single shot spinal</td> <td> <ul> <li>Rapid onset of block </li> <li>Reliably symmetric block, including sacral nerve roots </li> <li>Low doses of local anesthetic and opioids </li> <li>Technically easy </li> </ul> </td> <td> <ul> <li>Limited duration of action </li> <li>Limited ability to extend block </li> <li>Requires dural puncture </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Epidural</td> <td> <ul> <li>Can prolong the duration and extend block </li> <li>Relatively slow onset of anesthesia* </li> <li>May be used to provide postoperative analgesia </li> </ul> </td> <td> <ul> <li>Relatively slow onset of anesthesia* </li> <li>Higher doses of local anesthetics and opioids than spinal </li> <li>High risk of PDPH with unintentional dural puncture </li> <li>Possibility of patchy or asymmetric block </li> <li>Unreliable sacral block </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Combined spinal epidural</td> <td> <ul> <li>Rapid onset of block </li> <li>Reliably symmetric block, including sacral nerve roots </li> <li>Can prolong the duration and extend block </li> <li>Option to titrate level of block </li> <li>Low doses of local anesthetic and opioids (spinal component) </li> <li>May be used to provide postoperative analgesia </li> </ul> </td> <td> <ul> <li>May take longer than single shot spinal </li> <li>Delayed confirmation of functional epidural catheter<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td>Continuous spinal</td> <td> <ul> <li>Rapid onset of block </li> <li>Reliably symmetric block, including sacral nerve roots </li> <li>Can prolong the duration and extend block </li> <li>Low doses of local anesthetic and opioids </li> <li>Option to titrate onset of block </li> </ul> </td> <td> <ul> <li>High incidence of PDPH with large dural puncture </li> <li>Possible higher risk of medication errors leading to a high spinal </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PDPH: post-dural-puncture headache.<br />* Speed of onset of anesthesia depends on the drug, speed of medication administration, concentration, and volume of the epidural solution. Slower onset may be a disadvantage in some clinical situations (eg, emergent cesarean delivery), but may be an advantage for patients who would benefit from slow onset of sympathectomy (eg, patients with preload dependent cardiac lesions).<br />¶ Sequential combined spinal epidural (CSE) technique verifies epidural catheter function soon after placement.</div><div id=\"graphicVersion\">Graphic 110997 Version 2.0</div></div></div>"},"110998":{"type":"graphic_algorithm","displayName":"Surgical treatment algorithm for rectovaginal endometriosis","title":"Surgical treatment algorithm for rectovaginal endometriosis","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Surgical treatment algorithm for rectovaginal endometriosis</div><div class=\"cntnt\"><img style=\"width:462px; height:586px;\" src=\"images/OBGYN/110998_Trtmntrectovaginlendomtrs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VAS: visual analogic scale.</div><div class=\"graphic_reference\">Reproduced from: Abrão MS, Petraglia F, Falcone T, et al. Deep endometriosis infiltrating the recto-sigmoid: critical factors to consider before management. Hum Reprod Update 2015; 21(3):329-39, by permission of Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. Copyright © 2016.</div><div id=\"graphicVersion\">Graphic 110998 Version 2.0</div></div></div>"},"110999":{"type":"graphic_table","displayName":"Thymic tumors TNM staging AJCC 2017","title":"Thymic tumors TNM staging AJCC 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Thymic tumors TNM staging AJCC 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Primary tumor (T)*<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>T category</strong></td> <td colspan=\"3\"><strong>T description</strong></td> </tr> <tr> <td class=\"indent1\">TX</td> <td colspan=\"3\">Primary tumor cannot be assessed</td> </tr> <tr> <td class=\"indent1\">T0</td> <td colspan=\"3\">No evidence of primary tumor</td> </tr> <tr> <td class=\"indent1\">T1</td> <td colspan=\"3\">Tumor encapsulated or extending into the mediastinal fat; may involve the mediastinal pleura</td> </tr> <tr> <td class=\"indent2\">T1a</td> <td colspan=\"3\">Tumor with no mediastinal pleura involvement</td> </tr> <tr> <td class=\"indent2\">T1b</td> <td colspan=\"3\">Tumor with direct invasion of mediastinal pleura</td> </tr> <tr> <td class=\"indent1\">T2</td> <td colspan=\"3\">Tumor with direct invasion of the pericardium (either partial or full thickness)</td> </tr> <tr> <td class=\"indent1\">T3</td> <td colspan=\"3\">Tumor with direct invasion into any of the following: Lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins</td> </tr> <tr> <td class=\"indent1\">T4</td> <td colspan=\"3\">Tumor with invasion into any of the following: Aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">* Involvement must be microscopically confirmed in pathologic staging, if possible.<br /> &#182; T categories are defined by \"levels\" of invasion; they reflect the highest degree of invasion regardless of how many other (lower-level) structures are invaded. T1, level 1 structures: thymus, anterior mediastinal fat, mediastinal pleura; T2, level 2 structures: pericardium; T3, level 3 structures: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, hilar pulmonary vessels; T4, level 4 structures: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Regional lymph nodes (N)<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>N category</strong></td> <td colspan=\"3\"><strong>N description</strong></td> </tr> <tr> <td class=\"indent1\">NX</td> <td colspan=\"3\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class=\"indent1\">N0</td> <td colspan=\"3\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"indent1\">N1</td> <td colspan=\"3\">Metastasis in anterior (perithymic) lymph nodes</td> </tr> <tr> <td class=\"indent1\">N2</td> <td colspan=\"3\">Metastasis in deep intrathoracic or cervical lymph nodes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">&#916; Involvement must be microscopically confirmed in pathologic staging, if possible.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Distant metastasis (M)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>M category</strong></td> <td colspan=\"3\"><strong>M description</strong></td> </tr> <tr> <td class=\"indent1\">M0</td> <td colspan=\"3\">No pleural, pericardial, or distant metastasis</td> </tr> <tr> <td class=\"indent1\">M1</td> <td colspan=\"3\">Pleural, pericardial, or distant metastasis</td> </tr> <tr> <td class=\"indent2\">M1a</td> <td colspan=\"3\">Separate pleural or pericardial nodule(s)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">M1b</td> <td colspan=\"3\">Pulmonary intraparenchymal nodule or distant organ metastasis</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Prognostic stage groups</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">The T, N, and M categories are organized into stage groups, as shown in the table. This schema was developed based primarily on outcomes; in the lower stages, recurrence rates in patients with complete resections were judged most relevant, whereas in higher stages, survival in all patients, regardless of resection status, was weighed more heavily. Practical applicability and clinical implications also were considered. Differences among the stage groups were subjected to statistical analysis and generally were found to have a stepwise progression toward worse survival in multiple patient cohorts (eg, R0, R-any).</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td><strong>When T is...</strong></td> <td><strong>And N is...</strong></td> <td><strong>And M is...</strong></td> <td><strong>Then the stage group is...</strong></td> </tr> <tr> <td class=\"indent1\">T1a,b</td> <td>N0</td> <td>M0</td> <td>I</td> </tr> <tr> <td class=\"indent1\">T2</td> <td>N0</td> <td>M0</td> <td>II</td> </tr> <tr> <td class=\"indent1\">T3</td> <td>N0</td> <td>M0</td> <td>IIIA</td> </tr> <tr> <td class=\"indent1\">T4</td> <td>N0</td> <td>M0</td> <td>IIIB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N1</td> <td>M0</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N0,1</td> <td>M1a</td> <td>IVA</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>N2</td> <td>M0, M1a</td> <td>IVB</td> </tr> <tr> <td class=\"indent1\">Any T</td> <td>Any N</td> <td>M1b</td> <td>IVB</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNM: tumor, node, metastasis; AJCC: American Joint Committee on Cancer.</div><div class=\"graphic_reference\">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.</div><div id=\"graphicVersion\">Graphic 110999 Version 2.0</div></div></div>"}};